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Abstract 
 
 
The DNA Mismatch repair (MMR) pathway is responsible for the repair of base-
base mismatches and insertion/deletion loops, formed during DNA replication. 
Mutations in MMR genes significantly increase the predisposition to cancer with 
MMR deficiency estimated to be present in 15-17 % of all colorectal cancers. 
5-fluorouracil is the main treatment for advanced colorectal cancer however the 
majority of studies suggest that MMR deficient tumours are more resistant to 
5-fluorouracil than MMR proficient tumours. Therefore, there is a critical clinical 
need to identify novel therapeutics to treat these tumours.  
To this end, we have performed a high-throughput compound screen, to identify 
compounds that cause selective lethality in MMR deficient cell lines. We identified 
the potassium-sparing diuretic drug, Triamterene, as selectively lethal in vitro and in 
vivo in MMR deficient cell lines. Our data suggest that this selectivity is through its 
antifolate activity, leading to the accumulation of reactive oxygen species and DNA 
double strand breaks in MMR deficient cells. Interestingly, we identified a 
requirement, for thymidylate synthase expression, the only de novo enzyme for 
dTTP synthesis for the Triamterene cytotoxicity. NRF2 and NRF2-induced 
antioxidants were regulated upon Triamterene treatment and thymidylate synthase 
silencing, therefore suggesting a role for the antioxidant response in Triamterene 
toxicity. Taken together, our results suggest Triamterene as a promising novel 
therapeutic for the treatment of MMR deficient cancers.  
In order to identify novel therapeutics to treat MMR deficient tumours, we have also 
performed a high-throughput siRNA screen, to identify genes that cause selective 
lethality in MMR deficient cell lines. We identified AURKA gene as synthetically 
lethal in MSH6 deficient cell lines which suggests AURKA as a promising novel 
therapeutic target for the treatment of MMR deficient cancers.  
Taken together, in this PhD thesis we have identified two novel therapeutic strategies 
for the treatment of MMR deficient cancers. 
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1 DNA damage response 
Cancer causes around 8.2 million deaths per year, which represent 14.6 % of all 
human deaths worldwide. The most common types of cancer are lung, prostate, 
colorectal (CRC) and breast cancer [1]. One of the major driving causes for 
tumorigenesis is genomic instability, which is associated with all cancer types [2-4]. 
Genomic instability can be due to an increase in basal DNA mutation rate, for 
example microsatellite instability (MSI) [5, 6]. Genomic instability can also be due 
to a vast hypermethylation of promoter CpG island sites resulting in the epigenetic 
silencing of tumour suppressor genes known as CpG island methylator phenotype 
(CIMP) [7-9]. The other cause for genomic instability is an increase in numerical 
and/or structural chromosome aberrations rate also called chromosome instability 
(CIN) [10, 11]. Genomic instability is prevented in normal cells by the DNA damage 
response (DDR). DDR comprises of both DNA damage signalling and DNA damage 
repair. DNA repair is composed of a group of pathways including direct repair, base 
excision repair (BER), nucleotide excision repair (NER), DNA mismatch repair 
(MMR), fanconi anemia repair (FAR), non-homologous end joining (NHEJ) and 
homologous recombination (HR) [12]. Deregulation of the DDR, by activation or 
inactivation, leading to genomic instability, has been found in various cancers [13, 
14]. Therefore, DDR is a strategic target for cancer therapy. Most cancer 
radiotherapy and chemotherapy are designed to trigger DNA damage, which 
predominantly impact cancer cells due to their deregulated DDR and to their rapid 
proliferation rates relative to normal, non-cancerous cells [15-17].  
 
1.1 DNA damage 
DNA damage is widely present in cancer cells. It is estimated that up to one million 
DNA lesions occur in each mammalian cancer cell per day [18]. There is a wide 
range of DNA damage that can occur such as nucleotide, oxidative and alkylating 
damage, mismatches, insertion deletions loops (IDLs), apurinic/apyrimidinic (AP) 
sites, intra-cross links and inter-cross links (ICLs), single strand breaks (SSBs) and 
double strand breaks (DSBs) (Figure 1). The type of damage formed will determine 
which DNA damage pathway will be recruited. 
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Figure 1: Types of DNA damage that can occur in mammalian cells 
The different types of DNA damage are DNA mismatch, IDL, nucleotide, oxidative 
and alkylating damage, intra-cross link, ICL, AP site, SSB and DSB. Nucleotide, 
oxidative and alkylating damage can also be associated with a mismatch. 
 
 
1.1.1 Oxidative stress 
1.1.1.1 Reactive oxygen species 
The main cause of endogenous DNA damage is reactive oxygen species (ROS) [19, 
20]. They include superoxide anions (•O2
-
), peroxide (•O2
2-
), hydroxyl radicals 
(•OH), oxygen (O2), peroxynitrite (ONOO
-
) and hydrogen peroxide (H2O2). A basal 
level of ROS is necessary for cellular homeostasis. Mitochondria are considered as 
the major source of ROS with 2 % of the oxygen consumed by mitochondria reduced 
to superoxide [21]. However, an imbalance between ROS production and 
degradation via the antioxidant response can lead to oxidative stress and ultimately 
to oxidative DNA damage. ROS is naturally increased in cancers to promote tumour 
progression and development [22, 23]. ROS levels can also be increased 
exogenously by ultraviolet (UV), ionizing radiation (IR), pollutants, tobacco and 
drugs. 
 
1.1.1.2 Antioxidant response 
Oxidative stress can be induced by an increase in ROS levels but also by a decrease 
in the antioxidant response. The antioxidant response can be non-enzymatic. 
Glutathione, vitamins C and E are important non-enzymatic antioxidants. 
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Glutathione serves as an electron donor to reduce disulfide bonds in protein cysteines 
[24]. Antioxidant response can also be enzymatic. For example the superoxide 
dismutases SOD1 and SOD2 catalyze •O2
-
 into H2O2 and O2 and the catalase 
peroxidase catalyzes H2O2 into H2O. The antioxidant response is mainly regulated by 
nuclear factor erythroid 2-related factor 2 (NRF2), a member of the Cap’n’Collar 
family of basic region-leucine zipper transcription factors [25]. In the absence of 
oxidative stress, NRF2 is constitutively inactivated and degraded by forming a 
complex with the kelch-like ECH-associated protein 1 (Keap1). In the presence of 
oxidative stress, Keap1 cysteine residues are oxidized which allows Keap1 to 
uncouple from NRF2 [26]. Similarly, oxidative stress mediated phosphorylation of 
NRF2 by protein kinase C can lead to NRF2 dissociation from Keap1 [27, 28]. 
Disruption of the NRF2/Keap1 interaction leads to subsequent activation and 
translocation of NRF2 to the nucleus. In the nucleus, NRF2 binds to the antioxidant 
response elements (AREs) sequence (core sequence: TGAG/CNNNGC) present in 
the promoter region of many antioxidant genes and initiates their transcription [29-
32]. Through ARE binding, NRF2 regulates itself and a number of antioxidant genes 
including the ones described previously, SOD1, SOD2 and catalase peroxide, in 
addition to genes maintaining homeostasis such as NADPH:quinone oxidoreductase 
1 (NQO1) or heme oxygenase 1 (HO-1) and glutathione reductase and glutathione 
oxidase (Table 1) [33-38]. The nuclear factor 1 (NRF1), is another member of the 
Cap’n’Collar family of basic region-leucine zipper transcription factors able to bind 
AREs [39]. The understanding of the role of NRF1 in the antioxidant stress response 
is not as extended as for NRF2. However, it has been shown that NRF1 and NRF2 
have compensatory but also distinct roles in the activation of antioxidant genes [39]. 
Knockout NRF1/NRF2 mice have elevated ROS levels, but it is not the case for 
NRF1 or NRF2 single knockout mice. Therefore, the role for NRF1 and NRF2 in the 
basal expression of antioxidant genes is thought to overlap [40]. Studies have shown 
that silencing NRF1 induced an increased expression of NRF2 leading to an 
increased antioxidant response [39, 41, 42]. Therefore, NRF1 might be a regulator of 
the NRF2 antioxidant response. Hence, the expression of inducible antioxidant 
response is thought to be largely dependent on NRF2 [41, 42].  
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Table 1: Genes positively regulated by Nrf2  
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1.1.1.3 Oxidative DNA damage 
Oxidative stress leads to an interaction between ROS and cellular biomolecules such 
as DNA which causes oxidative DNA damage. ROS can cause more than 20 
different DNA base lesions (Table 2). Guanine is the most susceptible DNA base to 
oxidation due to its lower electron potential. Therefore, 8-Oxo-2'-deoxyguanosine 
(8-oxodG) is one of the most abundant and best investigated oxidative DNA damage 
and is considered as the reference in oxidative DNA damage studies. Oxidative DNA 
damage, is recognized by different DNA repair proteins depending on the DNA base 
pair oxidized and, if unrepaired, leads ultimately to an accumulation of DSBs [43, 
44].  
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Base 
oxidized 
Oxidized product 
DNA repair 
pathway 
Proteins 
Guanine 
8-Oxo-2'-deoxyguanosine (8-oxodG) 
BER OGG1; MUTYH 
MMR 
MSH2, MSH6; 
MLH1 
NER   
dNTP pool 
sanitisation 
MTH1, MMR 
2,6-diamino-4-hydroxy-5-
formamidopyrimidine 
BER 
OGG1; NEIL1; 
NEIL3 
spiroiminodihydantoin BER NEIL1; NEIL3 
guanidinohydantioin BER NEIL1; NEIL3 
Cysteine 
hydroxycytosine BER 
NEIL2; NEIL3; 
NTH1 
5,6-dihydroxycytosine BER NEIL1 
5-hydroxyuracil BER 
NEIL2; NEIL3; 
NTH1 
5,6-dihydrouracil BER NEIL2 
Adenine 
8-hydroxyadenine 
dNTP pool 
sanitisation 
MTH1 
4,6-diamino-5-formamidopyrimidine BER NEIL1; NEIL3 
2-hydroxyadenine 
BER MUTYH 
MMR MSH2, MSH6 
dNTP pool 
sanitisation 
MTH1 
Thymine 
5-hydroxy-6-hydrothymine BER NTH1 
thymine glycol 
BER 
NEIL1; NEIL3; 
NTH1 
MMR MSH2 
NER   
5-hydroxy-5-methylhydantoin BER NEIL2; NEIL3 
Table 2: DNA repair pathway responsible for oxidative DNA lesions removal 
They are four pathways able to repair oxidative DNA damage: dNTP pool 
sanitisation which repairs the oxidized nucleotide prior its incorporation into DNA; 
BER, NER and MMR which repair the oxidative nucleotide incorporated into DNA. 
  
Introduction 29 
 
1.1.2 Other causes of DNA damage 
1.1.2.1 Endogenous DNA damage 
Endogenous DNA damage is mainly caused by oxidative stress but also by a range 
of other endogenous modifications. DNA alkylation, usually DNA methylation, is 
another cause of DNA damage. An increase in S-adenosylmethionine (SAM), a 
reactive methyl group donor contributes to DNA methylation. The most frequent 
lesions due to DNA methylation are N
7
-methylguanine (N
7
meG) and O
6
-
methylguanine (O
6
meG). Guanine is the most susceptible DNA base to methylation 
and O
6
meG is thought to be the most mutagenic lesion due to nucleotide methylation 
[45]. N
7
meG does not possess cytotoxic properties. The N
3
-methyladenine (N
3
meA) 
is the second most abundant alkylation lesion and also the most cytotoxic [45, 46]. 
N
7
meG lesions can cause spontaneous depurination; which is another known cause 
of endogenous DNA damage and leads to AP sites. AP sites correspond to the 
cleavage of the glycosidic bond in DNA. Other sorts of DNA damage can also occur 
endogenously. During DNA replication, DNA mismatches and IDLs can occur. 
Helix-distorting damage caused by DNA supercoiling (over and under-winding) and 
ICLs which are the reaction of endogenous and exogenous agents to two different 
positions in the DNA can occur. The other types of DNA damage are AP sites, SSBs 
and DSBs which are intermediates in DDR pathways and therefore have various 
causes [47].  
 
1.1.2.2 Exogenous DNA damage 
DNA damage can also be generated exogenously. Most cancer therapies 
(chemotherapies and radiotherapies) are designed to trigger DNA damage. For 
example, alkylating agents, such as Temozolomide (TMZ) and N-methyl-N’-nitro-
N-nitrosoguanidine (MNNG), cause methylation DNA damage including, N
3
meG, 
N
7
meG and O
6
meG adducts; platinum compounds, such as Cisplatin, cause ICLs 
damage; topoisomerase inhibitors, such as Irinotecan, inhibit DNA unwinding and 
induce persistent SSBs or ICLs; and fluoropyrimidine agents, such as the pyrimidine 
analogue 5-fluorouracil (5-FU), are misincorporated into DNA and induce an 
accumulation of nucleotides lesions leading ultimately to DSBs. Radiotherapy leads 
to a range of DNA damage: mainly DSBs, but also SSBs, ICLs and oxidative DNA 
damage.  
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1.2 Mechanism of DNA repair 
As discussed above, there is a wide variety of DNA damage that can occur and it is 
widely present in our cells [18]. The type of DNA damage that occurs will determine 
which DNA repair pathway is recruited to prevent genomic instability. DNA damage 
can be categorized in two groups: single stranded DNA damage, including SSBs and 
nucleotides damage (methylation, oxidation, mismatch, AP sites, intra-cross links, 
ICLs); and DSBs (Figure 2). 
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Figure 2: DDR pathways recruited for the repair of a range of DNA damage 
They are two main families of DNA damage: single stranded DNA damage and 
double stranded DNA damage. They can be both induced endogenously or 
exogenously and be repaired by a range of DNA damage repair pathways. 
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1.2.1 Single stranded DNA damage 
There is a range of DNA damage repair pathways able to repair single stranded 
damage. The recruitment of a specific DNA repair pathway will depend on the DNA 
adduct itself. All the DNA repair pathways, except direct repair, can process and 
repair single stranded damage in 4 steps: recognition, excision, resynthesis and 
ligation.  
 
1.2.1.1 Direct repair 
Direct repair is the simplest DNA repair pathway by directly reversing the lesion. It 
is the only pathway that does not need excision, resynthesis and ligation of DNA. 
The O
6
meG lesions are removed by O
6
meG DNA methyltransferase (MGMT) 
through the irreversibly transfer of the alkyl groups to nucleophilic cysteine residues 
in repair proteins. If not repaired, O
6
meG lesions could trigger O
6
meG:C to A:T 
transitions [45, 46, 48]. 
 
1.2.1.2 Mismatch repair (MMR) 
MMR is the primary pathway responsible for the repair of base-base mismatches and 
IDLs that occur during DNA replication. This is the only DNA repair pathway able 
to recognize the lagging strand from the leading strand and therefore recognize the 
erroneous nucleotide in a mismatch [49]. The mechanism of MMR will be discussed 
in greater detail in section 2.1. 
 
1.2.1.3 Base excision repair (BER) 
BER is responsible for the repair of uracil misincorporation, oxidized base (Table 2), 
alkylated bases, deaminated bases, AP sites and SSBs. N
7
meG is the most abundant 
product of alkylation damage. It is relatively innocuous; however, it is prone to 
spontaneous depurination leading to AP sites repaired by BER. 
The damaged bases are recognized and removed by BER glycosylases to form AP 
sites [50]. There is a wide variety of DNA glycosylases involved in BER (Table 3) 
[51]. Two enzymes are responsible for the repair of 8-oxodG lesions: 8-oxodG 
glycosylase (OGG1) and mutY Homolog (E. coli) (MUTYH) [52, 53]. OGG1 is 
responsible for the repair of 8-oxodG:C to G:C; however, MUTYH is responsible for 
the repair of 8-oxodG:A mismatch to 8-oxodG:C. Therefore, MUTYH can prevent 
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the mutagenic transition of 8-oxodG:C to A:T by repairing the mismatch and giving 
time for OGG1 to repair the oxidized nucleotide. Other enzymes such as uracil-DNA 
glycosylase (UDG) [54], thymidine-DNA glycolase (TDG) [55], single-strand 
selective monofunctional uracil DNA glycosylase (SMUG1) [56] and methyl-CpG-
binding domain protein 4 (MBD4) recognize and cleave a number of specific DNA 
lesions [57]. Redundancy amongst the BER glycosylases has been shown by 
knocking out the different enzymes in vivo. Only double or triple knockout mice 
displayed severe phenotypes [58-61]. For example MUTYH/OGG1 knockout mice 
have a shortened life span and are more prone to develop cancer in comparison with 
single knockout mice [62].  
Symbol BER glycosylase Substrates 
OGG1 8-oxoguanine glycosylase  8-oxodG:C; 7meG:C 
MUTYH mutY Homolog (E. coli)  8-oxodG:A 
UNG uracil-DNA glycosylase  U:G 
TDG thymidine-DNA glycolase  T:G; thymine glycol:G; U:G 
SMUG1 
single-strand selective monofunctional 
uracil DNA glycosylase  
U; 5-hydroxyuracil; 5-formyluracil;  
5-hydroxymethyluracil 
MBD4 methyl-CpG-binding domain protein 4  T:G; T:T; T:C; U:G 
NTH1 ntu endonuclease III-like 1 Tg; 5-oxodC; 5-oxodU 
NEIL1 nei endonuclease VIII-like 1 FapyA; FapyG; Tg; 5-oxodU; 5-oxodC 
NEIL2 nei endonuclease VIII-like 2 5-hydroxy-5-methylhydantoin 
NEIL3 nei endonuclease VIII-like 3 FapyA; FapyG; Tg 
MPG methyl adenine glycosylase 3-meA 
Table 3: BER glycosylases recognize different substrates 
BER is implicated in the repair of a range of DNA damage and in red are represented 
the DNA base recognized by the different BER glycosylases. 
 
 
After the damaged base is recognized and removed by BER glycosylases, the formed 
AP sites are recognized by AP endonuclease 1 (APE1) which generates SSBs [63]. 
SSBs are then repaired by the short-patch BER (one nucleotide replacement) or the 
long-patch BER (2-13 nucleotides replacement) [64]. The first step for both patches 
consists of DNA resynthesis by DNA polymerases (DNA pol). DNA pol β is 
implicated in the short-patch BER and DNA pol δ and ε are mediators for the 
resynthesis during long-patch BER [65]. The resynthesis step is followed by DNA 
ligation mediated by DNA ligase III for the short-patch and DNA ligase I for the 
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long-patch BER [66]. Poly(ADP-ribose) polymerase 1 (PARP1) has a major role in 
BER mediated SSB repair by facilitating the recruitment of repair enzymes such as 
the X-ray repair cross-complementing protein 1 (XRCC1) to form a PARP1-
XRCC1-DNA pol β-DNA ligase III complex required for the short-patch BER [67]; 
and Flap endonuclease 1 (FEN1) for the long-patch BER [68]. Oxidative DNA 
damage is described as the main cause of endogenous DNA damage; therefore, BER 
is thought to be a critical pathway of DDR [69]. 
 
1.2.1.4 Nucleotide excision repair (NER) 
NER removes helix-distorting damage such as intra-cross links caused by UV; but 
also plays a role in the repair of ROS-induced damage (Table 2) [70]. There are two 
types of NER pathways: the global genome NER (GG-NER) and the transcription-
coupled NER (TC-NER). They only differ in the damage recognition step [70]. The 
GG- NER consists of a scan of the entire genome by xeroderma pigmentosum group 
C (XPC) to recognize helix distortion [71]. The TC-NER is recruited when the RNA 
polymerase II is stalled by a lesion during transcription [72]. After recognition of a 
helix distortion, the DNA up-stream and down-stream of the damage is removed by 
the excision repair cross-complementing protein 1 (ERCC1) leading to SSBs (around 
30 nucleotides long), that are repaired by DNA pol δ and ε and DNA ligase I or III 
[70, 71, 73]. The role for NER in ROS-induced damage repair is controversial. It is 
unclear whether RNA polymerase II is stalled at oxidative DNA lesions [74]. 
However, only cells deficient in TC-NER (and not cells deficient in GG-NER) are 
sensitive to oxidative DNA damage [70]. 
 
1.2.1.5 Fanconi anemia repair (FAR) 
FAR is not an independent DNA damage repair pathway but it is involved in ICLs 
repair and in NER and HR pathways [75]. This is the least understood pathway of 
the DDR. A core complex comprising 8 proteins (FANCA/B/D/E/F/G/L/M) is 
activated by ICLs and monoubiquitinates FANCD2 and FANC1. They play a 
platform role for the recruitment of endonucleases. Unhooking of the ICL by dual 
incision of the DNA strand is followed by the recruitment of translesion synthesis 
(TLS), NER and HR pathway proteins [76, 77].  
 
Introduction 35 
 
1.2.2 Double strand breaks repair (DSBs) 
DSBs can be directly induced by IR, or indirectly by accumulation of DNA lesions 
or collision of replication forks with SSBs. Single stranded DNA damage can be 
repaired with the help of the opposite strand as a template, which is not possible in 
case of DSBs making them the most deleterious DNA damage. There are two 
mechanisms for DSB repair: NHEJ and HR. NHEJ is active throughout the cell 
cycle, however, HR activity is restricted to S-phase [78, 79]. 
 
1.2.2.1 Non-homologous end joining (NHEJ) 
NHEJ is the predominant pathway for the repair of DSBs, considered to account for 
more than 80 % of IR-induced DSBs repair [80, 81]. NHEJ is active throughout the 
cell cycle. It is an error-prone pathway as it drives direct joining of the two broken 
ends. DSBs are recognized by the proteins Ku70 and Ku80. They recruit DNA-
dependent protein kinase catalytic subunit (DNA-PKcs) which is part of the 
phosphatidylinositol 3-kinaserelated kinase (PIKK) family. Ku70, Ku80 and DNA-
PKcs form the DNA-PK complex for DBS stability, followed by the recruitment of 
p53 binding protein 1 (53BP1) for DBS resection prevention. Subsequently, DNA 
ligase IV, X-ray repair cross-complementing protein 4 (XRCC4) and XRCC4-like 
factor (XLF) ligate the broken ends to complete repair [82]. This pathway is essential 
in DSBs that do not occur during the S-phase of the cell cycle but it is also important 
in the process of the immune response for the development of a wide range of 
antibodies [83]. 
 
1.2.2.2 Homologous recombination (HR) 
HR is the preferred pathway during S-phase since it is an error-free pathway. It takes 
place in 3 steps: end resection, strand invasion (DNA end-pairing or single-strand 
annealing) and resynthesis. The first step of the pathway is the resection of the DSB, 
which corresponds to the excision of the 5’ ends of the break, for accurate 
resynthesis of the damaged DNA using the non-damaged sister chromatid to serve as 
a template for repair. This step involves the MRE11-RAD50-NBS1 (MRN) complex 
which initiates the repair; and the BRCA1-BRCA2-PALB2 complex, composed of 
BRCA1, BRAC2, and partner and localizer of BRCA2 (PALB2) [84]. This complex 
is essential for RAD51 recruitment which is involved in the second step of the 
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pathway, the DNA end-pairing. Thereby, RAD51 mediates the search for 
homologous sequence on the sister chromatid to initiate the DNA resynthesis step 
[85]. An alternative model, called the single-strand annealing, does not use a sister 
chromatid, is RAD51 independent but depends on RAD52 for DNA ends annealing 
using sequence homologies of the complementary strand for DNA resynthesis [86].  
 
1.2.3 Translesion synthesis (TLS) 
TLS is a DNA damage tolerance process able to bypass damaged bases that stall 
replication forks. Under certain circumstances, it is favourable for the cell to bypass 
the damage and to repair it at a later time point in order to prevent the damaged bases 
to become DSBs. At an unrepaired DNA lesion site, TLS switches the regular DNA 
polymerase with a TLS polymerase. The main TLS polymerases are η, κ and Rev1. 
They are characterized by a larger active site to facilitate DNA synthesis over a 
damaged nucleotide. TLS polymerases have a poor processivity and low fidelity and 
are only used to bypass DNA damage [87]. Cells switch polymerases through 
proliferating cell nuclear antigen (PCNA). The ubiquitin conjugase Rad6 and the 
ubiquitin ligase Rad18 are recruited to stalled replication forks where they catalyze 
monoubiquitylation of PCNA at Lys164. TLS polymerases have increased affinity 
for monoubiquitylated PCNA, which facilitates their recruitment and the completion 
of TLS. The E3 ubiquitin-protein ligase SHPRH and the helicase-like transcription 
factor (HLTF) are thought to be involved in the switch back to error-free 
polymerases by restoring PCNA ubiquitylation status, which blocks TLS 
polymerases and activates error-free polymerases [88-90]. 
 
1.3 DNA damage signalling and cell cycle arrest 
The DNA damage signalling pathways will recognize the DNA damage and recruit 
the appropriate DNA damage repair pathway and the cyclin-dependent kinases 
(CDKs) required for cell cycle arrest to allow time for repair. 
 
1.3.1 Cell cycle 
The cell cycle is the process of cell division and replication to obtain two identical 
daughter cells. It is divided in 4 phases, gap 1 (G1), synthesis (S), gap 2 (G2) and 
mitosis (M). S-phase is the replication phase (DNA synthesis), and M-phase is the 
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physical cell division phase. G1 and G2-phases are two important phases to monitor 
and ensure that the cells are ready to enter S and M-phase respectively. In the case 
where cells are not in a favourable condition for cell division, there is a cell cycle 
arrest [91-93]. As soon as the cell is ready and damage has been repaired, the cell 
cycle is resumed but, if the damage persists, the cells will undergo apoptosis through 
the activation of p53 [94].  
 
1.3.2 DNA damage signalling 
One of the main causes of cell cycle arrest is the presence of DNA damage [78]. 
DDR requires regulation of cell cycle checkpoints to allow time for repair. Ataxia 
telangiectasia mutated (ATM) and ATM and Rad3-related protein (ATR) are part of 
the PIKK family. They are two crucial proteins for the recruitment of DNA damage 
repair pathways (Figure 3) [95]. ATM is activated by the MRN complex, itself 
activated by binding DSBs [96]. ATM phosphorylates the histone H2A.X (γH2AX) 
which localize to the DSB, this is a crucial step for the recruitment of other DDR 
proteins [97]. ATM also phosphorylates the checkpoint kinase 2 (Chk2), which then 
either activates CDKs responsible for an S-phase arrest of the cell cycle, leading to 
HR repair. ATM can also recruit 53BP1 and cyclins responsible for a G1-phase 
arrest in the cell cycle leading to a NHEJ repair. ATR, the other kinase required for 
DNA damage signalling, is activated by ATR Interacting Protein (ATRIP), itself 
activated by SSBs or DNA replication fork collapse. It phosphorylates checkpoint 
kinase 1 (Chk1) leading to an S and G2/M-phase arrest of the cell cycle which gives 
time to the cell to repair the damage. It also recruits FAR for ICLs repair and 
BRCA1, RAD51 for HR repair [78, 98]. If the damage is repaired, the cells can 
resume their cell cycle. If the damage is too extreme for repair and therefore persists, 
the cells can undergo apoptosis through the activation of p53 [94]. ATM and ATR 
recruit Chk1 and Chk2 respectively, but the two pathways are not mutually exclusive 
and might be compensatory to ensure DNA damage repair [99].  
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Figure 3: DNA damage signalling pathway 
ATM is the enzyme responsible for DSBs signalling and ATR is the enzyme 
responsible for SSBs signalling. Their activation leads to the recruitment and 
activation of Chk2 and Chk1 responsible for the recruitment of proteins for cell cycle 
arrest and DNA damage repair. 
 
  
1.4 Oxidative stress in cancer therapy 
Oxidative DNA damage is a cause major of DNA damage and can be caused by an 
increase in ROS levels and/or a decrease in antioxidant response [19, 20]. ROS is 
naturally increased in cancers to promote tumour progression and development. An 
increase in ROS levels can act to induce tumour development by promoting cell 
cycle progression, proliferation, cell survival and energy metabolism [22, 23]. For 
example, ROS have been shown to up-regulate the transcription of cyclins to 
facilitate G1/S transition of the cell cycle [100]. However, an excessive increase in 
intracellular ROS levels (by chemotherapeutic treatment for example) can act as a 
tumour suppressor [22, 23]. Conversely, antioxidants inhibit tumour progression and 
excessive antioxidant response promotes tumour growth [101, 102]. For example, 
over-activation of NRF2 directly increases B-cell lymphoma 2 (Bcl2) protein 
expression, causing apoptosis inhibition; but also drug resistance and cell 
proliferation (Table 1) [101, 102]. As NRF2 is highly expressed in cancer cells, it 
represents an interesting chemotherapeutic target [25]. 
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The role of oxidative stress in cancer has been exploited in the development of new 
chemotherapeutic strategies. Oxidative stress can be caused directly or indirectly 
[21]. For example, buthionine sulfoximine is a direct inhibitor of glutamate-cysteine 
ligase leading to an inhibition of glutathione synthesis [103]. Buthionine sulfoximine 
has been tested in phase I clinical trial for the treatment of children with 
neuroblastoma (NCT00002730). Phenylethyl isothiocyanate also depletes 
glutathione levels and has been used in phase I clinical trial as a preventive treatment 
of lung cancer in smokers (NCT00005883) [104]. Other drugs can cause oxidative 
stress indirectly. For example, one of the strategies to treat pancreatic tumours is a 
combination of drugs, including Gemcitabine, that all indirectly induce intracellular 
ROS levels to trigger apoptosis [23]. Sulindac, a FDA-approved non-steroidal anti-
inflammatory drug, enhances intracellular ROS levels and has been used in phase II 
clinical trial for the treatment of healthy participants with increased risk of 
developing melanoma (NCT00841204) [105]. Other treatment such as 5-FU and IR 
can also induce oxidative stress indirectly [21]. 
NRF2 is the main mediator of the antioxidant response. Its role in cancer 
development and progression has been exploited in the clinic by two different 
strategies: NRF2 activation to prevent tumour development and NRF2 inhibition to 
prevent chemo-resistance and tumour progression. For example, the synthetic NRF2 
inhibitor IM3829 has been shown to increase IR response in the treatment of lung 
tumours in vitro and in vivo [106]. Taken together, oxidative stress, a major cause of 
endogenous DNA damage, has a critical role in cancer development and progression; 
therefore, modulation of the cellular oxidative stress represents an interesting 
therapeutic strategy. 
 
1.5 DNA damage response in cancer therapy 
A large proportion of current cancer therapies have been designed to induce DNA 
damage. Deregulation of DDR, by activation or inactivation, has been found in 
various cancers [13, 14] and can often confer higher sensitivity to chemotherapy. 
Therefore, therapeutic strategies targeting the different proteins involved in DDR 
have been developed and translated into clinic in order to enhance therapy response 
(Table 4) [15, 17]. The over-expression of MGMT has been identified as the main 
mechanism of resistance in TMZ treatment [107]. O
6
-benzylguanine is one of the 
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most potent MGMT inhibitors available. However, inhibition of MGMT is toxic in 
non-cancer cells by leading to myelosuppression [108]. Novel approaches have been 
developed to counteract MGMT inhibition induced side effect such as coupling 
MGMT inhibitors to D-glucose to specifically target cancer cells that are known to 
have higher glucose consumption [109]. Mutations in BER pathway, for example in 
DNA pol β, have been associated with a range of cancers [110, 111]. The most 
advanced therapeutic strategies targeting BER are APE1 inhibitors and PARP1 
inhibitors. These two enzymes are generally highly expressed in tumours. The 
inhibition of APE1 or PARP1 increases IR and alkylating agent sensitivity [112-
115]. Defects in NER, also called xeroderma pigmentosum, causes skin cancer 
development, and leads to UV and platinum agent sensitivity [116-118]. Fanconi 
anemia (FAR deficiency) is a disorder leading predominantly to acute myeloid 
leukemia [119]. It has been shown that the loss of at least one of the FAR genes 
triggers increased sensitivity to ICLs damage [76]. Defects in NHEJ have also been 
associated with cancer [120-122]. The inhibition of DNA-PKcs has shown to induce 
IR sensitivity [123]. HR is essential for genomic stability. HR defects are associated 
with IR and crosslinking agent sensitivity [124].  
 
DNA damage signalling has also been associated with cancer. Increased expression 
and activation of the ATR/ATM dependent pathways are reported to be associated 
with cancer [15, 97]. The development of MRN, ATM, ATR, Chk1 and Chk2 
inhibitors have been under investigations [15, 99, 125]. It is difficult to develop an 
inhibitor that targets specifically Chk1 and/or Chk2 with not multiple kinase targets 
[125]. Chk1/Chk2 double knockout mice are tumour prone, therefore it is arguable to 
use inhibitors of Chk1/Chk2 as chemotherapy [126]. However, recent studies have 
shown promising preliminary results in the development of Chk1 or Chk2 inhibitors; 
with, for example, the development of CCT244747, an orally bioavailable Chk1 
inhibitor which showed promising response as a single agent or in combination with 
Gemcitabine and Irinotecan in vivo [127]. TP53, the gene coding for p53 protein, is 
considered to be mutated or inactivated in all cancer tumours [128]. TP53 
inactivation confers radiotherapy and chemotherapy resistance [129]. Molecules, 
such as APR-246, targeting p53 mutations able to re-express its function have been 
developed and tested in phase I/II clinical trial with promising results [130]. 
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Inhibition of direct repair, BER, NER, FAR, NHEJ, HR and ATM/ATR pathways 
have been associated with increased sensitivity to therapeutic treatments. However, 
this is not the case for MMR pathway. Defect in MMR pathway has been observed 
in a wide range of cancers and results in a mutator phenotype leading to cancer 
development [49, 131]. Numerous studies agree that MMR deficient tumours are 
resistant to a wide range of chemotherapeutic agents. These include methylating 
agents, platinum compounds and fluoropyrimidine agents [132-134]. Therefore, 
targeting this pathway would be a striking novel therapeutic strategy in cancer 
treatment [135, 136]. 
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Table 4: Examples of completed clinical trials of DDR inhibitors 
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2 DNA mismatch repair 
2.1 DNA mismatch repair pathway 
MMR is the pathway responsible for the repair of base-base mismatches (G:T, G:A, 
G:G, C:A, C:T, A:A and T:T) and IDLs that occur during DNA replication [138]. 
The recognition of base-base mismatches and short IDLs is carried out by MutSα, an 
MSH2-MSH6 heteroduplex, while the recognition of large IDLs is carried out by 
MutSβ, an MSH2-MSH3 heteroduplex [139]. MutSα and MutSβ have distinct 
functions but have also redundant roles [140]. When MutS (α or β) binds to the 
DNA, it forms a sliding clamp, able to translocate in either direction on the DNA 
until it recognizes a mismatch [141]. This recognition alters the MutS conformation 
in an ATP-dependent manner, allowing recruitment of MutL to form an ATP-
dependent ternary complex. MutL, another MMR-associated heteroduplex, is always 
composed of MLH1 with another protein: either PMS2 (MutLα), PMS1 (MutLβ) or 
MLH3 (MutLγ). MutLα is the most prominent MutL complex and plays the most 
important role in MMR. MutLβ function is not yet known but it might play a backup 
role with MutLγ for MutLα [142, 143]. MutLγ is the only MutL complex with a role 
in meiotic recombination [144]. In the MMR pathway, when MutLα is complexed 
with MutS, it acts as an endonuclease [145]. MutLα recognizes the lagging strand 
from the leading strand. The mechanism by which MutLα discriminate the lagging 
strand is not fully understood. In prokaryotes, the newly synthesized strand is 
methylated by deoxyadenine methylase (Dam) at the position N6 of adenine in 
GATC sites which can be recognised by MutLα homolog [146]. Eukaryotes lack 
methylation in GATC sites therefore the mechanism of discrimination must be 
different. MutL might recognise the lagging strand by the Okazaki fragments or by 
the free 3’-terminus on the leading strand. However, pre-existing nicks in the two 
strands have unequal incidence [142]. Studies have also shown a role for 
ribonucleotide incorporation into the leading strand as entry sites for MMR; 
therefore ribonucleotide processing might contribute to the discrimination signal but 
other mechanisms remain to be elucidated [147-149]. MutL is able to recognize the 
lagging strand and excise it 5’, but also 3’, from the mismatch. Exonuclease 1 (Exo1) 
is recruited to excise nucleotides in a 5’→3’ direction [150]. In the case of 3’ 
excision, Exo1 recruits replication factor C (RFC) to perform a 3’→5’ excision. 
Replication protein A (RPA), a binding-factor, stabilizes the single-stranded DNA 
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and inhibits Exo1 to prevent further degradation [151]. After removing the 
mismatch, the final step is to resynthetize the excised-DNA by DNA pol δ and to 
ligate the remaining nick by DNA ligase I. PCNA, required during DNA synthesis 
for the processivity of the DNA pol, is also required during MMR for mismatch 
recognition by interacting with MutS [152] and activation of the endonuclease [153] 
(Figure 4). 
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Figure 4: DNA mismatch repair mechanism and role of proteins implicated 
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2.1.1 DNA mismatch repair mediated apoptosis 
MMR is the pathway to repair base-base mismatches and IDLs that occur during 
replication. MMR can also recognize DNA lesions such as 5-FU and alkylating 
agents-induced DNA lesions [46, 154]. The MMR pathway is not always able to 
repair the lesions and subsequently triggers apoptosis. In this case, after recognition 
of a lesion, MutS recruits MutL, followed by the recruitment of ATM and ATR 
[155]. These proteins, once activated, recruit DNA damage repair proteins that cause 
cell cycle arrest with a delay in S-phase progression and an arrest in G2-phase 
leading to apoptosis via stabilization of p53 [156]. There are currently two models to 
explain ATM/ATR recruitment by MutS. The first model, called the direct signalling 
model, proposes that the MutS-MutL complex, after recognition of a lesion, directly 
recruits ATM/ATR. The alternate model, called the futile cycle model, suggests that 
MMR can recognize and excise the lesion. However, the continued exposure to DNA 
damaging agents such as 5-FU or alkylating agents, leads to further damage 
accumulation due to continuous excision of the adducts during the DNA resynthesis 
step of MMR, which leads to repeated cycles of MMR. The accumulation of lesions 
into DNA, and therefore, the initiation of the MMR process results in the formation 
of DNA strand breaks, that initiate the recruitment of ATM/ATR (Figure 5) [157]. 
Cell cycle arrest has been shown to occur during the first cell cycle after 5-FU and 
alkylating treatment; furthermore, a direct interaction between MSH2 and ATR has 
been identified [46, 158, 159]. These results support the direct signalling model, 
however, it is likely that both models are not mutually exclusive and might be 
compensatory to ensure apoptosis is initiated [156].  
Introduction 47 
 
 
Figure 5: DNA lesions recognized but unrepaired by MMR pathway trigger 
apoptosis 
When MMR pathway is not able to repair a lesion it recruits ATR/ATM through two 
possible mechanisms: either by direct recruitment or futile cycles of MMR. In both 
cases, ATR/ATM recruitment initiates cell cycle arrest and apoptosis. 
 
 
2.2 MutSα structure and function 
MutSα is the main complex of the MMR pathway required to recognize DNA 
damage. MSH6 protein was first described as an MSH2 partner in 1995 [160]. 
MSH6 and MSH2 have similar structures divided in 5 domains with the exception of 
an additional N-terminal disordered domain for MSH6 [139, 161]. MutSα dimerizes 
as an asymmetric mirror image with each domain (1-5) juxtaposed. Domain 1 is the 
DNA mismatch binding domain; domain 2 is a connector; domain 3 is a lever; 
domain 4 is a clamp region for unspecific DNA binding and domain 5 is an ATP 
binding domain (Figure 6). The precise mechanistic role of ATP binding and 
hydrolysis is not yet completely understood, however, the domain 5 is likely 
involved in altering MutSα structural conformation and DNA binding activity [162]. 
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The N-terminal disordered domain of MSH6 contains 389 amino acids upstream of 
domain 1. Several activities dependent on this N-terminal domain unique to MSH6 
have been identified but are still not fully understood [162]. It contains three nuclear 
localization sequences (NLSs). Transport to the nucleus is believed to occur only 
after dimerisation of MutSα in the cytosol as MSH2 does not contain an NLS and the 
level of MSH2 in the nucleus decreases in cells lacking MSH6 [163]. The N-
terminus of MSH6 also has a motif allowing interaction with PCNA. PCNA is an 
essential DNA replication sliding clamp for various DNA replication and repair 
pathways. PCNA is required for MMR at the pre-excision step and during DNA 
resynthesis [164]. It initiates MMR by coordinating the MutSα directionality at the 
replication fork in an N-terminal MSH6 dependent manner [165]. 
 
 
Figure 6: Structure of MutSα heterodimer 
MSH2 and MSH6 proteins have 5 domains: domain 1 is the DNA mismatch binding 
domain; domain 2 is a connector; domain 3 is a lever; domain 4 is a clamp region for 
unspecific DNA binding and domain 5 is an ATP binding domain. MSH6 also have 
an N-terminal disordered domain. 
 
 
2.3 Non-canonical role for DNA mismatch repair 
We have previously detailed the canonical mechanism of MMR pathway in repairing 
replicating errors. In addition, a number of non-canonical roles for the MMR 
pathway have been identified. Such that, MMR has been implicated for example in 
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oxidative DNA damage, O
6
meG, ICLs and DSBs repairs but also in chromatin 
assembly and immunoglobulin diversification (Figure 7) [166]. 
 
 
Figure 7: Different roles for MMR pathway 
MMR is the pathway responsible for the repair of base-base mismatches and IDLs 
that occur during DNA replication. It also recognizes 5-FU lesions, alkylating and 
oxidative mismatches. MMR has non-canonical roles in DNA damage signalling, 
HR, NHEJ and FAR pathways; in chromatin assembly and in immunoglobulin 
diversification. 
 
2.3.1 DNA mismatch repair and oxidative stress 
Oxidative DNA damage is the primary cause of endogenous DNA damage. It is 
repaired by BER, NER but also MMR. Numerous studies report a link between 
oxidative DNA damage and MMR. The baseline 8-oxoG levels were shown to be 
higher in DNA extracted from MSH2 and MLH1 deficient cell lines compared to 
MMR proficient cell lines [167]. It has also been shown that MSH2 deficient 
embryonic stem (ES) cells treated with low doses of IR, accumulated more ROS-
induced damage (8-oxodG and thymine glycol) compared to the wild type control 
[168]. The role for MMR in 8-oxodG repair has been further elucidated. MutSα but 
not MutSβ can recognize 8-oxodG mismatches. MutSα has a high affinity for 8-
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oxodG mismatches and no affinity for 8-oxodG:C. MutSα evaluated affinity for 8-
oxodG mismatches was 8-oxodG:T > 8-oxodG:G > 8-oxodG:A > 8-oxodG:C ≈ G:C 
[169, 170]. 8-oxodG mismatches, if not repaired can lead to the mutagenic T:A 
transition. Earley et al. observed that the mutation rate associated with MMR 
deficiency could be reduced by growing S. Cerevisiae under anaerobic conditions. 
These observations suggest a role for oxidative stress and more precisely for the 
mismatches occurring opposite oxidized bases in MMR associated mutation rate 
[171]. As previously mentioned, MUTYH plays a role in the repair of 8-oxodG:A 
mismatches. Evidence has been reported that MUTYH interacts with MSH6 [172] 
and that silencing MSH2, MUTYH or both have the same effect on 8-oxodG levels 
in comparison with the wild type mouse embryo fibroblasts (MEF) suggesting a 
shared pathway for MMR and MUTYH in 8-oxodG:A repair [173]. Therefore 
MUTYH and MMR can repair 8-oxodG:A mismatches to 8-oxodG:C, that can then 
be recognized and repaired by OGG1. Another important enzyme for the 
detoxification of oxidative DNA bases is MTH1. Over-expression of MTH1 has 
been shown to decrease genomic 8-oxodG. It has also been shown that MTH1 can 
decrease oxidative DNA damage with a greater extent in MSH2 deficient cells 
compared to MSH2 proficient cells, triggering a decrease in spontaneous mutation 
rate [167, 168]. Moreover, MMR also have a specific role for the recruitment of TLS 
polymerases to bypass oxidative damage during replication. 
Monoubiquitinated PCNA and TLS polymerase η recognize oxidative DNA damage 
in a BER independent and MutSα dependent manner [174]. Therefore, MMR 
pathway is important in the repair of oxidative stress-induced DNA damage. 
 
2.3.2 DNA mismatch repair and direct repair 
Cells proficient in MMR and deficient in MGMT, the main enzyme for the direct 
repair of O
6
meG, are highly sensitive to alkylating agents by undergoing MMR 
dependant lethal G2-phase arrest. Cells deficient in MGMT are not able to directly 
repair O
6
meG lesions which leads to an accumulation of O
6
meG:T mismatches 
recognized by the MMR pathway, leading to apoptosis. Cells that are MGMT and 
MMR deficient have a high tolerance for O
6
meG lesions and high mutation rate due 
to O
6meG:C → O6meG:T → A:T transitions. Therefore, MMR is required for the 
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repair of O
6
meG:T into O
6
meG:C, to enable cells to enter another cell cycle in order 
to repair O
6
meG adducts [175, 176].  
 
2.3.3 DNA mismatch repair and DNA double strand breaks repair 
In addition, MMR proteins have been implicated in DSB repair. After IR treatment, 
MSH6 interacts with KU70, a NHEJ repair protein, and colocalizes with γH2AX 
[177]. Defects in MSH6 result in an impaired NHEJ repair pathway and an 
accumulation of IR-induced DSBs, therefore suggesting a potential role for MSH6 in 
NHEJ dependent DSBs repair [177]. MutSα also has a role in HR-dependent IR-
induced DSBs repair by suppressing recombination with mismatched DNA [178, 
179]. In S. cerevisiae, the MMR pathway plays a role in the RAD51-dependent 
recombination fidelity. Therefore, MMR plays an important role in the high fidelity 
associated with HR. However, the detailed mechanism is still unclear [178-181]. 
 
2.3.4 DNA mismatch repair and Fanconi anemia 
MSH2 and MLH1 have been found to interact with FAR proteins such as FANCD2 
[182]. MMR deficient cells exhibit an ICL repair defect, through the inhibition of 
FAR recruitment. Unexpectedly, defects in both MSH2 and MLH1, restore the FAR 
pathway and can confer resistance to ICLs. One report has measured MMR and FAR 
proteins in 206 CRC patients and identified that only 5 % of the cohort had a defect 
in both FAR and MMR pathways [182]. FANCD2 or MLH1 knockout mice are 
viable but FANCD2/MLH1 double knockout mice displayed embryonic lethality 
[183]. Taken together, these reports suggest a vital cross-talk between the MMR and 
FAR pathway and a key role of the interactions between MMR and FAR proteins in 
these pathways [184, 185]. 
 
2.3.5 DNA mismatch repair and immunoglobulin diversification 
Our immune system constantly develops new antibodies to combat antigens. Low 
affinity antibodies are diversified when exposed to antigens through the activation-
induced deaminase (AID) which converts cytosines to uracils followed by mutagenic 
process involving the TLS DNA pol η, BER, MMR and NHEJ. The G:U mismatches 
are recognised by BER and MMR; if repaired, DNA pol η introduces further 
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mutations during the resynthesis step; if not repaired, BER and MMR generate DSBs 
that are repaired with the low fidelity NHEJ pathway creating recombination. 
Mutations in MMR pathway have been shown to affect the immunoglobulin 
diversification process [166, 186].  
 
2.3.6 DNA mismatch repair and chromatin assembly 
A crosstalk between chromatin assembly and MMR pathway has been proposed to 
extend the time-frame for MMR after replication [162]. This crosstalk is through the 
interaction of the histone chaperone chromatin assembly factor 1 (CAF1) and the N-
terminal domain of MSH6, in S-phase of the cell cycle [187]. The histone mark 
H3K36me3 can also interact and recruit MSH6, via its N-terminal domain, to 
chromatin in early S-phase before DNA replication [188]. Furthermore, data suggest 
that histone acetylation and deacetylation cooperate with MMR in mutation and 
chromosome rearrangement avoidance [189]. In addition, inhibition of SET domain 
containing 2 (SETD2), the enzyme responsible for H3K36 trimethylation, has shown 
conflicting data with regards to induction of MSI in clear-cell renal carcinomas [190, 
191]. A first report identified that cells lacking SETD2 displayed MSI in vitro [190]. 
More recently, a bioinformatic study did not validate a correlation between SETD2 
mutations and MSI in renal cancer tumours which might be explained by an in vivo 
adaptation mechanism to prevent MSI induced by SETD2 [191]. Therefore, MSH6 
has a potential role in the crosstalk between MMR pathway and chromatin assembly 
and further investigations to understand better this crosstalk is necessary. 
 
2.3.7 DNA mismatch repair and cell cycle 
There is emerging evidence for role of the MSH6 N-terminal domain in MMR-
dependent cell cycle progression [192]. In the MSH6 N-terminal domain, 22 distinct 
phosphorylation sites of MSH6 were identified, including cyclin-dependent kinase 2 
(CDK2), ATM/ATR and Aurora kinases binding sites [192]. CDK2 is a member of 
the cyclin-dependent kinase family essential for the G1/S transition of the cell cycle 
[193]. Aurora kinase family is composed of AURKA, AURKB and AURKC and 
plays an important role during the different phases of the mitosis [194]. These 
phosphorylation sites in MSH6 suggest a potential crosstalk between cell cycle 
proteins and MSH6.  
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Taken together, we reported the canonical and non-canonical roles for MMR 
pathway. MMR is implicated in the repair of mismatches, in other repair pathways 
and signalling, in chromatin assembly and in immunoglobulin diversification. 
 
2.4 Epidemiology of DNA mismatch repair deficiency 
Loss of expression of one of the MMR proteins (MSH2, MSH6, MSH3, MLH1, and 
PMS2) leads to MMR deficiency. This loss can be due to mutation, methylation or a 
combination of both. Germline mutations in any of the MMR genes can give rise to 
the autosomal dominant condition referred to as Lynch syndrome (LS), also called 
hereditary nonpolyposis colon cancer (HNPCC) [131]. This syndrome is one of the 
most prevalent hereditary cancer-prone syndromes. LS represents 1-5 % of all CRCs. 
It is associated with an increased predisposition to cancer, with an 80 % risk of 
developing CRC; and a 60 % risk in female patients of developing endometrial 
cancer. LS is also associated with cancers of the ovary, urologic tract, glioblastomas, 
small bowel, stomach, pancreas, breast and prostate [195-203]. In LS, only one 
mutated allele of an MMR gene is inherited. Loss of the second allele occurs 
somatically either by mutation or methylation. The rare case where both inherited 
alleles are mutated is called the constitutional MMR deficiency syndrome and leads 
to cancer during childhood [204]. The contribution of each MMR gene to LS is 
variable. MLH1 is the most common MMR protein found silenced, it represents 
42 % of all LS cases; 10-20 % of MLH1-deficent LS cases are due to MLH1 
methylation. MSH2, MSH6 and PMS2 are also notably important (mutated in 33, 18 
and 7.5 % of LS cases respectively), while MSH3 mutations are moderately 
implicated in LS. MSH2 has been estimated to be lost due to methylation in 17-24 % 
of MSH2-deficient LS cases, 29 % of PMS2 deficient LS cases were associated with 
methylation and no case of MSH6 methylation has been reported (Table 5) [205, 
206]. Cancer development and expression in LS is variable. MLH1 and MSH2 
mutations are associated with a higher penetrance and earlier mean age of cancer 
onset compared to MSH6 and PMS2 mutations. MSH6 mutations have a higher risk 
of endometrial cancer [207]. MMR loss can be inherited but can also be somatic 
which represents 10-15 % of all CRC. All MMR genes can be somatically lost, 
however loss of MLH1 is identified in 60 % of cases, mainly due to 
hypermethylation of the MLH1 promoter [208]. No case of MSH2 and MSH6 
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methylation in sporadic cancers with somatic defect in MMR has been reported [209, 
210]. Overall, data suggest that MMR deficient tumours have a better disease free 
survival rate in comparison to MMR proficient tumours. A meta-analysis estimated a 
hazard ratio of 0.65 for MSI which means tumours with MSI have a significantly 
better prognosis than microsatellite stable tumours [211]. One of the hypotheses to 
explain this better disease survival rate is a differential immune response in the 
MMR deficient tumours compare to the MMR proficient tumours [212]. MMR 
deficient tumours accumulate mutations that can trigger the generation of potentially 
immunogenic peptides recognized by the immune system [213]. However, MMR 
deficient tumours are not eliminated due to potential immune evasion strategies. 
Further investigations are necessary to understand the role for the immune system in 
MSI tumours development (see section 3.2.3.3) [214, 215].  
 
Affected 
genes 
Contribution to 
LS cases 
Proportion due to 
gene methylation 
MLH1 42 % 10-20 % 
MSH2 33 % 17-24 % 
MSH6 18 % 0 % 
PMS2 7.50 % 29 % 
Table 5: MMR genes associated with Lynch syndrome 
 
Knockout mouse models have been developed to study MMR genes [155]. All 
models were cancer-prone, except MSH3 deficient mice [140]; and all models except 
MSH6 deficient mice had MSI [216]. MLH1, MSH2 and PMS2 knockout mice 
showed cancer susceptibility primary to lymphoma, not CRC as in humans, and 
secondary to gastrointestinal tumours, skin neoplasms and sarcomas [217]. The 
phenotype of MSH6 knockout mice is similar to MSH2 knockout mice except for the 
MSI [216, 218]. Double knockout for MSH6 and MSH3 have identical phenotype as 
MSH2 knockout mice [140].  
 
2.5 Identification of DNA mismatch repair deficiency 
The diagnosis of MMR deficiency is based on the Revised Bethesda Guidelines 
[219]. The diagnosis consists of either evaluation of MMR deficiency by sequencing 
or immunohistochemistry (IHC), or evaluation of MSI [220]. Microsatellites are 1-6 
base pairs tandem repeated (most commonly dinucleotide CA repeats) present 
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throughout the whole genome. DNA polymerases can slip over the tandem repeats 
leading to replication length errors and MSI [221]. These errors can be repaired by 
MMR but, in MMR deficiency, the errors remain fixed. Five microsatellite markers 
(BAT26, BAT25, D5S346, D2S123 and D17S250) have been identified as good 
predictors of MMR deficiency and are used to analyze MSI [222, 223]. High MSI 
(MSI-H) is defined by two or more of the markers showing instability; MSI-low 
(MSI-L) is the term when one of the markers is instable; and microsatellite stability 
(MSS) when no marker shows instability [222, 223]. Loss of MMR is known to give 
rise to MSI-H. 25 % of all MSI-H are caused by inherited MMR deficiency and are 
diagnosed as LS, 75 % are due to somatic loss of MMR. MSI-L has, to date, an 
unclear clinical significance. It is sometimes classified as MSI and sometimes as an 
independent group. In this case, another method of diagnosis may be required to 
classify patients [224].  
The other method is to diagnose MMR deficiency is by sequencing or IHC. 
Sequencing is a fast, reliable and low cost experiment. However, it detects only 
MMR mutations and not methylation. Therefore, this technique needs to be used in 
complement with another one [225, 226]. IHC consists of the assessment of loss of 
expression of MMR proteins in tumour samples. This is a good complement to MSI 
analysis as not all MMR deficiency give rise to MSI-H. For example, in the case of 
MSH6 deficiency, only 25 % of patients have MSI-H, although instability 
specifically at mononucleotide repeat sequences was consistently observed [207]. 
This is thought to be due to MSH3 compensation as MSH6 and MSH3 can both 
complex with MSH2 to form MutS α and β, and are both implicated in mismatch 
recognition. IHC is actually the best technique to diagnose MSH6 deficiency, but it 
cannot be the only technique clinically used as its sensitivity is around 90 %. This 
can be explained by the lack of standardization in this technique and the 
interpretation of the IHC staining results. In summary, MSI testing is cost effective 
and the best standardization in the technique but it does not identify all MMR 
deficiency (identify only 25 % MSH6 deficient tumours). IHC testing identifies 
mutations and methylation in all MMR genes but it is not well standardized. 
Sequencing allows a panel-based testing rather than a syndrome-based testing which 
means sequencing allows to test for mutation in MMR genes as well as other 
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oncogenes, but it does not identify methylation in MMR genes [227]. Therefore, 
these three techniques are, to date, complementarily used in the clinic [228].  
 
2.6 Secondary mutations and DNA mismatch repair deficiency 
Unsurprisingly, due to its role in genome stability, MMR deficiency can lead to a 
mutator phenotype, which is characterized by an accumulation of mutations in the 
DNA. The mutation rate is evaluated to be 100-1000-fold increased in MMR 
deficient cells [49]. This mutator phenotype is primarily due to MSI [229]. Many 
oncogenes and tumour suppressor genes contain microsatellites; therefore, MMR 
deficiency can give rise to mutations in many genes implicated in tumorigenesis 
(Table 6). For example, the Transforming Growth Factor-β type II Receptor 
(TGFβR2), a signal transduction gene, was the first MSI-H target gene reported in 
1995 [230]. Later, BCL2-associated X protein (BAX), a gene involved in apoptosis; 
adenomatous polyposis coli (APC), a gene involved in cell adhesion; and insulin-like 
growth factor 2 receptor (IGF-IIR), a gene involved in signal transduction, were also 
identified [231-233]. Further secondary mutations to MMR deficiency, such as DSB 
repair genes including MRE11 and RAD50 have all been identified to have 
mutations in their microsatellite regions upon MMR loss and are thought to drive the 
tumourigenic phenotype. Therefore, it is thought that the cancer phenotype in MMR 
deficient tumours may be further driven by secondary mutations in cancer-associated 
genes [134, 234].  
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Pathway Genes affected mutational frequency 
in tumours 
DNA repair MRE11 74 % 
RAD50 21-46 % 
DNA-PKcs 34 % 
BRCA2 2 % 
Ligase III 13 % 
XRCC2 3 % 
Damage signalling CDC25 11 % 
ATR 44 % 
Chk1 10 % 
Apoptosis BAX 24-54 % 
Signal transduction BRAF V600E 31-83 % 
PTEN 19 % 
TGF2R 61-100 % 
IGF2R 6-36 % 
Transcription regulation E2F4 35 % 
HDAC2 20 % 
TCF4 34-53 % 
Table 6: List of MSI-containing genes and their mutation frequency in MMR 
deficient tumours 
 
 
2.7 DNA mismatch repair deficiency and drug response 
Numerous studies agree that MMR deficient tumours are more resistant to a wide 
range of chemotherapeutic agents [132-134]. These include alkylating agents, 
platinum compounds and fluoropyrimidine agents.  
 
2.7.1 DNA mismatch repair deficiency and alkylating agents response 
Alkylating agents, such as TMZ, modify predominantly the ring nitrogen atom of 
purines. TMZ is the standard of care for patients with newly diagnosed glioblastoma 
tumours. In glioblastoma patients, resistance to TMZ in up to 40 % of patients is due 
to an acquired mutation in MSH6 [133, 235]. Long-term exposure to TMZ treatment 
can result in acquisition of an MSH6 mutation in glioblastoma cells, which mediates 
resistance to the drug [235, 236]. These observations are not surprising knowing that 
MMR pathway plays an important role in response to alkylating agents by repairing 
O
6
meG:T mismatches [175, 176]. Acquired MSH6 mutations in the human 
lymphoblastoid cell line (A-to-T transversion at codon 1145, G-to-A transition at 
codon 1192) after MNNG treatment has also been reported and associated with 
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MNNG resistance [237]. MSH6 is not the only protein implicated in alkylating agent 
response. Loss of MLH1, MSH2 and PMS2 also confers resistance to alkylating 
agents [238, 239]. 
 
2.7.2 DNA mismatch repair deficiency and platinum compounds response 
Platinum compounds, such as Carboplatin and Cisplatin, are the most effective 
treatments for endometrial, ovarian and testicular cancer. They act by crosslinking 
into DNA [240]. It has been well studied in patients and cell lines that MMR 
deficiency confers resistance to Cisplatin [133]. An in vitro study, comparing MMR 
proficient and deficient matched paired cell lines identified a role for MLH1 and 
MSH2 deficiency in Cisplatin resistance [241]. Resistance to platinum agents in 
ovarian and endometrial cancers has also been shown to be due, in part, to an 
acquired loss of MMR, primarily due to MLH1 methylation [242]. A study 
compared the MSI and MMR status of 24 primary resected tumours, prior and after 
Cisplatin treatment. They evaluated that all cases with MSS (72.5 %) exhibited MSI 
after Cisplatin treatment, from which 73.3 % acquired a loss in MLH1 protein [243]. 
A study on 38 ovarian cancer patients reported that 66 % of tumours had a loss of 
MLH1 after platinum based therapy which was associated with treatment resistance 
[244]. A study on 20 ovarian cancer patients correlated MSH2, but not MSH6 
deficiency, with resistance to Cisplatin treatment [245]. Samimi et al. confirmed the 
significant decrease in MLH1 and MSH2 protein expression after treatment with 
platinum-based therapy. However, they did not confirm the correlation between 
MMR deficiency and treatment response [246]. One possible mechanism of 
resistance in MMR deficiency is the interaction between MLH1, MSH2 and 
FANCD2, a protein of FAR pathway implicated in ICLs repair which causes, in 
MMR deficient cells an inhibition of FAR leading to an ICLs repair defect [184]. 
 
2.7.3 DNA mismatch repair deficiency and IR response 
The role of the MMR pathway in IR response is not completely understood and is 
particularly important for the treatment of MMR-deficient endometrial, glioblastoma 
and rectal cancers. IR has been shown to induce a wide range of DNA damage, for 
example, 1 Gy have been estimated to induce 1000 base damage, 1000 SSBs, 
40 DSBs and 20 ICLs, and IR-induced DSBs are thought to be the main event in IR-
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induced cell cytotoxicity [247]. In order to understand the role for MMR in IR-
induced damage, Martin et al. have carried out meta-analysis on published reports 
regarding IR response in MMR deficiency. They concluded that following high-dose 
IR, MMR deficient cells appear to be more sensitive to IR whilst following low-dose 
rate IR, MMR deficient cells have been shown to be more resistant compared to 
MMR proficient cells [247]. We previously mentioned that MMR pathway plays a 
role in the RAD51-dependent recombination fidelity [178-181]. Loss of MSH2 
induces aberrant RAD51 focus formation. Therefore, IR sensitivity in MMR 
deficient cells might be due to MMR dependent regulation of HR pathway [248, 
249]. IR induces DSBs but also other lesions such as methylation and oxidative 
DNA damage [250]. MMR pathway is known to be implicated in the repair of those 
lesions which could also explain IR sensitivity in MMR deficient cell lines [166]. 
 
2.7.4 DNA mismatch repair deficiency and topoisomerase inhibitor response 
Topoisomerase inhibitors, such as Irinotecan and Etoposide, induce stalled 
replication forks or SSBs and ultimately DSBs [251]. Studies examining their 
response in MMR deficiency are conflicting. It is known that MRE11 and RAD50 
genes contain microsatellites in their DNA and therefore MMR tumours often have 
secondary mutations in these genes (Table 6). It is also known that cells with a defect 
in DSB repair pathways are sensitive to topoisomerase inhibitors [252]. Therefore, 
Irinotecan sensitivity in MSI compared to MSS tumours could be due to secondary 
mutations in RAD50 or MRE11 [253, 254]. However, an in vitro study, comparing 
MMR deficient and proficient matched paired cell lines that differ only due to their 
MMR status, showed resistance to topoisomerase inhibitors in MMR deficient cell 
lines [255]. Taken together, these reports showed that secondary mutations due to 
MMR deficiency, and not MMR deficiency itself, cause sensitivity to topoisomerase 
inhibitors. 
 
2.7.5 DNA mismatch repair deficiency and nucleoside analogue response 
2.7.5.1 Mechanism of action of 5-Fluorouracil (5-FU) 
The nucleoside analogue, 5-FU is currently standard of care for many cancers, 
including CRC [256]. Developed in 1957 by Charles Heidelberger, 5-FU is a 
member of the fluoropyrimidine agents [257]. Presently, 5-FU remains an active 
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agent against CRC but its treatment response rate is only 10-15 % alone or 20-25 % 
in combination [256]. 5-FU is primarily catabolised in the liver into 
dihydrofluorouracil (DHFU) which account for 80 % of its catabolism [258]. 5-FU is 
converted into different cytotoxic metabolites which have different modes of action. 
FdUrd-5’monophosphate (FdUMP) blocks the activity of thymidylate synthase (TS) 
causing imbalance in deoxyribonucleotide (dNTP) pool triggering DNA damage; 
FdUrd-5’-triphoshate (FdUTP) is incorporated into DNA and causes DNA damage; 
and 5-fluorouridine-5’-triphosphate (FUTP) is incorporated into RNA triggering 
cytotoxicity [256] (Figure 8).  
 
 
Figure 8: Mechanisms of action of 5-FU 
In the liver, 80 % of 5-FU is catabolised into DHFU. 5-FU is also converted into 
different metabolites including FUTP which is misincorporated into RNA, FdUTP 
which is misincorporated into DNA and FdUMP which inhibits TS activity. 
 
 
2.7.5.2 Resistance to 5-FU in MMR deficiency 
Conflicting studies have been reported with regards to MMR deficiency and 
resistance to 5-FU treatment [259] potentially due to differences in study design, 
different adjuvant chemotherapies and the secondary mutations associated with MSI 
[211]. However, the majority of studies suggest that MMR deficient CRCs are more 
resistant to 5-FU than MMR proficient CRCs [260]. In vitro, where the resistance 
can be studied with a better control of parameters, MMR deficient cell lines have 
been shown to be 18-fold more resistant to 5-FU in comparison to MMR proficient 
cell lines [261, 262]. MMR is the first and predominant pathway to recognize DNA 
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misincorporation by 5-FU. It has been shown that MutSα and, with a lower affinity, 
MutSβ can recognize 5-FU lesions [263, 264]. In the absence of MMR, 5-FU lesions 
cannot be recognized, therefore ATM/ATR cannot be recruited and apoptosis cannot 
be triggered; thus leading to 5-FU resistance [134, 157]. FdUTP and FdUMP are the 
metabolites implicated in 5-FU mediated DNA misincorporation, so the resistance 
mediated by loss of MMR is thought to be due to FdUTP and FdUMP rather than 
FUTP [265]. To date, no case of acquired mutations in MMR genes in response to 
5-FU treatment has been reported.  
 
2.7.5.3 5-FU modulators 
The treatment regime in CRC has evolved over time but primarily depends on the 
cancer stage [266]. Small tumours (stages I and II) are treated with surgical resection 
only; larger tumours with no metastases (stage III) are treated with surgery followed 
by chemotherapy treatment; and metastatic CRC (stage IV) are treated with an 
adapted chemotherapy regime. After surgical resection, 20-30 % experience disease 
recurrence or develop metastatic disease [267]. Adjuvant treatments in addition to 
5-FU have been rapidly developed. Ullman et al. in 1978 reported that Leucovorin 
(LV), a reduced folate, could significantly enhance 5-FU cytotoxicity in vitro. A 
large number of phase I and II clinical trials have tested and validated LV as an 
modulator of 5-FU [268, 269]. A meta-analysis reported 11 % response rate with 
5-FU alone and 21 % response rate with the combination 5-FU/LV [270]. In the 
early 2000s, Irinotecan and oxaliplatin were included in the 5-FU/LV combination 
treatment for stage III and metastatic CRCs. One study showed a 39 % response rate 
with Irinotecan/5-FU/LV compared to 21 % with 5-FU/LV [271]. The response rate 
with oxaliplatin/5-FU/LV compared to 5-FU/LV was also significantly increased 
(45 % and 31 % respectively) [272]. However, the comparison of 
Irinotecan/5-FU/LV with oxaliplatin/5-FU/LV did not show any difference in 
response rate (56 % and 54 % respectively) [273, 274]. The combination of these 
chemotherapy combinations with an anti-vascular endothelial growth factor-A 
antibody, bevacizumab, was tested in clinical trial to improve the treatment for 
metastatic CRCs. Better response rate were shown with bevacizumab/Irinotecan/ 
5-FU/LV and bevacizumab/oxaliplatin/5-FU/LV treatments comparison with 
Irinotecan/5-FU/LV (44.8 % vs. 34.8 %) and oxaliplatin/5-FU/LV (22.7 % vs. 
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8.6 %) respectively [275, 276]. The different clinical trials have shown differences in 
response rate for the same treatment regime which might be dependent on the 
patients and/or cancer heterogeneity [267]. However, they all converged toward a 
better response rate with the different combined chemotherapy regimens compared 
to 5-FU alone. If the combined chemotherapy regimens showed better response rate, 
they also showed increased toxicity [277]. This is why 5-FU is still intensely studied 
and novel therapeutic strategies are investigated. Moreover, with a MMR loss in 
10-15 % of CRCs, 5-FU resistance associated with MMR deficiency represents a 
major clinical concern.  
 
 
3 Synthetic lethality 
Ideally, an efficient chemotherapeutic treatment should be tumour cell specific. 
However, where loss of gene function is the determinant of disease, it is difficult to 
determine a therapeutic target as it is often technically difficult to recapitulate gene 
function efficiently. Recently, the concept of synthetic lethality has been proposed as 
a potential therapeutic approach for cancer treatment. Two genes are said to be 
synthetically lethal when a loss of function or mutation of either gene alone is 
compatible with viability but loss of both causes cell death (Figure 9) [278, 279]. 
Genetic changes that give rise to tumorigenesis, like MMR deficiency, are a potential 
target to identify genes or compounds that are synthetically lethal in order to identify 
new therapeutic strategies. Synthetic lethal relationship with DDR pathways have 
been identified and exploited in the clinic. High-throughput screens, using libraries 
of clinically-approved drugs, is a widely used technique to identify novel synthetic 
lethal relationships. The main advantage of this type of compound screen is the 
reposition of a drug already previously used in clinic and is therefore ready to be 
translated into clinical trial. it leads to faster drug approval by minimizing the risk of 
failure in late stage clinical trials [280]. Other screens, such as shRNA and siRNA 
screens using a library targeting genes of one specific pathway/mechanism, are also 
often used to identify novel therapeutic synthetic lethal targets. For example, the use 
of a kinome targeted siRNA library would be highly relevant as kinases play a key 
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role in many biological processes and have an inherent pharmacological tractability, 
and therefore often make good drug targets.  
 
 
Figure 9: The mechanism of Synthetic lethality 
Schematic of how synthetic lethality occurs. A: Loss of gene A alone, such as a 
mutation in a DDR gene, is compatible with cell viability. B: Loss of gene B alone is 
compatible with cell viability. C: A combined loss of both gene A and B, causes cell 
death. 
 
 
3.1 Synthetic lethality within DDR pathways 
3.1.1 Base excision repair and homologous recombination 
Synthetic lethal relationships have been shown with regards to HR and BER. 
BRCA1 and BRCA2 are part of the HR pathway responsible for DSBs repair [281] 
and a mutation in either BRCA1 or BRCA2 genes highly increases the risk of 
developing breast and ovarian cancer [282]. PARP is a polymerase involved in BER 
by recognizing SSBs generated by APE1 and recruiting proteins for their repair [283, 
284]. Inhibition of PARP leads therefore to unrepaired SSBs which, at the stalled 
replication fork, would generate DSBs. In the absence of BRCA1 or BRCA2, these 
DSBs cannot be repaired. Therefore, in BRCA1/2 deficient tumours, the inhibition of 
PARP gives rise to unrepaired SSBs leading to DSBs and ultimately cell death. 
Therefore, PARP and BRCA1/2 are involved in complementary pathways and are 
synthetically lethal [285]. This synthetic lethal relationship has been translated into 
A B C 
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the clinic and Olaparib, a PARP inhibitor, is currently FDA-licensed and approved 
for the treatment of BRCA mutated ovarian cancers (FDA-3675412). Unrepaired 
DSBs can be caused by BRCA1/2 deficiency but also by a HR defect in general 
[286]. Phosphatase and tensin homolog (PTEN), a gene well known for its role in the 
phosphoinositide 3 kinase (PI3K) pathway, has been recently identified to play a role 
in HR by regulating levels of RAD51 and to be synthetically lethal with PARP 
inhibitors [287-289]. PTEN mutations are present in a wide range of tumours making 
this synthetic lethal relationship extremely clinically relevant [287]. APE1, another 
important enzyme in BER has been recently shown to be synthetically lethal with 
DBSs repair proteins: BRCA1/2, ATM and DNA-PKcs deficiency through the same 
mechanism as PARP inhibition in HR deficiency [290]. Therefore there is not only 
synthetic lethal relationship between PARP and BRCA1/2 but more broadly between 
the BER and the HR pathway. 
 
3.1.2 Limitations in BRCA1/2 and PARP synthetic lethality 
Treatment with PARP inhibitors in BRCA1/2 deficient tumours is a promising 
therapeutic strategy. However, a substantial fraction of BRCA1 deficient cancers are 
resistant to PARP inhibitors agents either by acquired or inherent resistance [291-
293]. Different mechanisms of resistance have been proposed [294-296]. One of the 
mechanisms of resistance to PARP inhibitor is through the reactivation of HR 
pathway. The reversion of BRCA1/2 mutation, by acquired secondary mutation in 
the genes, results in restoration of the gene function, and has been identified as a 
mechanism of acquired resistance to PARP inhibitor, as well as platinum agents 
[297-300]. An inherent resistance to PARP inhibitors in HR deficiency due to loss of 
53BP51 has been identified in different laboratories and is characterized by the 
rescuing of HR function in cells with a mutation in 53BP51 [301-304].  
 
3.1.3 RAD52 and RAD51-dependent homologous recombination 
They are two alternative pathways in HR: the RAD51-dependant pathway through 
the recruitment of the BRCA1-BRCA2-PALB2 complex and the RAD52-dependent 
pathway. The inactivation of RAD52 has been recently shown to be synthetically 
lethal with the BRCA1-BRCA2-PALB2 complex [305, 306]. Deficiency in either of 
the proteins of the complex leads to an alternative RAD51-independent pathway for 
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the repair of DSBs. This alternative pathway depends on RAD52. Therefore, 
inhibition of RAD52 in BRCA1/2 or PALB2 deficient cells may lead to inhibition of 
the alternative repair pathway, and therefore to cell death. 
 
3.1.4 Fanconi anemia and other DNA damage signalling and repair proteins 
FAR is implicated in the NER and HR pathways. FANCD2, a protein of the FAR 
pathway, can be phosphorylated by ATM, ATR and Chk1 [307-309]. Synthetic 
lethality has been shown between ATM and FAR proteins, FANCG and FANCC 
[310]. A proposed explanation is that in FAR deficiency, stalled replication folks can 
collapse and form a DSB which will activate an ATM dependent DDR. Therefore, 
inhibition of ATM in Fanconi anemia will leave no alternative pathway leading to 
cell death [15]. The FAR pathway is also synthetically lethal with PARP and Chk1 
[311]. FAR is implicated in HR, therefore it is not surprising that defects in FAR and 
PARP are synthetically lethal. Chk1 inhibition and Cisplatin treatment were 
previously shown to be synergistic through Chk1-dependent G2 checkpoint 
regulation [311]. FAR is implicated in ICLs repair which can be induced by 
Cisplatin treatment. This suggests the role for Chk1-dependent G2 checkpoint in 
Chk1 and FAR synthetic lethality. There is, to date, no clinical trial to evaluate these 
synthetic lethal relationships.  
 
3.1.5 ATR and p53 
Another recent study identified ATR as being synthetically lethal with TP53 
deficiency [312]. This synthetic lethal relationship was dependant on a novel non-
canonical function for ATR. ATR was shown to phosphorylate and stabilise ETV1, a 
transcription factor for TERT, a catalytic subunit of telomerase implicated in 
proliferation maintenance [313]. TP53 is known to be mutated or inactivated in the 
majority of tumours [128]. Therefore TP53 is a potential critical target in cancer 
therapy [129, 314]. The preclinical synthetic lethal relationship between ATR, ETV1 
and TP53 is a novel and promising discovery for new chemotherapy development. 
 
3.2 Synthetic lethality with DNA mismatch repair pathway 
MMR deficient cells have a high-predisposition to cancer and an inherent drug 
resistance. Secondary mutations upon MMR loss can greatly influence cellular 
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response to drugs, such as topoisomerase inhibitors. Therefore, there is a clinical 
need to identify new therapeutic strategies to target MMR loss, also considering 
secondary mutations [136].  
 
3.2.1 Synthetic lethal with DNA mismatch repair deficiency and oxidative 
stress 
Several studies have applied a synthetic lethal approach and more recently, have 
identified new regulators of the MMR pathway, which may provide alternate means 
of treating MMR deficient patients, other than standard chemotherapies. Martin et al. 
have previously shown that inhibition of specific polymerases is synthetically lethal 
with MMR deficiency, through the accumulation of oxidative DNA damage. More 
precisely, MSH2 deficiency is synthetically lethal with inhibition of DNA pol β, the 
main DNA polymerase that catalyzes nuclear BER; and that MLH1 deficiency is 
synthetically lethal with inhibition of DNA pol γ, the only polymerase specific to 
mitochondrial DNA [315]. Interestingly, the MLH1/DNA pol γ synthetic lethality is 
characterised by an accumulation of mitochondrial oxidative DNA lesions, whereas 
the MSH2/DNA pol β synthetic lethality leads to an increase in oxidative lesions in 
nuclear DNA. The requirement for MLH1 in mitochondrial genome stability has also 
been confirmed in retinal endothelial cells, showing a role for MLH1 in the 
development and progression of diabetic retinopathy [316]. Furthermore, MSH2 
deficiency specifically, is cytotoxic with the drug, Methotrexate, through the 
accumulation of nuclear, but not mitochondrial, oxidative DNA damage [317]. No 
cytotoxicity was observed in MLH1 deficient cells upon treatment with 
Methotrexate, suggesting that synthetic lethal interactions with MLH1 loss, requires 
mitochondrial oxidative DNA damage. A randomized phase II clinical trial using 
Methotrexate treatment in MSH2 deficient colorectal cancer (NCT00952016) is 
currently underway which includes measurement of the oxidative DNA lesion, 
8-oxoG as a biomarker. In addition, further synthetic lethal interactions upon 
oxidative DNA damage and MMR mutations have been identified. Using a high-
throughput siRNA screen, inhibition of PTEN-induced putative kinase 1 gene 
(PINK1), a gene limiting oxidative-induced apoptosis, was identified to be 
synthetically lethal with MMR deficiency [318]. MMR deficient cells have also been 
shown to be sensitive to cytosine-based analogues through the induction of oxidative 
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stress [319]. Taken together, inducing oxidative DNA damage may be a promising 
therapeutic strategy for the treatment of MMR deficient cancers (Figure 10). 
 
 
Figure 10: Role of MMR in response to 5-FU treatment and oxidative stress 
A: Mismatches, naturally occurring during DNA replication, can be recognised and 
repaired by MMR pathway. In the absence of MMR, these mismatches accumulate 
in the DNA resulting in a “mutator phenotype”. B: Chemotherapeutic treatment, 
including 5-FU, can be recognized by MMR pathway and lead to apoptosis. In the 
absence of MMR, the lesions are not recognized and the cells become resistant to the 
drug treatment. C: Upon oxidative stress, 8-oxodG lesions are recognized and 
repaired by MMR proteins. In the absence of MMR, these lesions accumulate 
ultimately resulting in cell death. 
 
 
3.2.2 Targeting MMR-associated secondary mutations 
Secondary mutations to MMR deficiency are essential to consider with regards to 
drug response. I previously mentioned the role for secondary mutations in MMR 
deficiency in Irinotecan response (see section 2.7.2) [253]. Therefore, secondary 
mutations associated with MMR deficiency need to be taken into consideration with 
regards to response to treatment and as potential therapeutic targets. Mutations in 
DSB repair genes, such as MRE11, ATR, PTEN and RAD50, are associated with 
MMR deficiency (Table 6) [142, 234]. Due to their role in HR pathway, the loss of 
these genes is synthetically lethal with PARP inhibitors [289, 320]. Therefore MMR 
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deficient tumours with secondary mutations in these genes could be treated with 
Olaparib, a PARP inhibitor currently used in clinic. Oxidative DNA damage, if 
unrepaired, can accumulate and lead to lethal DSBs. However, MMR deficiency 
mediated secondary mutations in DSB repair genes could potentially lead to 
oxidative stress resistance. Therefore a combination treatment with Methotrexate and 
Olaparib, targeting both primary and secondary mutations, might be an efficient 
strategy to overcome this potential mechanism of resistance. A phase II clinical trial 
is currently evaluating the effect of Olaparib on MSI CRCs (NCT00912743) and a 
phase II clinical trial is evaluating the effect of a PARP inhibitor in inoperable 
advanced endometrial cancers (NCT02127151). In this trial, MRE11, PTEN and 
MSI will be evaluated. Both clinical trials should give us answers about PARP 
inhibitor response in MMR deficient tumours with or without secondary mutations in 
MRE11 and/or PTEN. Another phase I clinical trial is evaluating the benefit of the 
combination PARP inhibitor and TMZ treatment in relapsed glioblastoma patients 
(NCT01390571) where, amongst others, MSI, MMR, MGMT and PTEN status will 
be measured. This trial should determine the role for MMR deficiency and secondary 
mutations in Olaparib/TMZ treatment response. 
Another secondary mutation frequently present in MMR deficient tumours is the 
BRAF V600E activating mutation. Patients with metastatic melanoma with a BRAF 
V600E mutation can be treated with Vemurafenib, a BRAF inhibitor [321]. 
However, this drug has low response in BRAF V600E mutated CRCs due to a 
feedback activation of the epidermal growth factor receptor (EGFR). Therefore, the 
combination of Vemurafenib and an EGFR inhibitor has shown promising results for 
the treatment of BRAF V600E mutated CRCs [322]. Interestingly, EGFR has been 
shown for its role in Cisplatin and IR repair through DNA-PKcs binding [323]. To 
date, Vemurafenib has not been tested as a potential treatment of MSI tumours. 
 
3.2.3 Other clinical strategies in MMR deficient tumours 
3.2.3.1 Re-expression of MMR genes 
MMR deficiency confers resistance to numerous chemotherapeutic agents. 
Researchers have focused on attempts to reactivate methylated MLH1 by treatment 
with a demethylating agent, 2'-deoxy-5-azacytidine. Preclinical data were promising 
but adverse reactions was shown in a terminated phase II clinical trials 
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(NCT00748527) [324]. Another strategy to reexpress MMR proteins is by targeting 
the microRNA miR-155. An inverse correlation between miR-155 expression and 
the MMR proteins MLH1 and MSH2 was observed in CRC tumours. Moreover, 
tumours with MSI not associated with MMR deficiency were shown to highly 
express miR-155. Therefore, silencing miR-155 might be a promising novel strategy 
for the treatment of MSI tumours. 
 
3.2.3.2 MMR and aspirin 
A recent preclinical study identified a chemo-preventive effect of aspirin in a LS 
mouse model [325]. A cohort of 1 000 LS-carrier patients from 43 countries were 
selected to measure the effect of a daily dose of aspirin on the predisposition to 
cancer development. They observed patients who took aspirin were 59 % less likely 
to be diagnosed with CRC compared to the placebo group [326, 327]. Based on the 
same approach, a phase I clinical trial is currently testing the effect of naproxen, a 
non-steroidal anti-inflammatory alternative to aspirin, in LS CRC patients 
(NCT02052908). They will test naproxen as a potential CRC preventive and they 
will measure, amongst other criteria, the microRNA profiles of the tumours. It will 
be interesting to know if naproxen treatment regulates miR-155 expression. A role 
for MMR proteins in inflammation has previously been reported [328]. More 
precisely an epigenetic repression of MLH1 has been observed after colitis induced 
by G-protein alpha subunit Giα2 in mice which leaded to MSI tumours [328]. 
Therefore, it would be interesting to correlate the aspirin chemo-preventive effect 
and the somatic loss of MLH1 following inflammation. Aspirin has also an 
antioxidant activity [329-331]. As mentioned previously oxidative stress plays a role 
in tumour progression and in mutator phenotype associated with MMR deficiency 
(see sections 1.4 & 2.3.1). Therefore, aspirin might prevent LS associated CRC 
development through ROS scavenging. 
 
3.2.3.3 MMR deficiency and immunotherapy 
It has been shown that MSI tumours have a better outcome than MSS tumours [211]. 
It has been speculated that this was due to a better immune response. Immune 
response was measured in 100 MSI or MSS CRCs. Interestingly, the T helper type 1 
(Th1) response was found higher in MSI compared to MSS CRCs [213]. However, it 
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has been shown than despite their active Th1 microenvironment, MSI CRCs are not 
eliminated by the immune system. A possible explanation was the significant up-
regulation of immune checkpoint molecules (PD-1, PD-L1, CTLA-4, LAG- 3, and 
IDO) leading to an immunosuppressive microenvironment in MSI tumours [214, 
215]. Clinical trials are currently exploiting this immune microenvironment specific 
to MSI tumours. A phase II clinical trial is testing MK-3475, a T-cell inhibitor in 
MSI tumours (NCT01876511). Another phase I/II clinical trial is exploiting the role 
for MMR in frameshift peptides (FSP) generation by testing the efficacy of a 
vaccination with FSP antigens in MSI tumours (NCT01461148) [332]. These studies 
are recent and therefore there is yet no published investigation on a potential 
synthetic lethal relationship between immune checkpoint molecules and MMR 
deficiency.  
 
3.2.3.4 DNA mismatch repair and cell cycle 
The cell cycle related genes Cyclin D1 and AURKA have been associated with an 
early onset of CRCs in LS [333]. Cyclin D1 regulates G1/S transition. 
Polymorphisms in Cyclin D1 result in alternative splicing of Cyclin D1 mRNA and 
gives rise to two protein variants. The variants have been associated with differential 
onset of CRCs in LS (11 years difference) [334]. This has been confirmed by Talseth 
et al. in another study measuring the incidence of Cyclin D1 and AURKA 
polymorphisms on the onset of CRCs in LS [335]. However, other studies have not 
confirmed this correlation [336, 337]. In the Talseth et al. study, they found that the 
onset of CRCs in LS was correlated with polymorphisms in Cyclin D1 but not in 
AURKA, a regulator of G2/M transition of the cell cycle [335]. However, other 
studies have associated AURKA polymorphisms with a later onset of CRCs in LS 
[333, 338]. The differences in these studies might result from the difference in the 
cohort and the range of MMR genes affected. However it would be interesting to 
understand the role for AURKA and Cyclin D1 in the development of CRC 
associated with LS. To date, there is no preclinical or clinical study to exploit the 
potential role for Cyclin D1 and AURKA in the development of CRC in patients 
with LS. 
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3.2.3.5 DNA mismatch repair and antifolates 
Dihydrofolate reductase (DHFR), methylene tetrahydrofolate reductase (MTHFR) 
and TS are key enzymes of the folate pathway (Figure 11). DHFR converts 
dihydrofolate (DHF) into tetrahydrofolate (THF) which is converted into 5,10-
methylene THF (commonly referred as THF). TS produces dUTP and recycles DHF, 
and MTHFR produces 5-methylene THF for the methyl cycle. THF is a substrate for 
both enzymes. Polymorphisms in MTHFR and TS have been associated with an 
increased CRC risk; conversely, polymorphisms in DHFR have been associated with 
decreased CRC risk [339-342]. In LS associated CRCs, studies have found that 
polymorphisms in MTHFR had a protective effect on the disease onset [343, 344]. 
One study found a correlation between MTHFR 677TT mutation, low folate levels 
and MSI [345]. The association between MTHFR 677TT and MSI has been 
confirmed in a study by Hubner et al. [346] whilst others showed an inverse 
correlation between MTHFR 677TT and MSI in patients with adequate folate intake 
and no correlation in patients with low folate intake [347]. More investigations are 
necessary to understand whether any correlation exists between MTHFR 
polymorphisms, folate levels and MSI. No study has evaluated a possible correlation 
between DHFR and TS polymorphisms and onset of LS associated CRC.  
Antifolates have been developed and translated into clinic in order to inhibit the key 
enzymes of the folate pathway and thereby trigger inhibition of nucleotide 
biosynthesis leading to cell death [348]. The antioxidant role of the folate pathway 
has been described but is not well understood [349]. There is a potential role for the 
MMR pathway in antifolate response. Both Methotrexate, a DHFR inhibitor, and 5-
FU, a TS inhibitor, have been associated with oxidative stress which is known to be 
cytotoxic in MMR deficient cells [350]. However, MMR deficient cells are resistant 
to 5-FU, due to misincorporation of FdUTP and dUTP into DNA (see section 2.7.5). 
Raltitrexed, another TS inhibitor, competes with THF in the formation of the dUMP-
TS-THF active complex. It is used as a treatment in CRCs and in malignant pleural 
mesothelioma [351]. Raltitrexed response has not been associated with MMR status 
[265]. No publication has measured cell viability in MMR deficient and proficient 
cell lines upon TS silencing (by siRNA or shRNA transfection). Therefore, the role 
of MMR pathway in TS activity is not clear. Methotrexate, a DHFR inhibitor used 
for the treatment of breast, bladder and head and neck cancers, has been shown to be 
Introduction 72 
 
synthetically lethal in MSH2 deficient tumours specifically [317]. One study 
suggests that only 5 % of DHFR activity is necessary for the production of THF 
required for TS activity and therefore, high concentrations of DHFR inhibitors are 
necessary to inhibit TS activity through the decrease in the THF pool, the rate-
limiting factor for TS activity [352]. Pemetrexed is a multitargeted antifolate. It 
inhibits both the TS and DHFR enzymes. It is prescribed in combination with 
Cisplatin for the treatment of malignant pleural mesothelioma, non-squamous and 
non-small cell lung cancers [353, 354]. Pemetrexed has been shown to give better 
response in MSH2 deficiency in lung cancer [355] Therefore, there is a potential role 
for the MMR pathway in the cellular response to antifolates which is still unclear 
except for the synthetic lethal relationship between DHFR and MSH2 [317]. The 
role of MMR pathway in the folate pathway would require further investigation as it 
represents a potential novel therapeutic strategy for the treatment of MMR deficient 
tumours. 
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Figure 11: Folate pathway 
The folate pathway plays a crucial role in DNA synthesis and DNA methylation. 
Folic acid is reduced to DHF which is then reduced to THF by DHFR. THF is 
converted into 5,10-methylene THF by serine hydroxymethyltransferase (SHMT). 
5,10-methylene THF  is the rate limiting factor for TS activity to produce dTMP and 
DHF recycle into THF by DHFR. 5,10-methylene THF  is also the substrate for 
MTHFR activity to produce 5-methylene THF, itself a substrate, with homocysteine 
for 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR) activity to 
produce methionine catabolised into SAM. SAM is a cosubstrate in methyl transfer 
essential for DNA methylation. 
 
 
3.3 General remarks 
MMR deficiency is present in 15 % of CRCs and in a wide range of cancers. It leads 
to a mutator phenotype and to resistance to a wide range of chemotherapies. 
Therefore, further investigations are necessary to overcome MMR deficiency 
associated chemotherapy resistance. The synthetic lethal relationship between MMR 
and oxidative stress represents a promising novel therapeutic strategy for the 
treatment of MMR deficient tumours. However, further studies are necessary to 
understand the role for MMR deficiency and secondary mutations in this synthetic 
lethal relationship. The MMR pathway has been described to have diverse canonical 
and non-canonical roles (Figure 7). Therefore, the MMR pathway represent a 
promising target to identify novel synthetic lethal relationships in order to develop 
new therapeutic strategies for the treatment of MMR deficient tumours. 
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Aims of the PhD project 
 
 
Genomic instability can be caused by deficiency in DNA repair pathways [13, 14]. 
MMR, is a DNA repair pathway that repairs base-base mismatches and insertion 
deletion loops that occur during DNA replication [12]. Deficiency in MMR, which 
can be inherited (LS) or somatic, highly increases the predisposition to a wide range 
of cancers with, for example, results in an 80 % increased risk of developing CRC 
[131]. It has been shown that, in comparison to MMR proficient tumours, MMR 
deficient tumours are more resistant to a range of chemotherapies such as 5-FU, the 
major treatment for CRCs [134]. Synthetic lethality is a novel therapeutic strategy 
under investigation used to identify personalized treatment for tumours with DNA 
repair deficiencies [278]. To date, accumulating data has identified promising 
synthetic lethal interactions between MMR deficiency and oxidative stress [136]. 
My PhD project aimed to identify, via high-throughput screens, new potential 
therapeutic targets and drugs for the treatment of MMR deficient tumours and 
ultimately investigate the mechanisms of the identified synthetic lethality.  
To this end, we aimed to: 
 
 Identify drugs currently in clinical use that can modulate the resistance to 5-FU for 
the treatment of MMR deficient tumour cells using a high-throughput compound 
screen containing a library of 1120 drugs currently in clinical use.  
 Identify synthetic lethal relationships with MMR deficiency, using a high-throughput 
siRNA screen containing an siRNA library targeting 779 human kinases and kinase-
associated genes. Identification of new synthetic lethal relationship with MMR might 
allow better understanding of the non-canonical roles for MMR and/or identify new 
ones. 
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1 Cell culture 
1.1 Cell lines  
The human colon cancer cell lines DLD1 and DLD1+chr2 were a kind gift from Dr. 
T. Kunkel (National Institute of Environmental Health Sciences (NIEHS), Research 
Triangle Park, NC, USA). DLD1 and DLD1+chr2 cells were grown in Roswell Park 
Memorial Institute medium (RPMI 1640) supplemented with fetal bovine serum 
(FBS; 10 % v/v), L-glutamine, penicillin (5X v/v) and streptomycin (5X v/v). The 
human colon cancer cell line HCT116 and HCT116+chr3 were a kind gift from Dr. 
A. Clark (NIEHS) and were grown in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with FBS (10 % v/v), L-glutamine, sodium pyruvate, 
penicillin (5X v/v) and streptomycin (5X v/v). The human endometrial cell lines 
HEC59 and HEC59+chr2 were a kind gift from Dr. T. Kunkel (NIEHS), and were 
grown in DMEM supplemented with FBS (10 % v/v), L-glutamine, sodium 
pyruvate, penicillin (5X v/v) and streptomycin (5X v/v). The human ovarian cancer 
cell lines A2780cp70A2 and A2780cp70E1 were a kind gift from Dr. R. Brown 
(Institute of Cancer Research (ICR), London, UK) and were grown in RPMI 1640 
supplemented with FBS (10 % v/v), L-glutamine, penicillin (5X v/v) and 
streptomycin (5X v/v). The glioblastoma cell lines U251 and U251.TR3 were a kind 
gift from Dr. D. Louis (Massachusetts general hospital, MA, USA). U251 and 
U251.TR3 cells were grown in DMEM supplemented with FBS (10 % v/v), L-
glutamine, sodium pyruvate, penicillin (5X v/v) and streptomycin (5X v/v). 
DLD1+chr2, HCT116+chr3 and HEC59+chr2 cells were maintained under selective 
pressure of 400 µg/mL geneticin (G418 sulfate, Roche). A2780cp70E1 cells were 
maintained under selective pressure of 200 µg/mL of hygromycin (Calbiochem). 
U251.TR3 cells were maintained in 100 µM TMZ.  
 
1.2 Cell growing conditions 
Early passage cells were stored in 10 % Dimethyl sulfoxide (DMSO)/FBS in liquid 
nitrogen and at -80˚C. All cell lines were cultured in T75 flasks (Corning) at 37˚C in 
5 % CO2. Every 3 days, cells were washed with 1X phosphate buffered saline (PBS) 
and cultured in fresh media. When cells were 70-90 % confluent, they were split by 
firstly washing them with 5 mL 1X PBS and then trypsinizing them with 4 mL 1X 
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Trypsin. Cells were incubated in Trypsin until completely detached. To inactive the 
Trypsin, 12 mL complete media was added and a portion of the cells (depending on 
the confluency required the following days) was diluted in media for a final volume 
of 10 mL and was transferred to a new flask. No cell line was cultured at passage 
higher than 10. All cell lines were authenticated on the basis of STR-profile, 
viability, morphologic inspection, and were routinely mycoplasma tested. 
 
1.3 Cell seeding conditions 
All experiments were performed in triplicate with cells of passage less than 10. 
When cells were 70-90 % confluent in a T75 flask, they were seeded in either 96, 12 
or 6-well plates or 10 cm petri dishes (Corning), according to the experiments carried 
out, and in T75 flask for further experiments. Cells were washed with 5mL 1X PBS 
followed by addition of 4 mL 1X trypsin to allow the cells to detach and then 12 mL 
complete media was added to inactivate the trypsin. The cells were centrifuged at 
1200 rpm for 3 mins and the pellet was resuspended in fresh media. Cells were 
counted using a Cell counter (TC20, BioRad) in order to plate the appropriate cell 
density for experiments. 
 
2 High-throughput screens 
2.1 High-throughput compound screen 
The Prestwick compound library was a kind gift from Prof. Alan Ashworth (ICR, 
London, UK). This library was composed of 1120 small molecules which include 
90 % that are marketed drugs and 10 % that are bioactive alkaloids. This library was 
at a concentration of 10 mM, in 14*96-well plates, with no drug in the first and last 
columns. The library was diluted in media at a concentration of 200 µM the day 
before use. The first and last columns of each plate contained either media or 
200 µM 5-FU. DLD1 and DLD1+chr2 cells were plated in 96-well plates at a density 
of 1000 cells/well. The following day, cells were treated with either 2 µM 5-FU or 
media alone. On day 4, cells were exposed to 10 µM of each of the library 
compounds (5 µL of the 200 µM library stock into 95 µL of media). Cell viability 
was measured on day 7, using the CellTiter-Glo assay according to the 
manufacturer’s instructions (refer to section 3.3) (Figure 12).  
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Figure 12: High-throughput compound screen 
DLD1 and DLD1+chr2 cells were plated at the density of 1000 cells per well in 
28*96-well plates each and treated, the following day, with the optimized 
concentration of 5-FU (2 µM) or media. After 2 days, cells were treated with 10 µM 
of each of the library compounds. After 3 days, cell viability was measured using an 
ATP-based luminescent assay. The library, after dilution in media, was stored at 4˚C 
and used after 24 and 48 hrs for replicate 1 and 2 respectively. 
 
 
Luminescence readings from each well were log transformed and normalized 
according to the median signal on each plate and then standardized by use of a Z-
score statistic, using the median absolute deviation (MAD) to estimate the variation 
in each screen (Figure 13) [356]. Z-score analysis has been described as a reliable 
method to analyse high-throughput screens [356]. In our case, a Z-score represented 
the magnitude of difference between one compound and the rest of the screen. This 
was based on the assumption of a normal distribution of cell viability upon treatment 
in a specific cell line. The standardization and normalization of the data in each cell 
line allowed comparing the 4 conditions (with or without 5-FU treatment in both 
DLD1 and DLD1+chr2 cell lines). A Z-score = 0 represented a compound that was 
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not cytotoxic and a Z-score < 0 represented a compound that was cytotoxic for the 
cells. We considered as potential hits the compounds with a Z-score lower than -1.5 
and selected 5 compounds. A heatmap graph was generated using R software to 
represent the Z-scores of our selected compounds. 
 
          
              
           
                                           
Figure 13: Z-score equation 
 
2.2 Compound screen validation 
Validation experiments were carried out with the following compounds: 
Triamterene, Clotrimazole, Quinacrine, Disulfiram and Astemizole (Table 7). Cells 
were plated in 96-well plates at a density of 1000 cells/well. The following day, cells 
were treated with either 2 µM 5-FU or increasing concentrations of the compound 
(from 1 nM to 10 µM). On day 4, 5-FU pre-treated cells were exposed to increasing 
concentrations of the compound (from 1 nM to 10 µM), and the media was replaced 
for cells previously treated with the hits compounds. Cell viability was measured on 
day 6, using the CellTiter-Glo assay. Luminescence data were normalized to the 
average luminescence reading of the untreated or the 5-FU treatment alone 
conditions to obtain the surviving fraction. 
 
2.3 High-throughput siRNA screen  
The siKinome SMARTpool library (Thermo-Fisher) used for this screen was 
composed of 779 SMARTpool siRNAs targeting protein kinases and kinase-related 
genes. This library was used at a concentration of 50 nM, with 5 µL of each siRNA 
(2 µM) in 9*96-well plates, no siRNA in the first and last columns. In the first and 
last columns of each plate media, 5 µL non-targeting control siRNA (siCtrl), or polo-
like kinase 1 (PLK1) targeting siRNA (siPLK1) at 2 µM concentration were added. 
DLD1 and DLD1+chr2 cells were plated in 96-well plates at a density of 1800 
cells/well. The following day, cells were transfected with the siKinome library using 
lipofectamine RNAiMAX transfection reagent (TR) (Invitrogen) according to the 
manufacturer’s instructions (refer to section 6.1). Media was changed 24 hrs after 
transfection. Cell viability was measured after 4 days, using the CellTiter-Glo assay 
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(Figure 14). Luminescence readings from each well were normalized as described 
for the high-throughput compound screen (see section 2.1). Data were log 
transformed, normalized to the median signal on each plate, and standardized to Z-
scores using the MAD (Figure 13) [356]. In our case, a Z-score represents the 
magnitude of difference between one siRNA compared to the rest of the screen. This 
was based on the assumption of a normal distribution of cell viability upon siRNA 
library transfection in a specific cell line. The standardization and normalization of 
the data in each cell line permit to compare the 2 cell lines using ΔZ-scores: 
ΔZ-scores = Z-score (DLD1 cells) – Z-score (DLD1+chr2 cells) 
Negative ΔZ-scores represent genes synthetically lethal in DLD1 compared to 
DLD1+chr2 cells. We enforced a threshold of ΔZ-score <-1.5 to select 5 potential 
hits. 
 
 
Figure 14: High-throughput siRNA screen 
1 800 DLD1 and DLD1+chr2 cells were plated in 9*96-well plates and transfected 
with the siKinome library using RNAiMAX TR according to the manufacturer’s 
instructions. We included 6*siCtrl and 4*siPLK1 in each plate for transfection 
controls. 24 hrs after transfection, the media was changed. Four days after 
transfection, cell viability was measured using the CellTiter-Glo ATP luminescence 
assay.  
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2.4 siRNA screen validation 
After analysing the siRNA screen ΔZ-score data, 5 genes were selected for 
validation. A 96-well plate (GE Healthcare), containing one siRNA SMARTpool 
(the same as in the original siRNA screen) and 4 single siRNAs (deconvoluted from 
the SMARTpool siRNA) per hit gene, as well as 3* siCtrl and 2* siPLK1 was used 
following the same protocol as for the screen. In brief, 1800-2000 cells were seeded 
on day 1, followed by siRNA transfection using RNAiMAX TR, the media was 
replaced 24 hr after transfection and the cell viability was measured by an ATP-
luminescence assay, 4 days after transfection. 
 
3 Cell viability upon compound treatment 
3.1 Compounds 
All compounds were diluted according to manufacturer’s instructions (Table 7). The 
compounds were stored in -20˚C except 5-FU, which was stored at room 
temperature.  
 
Compounds Catalogue number Company Stock concentration 
5-FU sud-5fu Invivogen 70 mM (water) 
Alisertib MLN8237 M76000 Epigentek 10 mM (DMSO) 
Amiloride sc-3578 Santa Cruz 10 mM (DMSO) 
Astemizole SIH-302 StressMarq 10 mM (DMSO) 
Clotrimazole 2735 Sigma-Aldrich 10 mM (DMSO) 
DHF sc-214895 Santa Cruz 10 mM (DMSO) 
Disulfiram sc-205654 Santa Cruz 10 mM (DMSO) 
Folate sc-204758 Santa Cruz 10 mM (DMSO) 
Leucovorin  sc-205701A Santa Cruz 10 mM (DMSO) 
NAC sc-202232A Santa Cruz 100 mg/mL (PBS) 
Quinacrine Q3251 Sigma-Aldrich 10 mM (water) 
Raltitrexed R9156 Sigma-Aldrich 10 mM (DMSO) 
THF sc-215955 Santa Cruz 100 mM (DMSO) 
TMZ sc-203292 Santa Cruz 100 mM (DMSO) 
Triamterene T4143 Sigma-Aldrich 10 mM (DMSO) 
Table 7: Compounds 
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3.2 Short-term experiment 
For short-term experiments, we carried out two different experiment scheduling. In 
general, i) Day 1, cells were plated in 96-well plates at a density of 1000 cells/well; 
day 2, cells were treated with the compound of interest (or a combination); day 6, 
cell viability was measured using the CellTiter-Glo assay. Alternatively, ii) Day 1, 
cells were plated in 96-well plates at a density of 1000 cells/well; day 2, cells were 
treated with the appropriate, indicated concentration of 5-FU or increasing 
concentrations of the compound of interest; day 4, the 5-FU pre-treated cells were 
treated with increasing concentrations of the compound of interest and the media was 
replaced on the previously drug-treated cells; day 6, cell viability was measured 
using the CellTiter-Glo assay. Luminescence data were normalized to the average 
luminescence reading of the untreated condition to obtain the surviving fraction. In 
the case of combination treatment, luminescence data were normalized to the 
average luminescence reading of the cells treated with the compound used at a 
constant concentration only. 
 
3.3 Cell viability 
Cell viability was measured using the ATP-based luminescent CellTiter-Glo assay 
(Promega). The luciferase reaction of this assay is:  
Beetle luciferin + ATP + O2  Oxyluciferin 
CellTiter-Glo reagent was diluted 1:4 in 1X PBS prior to use. The media was 
removed from the cells and 100 µL of diluted CellTiter-Glo was added. The plates 
were mixed for 2 mins using a plate shaker (Grant-bio) and incubated for 10 mins at 
room temperature. Luminescence was read using a Wallac 1420 plate reader 
(PerkinElmer). Luminescence data were normalized to the average luminescence 
reading of the untreated condition to obtain surviving fractions. 
 
3.4 Long-term clonogenic assay 
Approximately 100-500 cells were seeded in 6-well plates in duplicate and treated 
with Triamterene every 3-4 days. Once cells had formed clear and distinct colonies 
(10-14 days), they were washed in 1X PBS, fixed with cold methanol for 10 mins 
and stained with 0.057 % Sulforhodamine B (SRB). Colonies were then washed with 
1 % acetic acid prior to counting using a counter-pen (Fisherbrand). The number of 
Material and methods 83 
 
colonies counted per well was normalized to the average number of colonies in the 
untreated condition to obtain the surviving fraction. 
 
4 Protein expression analysis 
4.1 Protein extraction 
Cells were lysed in 50-150 µL NP-40 lysis buffer (20 mM Tris [pH 8.0], 200 mM 
NaCl, 0.5 % NP-40, 10 % glycerol, 1 mM EDTA) and protease inhibitors cocktail 
(Roche). After 10 mins incubation, lysed cells were scraped off and transferred in 1.5 
mL tubes (Eppendorf). After 15 mins incubation, lysed cells were centrifuged for 20 
mins at 12 000 rpm at 4˚C. The supernatant was transferred in a new 1.5 mL tube and 
used fresh or stored at -80˚C. Protein concentration was measured using the Bradford 
protein assay (Sigma). 2 µL of protein lysates and 5 µL of standard dilutions of 
bovine serum albumin (BSA) (0, 0.1, 0.25, 0.5, 1, 1.5 mg/mL) were incubated with 
250 μL Bradford reagent in triplicates in a 96-well plate. Plates were shaken and 
read at 560 nm using the microplate reader (Opsys MR, Dynex Technologies) and 
protein concentration was estimated using the BSA standard curve. 
 
4.2 Western blot 
Protein lysates (10-40 µg) were prepared in 10 % dithiothreitol (DTT) in 4X NuPage 
LDS sample buffer (Invitrogen) to a final volume of 25 µL. Lysates were incubated 
for 5 mins at 95˚C in order to denature the higher order structure. Boiled lysates were 
then electrophoresed on 4-12 % Novex precast gels (Invitrogen, UK) for 1 hr 30 
mins at 120V and transferred onto nitrocellulose membrane (Thermo Scientific) 
using a wet-transfer method for 2 hrs at 20V. Membranes were blocked in 5 % 
milk/0.1 % Tween/1X PBS for 1 hr to prevent non-specific binding and then 
immunoblotted using primary antibodies overnight, using the indicated dilution 
(Table 8). This was followed by 1 hr incubation with secondary antibodies (mouse or 
rabbit depending on host animal for the primary antibody), diluted in 5 % milk/0.1 % 
Tween/1X PBS (Table 8). Before and after incubation with the secondary antibodies 
the membranes were washed 3 times for 5 mins in 0.1 % Tween/1X PBS. Protein 
expression was detected by chemiluminescence (SuperSignal West Pico 
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Chemiluminescent Substrate, Pierce, UK). Immunoblotting for β-actin was used as a 
loading control.  
 
Antibody Catalog number Company Dilution 
alexa 488 A11034 Invitrogen 1:1000 
β-actin 5125 Cell signalling 1:1000 
DHFR sc-377091 Santa cruz 1:1000 
FLAG F1804 Sigma 1:1000 
γH2AX 05-636 Millipore 1:1000 
MLH1 4256 Cell signalling 1:1000 
MSH2 2017 Cell signalling 1:1000 
MSH3 sc-11441 Santa Cruz 1:1000 
MSH6 5424 Cell signalling 1:1000 
PMS2 sc-618 Santa Cruz 1:1000 
Thymidylate synthase 9045 Cell signalling 1:1000 
anti-rabbit IgG 7074 Cell Signalling 1:4000 
anti-mouse IgG  7076 Cell Signalling  1:4000 
Table 8: Antibodies 
 
5 Quantification of mRNA level 
5.1 RNA extraction 
Cells were plated in 6-well plates. After appropriate drug treatment or siRNA 
transfection, cells were washed in 1X PBS and 1 mL Trizol was added to lyse the 
cells and maintain the RNA integrity. Samples were transferred in 1.5 mL tubes, 
200 µL chloroform was added and the tubes were centrifuged for 15 mins at 12 000 
rpm at 4˚C to separate proteins, DNA and RNA. The aqueous phase containing RNA 
was transferred to a new tube and precipitated with 1 mL isopropyl alcohol for 10 
mins at room temperature, centrifuged for 10 mins at 12 000 rpm at 4˚C and then 
washed with 1 mL 75 % ethanol and centrifuged for 5 mins at 7 000 rpm at 4˚C. 
RNA, after purification, was resuspended in water. Concentration and purity was 
measured with a ND-1000 NanoDrop.  
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5.2 Multiplexed Real-time PCR 
To measure mRNA expression, we performed a reverse transcription quantitative 
polymerase chain reaction (RT-qPCR). The mRNA was firstly reversely transcribed 
to cDNA for better stability using the omniscript RT kit, according to manufacturer’s 
instructions (Qiagen). In brief, 1 µg of RNA was incubated with 2 µL oligodT 
(10 µM), 2 µL dNTP pool (5 mM each dNTP), 0.25 µL RNAse inhibitor (40 
units/µL) and 1 µL reverse transcriptase (4 units/µL) for a final volume of 20 µL in 
Buffer RT. The reaction was incubated for 1 hr at 37˚C. The cDNA was then 
incubated on ice to stop the reaction. The diluted cDNA was used to measure the 
mRNA expression levels. For each sample replicate, 1.2 µL GAPDH probes/primers 
(4310884E) and 1.2 µL gene specific Taqman DNA probes/primers (SOD1: 
Hs00533490_m1; SOD2: Hs00167309_m1; NRF1: Hs00192316_m1 and NRF2: 
Hs0095961_g1 from Applied Biosystems) were added to 10 µL 2X Taqman 
mastermix (Applied Biosystems). In a 96-well plate, 12 µL 
probes/primers/maxtermix was added to 8 µL cDNA (diluted 1:8 in water) and the 
gene specific sequence of cDNA was amplified and measured by real-time qPCR 
(750 real-time PCR system, Applied Biosystems). The PCR program used to amplify 
the cDNA was 2 mins at 50˚C, 10 mins at 95˚C followed by 40 cycles of 15 sec at 
95˚C and 1 min at 60˚C. The fluorescence was read at the end of each cycle. In a 
Taqman qPCR, a fluorophore-bounded probe recognizes and binds single stranded 
DNA of a specific gene. During DNA synthesis of this specific gene (using specific 
primer), the fluorophore probe is degraded and fluoresces. Therefore, the 
fluorescence is proportional to the DNA synthesis. The quantification of cDNA was 
calculated by measuring the number of PCR cycles (Ct) necessary to reach a defined 
quantity of cDNA. The Ct results for each gene of interest were normalized to 
GAPDH mRNA level. Results were expressed in relative quantity (RQ) according to 
the following equation:  
RQ=2
-(Ct (cDNA interest) – Ct (cDNA GAPDH))
 
Samples were run in triplicate and experiments were carried out in triplicate. Results 
were normalized to the untreated condition of the MMR deficient sample. 
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6 Transfection 
6.1 siRNA transfection 
In order to silence gene expression, cells were transfected with individual small 
interfering RNA (siRNA) (Table 9; Qiagen) using lipofectamine 2000 or RNAiMAX 
according to manufacturer’s instructions (Invitrogen). Briefly, cells were seeded in 
96-well plates or 6-well plates at 1000-2000 cells/well and 100 000-150 000 
cells/well, respectively. The following day, cells were transfected and the media was 
replaced after 24 hrs post transfection. For transfection in 96-well plates, each 
siRNA was transfected into the two paired cell lines using the same transfection 
reaction as follows; 0.4 µL TR and 50 µL OptiMEM media (Invitrogen) were 
incubated in a 50 mL tube for 5 mins. In a clear 96-well plate, 50 µL of TR in 
OptiMEM was added to 5 µL of siRNA (2 µM). After 20 mins incubation, 155 µL 
complete media was added. The media of the cells was then replaced by 100 µL of 
the siRNA/TR/OptiMEM mix for a final siRNA concentration of 50 nM. In the case 
of transfections in 6-well plates, for each siRNA transfected in two cell lines, 10 µL 
TR and 500 µL OptiMEM media (Invitrogen) were incubated in a 50 mL tube for 
5 mins; In a 1.5 mL tube, 500 µL of TR in OptiMEM was added to 10 µL of siRNA 
(20 µM) and incubated for 20 mins. The media of the cells was changed and 250 µL 
of the siRNA/TR/OptiMEM mix was added for a final siRNA concentration of 
100 nM.  
Cells were transfected with siCtrl or siPLK1. The cell viability of cells transfected 
with siCtrl was compared to the cells grown in media alone to assess whether the 
transfection itself did not affect cell viability. Transfection with siPLK1 was used as 
a positive control for transfection efficiency. PLK1 was a polo-like kinase implicated 
in mitosis and apoptosis, its silencing causes cell death in most cell lines [357]. It 
was expected to have 80-100 % cell viability in siCtrl transfected cells and 0-20 % in 
siPLK1 transfected cells in comparison to un-transfected cells.  
In case of a combination of siRNAs, the final siRNA concentration was the same in 
all conditions. For example, for a combination of 3 siRNAs in 96-well plates, we 
used 50 nM of each siRNA (i.e. with siRNA targeting the subunits (α, β and γ) of the 
epithelial sodium channel (ENaC), 50 nM siENaCα, 50 nM siENaCβ and 50 nM 
siENaCγ) which correspond to a 150 nM final concentration. To compare this 
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combination of 3 siRNAs to a single siRNA, we used a combination of 50 nM of a 
single siRNA (i.e. siENaCα) and 100 nM of siCtrl in order to have the same final 
concentration of 150 nM siRNA and the same 50 nM concentration of the siRNA of 
interest (i.e. siENaCα). Similarly, to compare a combination of 3 siRNAs to a 
combination of 2 siRNAs, we used a combination of 50 nM of both siRNAs (i.e. 
50 nM siENaCα and 50 nM siENaCβ) and 50 nM of siCtrl. 
 
Name Target sequence 
Ctrl 5’-CATGCCTGATCCGCTAGTC-3’ 
PLK1 5'-CCGGATCAAGAATGAATA-3' 
ENaC_α SMARTpool 
ENaC_β SMARTpool 
ENaC_γ SMARTpool 
DHFR_1 5'-TACGGAGAAACTGAACTGAGA-3' 
DHFR_2 5-'AACCTCCACAAGGAGCTCATT-3' 
TYMS_1 5'-CCAAACGUGUGUUCUGGAA-3' 
TYMS_2 SMARTpool 
Table 9: siRNAs 
 
6.2 Plasmid transformation and transfection 
In order to over-express a protein, cells were transfected with a plasmid using 
Fugene HD TR (Section 6.3; Promega). DHFR plasmid (#RC200089) and its 
corresponding empty vector (#PS100001) were purchased from OriGene. TYMS 
plasmid was cloned from a cloning library (see 6.2.1) into the pIREShyg3 empty 
vector (#631620 ClonTech). 
 
6.2.1 TYMS plasmid construction 
To generate a TYMS expression construct we ligated the amplified TYMS gene 
insert into the pIREShyg3 empty vector. The insert was amplified by PCR from the 
MegaMan cDNA library (Agilent) using 2 primers targeting TYMS: 
Fwd 5’-ATCTAGCTAGCATGCCTGTGGCCGGCTCG-3’ 
Rev 5’-TCGCGGATATCAGCACCCTAAACAGCCATTTC-3’ 
For each PCR reaction: 10 µL 5X HF buffer; 2.5 µL Fwd primer (10 µM); 2.5 µL 
Rev primer (10 µM); 1 µL dNTPs (10 mM); 0.5 µL Phusion polymerase and 0.5 µL 
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MegaMan library were mixed to a final volume of 50 µL in water. The PCR was run 
for 2 min at 98˚C; followed by 35 cycles of 1 min at 98˚C, 30 sec at 64˚C and 1 min 
at 72˚C; and 7 mins at 72˚C. The PCR product was electrophoresed for 1 hr at 150 V 
in a 1 % agarose gel (containing 1:2000 GelRed; Biotiom) and the appropriate band 
was extracted and purified with a Qiagen Gel Extraction kit according to the 
manufacturer’s instructions. 41 µL PCR product was then digested with 2 µL NheI 
and 2 µL EcoRV restriction enzymes (20 000 units/mL; BioLabs) in 5 µL 
CutSMART buffer for 2 hrs in a water-bath at 37˚C. The digested PCR product was 
purified using a Qiagen PCR Clean up kit according to the manufacturer’s 
instructions and electrophoresed for 1 hr at 150 V on a 1 % agarose gel (containing 
1:2000 GelRed; Biotiom) to validate the digestion. The last step was the ligation of 
the pIREShyg3 empty vector with the digested PCR product. To this end, 10 µL 
PCR product, 1 µL vector, 2 µL 10X ligase buffer, 1 µL ligase, 2 µL PEG 4000 and 
4 µL water were incubated for 1 hr at room temperature. 
 
6.2.2 Plasmid transformation 
All plasmids (empty vectors, DHFR plasmid and TYMS plasmid) were primarily 
transformed into NEB-5α competent E. Coli bacteria by heat shocking 25 µL of 
bacteria in presence of 1-5 µL of plasmid for exactly 30 seconds at 42˚C. 650 µL 
Lysogeny broth (LB) was added to the transformed bacteria and incubated and 
shaken at 3000 rpm for 1-2 hrs at 37 ˚C. Bacteria were spread on two LB agar plates 
complemented with the appropriate antibiotic (100 μg/mL Ampicillin or 30 μg/mL 
Kanamycin). In order to be able to select an individual colony in the case of either 
low or high transformation rate, 90 % bacteria were spread on one plate and 10 % on 
the other plate. One colony of each transformation was selected and grown in liquid 
LB for 12-18 hrs. Glycerol stocks were generated by mixing 1:1 ratio of bacterial 
culture with 50 % glycerol and stored at -80˚C. Plasmid DNA was extracted from the 
remaining bacterial culture using the Qiagen Plasmid Miniprep kit according to the 
manufacturer’s instructions. The DNA concentration and purity was measured with a 
ND-1000 NanoDrop.  
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6.3 Plasmid transfection 
Plated cells were transfected the following day with plasmids using Fugene HD TR. 
For transfections in 96-well plates, 100 ng/well of plasmid DNA was diluted in 
optiMEM to a total volume of 5 μL. After adding 0.6 μL Fugene, 5 μL of the 
transfection mix was added to the cells. In 6-well plates, 1 μg/well of plasmid was 
diluted in optiMEM for a total volume of 50 μL. After adding 6 μL Fugene, 50 μL of 
the transfection mix was added to the cells. The media was replaced 24 hrs after 
transfection.  
 
6.4 Qiagen kits protocols 
We used a number of Qiagen kits: Gel extraction kit, PCR Clean up kit and miniprep 
kit according to the manufacturer’s instructions. They all follow the same steps: 
sample preparation, DNA isolation, washes and elution. Samples for bacterial DNA 
extraction (miniprep kit) were prepared using an alkaline lysis buffer; DNA was 
isolated from an agarose gel and from the PCR enzymatic reaction by using a buffer 
containing chaotropic salts, a denaturating agent (Gel extraction kit and PCR Clean 
up kit). For all samples, DNA was absorbed onto a silica membrane in presence of 
high concentration of salts. The membranes were then washed with a buffer 
composed of 10 mM Tris-Cl [pH 7.5] and the DNA was eluted in water. 
 
7 DNA and RNA concentration 
The concentration and quality of DNA and RNA samples were measured using the 
ND-1000 NanoDrop. RNA and DNA absorb light at 260 nm, solvents at 230 nm and 
proteins at 280 nm. Therefore, to validate the quality, we looked at the absorbance 
ratio 260/230 and 260/280. A solvent contamination of our samples was observed by 
a ratio 260/230 lower than 1.7. A protein contamination of our samples was observed 
by a ratio 260/280 lower than 1.7.  
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8 Antioxidant Response Element (ARE) reporter assay 
The antioxidant response was measured using an ARE reporter assay kit (Qiagen) 
according to the manufacturer’s instructions. This kit includes different reporter 
plasmids: an ARE reporter to measure the activity of the ARE promoter (a firefly 
luciferase construct regulated by ARE); a negative control to measure the 
background (a firefly luciferase construct with no regulation promoter); and a 
positive control to measure the transfection efficiency (a firefly luciferase construct 
regulated by CMV). Each reporter plasmid contained an internal control (a renilla 
luciferase construct regulated by cytomegalovirus (CMV)) to measure cell viability 
(Table 10).  
 
Components Constructs 
ARE reporter 
 
Negative control 
 
Positive control 
 
Table 10: ARE reporter assay constructs 
 
In our experiment we combined siRNA transfection, ARE reporter plasmid 
transfection and drug treatments (Figure 15). The experiment schedule for this 
experiment was: on day 1, we plated 150 000 cells in 6-well plates; on day 2, we 
transfected the cells with siCtrl, siPLK1 and siTS as described previously (section 
6.1); on day 3, cells were washed with 1 mL 1X PBS incubated in 250 µL Trypsin at 
37 ˚C, when the cells were detached, 2 mL complete media was added and the cells 
were transferred in 15 mL tubes and centrifuged at 3 200 rpm for 3 mins. Cells were 
counted and seeded at the density of 3,000 cells/well into 96-well plates; on day 4, 
we transfected the cells with the ARE reporter assay using Fugene HD TR. We 
added per well 5 μL of a mix of 1 μL of the ARE reporter, negative control or 
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D B C 
positive control (100 ng/µL), 0.6 μL Fugene and 5 μL of optiMEM; on day 5, we 
treated the cells with DMSO or 10 µM Triamterene; and on day 6, we measured 
ARE promoter activity using a dual luciferase assay (Promega) according to the 
manufacturer’s instructions. In brief, we removed the media, washed the cells with 
PBS and added 20 µL of lysis buffer. Plates were mixed for 15 mins using a plate 
shaker (Grant-bio). In order to quantify the firefly luciferase activity, 100 µL 
Luciferase Assay Substrate was added and the luminescence was read using a Wallac 
1420 plate reader (PerkinElmer). After the first reading, 100 µL Stop&Glo Substrate 
was added and the luminescence read on the same plate reader to measure the 
Renilla luciferase activity. The firefly luciferase activity was normalized to the 
Renilla luciferase activity. 
 
 
Figure 15: ARE reporter assay scheduling experiment 
A: Cells transfected with siCtrl were then transfected with the negative control, 
positive control and ARE reporter from the ARE reporter assay; B, C: cells 
transfected with siTS are then transfected with the positive control and ARE 
reporter; D: cells transfected with siPLK1 are kept in 6-well plates to control the 
siRNA transfection efficiency. A-C: One day after ARE reporter assay, cells were 
treated in triplicates with DMSO or 20 µM Triamterene (Triam). 
 
 
9 DHFR activity assay 
DHFR activity was measured with a DHFR assay kit (Sigma, CS3040), according to 
the manufacturer’s instructions. Cells were plated in 10 cm dishes. After 5 and 
10 µM Triamterene treatment, proteins were extracted and the concentration was 
measured as indicated previously (section 4.1). All samples were diluted to 1 mg/mL 
in the assay buffer provided to a final volume of 1 mL. After addition of 5 µL DHF 
A 
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and 6 µL NADPH, the optical density (OD) at 340 nm was measured every 15 sec 
for 4 mins using a BioPhotometer plus (Eppendorf). Absorbance was normalized in 
ΔOD/min using the equation: ΔOD/min 
                  
    
 .  
 
 
10 Reactive oxygen species assay 
Cellular ROS was measured using DCFDA-Cellular Reactive Oxygen Species 
Detection Assay Kit (Abcam, ab113851) according to the manufacturer’s 
instructions. 2’,7’-dichlorofluorescein diacetate (DCFDA) - non fluorescent - was 
converted in DCF - fluorescence - by ROS (H2O2, •OH, ONOO
-
 and •O2
-
) [358-360]. 
To measure ROS levels in our cells, we plated 3 000 cells in one 96-well plate for 
cell viability, and one clear bottom black 96-well plate for the ROS assay. For a dose 
dependent experiment, cells were treated with the appropriate concentrations of 
Triamterene for 48 hrs. For a time course experiment, cells were treated with the 
appropriate concentration of Triamterene at different time points identically for both 
plates (24 hrs treatment corresponded to cells treated 24 hrs prior DCF 
measurement). After appropriate treatment in both plates identically, cells in the 
clear bottom black 96-well plate were washed in 1X PBS and treated 
with 20 μM DCFDA or incubated in assay buffer as a negative control. After 
30 mins incubation at 37˚C, cells were washed with 1X PBS and incubated for 4 hrs 
in fresh assay buffer at 37˚C in a 5 % CO2 incubator. Fluorescence was measured, 
using the Wallac 1420 plate reader (PerkinElmer), in the clear black bottom 96-well 
plate and cell viability was measured in the other 96-well plate using the CellTiter-
Glo assay. Fluorescence data were normalized to the cell viability luminescence data 
and to the average of the normalized fluorescence of the untreated MMR deficient 
condition. 
 
 
 
 
 
Material and methods 93 
 
11 Immunofluorescence 
Cells were seeded on coverslips coated in Poly-L-Lysine (Corning) in 6-well plates 
at a density of 75 000 DLD1 and DLD1+chr2 cells/well or 100 000 U251 and 
U251.TR3 cells/well. After 48 hrs treatment with 10 µM Triamterene in the DLD1 
and DLD1+chr2 cells, or 24 hrs treatment with 20 µM Triamterene in the U251 and 
U251.TR3 cells treatment; cells were fixed in 4 % Paraformaldehyde and 
permeabilised in 0.2 % 100X Triton. Cells were then blocked in 5 % BSA/1X PBS 
for a minimum of 30 mins. Coverslips were incubated in 50 µL γH2AX primary 
antibody (1:1000 in 5 % BSA) overnight at 4˚C. The coverslips were washed in 1X 
PBS and incubated with 50 µL Alexa Fluor® conjugated secondary antibody 
(1:1000 in 5 % BSA) for 1 hr in the dark (Table 8). Coverslips were then washed in 
4 % DAPI/1X PBS and mounted on a slide with 3 µL ProLong® gold antifade 
mounting solution (Invitrogen). When dry, the coverslips were stored at 4˚C and 
analysed using the confocal LSM 510 microscope (Zeiss). For the DLD1 and 
DLD1+chr2 cells, we used a 40x objective and captured at least 3 images per 
condition using the same settings. Images were analysed and cells positive for 
>5 γH2AX foci were counted using the cell counting software available using 
ImageJ. For U251 and U251.TR3 cells, cells positive for >5 γH2AX foci were 
counted directly on the confocal using a 40x objective. Images were captured with 
the same conditions as for DLD1 and DLD1+chr2 cells. Results were normalized to 
the total number of cells counted per cell line. 
 
 
12 In vivo experiments 
12.1 Drug preparation 
For in vivo experiments, Triamterene was used at concentrations of 25 mg/kg and 
50 mg/kg. The average weight for a mouse was 27.2 g therefore 25 mg/kg and 50 
mg/kg corresponded to 6.8 mg/mL and 13.6 mg/mL Triamterene, respectively. 
Triamterene was diluted in folate-free RPMI media (Sigma) and stored in aliquots in 
1.5 mL tubes at -20˚C. The vehicle used as a control for all the in vivo experiments 
was folate-free RPMI media, stored in aliquots in 1.5 mL tubes at -20˚C. A fresh 
aliquot was used for each treatment. 
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12.2 In vivo pilot experiment 
Cells were resuspended in 1X PBS at the density of 16 million cells per mL. We 
injected subcutaneously 100 μL of cells using 22 gauge needles, into both flanks of 
adult (~10 weeks old) male NOD-SCID mice (Charles-River Laboratories) [361]. 
When the tumours were all measurable, the mice were treated 3 times a week by 
gavage or intraperitoneal (IP) injection, with either 25 mg/kg, 50 mg/kg Triamterene 
or vehicle (only by IP, no gavage) (Figure 16). Tumours were measured twice 
weekly. Using callipers, we measured the width and the length of the tumours. The 
tumour growth was calculated as follows [362]: area (mm
2
) =width (mm) * length 
(mm). 
Each tumour measurement was normalized to the tumour size obtained on the first 
day of treatment. Results were analysed by calculating the slope linear regression 
using GraphPad Prism software, assuming the tumour growth was linear.  
 
12.3 In vivo experiment 
Cells were resuspended in 1X PBS at the appropriate number (1.6x10
6
 cells for the 
first experiment on 20 mice; 0.6x10
6
 DLD1 cells, 0.8x10
6
 DLD1+chr2 cells for the 
second experiment on 40 mice). We injected subcutaneously 100 μL of cells, into 
one flank of adult (~10 weeks old) male NOD-SCID mice. When the tumours were 
measurable, the mice were treated 3 times a week by gavage, with 25 mg/kg 
Triamterene or vehicle. Tumours were measured twice weekly. The mice were 
sacrificed in case of sickness or when the tumours reached 1.44 cm
2
. Tumours from 
each mouse were harvested on the day of sacrifice. The measurements were 
normalized to the size of the tumour on the first day of treatment.  
In the case of U251 and U251.TR3 xenografted mice, 2.5x10
6
 or 1x10
6
 cells in 1X 
PBS or 1x10
6
 cells in matrigel (1:1) were injected subcutaneously. No tumour was 
visible 4 weeks after injection; therefore, the mice did not receive treatment and were 
sacrificed.  
For all mice experiment, animals were sacrificed in the event of sickness or when the 
tumours reached 1.44 cm
2
. All animal procedures were carried out as per the 
Animals Scientific Procedures Act 1986, under the Home Office approval licences 
(PPL 70/7275 and PIL – 70/23444).   
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Figure 16: In vivo pilot experiment 
DLD1, DLD1+chr2, HCT116 and HCT116+chr3 cells were injected in both flanks 
of each mouse at the density of 1.6x10
6
 cells per tumour (5 mice per cell line). Mice 
were treated 3 times a week with either 25 mg/kg (T25) or 50 mg/kg (T50) 
Triamterene, by IP or by gavage (G); and with vehicle (V) by IP. Tumours were 
measured twice a week.   
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12.4 RNA extraction from tumours 
All the tumours were harvested on the day of sacrifice and stored at -80˚C. We 
extracted RNA from all the tumours from the second repeat experiment in DLD1 and 
DLD1+chr2 xenografted mice. We incubated a section of frozen tumour in 1 mL 
Trizol reagent. The frozen tumour was homogenized for 10 seconds using the cell 
homogenizer (Ultra Turrax T25basic, Labortechnik) and placed on dry ice. RNA 
from all the homogenized tumours was extracted following the RNA extraction 
protocol described previously (section 5.1). 
 
13 Data analysis and representation 
For data analysis, values unless otherwise stated were normalized to the average of 
the untreated condition in the cell line concerned. All graphs were generated using 
Graphpad Prism software except the heatmap which was generated using R software. 
All experiments were carried out in triplicate and error bars represent standard error 
of the mean (SEM). Statistics for data significance were measured using Graphpad 
Prism software. Stars were used to represent significance on graphs with:  
NS p-value > 0.05; * p-value < 0.05; ** p-value < 0.01; *** p-value < 0.001 
Results were considered non-significant (NS) when the p-value > 0.05. The test used 
to calculate the p-values was dependant on the conditions compared and was 
stipulated in the legend for each graph. The most frequently used statistical test was 
a 2way ANOVA, to compare surviving curves and time course experiments; and 
1way ANOVA to compare 2 conditions among a multi-condition test (often 
represented with a histogram). Both tests were followed by Bonferroni correction 
test which was considered the simplest and most conservative method to counteract 
the problem of multiple comparisons [363].  
For the mice experiment, it was not possible to use a 2way ANOVA as all the mice 
did not survive until the end of the experiment (2way ANOVA cannot be used in 
case of missing values). We did not want to assess the significance of the last 
measurement only as we considered it would be biased as not all mice survived until 
then. Therefore, we used a two-tailed paired t-test which has been previously used in 
other studies to evaluate differential tumours growth in vivo [364-367]. 
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Chapter 1: Identification of novel 
therapeutics for the treatment of MMR 
deficient tumours 
 
 
The MMR pathway is responsible for the repair of base-base mismatches and 
insertion/deletion loops, formed during DNA replication. Mutations in MMR genes 
significantly increase the predisposition to cancer with MMR deficiency estimated to 
be present in 15-17 % of all CRCs. 5-FU is the main treatment for advanced CRC, 
however the majority of studies suggest that MMR deficient tumours are more 
resistant to 5-FU than MMR proficient tumours. Therefore, there is a critical clinical 
need to identify novel therapeutics to treat these tumours.  
 
1 DNA mismatch repair deficient cell lines are resistant to 
5-FU treatment 
MMR deficient cells are reported to be more resistant to 5-FU treatment and this has 
critical clinical implications for the treatment of MMR deficient CRCs. In order to 
assess this resistance, we studied cell viability upon treatment with increasing 
concentrations of 5-FU in our panel of MMR deficient and MMR proficient paired-
cell lines (Table 11). We firstly confirmed the MMR status of our panel by analysing 
the protein expression of MLH1, MSH2, MSH6, MSH3 and PMS2 by western blot 
(Figure 17A). As previously described [368], PMS2 expression levels were 
decreased in MLH1 deficient cells. We confirmed this in our MLH1 deficient 
HCT116 and A2780cp70 A2 cell lines with loss of MLH1 by mutation or 
methylation, respectively, leads to a decrease in PMS2 expression. Similarly, MSH6 
and MSH3 expression levels have previously been shown to have decreased 
expression in MSH2 deficient cells [140]. Consequently, we observed that MSH3 
and MSH6 expression were reduced in the MSH2 mutated HEC59 cells. This is 
because, PMS2 is unstable without heterodimerization with MLH1, and MSH3 and 
MSH6 are unstable without heterodimerization with MSH2. However, loss of MSH6 
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in DLD1 cell lines, or MSH3 in HCT116 and HCT116+chr3 cell lines, does not lead 
to loss of MSH2 expression as MSH2 can remain stable by complexing with either 
MSH3 or MSH6 [369]. We also have in our panel of paired cell lines, another MSH6 
deficient and proficient paired cell lines, U251.TR3 and U251 glioblastoma cells. 
The U251.TR3 TMZ resistant cell lines were generated by continuous exposure of 
U251 cells to 100 µM of TMZ and were found to have generated a somatic MSH6 
mutation (resulting in a Thr
1219
Ile substitution) [235], and decreased MSH6 
expression was confirmed by western blot (Figure 17B).  
In our panel of cell lines, three cell lines (DLD1, HCT116 and HEC59) harbour 
mutations in MMR genes. They are matched paired with proficient cell lines 
generated by the stable addition of a chromosome (chr2 for re-expression of MSH2 
and MSH6, chr3 for re-expression of MLH1). The main advantage for these matched 
paired cell lines is that they only differ on the addition of a chromosome and 
therefore on the MMR status. They do not differ on secondary mutations that often 
occur in MMR deficiency [239, 370]. Our panel of cell lines is also composed of 
MMR deficient cell lines by other means. This is the case for U251.TR3 (MSH6 
mutation acquired by continuous exposure to TMZ) and A2780cp70 A2 (MLH1 
methylation acquired by continuous exposure to Cisplatin). Therefore the matched 
paired cell lines differ from MMR status and secondary mutations. Our panel is 
composed of matched paired cell lines representing a wide range of tumour types. 
Therefore, this panel represents a great tool for the study of MMR dependent 
mechanisms. 
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Origin Cell line MMR status Reference 
Colorectal 
DLD1 MSH6 mutation 
[370] 
DLD1+chr2 MMR proficient 
Colorectal 
HCT116 MSH3 and MLH1 mutation 
[239] 
HCT116+chr3 MSH3 mutation 
Ovarian 
A2780cp70 A2 MLH1 methylation 
[242, 315] 
A2780cp70 E1 MMR proficient 
Endometrial 
HEC59 MSH2 mutation 
[370] 
HEC59+chr2 MMR proficient 
Glioblastoma 
U251.TR3 MSH6 mutation 
[235] 
U251 MMR proficient 
Table 11: Matched paired cell lines panel 
 
 
 
Figure 17: MMR status in our panel of cell lines 
A: Cells were seeded in 6-well plates and proteins were extracted three days later. 
Protein expression was measured by western blot using MSH2, MSH3, MSH6, 
MLH1, PMS2 and β-actin antibodies. β-actin is used as a loading control. B: U251 
and U251.TR3 cells were seeded in 6-well plates and proteins were extracted three 
days later. Protein expression was measured by western blot using MSH6 and β-actin 
antibodies. β-actin is used as a loading control. 
 
 
  
A B 
Results – Chapter 1 101 
 
In order to assess 5-FU resistance in MMR deficient cells, we treated our panel of 
MMR deficient and MMR proficient cell lines with 5-FU (increasing concentrations 
from 1 µM to 10 µM) to determine their sensitivity to 5-FU treatment. We observed 
that all MMR deficient cell lines were more resistant to 5-FU treatment in 
comparison to their MMR proficient matched paired cell lines (Figure 18 & Figure 
19). Therefore, our results validate that MMR deficiency confers resistance to 5-FU 
treatment.  
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Figure 18: 5-FU response on our panel of MSH6 proficient and deficient cell 
lines 
A, B: Cells were seeded in 96-well plates and treated with increasing concentrations 
of 5-FU (1, 2.5, 5, 7.5 and 10 μM in DLD1 and DLD1+chr2 cells; 2, 4, 6, 8 and 
10 μM in U251 and U251.TR3 cells). After 4 days treatment, cell viability was 
assessed by ATP-luminescence assay. Experiments were carried out in triplicate and 
error bars represent SEM. P-values derived from 2way ANOVA (*** p < 0.001). 
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Figure 19: 5-FU response on our panel of MLH1 and MSH2 MMR proficient 
and deficient cell lines 
A-C: Cells were seeded in 96-well plates and treated with increasing concentrations 
of 5-FU (1, 2.5, 5, 7.5 and 10 μM). After 4 days treatment, cell viability was 
assessed by ATP-luminescence assay. Experiments were carried out in triplicate and 
error bars represent SEM. P-values derived from 2way ANOVA (* p < 0.05, 
** p < 0.01, *** p < 0.001). 
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2 High-throughput compound screen 
2.1 High-throughput compound screen optimization 
Our initial results confirm that a deficiency in the MMR pathway leads to a 
resistance to 5-FU treatment. The MSH6 deficient colorectal cell line DLD1 showed 
the most consistent resistance to 5-FU in comparison to the MSH6 proficient cell 
line DLD1+chr2 and therefore, these matched-paired cell lines were chosen to carry 
out a high-throughput compound screen in order to identify modulators of this 
resistance. Initially, we carried out a series of optimization experiments to determine 
an appropriate schedule of treatment, 5-FU concentration and cell number to perform 
the compound screen. We firstly determined the experiment scheduling: day 1, cell 
seeding; day 2, 5-FU treatment; day 4, compound library treatment; and day 7, cell 
viability assay. Our previous experiments to confirm 5-FU resistance in MMR 
deficient cell lines, helped us to determine that, to have cells at 90 % confluency on 
day 7, we needed to seed 1000 cells per well. We also previously determined that 
2 µM 5-FU was the lowest concentration to have the highest difference between 
DLD1 and DLD1+chr2 cell viability (Figure 18A). The compound library was 
successfully used in previous studies at the concentration of 10 µM and 100 µM 
[317, 319]. We decided to carry out our screen with a compound library diluted at 
10 µM in order to identify modulators of 5-FU that are active at a lower 
concentration and therefore are potentially less toxic. We determined that the 
optimized schedule to carry out the high-throughput compound screen was to treat 
1000 DLD1 and DLD1+chr2 cells with either DMSO or 2 µM of 5-FU followed by 
10 µM 5-FU, which correspond to the concentration of the compound library (Figure 
20). Therefore, to perform the compound screen, 1000 DLD1 and DLD1+chr2 cells 
were plated in 28*96-well plates each and treated, the following day, with either 
DMSO or the optimized concentration of 5-FU (2 µM). After 2 days, all cells were 
treated with 10 µM of each of the library compounds. Cell viability was measured 
using an ATP-based luminescent assay after 72 hrs treatment with the library (Figure 
12). The high-throughput screen was carried out using a compound library of 1120 
drugs previously used in the clinic, 90 % of which were marketed drugs, the 
remaining 10 % being bioactive alkaloids. The screen included one well per 
compound and we carried out the screen in duplicate. 
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Figure 20: High-throughput compound screen 
DLD1 and DLD1+chr2 cells were plated in 96-well plates at the density of 
1000 cells/well and treated with either DMSO or 2 µM 5-FU the following day. 
After 2 days treatment, cells were treated with either DMSO or 10 µM 5-FU which 
corresponds to the drug library concentration. After 3 days, cell viability was 
measured using an ATP-based luminescent assay. Experiments were carried out in 
triplicate and the error bars represent the SEM. P-values derived from 2way 
ANOVA (*** p < 0.001). 
 
 
2.2 High-throughput compound screen analysis 
In order to be able to analyse the compound screen results, the cell viability 
luminescent readings were normalized into Z-scores (Figure 21A & Appendix 1). 
Luminescence readings from each well were log transformed and normalized 
according to the median signal on each plate and then standardized by use of a 
Z-score statistic, using the median absolute deviation (MAD) to estimate the 
variation in each screen (Figure 13). Z-score analysis has been described as a reliable 
method to analyse high-throughput screens [356]. In our case, a Z-score represented 
the magnitude of difference between one compound and the rest of the screen. This 
was based on the assumption of a normal distribution of cell viability upon treatment 
in a specific cell line. The standardization and normalization of the data in each cell 
line enabled us to compare the 4 conditions with or without 5-FU in both MMR 
deficient and proficient cell lines. A Z-score = 0 represented a compound that was 
not cytotoxic to the cells and a Z-score < 0 represented a compound that was 
cytotoxic for the cells. We enforced a threshold of hit identification based Z-scores 
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lower than -1.5. Based on this threshold, we identified a number of compounds 
which either: 1) caused synthetic lethality in the MSH6 deficient cell lines, 2) 
modulated resistance to 5-FU in the MSH6 deficient cell lines, or 3) modulated 5-FU 
treatment response regardless of MMR status. Methotrexate has been previous 
identified for its synthetic lethal relationship with MSH2 deficiency [317]. In this 
screen, Methotrexate was cytotoxic regardless of MSH6 status. This is in agreement 
with the previous study which showed selectivity for Methotrexate with MSH2 
deficiency only and not other MMR genes. From the screen results, we selected 
5 drugs, Quinacrine, Disulfiram, Clotrimazole, Astemizole and Triamterene, which 
showed synthetic lethality in MSH6 deficiency and a potential re-sensitization of 
MSH6 deficiency mediated 5-FU resistance. Quinacrine is an antimalarial treatment. 
Its mechanism of action against protozoa is uncertain, however, a role for Quinacrine 
in the inhibition of NFκB and activation of p53 in mammalian cells has been 
reported [371, 372]. Disulfiram inhibits the enzyme acetaldehyde dehydrogenase 
which plays a key role in alcohol degradation and therefore, Disulfiram is a 
prescribed treatment of alcoholism [373]. It has been previously shown that 
Disulfiram and Quinacrine can synergize with 5-FU treatment [371, 373]. 
Clotrimazole is an antifungal treatment which alters the permeability of the fungus 
membrane; it has also been described as a Calmodulin antagonist [374, 375]. 
Astemizole is an anti-histaminic treatment which is metabolized by CYP3A4 and 
inhibits CYP24A1, two members of the cytochrome P450 family of oxidizing 
enzymes [376, 377]. Triamterene is an epithelial sodium channel (ENaC) antagonist 
and an antifolate [378, 379]. All the selected compounds apart from Triamterene had 
previously been shown to induce an anticancer activity. No study has been published 
connecting the selected drugs with MMR deficiency (Table 12). The screen results 
from both replicates showed variability, which was expected as the screen includes 
only one well per compound (Figure 21B). Therefore further validation experiments 
were necessary. Taken together, we identified 5 potential compounds synthetically 
lethal with MSH6 and/or modulators of MMR deficiency mediated 5-FU resistance. 
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Figure 21: Z-scores obtained from the compound screen data analysis 
A: Z-score for each compound in the 4 conditions (DLD1 and DLD1+chr2 with or 
without 5-FU pre-treatment). B: The cell viability results from the compound screens 
were normalized to Z-scores. Z = 0: no effect of the drug compared to the control; 
Z < 0: cell sensitivity to the drug. The heatmap represents the screen results for the 
selected compounds. The colour key represents the Z-scores of the compound effects 
in the different conditions in each replicate.  
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  Activity 
Previously 
reported anti-
cancer activity 
Mechanism of action  
Quinacrine  Antimalarial √ 
inhibits topoisomerase activity; activates 
p53, p21; inhibits NFκB [371, 372] 
Disulfiram  
Sensitivity to 
alcohol 
√ 
inhibits topoisomerase activity; activates 
p53 and inhibits NFκB [373] 
Clotrimazole  antifungal √ Calmodulin antagonist [374, 375] 
Astemizole  
anti-
histaminic  
√ 
Inhibits Eag1 potassium channel; 
inhibits CYP24A1 [376, 377] 
Triamterene  hypertension   x 
blocks epithelial sodium channel, folate 
antagonist [378, 379] 
Table 12: Clinical use and known mechanisms of action for the selected drugs 
 
 
2.3 Validation of selected drugs on DLD1 and DLD1+chr2 cells 
We previously carried out a high-throughput compound screen in DLD1 and 
DLD1+chr2 cells in order to identify modulators of 5-FU resistance and/or 
compounds synthetically lethal in MMR deficient cells. We selected 5 compounds 
which showed synthetic lethality and a potential re-sensitization to 5-FU resistance 
in MSH6 deficient cells (Figure 21B). As mentioned previously, the results from 
both replicates were variable and the selected compounds were tested at the one 
concentration of 10 µM; therefore, validation experiments are required to further 
investigate these compounds. We performed validation experiments with the selected 
drugs in short-term cell viability assays (Figure 22 & Figure 23). DLD1 and 
DLD1+chr2 cells were treated with either 2 µM 5-FU or increasing concentrations of 
the hit compound alone (from 1 nM to 10 µM). After 48 hrs, 5-FU pre-treated cells 
were exposed to the hit compound (from 1 nM to 10 µM), and the media was 
replaced on the cells previously treated with the hit compound. After 48 hrs, cell 
viability was measured using an ATP-luminescence assay. Our results showed that 
treatment with both Triamterene and Clotrimazole could re-sensitize the 5-FU pre-
treated cells (Figure 22A, B). More precisely, 5 µM Triamterene treatment sensitized 
specifically the 5-FU pre-treated DLD1 cells; 10 µM Triamterene sensitized both 
5-FU pre-treated cell lines but with significant higher toxicity in the 5-FU pre-treated 
DLD1 cells than in the 5-FU pre-treated DLD1+chr2 cells. Clotrimazole re-
sensitizes the cells to 5-FU treatment in DLD1 cells specifically with 1, 5 and 10 µM 
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Clotrimazole; 5 and 10 µM Clotrimazole alone were synthetically lethal in DLD1 
compared to DLD1+chr2 cells. No re-sensitization was observed with Disulfiram, 
Quinacrine and Astemizole (Figure 23). Based on these results, we confirmed the 
modulation of the 5-FU resistance in MMR deficient cells by Triamterene and 
Clotrimazole. The other selected drugs, Disulfiram, Quinacrine and Astemizole were 
not validated by this experiment and previously gave varying results in the screen 
analysis (differences between the duplicates). Quinacrine and Disulfiram were 
previously described to modulate 5-FU response [371, 373]. Both of these published 
studies assessed DLD1 cell viability after 72 or 96 hrs treatment with a combination 
of Disulfiram and 5-FU or Quinacrine and 5-FU. We carried out our experiments by 
treating the cells first with 5-FU followed by Disulfiram or Quinacrine treatment. 
The difference in experiment scheduling might explain why we did not validate 
Disulfiram and Quinacrine as modulators of 5-FU resistance in our MMR deficient 
cell lines. Further validation experiments could be done using these drugs, by testing 
different drug scheduling regimes. However, in this project, we decided to focus on 
Clotrimazole and Triamterene as the most promising modulators of 5-FU resistance 
in MMR deficient cells. 
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Figure 22: Triamterene and Clotrimazole are apparent modulators of 5-FU 
resistance in the MMR deficient DLD1 cell line 
A, B: DLD1 and DLD1+chr2 cells were treated with either DMSO, 2 µM 5-FU or 
with 10-fold-diluted concentrations of Triamterene (A) or Clotrimazole (B). After 
48 hrs, the 5-FU pre-treated cells were treated with 1 nM to 10 µM of the selected 
drugs and the media was replaced on the other drug-treated cells. After 48 hrs, cell 
viability was measured using an ATP-luminescence assay. Experiments were carried 
out in triplicate and the error bars represent the SEM. P-values derived from 2way 
ANOVA (*** p < 0.001, ** p < 0.01, * p < 0.05). 
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Figure 23: Disulfiram, Quinacrine and Astemizole were not validated in short 
term cell viability assays 
A-C: DLD1 and DLD1+chr2 cells were treated with either DMSO, 2 µM 5-FU or 
with 10-fold-diluted concentrations of the selected drugs. After 48 hrs, the 5-FU pre-
treated cells were treated with 10
-5
 to 10
-9
 M of the selected drugs and the media was 
replaced on the other drug-treated cells. After 48 hrs, cell viability was measured 
using an ATP-luminescence assay. Experiments were carried out in triplicates and 
the error bars represent the SEM. 
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3 Clotrimazole modulates 5-FU response in DLD1 cells 
Clotrimazole was identified and validated to be a modulator of 5-FU resistance in 
DLD1 and DLD1+chr2 cells. To investigate this modulation, we treated our panel of 
paired MMR deficient and proficient cell lines with Clotrimazole and 5-FU. Cells 
were treated with either 5 µM 5-FU or increasing concentrations of Clotrimazole 
(from 1 nM to 10 µM). After 2 days, 5-FU pre-treated cells were exposed to 
increasing concentrations of Clotrimazole (from 1 nM to 10 µM), and the media was 
replaced for the remaining cells. Cell viability was then measured after 2 days, using 
the ATP-luminescence assay (Figure 24). Our results did not suggest that 
Clotrimazole can modulate 5-FU resistance in other MMR deficient cell lines 
compared to their MMR proficient matched paired cell lines. Based on these results, 
our data suggests that Clotrimazole is a modulator of 5-FU resistance specifically in 
the MSH6 deficient DLD1 cells. We did not measure the Clotrimazole mediated re-
sensitization of 5-FU in our other MSH6 proficient and deficient matched paired cell 
lines (U251 and U251.TR3 cells). Therefore, we cannot conclude if the modulation 
observed in DLD1 is specific to this cell line or if it is MSH6 specific. Taken 
together, we identified Clotrimazole as a novel modulator of 5-FU resistance in the 
colorectal DLD1 cell line. Further investigations are necessary to further validate the 
role for MSH6 in Clotrimazole response and to understand the mechanism of 
Clotrimazole as a modulator of 5-FU response in MSH6 deficient cell lines. We 
would primarily measure the Clotrimazole response in the U251 and U251.TR3 cells 
pre-treated with 5-FU and we would investigate the role for the experiment 
scheduling in this cytotoxicity by testing different treatment regimes such as a 
combination of 5-FU and Clotrimazole in a longer-term experiment. 
 
From our high-throughput compound screen, we validated Clotrimazole and 
Triamterene as modulators of 5-FU resistance in DLD1 compared to DLD1+chr2 
cells. Due to the specific nature of the Clotrimazole re-sensitization in DLD1 cells 
only, we therefore decided to carry out our further experiments to investigate 
Triamterene in our panel of cell lines. 
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Figure 24: Clotrimazole response on a panel of cell lines 
A-C: Cells were treated with either DMSO, 5 µM 5-FU or with increasing 
concentrations of Clotrimazole (from 1 nM to 10 µM). After 2 days treatment, 5-FU 
pre-treated cells were treated with Clotrimazole (from 1 nM to 10 µM) and media 
was replaced on the remaining cells. After 2 days, cell viability was measured using 
an ATP-based luminescence assay. Experiments were carried out in triplicate and the 
error bars represent the SEM. P-values derived from 2way ANOVA, no significant 
different observed by comparing the different conditions. 
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4 Triamterene is synthetically lethal with MMR deficiency 
4.1 Triamterene alone is synthetically lethal in DLD1 cells 
From our high-throughput compound screen, we validated Triamterene as a 
modulator of 5-FU resistance in DLD1, compared to DLD1+chr2 cells. We next 
carried out further experiments to validate Triamterene as a modulator of 5-FU 
resistance. Our initial results identified Triamterene as a modulator of 5-FU response 
in DLD1 and DLD1+chr2 cells, at 5 and 10 µM concentrations. In order to further 
validate these results, we tested the effect of 0, 2, 4, 6, 8 and 10 µM of Triamterene 
alone or upon 5-FU treatment in DLD1 and DLD1+chr2 cells (Figure 25A). This 
experiment validated the specific modulation of Triamterene upon 5-FU treatment in 
DLD1 cells compared to DLD1+chr2 cells in the range of 4 to 10 µM concentration 
of Triamterene.  
To further investigate the requirement of 5-FU in the Triamterene-induced 
cytotoxicity, we repeated a short-term experiment with Triamterene only; we treated 
the cells for 4 days with Triamterene (instead of 2 days in drug followed by 2 days in 
media, as in previous validation experiments). Interestingly, we observed reduced 
cell viability in the MSH6 deficient DLD1 cells compared to DLD1+chr2 cells with 
Triamterene independently of 5-FU, suggesting a potential synthetic lethality with 
Triamterene treatment upon MSH6 deficiency (Figure 25B). Our initial validation 
experiments showed no cytotoxicity of Triamterene alone (Figure 25A); however, 
further validation showed a selective cytotoxicity of Triamterene alone in MSH6 
deficient DLD1 cells (Figure 25B). These contradictory results can be explained by 
the difference in experiment scheduling: in the initial validation experiment, we 
either treated the cells for 2 days with Triamterene, followed by 2 days in media 
which triggered no cytotoxicity; or we treated the cells 2 days with 5-FU and 2 days 
with Triamterene which triggered cytotoxicity compared to 5-FU alone. In this 
experiment, we treated the cells for 4 days with Triamterene, which triggered 
cytotoxicity in the absence of 5-FU. These results suggest that Triamterene is 
synthetically lethal in DLD1 cells, when the cells are kept in treatment for longer. 
This result will be explained in greater detail in chapter 2, section 1.3. The aim of 
this project was to identify modulators of 5-FU resistance mediated by MMR 
deficiency; however, it would be clinically relevant to identity novel compounds 
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synthetically lethal with MMR deficiency. Further experiments are required to 
investigate Triamterene as a potential synthetic lethal agent for the treatment of 
MMR deficient tumours.  
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Figure 25: Triamterene alone is synthetically lethal in DLD1 cells 
A: Cells were treated with either DMSO, 2 µM 5-FU or with increasing 
concentrations of Triamterene (0, 2, 4, 6, 8 and 10 µM). After 48 hrs treatment, the 
5-FU pre-treated cells were treated with increasing concentrations of Triamterene (0, 
2, 4, 6, 8 and 10 µM) and the media was replaced for the remaining cells. After 
48 hrs, cell viability was measured using an ATP-luminescence assay. B: Cells were 
treated with increasing concentrations of Triamterene (0, 2, 4, 6, 8, and 10 µM). 
After 4 days treatment, cell viability was measured using an ATP-based 
luminescence assay. A, B: Experiments were carried out in triplicate and the error 
bars represent the SEM. P-values derived from 2way ANOVA (*** p < 0.001).  
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4.2 Triamterene is synthetically lethal in MSH6 deficient cell lines 
We previously showed that Triamterene alone was synthetically lethal in DLD1 
cells. To further validate this Triamterene-induced synthetic lethality in MSH6 
deficient cell lines, we performed longer-term clonogenic assays in DLD1 and 
DLD1+chr2 cells treated with increasing concentrations of Triamterene (0, 2, 4, 6, 8 
and 10 µM) alone. After 14 days treatment, we observed an inhibition of colony 
formation in the MSH6 deficient DLD1 cells upon Triamterene treatment, compared 
to DLD1+chr2 cells (Figure 26A). These results further suggest that Triamterene 
alone is synthetically lethal in DLD1 cells. We also performed longer-term 
clonogenic assays in the MSH6 deficient and proficient, U251 and U251.TR3 cells 
treated with increasing concentrations of Triamterene (0, 4, 8, 12, 16 and 20 µM) 
alone. After 14 days treatment, we also observed an inhibition of colony formation 
specifically in the MSH6 deficient U251.TR3 cells upon Triamterene treatment, 
compared to U251 cells (Figure 26B). Taken together, these results suggest that 
Triamterene alone is synthetically lethal in MSH6 deficient cell lines. 
  
Results – Chapter 1 116 
 
A 
B 
0 2 4 6 8 10
0.0
0.2
0.4
0.6
0.8
1.0
1.2
DLD1 (MSH6-ve)
DLD1+chr2 (MSH6+ve)
**
Triamterene (M)
S
u
rv
iv
in
g
 F
ra
c
ti
o
n
0 5 10 15 20
0.0
0.2
0.4
0.6
0.8
1.0
1.2
U251.TR3 (MSH6-ve)
U251 (MSH6+ve)
* *** ***
Triamterene (M)
S
u
rv
iv
in
g
 F
ra
c
ti
o
n
  
Figure 26: Long-term clonogenic assay of Triamterene treatment in MSH6 
deficient and proficient matched paired cell lines 
A: DLD1 and DLD1+chr2 cells were plated at low density (300 and 350 cells per 
well respectively) in 6-well plates and treated every 3 days with increasing 
concentrations of Triamterene (0, 2, 4, 6, 8 and 10 µM). After 14 days, colonies were 
fixed, stained with SRB and counted. B: U251 and U251.TR3 cells were plated at 
low density (350 and 400 cells per well respectively) in 6-well plates and treated 
every 3 days with increasing concentrations of Triamterene (0, 4, 8, 12, 16 and 
20 µM). After 14 days, colonies were fixed, stained with SRB and counted. A, B: 
Experiments were carried out in triplicate and error bars represent the SEM. P-values 
derived from 2way ANOVA t-test, (* p < 0.05; ** p < 0.01; *** p < 0.001).  
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4.3 Triamterene is synthetically lethal in a panel of MMR deficient cell lines 
We previously showed that Triamterene was synthetically lethal in MSH6 deficient 
cell lines. To establish whether the Triamterene is synthetically lethal in MSH6 
deficiency specifically or in MMR deficiency in general, we tested this compound on 
our panel of MMR deficient and proficient paired cell lines described previously 
(Figure 17A; Table 11). Significantly, treatment with Triamterene caused a selective 
cytotoxic effect in all MMR deficient cell lines compared to their paired MMR 
proficient cells, regardless of tumour type (Figure 27). These results suggest a 
potential role for Triamterene as a synthetic lethal compound for the treatment of 
MMR deficient tumour cells. 
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Figure 27: Triamterene response in our panel of MMR deficient and proficient 
matched paired cell lines 
A: A panel of MMR proficient and deficient matched paired cell lines was treated 
with Triamterene (0, 2, 4, 6, 8 and 10 μM in HEC59, HEC59+chr2, HCT116, 
HCT116+chr3, A2780cp80 A2 and A2780cp80 E1 cells; and 0, 5, 10, 20 and 50 μM 
in U251 and U251.TR3 cells). Cell viability was measured after 4 days treatment. 
Experiments were carried out in triplicate and error bars represent the SEM. P-values 
derived from 2way ANOVA (* p < 0.05, *** p < 0.001). 
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5 In vivo experiment 
5.1 Pilot experiment 
5.1.1 Experiment set up 
We have previously shown that Triamterene is synthetically lethal in MMR deficient 
cell lines in vitro. To assess Triamterene efficacy in vivo, we performed a pilot study 
on 20 mice to select the best experimental conditions for further xenograft studies. 
We carried out in vivo experiments using DLD1, DLD1+chr2, HCT116 and 
HCT116+chr3 cells. We injected 1.6 million cells in both flanks (2 tumours per 
mouse) into male NOD-SCID mice. Treatment was started as soon as the tumours 
were measurable in all mice. As illustrated in Figure 16, each mouse received, 
3 times a week, the following treatment regimes: (1) vehicle (folate-free RPMI) by 
IP injection; (2) 25 mg/kg Triamterene by IP; (3) 25 mg/kg by gavage; (4) 50 mg/kg 
by IP and (5) 50 mg/kg by gavage [380, 381]. Triamterene is more soluble in media 
than in 1X PBS; therefore we decided to dilute the drug in media for the in vivo 
experiment. Furthermore, Triamterene has an antifolate activity [382], therefore, we 
decided to dilute the compound in folate-free RPMI to avoid any potential antagonist 
effect of the folate present in the media with Triamterene. The tumours were 
measured twice a week by measuring the width and the length using callipers. The 
mice were sacrificed when the tumour area reached 1.44 cm
2
,
 
in case of sickness or 
after 25 days treatment (Table 13).  
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tumour size (mm
2
) day 1 sacrifice (days) 
 
DLD1 DLD1+chr2 DLD1 DLD1+chr2 
IPV 32.7 53.72 41.95 54.35 10 25 
GT25 52.42 67.2 16.32 36.86 23  >25 
GT50 12.41 128.13 15.74 22.05 2 >25  
IPT25 27.84 22.8 42.56 47.62 7 (sick) 23 
IPT50 37.44 102.91 40.77 57.73 4  >25 
 
 
tumour size (mm
2
) day 1 sacrifice (days) 
 
HCT116 HCT116+chr3 HCT116 HCT116+chr3 
IPV 40.67 82.88 22.58 39.01 23 (sick) 17 (sick) 
GT25 61.09 25.48 20.38 56.23 4 14 
GT50 37.9 24.2 13.44 18.72 23 4 (no tumour) 
IPT25 55.14 29.4 17.47 58.61 4 17 
IPT50 38.16 34.11 12.8 104.43 23 10 (sick) 
Table 13: Tumour sizes on the first day of treatment and number of days of 
treatment before sacrifice 
IPV: vehicle (folate-free RPMI) by IP injection; GT25: 25 mg/kg by gavage; GT50: 
50 mg/kg by gavage; IPT25: 25 mg/kg Triamterene by IP; and IPT50: 50 mg/kg by 
IP. 
 
 
5.1.2 Pilot experiment results and analysis 
As explained in the previous section, we started treating the mice when all the 
tumours were measurable. The tumour sizes on the first day of treatment were 
heterogeneous and the majority of tumours grew rapidly which limited the 
interpretation of this experiment on treatment efficacy (Table 13, Figure 28 & Figure 
29). All tumour sizes were normalized to the first tumour measurements in order to 
analyse the tumour growth. As a linear tumour growth was expected and observed, 
and to make the interpretation easier, we represented the slope linear regression for 
each condition (Figure 30A, B). Our results showed no interpretable results in the 
HCT116 and HCT116+chr3 mice, probably due to the limited number of mice 
analysed and the variability between them. Also during the experiment, two 
HCT116+chr3 xenografted mice became sick and one HCT116+chr3 xenografted 
mouse did not grow tumour. Therefore, we could not interpret the results from the 
HCT116 and HCT116+chr3 xenografted mice and decided not to carry out more 
mice experiment using HCT116 and HCT116+chr3 cells (Table 13, Figure 29 & 
Figure 30B). One DLD1 xenografted mouse showed signs of sickness; this mouse 
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was smaller than the others (19 grams vs 27 grams in average) which might explain 
why it was sick (Table 13). The DLD1 and DLD1+chr2 xenografted mice treated 
with 25 mg/kg Triamterene by gavage gave us the most conclusive and significant 
results (p < 0.0001) (Figure 28 & Figure 30A, C). Therefore, for further in vivo 
experiment, we selected the concentration of 25 mg/kg Triamterene by gavage in 
DLD1 and DLD1+chr2 cells xenografted into NOD-SCID mice.  
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Figure 28: In vivo pilot experiment on DLD1 and DLD1+chr2 xenografted mice 
A-E: Tumour growth measurements upon treatments with IPV: vehicle (folate-free 
RPMI) by IP injection; IPT25: 25 mg/kg Triamterene by IP; GT25: 25 mg/kg by 
gavage; IPT50: 50 mg/kg by IP; or GT50: 50 mg/kg by gavage of the DLD1, 
DLD1+chr2 xenografted mice. Each mouse had 2 tumours. Tumours were measured 
twice a week and normalized to the first day treatment measurements.  
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Figure 29: In vivo pilot experiment on HCT116 and HCT116+chr3 xenografted 
mice 
A-E: Tumour growth measurements upon treatments with IPV: vehicle (folate-free 
RPMI) by IP injection; IPT25: 25 mg/kg Triamterene by IP; GT25: 25 mg/kg by 
gavage; IPT50: 50 mg/kg by IP; or GT50: 50 mg/kg by gavage of the HCT116, 
HCT116+chr3 xenografted mice. Each mouse had 2 tumours. Tumours were 
measured twice a week and normalized to the first day treatment measurements. 
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Figure 30: In vivo pilot experiment 
A, B: Slope linear regression as a representation of tumour growth for the DLD1, 
DLD1+chr2, HCT116 and HCT116+chr3 xenografted mice. C: Tumour growth in 
DLD1 and DLD1+chr2 xenografted mice treated with vehicle by IP injection or 
25 mg/kg Triamterene by gavage. Error bars represent SEM. 
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5.2 In vivo experiment in DLD1 and DLD1+chr2 cells 
5.2.1 In vivo experiment on 20 NOD-SCID mice with DLD1 and DLD1+chr2 
cells 
We previously selected the concentration of 25 mg/kg Triamterene by gavage in 
DLD1 and DLD1+chr2 cells xenografted into NOD-SCID mice for further in vivo 
experiments. We next carried out an in vivo experiment in 20 NOD-SCID mice 
xenografted with DLD1 and DLD1+chr2 cells. We injected 1.6x10
6
 cells in both 
flanks (2 tumours per mouse) by gavage, with 25 mg/kg Triamterene or vehicle. The 
width and the length of the tumours were measured twice a week using callipers. The 
mice were sacrificed in case of sickness or when the tumours reached 1.44 cm
2
. Our 
results showed a significant tumour growth reduction (p < 0.01) in DLD1 
xenografted mice treated with Triamterene compared to the vehicle treated mice 
(Figure 31A). However we did not observe any significant tumour growth difference 
in the DLD1+chr2 xenografted mice treated with Triamterene or vehicle (Figure 
31B). We observed a faster tumour growth in DLD1 xenografted mice compared to 
the DLD1+chr2 xenografted mice. These results were expected as we observed, in 
vitro, a slower growth for DLD1+chr2 compared to DLD1 cells. These results 
suggest a Triamterene-induced decrease in tumour growth in the MSH6 deficient 
DLD1 xenografted mice specifically, which further validates Triamterene as 
synthetically lethal in MMR deficiency.  
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Figure 31: In vivo experiment on 20 NOD-SCID mice with DLD1 and 
DLD1+chr2 cells treated with Triamterene 
A, B: Initial in vivo mouse experiment on 20 NOD-SCID mice injected in both 
flanks with DLD1 or DLD1+chr2 cells (1.6x10
6
 cells per flank). Mice were treated 3 
times a week by gavage with 25 mg/kg Triamterene or vehicle. Tumours were 
measured twice a week and normalized to the first day treatment measurements. 
Error bars represent SEM. P-values derived from paired two-tailed t-test 
(** p < 0.01, NS p > 0.05). 
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5.2.2 In vivo experiment on 40 NOD-SCID mice with DLD1 and DLD1+chr2 
cells 
Our previous experiment showed a Triamterene-induced decrease in tumour growth 
in the DLD1 xenografted mice specifically. However, we observed a difference in 
tumour growth in the vehicle treated DLD1 compared to the DLD1+chr2 
xenografted mice. To further confirm that the effect of Triamterene observed in vivo 
is not due to the tumour growth but to MSH6 deficiency, we repeated this 
experiment with an adjusted number of cells injected. We injected either 0.6x10
6
 
DLD1 cells or 0.8x10
6
 DLD1+chr2 cells in only one flank of 40 NOD-SCID mice. 
The treatment regime and tumour measurements were done as previously. In this 
experiment, we observed again a slower growth in DLD1+chr2 xenografted mice 
compared to DLD1 xenografted mice. We also confirmed a significant decrease in 
tumour growth in mice treated with Triamterene compared with mice treated with 
vehicle (p < 0.05) in the DLD1 xenografted mice only (Figure 32A, B). These results 
further suggest a Triamterene-induced decrease in tumour growth in the MSH6 
deficient DLD1 xenografted mice specifically. 
 
The treatment regime and tumour measurements for both experiments were similar. 
Therefore, we compared both experiments and observed similar tumour growth for 
the vehicle treated DLD1 xenografted mice from the first experiment (Figure 31A) 
and for the vehicle treated DLD1+chr2 xenografted mice from the second 
experiment (Figure 32B). We observed a decreased tumour growth in DLD1 
xenografted mice but not in DLD1+chr2 xenografted mice by comparing the 
Triamterene treated mice to the vehicle treated mice. This further suggests that the 
Triamterene effect observed is not due to a greater tumour cell proliferation, but 
rather to MSH6 deficiency. Taken together these results confirm a synthetic lethal 
interaction between Triamterene treatment and MSH6 deficiency in vivo.  
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Figure 32: In vivo experiment on 40 NOD-SCID mice with DLD1 and 
DLD1+chr2 cells treated with Triamterene 
A, B: Second in vivo mouse experiment on 40 NOD-SCID mice injected in one flank 
with DLD1 or DLD1+chr2 cells (0.6x10
6
 cells and 0.8x10
6
 cells respectively). Mice 
were treated 3 times a week by gavage with either vehicle or 25 mg/kg Triamterene. 
Tumours were measured twice a week and normalized to the first day treatment 
measurements. Error bars represent SEM. P-values derived from paired two-tailed 
t-test (* p < 0.05, NS p > 0.05).  
A 
B 
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5.2.3 In vivo experiment with U251 and U251.TR3 cells 
Our previous results confirm a synthetic lethal interaction between Triamterene 
treatment and MSH6 deficiency in vivo. To further validate that the effect observed 
in vivo was due to MSH6 deficiency rather than increased tumour growth; we carried 
out an in vivo experiment on U251 and U251.TR3 xenografted mice. We previously 
observed that the MSH6 proficient U251 cells have a higher proliferation rate than 
U251.TR3 cells in vitro, the opposite to the DLD1 and DLD1+chr2 cells. Therefore, 
any decrease in tumour growth upon Triamterene treatment in U251.TR3 compared 
to U251 xenografted mice, would confirm a proliferation-independent synthetic 
lethality between Triamterene and MSH6 deficiency in vivo. To determine cell 
number, we carried out a pilot experiment on 6 NOD-SCID mice. We injected the 
mice subcutaneously with U251 and U251.TR3 cells at different densities: 2.5x10
6
 
or 1x10
6
 cells in PBS or 1x10
6
 cells in matrigel (1:1). None of the mice grew 
tumours after 4 weeks; therefore due to technical constraints we could not conclude 
the selectivity in vivo experiment, using these cells.  
 
Taken together, we have identified, using a high-throughput compound screen, 
Clotrimazole and Triamterene as modulators of 5-FU resistance in the MSH6 
deficient DLD1 cells. We observed that Clotrimazole is a specific modulator of 5-FU 
resistance in DLD1 cells, rather than MMR deficient cell lines in general. Our data 
also suggest a synthetic lethal relationship between Triamterene treatment and MMR 
deficiency, in the absence of 5-FU. Our results confirmed this synthetic lethality in 
vitro and in vivo. Therefore, using a high-throughput compound screen, we have 
identified a novel agent, Triamterene for use in the treatment of MMR deficient 
tumours. Further investigations are necessary to understand the mechanism of 
synthetic lethality upon Triamterene treatment and MMR deficiency. 
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Chapter 2: Investigation into Triamterene 
as a synthetic lethal drug for the treatment 
of MMR deficiency 
 
1 Triamterene synthetic lethality is through its antifolate 
activity 
1.1 The known mechanisms of action of Triamterene 
Our previous results showed a novel synthetically lethal relationship between 
Triamterene and MMR deficient tumours. To understand the mechanism by which 
Triamterene is cytotoxic in MMR deficient cell lines, we first needed to understand 
the known mechanisms by which Triamterene has been reported to act. Triamterene 
(6-phenylpteridine-2,4,7-triamine) was first described in 1962 for its pteridine 
structure and its diurectic activity [383-385]. Triamterene has been used in clinic 
since 1963 for the treatment of oedemas, ascites, hypertension and congestive heart 
failure [386-389]. Triamterene has been shown to share the same mechanism of 
action as Amiloride by direct inhibition of the ENaC [378]. It has also been reported 
to be a regulator of DHFR activity. Conflicting studies have been published with 
regards to this regulation, therefore, it is not clear if Triamterene increases or 
decreases DHFR activity [390-392]. However, it is clear that Triamterene has an 
antifolate activity due to its pteridine structure (Figure 33) [382]. 
      `      
Triamterene     Folic acid 
Figure 33: Triamterene has an antifolate activity due to its pteridine structure 
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1.2 Triamterene cytotoxicity in MMR deficient cells, is not due to its role as 
a sodium channel antagonist 
1.2.1 Amiloride is not synthetically lethal in MMR deficient cells 
We identified Triamterene, a potassium-sparing diuretic, to be synthetically lethal 
with MMR deficiency. We firstly wanted to determine if Triamterene was 
synthetically lethal through its diuretic action by the inhibition of the ENaC. 
Amiloride is a drug known to inhibit the ENaC through the same mechanism as 
Triamterene [393]. Kellenberger et al previously showed that mutations in the 
different subunits of the ENaC could induce a comparable reduction of the ENaC 
inhibition mediated by Triamterene and Amiloride treatment. Therefore, they 
concluded that these two compounds have the same binding sites on the ENaC [394]. 
In the clinic, Triamterene is prescribed as an alternative to Amiloride for the 
treatment of hypertension [394, 395]. We hypothesised that if Triamterene was 
synthetically lethal through the inhibition of the ENaC, Amiloride, which shares the 
same mechanism of action, would also be synthetically lethal in MMR deficient cell 
lines. We treated DLD1 and DLD1+chr2 cells with increasing concentrations of 
Amiloride (0, 0.5, 5, 10 and 50 µM) and measured cell viability after 4 days. As 
shown in Figure 34, only at high concentrations of Amiloride (50 µM) we observe 
cytotoxicity for the cells and Amiloride does not show selective lethality in the 
MMR deficient DLD1 cells, compared to DLD1+chr2 cells. These results suggest 
that Triamterene is not synthetically lethal in MMR deficient cells through its shared 
mechanism of action with Amiloride, as a sodium channel antagonist. 
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Figure 34: Amiloride, another ENaC inhibitor, is not synthetically lethal in 
MMR deficient cells 
Cells were seeded in 96-well plates and treated with increasing concentrations of 
Amiloride (0, 0.5, 5, 10 and 50 µM). After 4 days treatment, cell viability was 
assessed by ATP-luminescence assay. Experiments were carried out in triplicate and 
error bars represent SEM. P-values derived from 2way ANOVA (NS p > 0.05). 
 
 
1.2.2 Silencing of the different subunits of the ENaC is not synthetically lethal 
in MMR deficient cell lines 
Our results suggest that Triamterene is not synthetically lethal in MMR deficient 
cells through its shared mechanism of ENaC inhibition with Amiloride. The ENaC is 
composed of 2 x α, 1 x β and 1 x γ subunits [396]. In order to further investigate the 
role of ENaC inhibition in Triamterene synthetic lethality in MMR deficient cells, 
we silenced the three different subunits of ENaC (α, β and γ) by siRNA transfection 
in a range of MMR deficient and proficient matched paired cell lines (Figure 35). 
We silenced the different subunits individually or in combination using the same 
final siRNA concentration to allow the comparison of the different conditions (see 
the material and methods section 6.1). We validated siENaC transfection efficiency 
with internal siRNA controls (siCtrl and siPLK1). In DLD1 and DLD1+chr2 cells, 
the inhibition of the ENaC subunits was not lethal for the cells, with higher toxicity 
observed upon silencing of the ENaC γ subunit. However, we did not observe any 
selective lethality in the MSH6 deficient DLD1 cells compared to the MSH6 
proficient DLD1+chr2 cells (Figure 35A). In HCT116 and HCT116+chr3 cells, the 
inhibition of the ENaC subunits was not lethal. Again, we did not observe any 
selective lethality in the MLH1 deficient HCT116 cells compared to the MLH1 
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proficient HCT116+chr3 cells (Figure 35B). In U251 and U251.TR3 cells, again the 
inhibition of the ENaC subunits were not selective lethality in the MSH6 deficient 
U251.TR3 cells compared to the MSH6 proficient U251 cells. We observed higher 
toxicity upon silencing of the ENaC β subunit (Figure 35C). Taken together, our 
results suggest a cell line dependent toxicity upon inhibition of the different ENaC 
subunits. Moreover, silencing of the ENaC subunits either alone or in combination 
was not synthetically lethal in MMR deficient cell lines and therefore suggests that 
ENaC inhibition is not the mechanism by which Triamterene induces synthetic 
lethality in MMR deficient cells. 
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Figure 35: Triamterene is not cytotoxic through the inhibition of the ENaC 
A-C: Cells were transfected with siCtrl, siPLK1 or siRNAs targeting the different 
subunits of the ENaC (α, β and γ), individually or in combination. To be able to 
compare the different silencing conditions, we used the same siRNA concentration 
and the same final concentration for each condition (50 nM of each siRNA in 
addition of the appropriate concentration of siCtrl for a final concentration of 
150 nM). After 24 hrs transfection, the media was replaced and after 5 days 
transfection, cell viability was measured, by an ATP-luminescence assay. 
Experiments were carried out in triplicate, data were normalized to the siCtrl 
condition and error bars represent SEM. P-values derived from 2way ANOVA 
(NS p > 0.05).  
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1.3 Triamterene cytotoxicity is due to its antifolate activity 
Our data suggested that the synthetic lethality observed upon Triamterene treatment 
in MMR deficient cells is not due to its role as an ENaC inhibitor; therefore we 
investigated the other reported roles of the compound. Structural analysis and 
previous studies have shown that Triamterene shares the same structure as a folate 
and therefore can compete with folate binding and function as an antifolate, which 
may regulate DHFR activity (Figure 33) [397].  
 
1.3.1 Addition of folates can rescue Triamterene synthetic lethality in MMR 
deficient cells. 
To investigate if Triamterene was synthetically lethal in MMR deficient cell lines 
through its antifolate activity, we hypothesised that the addition of folic acid could 
rescue Triamterene selective cytotoxicity. We treated DLD1 and DLD1+chr2 cells, 
grown in folate-free media (folate-free RPMI supplemented with 10 % dialysed 
FBS), with 10 µM Triamterene and increasing concentrations of folic acid (0, 0.01, 
0.1, 1, 2, 10 µM) (Figure 36A). Our results showed that 4 days folate starvation was 
not cytotoxic in DLD1 and DLD1+chr2 cells. The residual levels of folates present 
in the dialysed FBS may be sufficient to retain cell viability. In the presence of 
0.1 µM folic acid or less, Triamterene was cytotoxic in both cell lines. With higher 
concentration of folic acid (1, 2 and 10 µM), we observed a folic acid concentration 
dependant rescuing effect of Triamterene cytotoxicity. With 2 µM folic acid, we 
observed a selective cytotoxicity upon Triamterene treatment in the DLD1 cells. 
With 10 µM folic acid, we observed a rescued Triamterene-induced cytotoxicity. 
Our results suggest that addition of folic acid can rescue the Triamterene selective 
effect in MMR deficient cells. However folate-free media is not cytotoxic to the cells 
and Triamterene treatment can induce cytotoxicity in folate-starved media. We 
hypothesize that this may be due to residual folate remaining in the media due to 
addition of dialysed FBS. Furthermore, we previously showed that Triamterene is 
cytotoxic alone, only when the cells are kept in drug and not if the media is replaced 
with fresh drug-free media after 2 days treatment (Figure 25). To know if this was 
due to the presence of folate in the replaced media, we treated the cells with 
Triamterene for 2 days and either replaced the media with media containing 
Triamterene, folate-free media or complete media containing folate (Figure 36B). 
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We observed the same selective cytotoxicity in MMR-deficient cells treated with 
Triamterene alone or treated with Triamterene followed by folate-free media. 
However, we observed a rescuing effect of the Triamterene cytotoxicity in cells 
treated with Triamterene followed by normal media containing folate. Taken 
together, these results suggest a critical role for the folate pathway in Triamterene 
synthetic lethality in MMR deficient cells. 
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Figure 36: Addition of folic acid and media containing folate can rescue 
Triamterene synthetic lethality in MMR deficient cells 
A: Cells were treated in folate-free media with increasing concentrations of folic 
acid (0, 0.01, 0.1, 1, 2, 10 µM) alone or in addition of 10 µM Triamterene. Cell 
viability was measured after 4 days treatment by an ATP-luminescence assay. Data 
were normalized to the cell viability upon 10 µM folic acid alone in order to see a 
potential folate-free-induced cytotoxicity. Experiments were carried out in triplicate 
and error bars represent SEM. P-values derived from 2way ANOVA representing the 
difference between DLD1 and DLD1+chr2 cells treated with Triamterene 
(*** p < 0.001). B: On day 1, cells were plated in a 96-well plate; on day 2 cells 
were treated with 10 µM Triamterene (T) or media (m); on day 4, cells were treated 
with 10 µM Triamterene (T), media (m) or folate-free media (mFA); Cell viability 
was measured using an ATP-luminescence assay on day 6. Experiments were carried 
out in triplicate and error bars represent SEM. P-values derived from 2way ANOVA 
(NS p > 0.05, *** p < 0.001). 
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1.3.2 Triamterene synthetic lethality in MMR deficient cell lines could be 
rescued by a range of different folates 
We previously showed that the addition of folic acid or folate-containing media 
could rescue Triamterene cytotoxicity in the MMR deficient cell lines. We 
investigated any specificity for the requirement of folates to reverse the cytotoxicity, 
by using a range of different folates (folic acid (FA), dihydrofolate (DHF), 
tetrahydrofolate (THF) and Leucovorin (LV)) implicated in the folate pathway 
(Figure 11). We wanted to understand whether different folates could have different 
rescuing effect on Triamterene selective cytotoxicity, leading us to a better 
understanding of the role of Triamterene in the folate pathway.  
To this end, we treated cells with 10 µM or 20 µM Triamterene, in addition to 
10 µM or 50 µM of a range of different folates (DHF, THF, FA and LV) in the 
DLD1, DLD1+ch2 cells and U251, U251.TR3 cells respectively, and measured cell 
viability after 4 days treatment. In the DLD1 and DLD1+chr2 cells, the addition of 
FA, DHF, THF and LV could completely rescue Triamterene selective lethality 
(Figure 37A). In the U251 and U251.TR3 cells, the addition of DHF and LV could 
partially rescue the MSH6 deficient U251.TR3 cells from Triamterene cytotoxicity. 
However the addition of FA and THF could completely rescue Triamterene selective 
lethality (Figure 37B). We observed a greater reduction in cell viability upon 
Triamterene treatment in the U251.TR3 cells (58 %) in comparison to the DLD1 
cells (30 %). This difference may explain the only partial rescuing of the 
Triamterene cytotoxic effect in the U251.TR3 compared to the DLD1 cells, upon 
addition of DHF and LV. Taken together, our results showed that Triamterene 
cytotoxicity in MMR deficient cells could be rescued by the addition of a range of 
different folates. These results suggest that Triamterene is synthetically lethal in 
MMR deficiency through its antifolate activity. However, as we observed the ability 
of all of the folate compounds tested to rescue the cytotoxic effect of Triamterene, 
this data did not enable us to elucidate a specific role for Triamterene in the folate 
pathway. 
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Figure 37: Addition of a range of different folates can rescue Triamterene 
synthetic lethality in MMR deficient cells 
A: Cells were treated with 10 µM Triamterene combined with either 10 µM folic 
acid (FA), dihydrofolate (DHF), tetrahydrofolate (THF) or Leucovorin (LV). Cell 
viability was measured after 4 days treatment by ATP-luminescence assay. B: Cells 
were treated with 20 µM Triamterene combined with either 50 µM FA, THF, DHF 
or LV. Cell viability was measured after 4 days treatment by ATP-luminescence 
assay. A, B: Experiments were carried out in triplicate and error bars represent SEM. 
P-values derived from 2way ANOVA (* p < 0.05, *** p < 0.001). 
 
  
A 
B 
Results – Chapter 2 142 
 
1.4 Triamterene cytotoxicity is not due to the DHFR up-regulation 
1.4.1 Triamterene induces an up-regulation of DHFR 
Structural analysis and previous studies have shown that Triamterene shares the 
same structure as a folate and therefore can function as an antifolate which may 
regulate DHFR activity (Figure 33) [397]. DHFR is the main enzyme required for 
the folate pathway. It converts folate into DHF, and DHF into THF which is the rate 
limiting factor of TS activity and therefore, for dTMP synthesis (Figure 11) [398]. 
We next investigated whether Triamterene was synthetically lethal in MMR 
deficiency through the regulation of DHFR. In order to investigate the potential role 
for DHFR in Triamterene synthetic lethality in MMR deficient cells, we measured 
DHFR protein expression by western blot upon Triamterene treatment in a range of 
MMR deficient and proficient matched paired cell lines (DLD1 and DLD1+chr2; 
U251 and U251.TR3 cells). DHFR expression was similar in the MMR deficient 
cells when compared with their matched-paired MMR proficient cells (Figure 
38A&B). Interestingly, the Triamterene-induced DHFR up-regulation was higher in 
the MSH6 deficient DLD1 and U251.TR3 cells in comparison to the MSH6 
proficient DLD1+chr2 and U251 cells. However, we observed an increase in DHFR 
protein expression upon Triamterene treatment, independent of drug concentration 
and in both MMR deficient and proficient cell lines. We measured DHFR protein 
levels in DLD1 and DLD1+chr2 cells upon 0, 2, 4, 6, 8 and 10 µM Triamterene 
(Figure 38C). We confirmed that DHFR up-regulation was independent of 
Triamterene concentration and also observed that it was independent of Triamterene 
cytotoxicity if compared to the cell viability and clonogenic assays (Figure 25B & 
Figure 26A). We next investigated if the observed Triamterene-induced up-
regulation of DHFR expression was correlated with an increase in DHFR activity. 
We measured DHFR activity, by measuring the DHFR dependent consumption of 
NADPH, in the protein lysates used for western blotting (Figure 38A). As shown in 
Figure 38D, Triamterene treatment induced an increase in DHFR activity in DLD1 
and DLD1+chr2 cell lines. However, the difference in DHFR regulation in the 
DLD1 cells compared to the DLD1+chr2 cells was not significant. We also 
observed, in DLD1 and DLD1+chr2 cells that the DHFR protein expression 
correlated with the DHFR activity (Figure 38A & D). Taken together, our data 
suggest that the differential increase in DHFR expression and activity upon 
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Triamterene treatment in the MSH6 deficient cells may contribute to the synthetic 
lethal interaction we observe. 
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Figure 38: Triamterene induces a DHFR up-regulation 
A, C: Cells were plated in 10 cm dishes and were treated with either media, 5 µM or 
10 µM Triamterene. After 48 hrs treatment, protein was extracted. B: Cells were 
plated in 6-well plates and were treated with 10 µM Triamterene. After 48 hrs 
treatment, protein was extracted. A, B: DHFR and TS expression were measured by 
western blot using DHFR, TS and β-actin antibodies. β-actin is used as a loading 
control. C: Cells were plated in 6-well plates and were treated with 0, 2, 4, 6, 8 and 
10 µM Triamterene. After 48 hrs treatment, protein was extracted. DHFR expression 
were measured by western blot using DHFR and β-actin antibodies. β-actin is used 
as a loading control. D: DHFR activity was measured by measuring the DHFR-
dependant consumption of NADPH by monitoring the decrease in absorbance at 340 
nm. Experiments were carried out in triplicate and error bars represent SEM. P-
values derived from 1way ANOVA (NS p > 0.05, * p < 0.05, ** p < 0.01).  
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1.4.2 Triamterene is not synthetically lethal through DHFR up-regulation 
We previously observed that Triamterene was synthetically lethal in MMR deficient 
cells lines through its antifolate activity. We also showed that Triamterene treatment 
induced a greater, but not significant, increase in DHFR expression and activity in 
MMR-deficient cells. We hypothesised that if Triamterene was synthetically lethal 
with MMR deficiency, through DHFR up-regulation, DHFR silencing would rescue 
the cells from Triamterene cytotoxicity and DHFR over-expression would induce 
synthetic lethality in MMR deficient cells. To assess the role of DHFR up-regulation 
in Triamterene cytotoxicity, we treated cells transfected with siDHFR or siCtrl, with 
increasing concentrations of Triamterene (0, 2, 4, 6, 8, 10 µM) and measured cell 
viability after 2 days treatment (Figure 39). We firstly validated that the transfection 
using siRNAs targeting DHFR was efficiently reducing DHFR protein expression in 
DLD1 and DLD1+chr2 cells by western blot (Figure 39B). We observed that 
silencing DHFR increased Triamterene cytotoxicity in both cell lines regardless of 
their MMR status (Figure 39A). These results suggest that the Triamterene-induced 
up-regulation of DHFR activity and expression is not mediating the synthetic 
lethality in MMR deficient cells. To further investigate this, we over-expressed 
DHFR by plasmid transfection with an empty or DHFR-expression construct and 
measured the effect of DHFR over-expression alone or in combination with 
Triamterene treatment on DLD1 and DLD1+chr2 cell viability (Figure 40). Over-
expression of DHFR was not cytotoxic in DLD1 and DLD1+chr2 cells in 
comparison with the control plasmid. Moreover, DHFR over-expression did not 
modulate Triamterene selective lethality (Figure 40A). We validated DHFR over-
expression by western blotting (Figure 40B); however, we did not validate the 
correlation between DHFR over-expression and DHFR activity and cannot conclude 
on the role of DHFR over-expression in Triamterene synthetic lethality. DHFR 
activity might depend on the substrates availability in the cells and therefore, DHFR 
over-expression alone might not be correlated with an up-regulation of DHFR 
activity. We did not include a positive control such as Methotrexate, a well known 
inhibitor of DHFR activity, in the assay and therefore, we cannot be assured that the 
DLD1 and DLD1+chr2 cells had an increased DHFR activity. Taken together, our 
results suggest that DHFR up-regulation is not the mechanism of cytotoxicity of 
Triamterene.   
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Figure 39: Triamterene is not synthetically lethal with MMR deficiency, 
through DHFR up-regulation 
A, B: Cells were transfected in 6-well plates with a siCtrl or two different siRNAs 
targeting DHFR. A: The following day cells were counted, plated in 96-well plates 
and treated with increased concentration of Triamterene. After 2 days treatment, cell 
viability was measured using ATP luminescence assay. Experiments were carried 
out in triplicate and error bars represent SEM. B: The following day, cells were split 
in 6-well plates. After 2 days treatment, protein was extracted and DHFR expression 
was measured by western blot using DHFR and β-actin antibodies. β-actin is used as 
a loading control.  
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Figure 40: DHFR over-expression does not modulate cell viability alone or in 
combination of Triamterene treatment in DLD1 and DLD1+chr2 cells 
A: Cells were transfected in 96-well plates with an empty vector or a DHFR 
plasmid. The following day, cells were treated with either DMSO or 10 µM 
Triamterene. After 4 days treatment, cell viability was measured using ATP 
luminescence assay. P-values derived from 1way ANOVA (NS p > 0.05 and 
*** p < 0.001). Experiments were carried out in triplicate and error bars represent 
SEM. B: Cells were transfected in 6-well plates with an empty vector or a DHFR-
expressing vector. Two days after transfection, protein was extracted and DHFR 
over-expression was measured by western blot using FLAG and β-actin antibodies. 
β-actin is used as a loading control. 
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1.5 Triamterene cytotoxicity requires thymidylate synthase expression 
1.5.1 Triamterene synthetic lethality requires thymidylate synthase expression 
We previously showed that Triamterene treatment induced an increase in DHFR 
expression and activity, which is not required for the Triamterene synthetic lethality 
in MMR deficient cells. DHFR produces THF, the rate limiting factor of TS activity 
(Figure 11) [398]. We hypothesised that if treatment with Triamterene could up-
regulate DHFR, it may also regulate TS activity, as TS activity depends on DHFR 
activity [399]. Therefore, we next measured TS protein expression by western blot 
upon Triamterene treatment in a range of MMR deficient and proficient matched 
paired cell lines (DLD1 and DLD1+chr2; U251 and U251.TR3 cells). As shown in 
Figure 38A & B, TS expression is similar in the MMR deficient cells in comparison 
to their matched-paired MMR proficient cells. TS protein expression was unchanged 
upon Triamterene treatment. Taken together, these results show no Triamterene-
induced regulation of TS protein expression in our panel of cells. To further assess 
the role of TS in Triamterene cytotoxicity, we hypothesised that if Triamterene was 
synthetically lethal through TS regulation, TS silencing would rescue the cells from 
Triamterene selective lethality. DLD1 and DLD1+chr2 cells, transfected with two 
different siRNA targeting TS or siCtrl, were treated with increasing concentrations 
of Triamterene (0, 2, 4, 6, 8 and 10 µM) and cell viability was measured after 4 days 
treatment. We firstly validated that the transfection using siRNAs targeting TS-
induced a decrease in TS protein expression in DLD1 and DLD1+chr2 cells by 
western blot (Figure 41A). Interestingly, we observed that TS silencing by siRNA 
transfection prevented the Triamterene-induced lethality in the MSH6 deficient 
DLD1 cells, suggesting the TS is required for Triamterene cytotoxicity in MSH6 
deficient cells (Figure 41B). To further validate these results, we carried out the 
same experiment in the matched paired U251 and U251.TR3 cell lines (Figure 41C). 
We observed that TS silencing also prevented the Triamterene-induced lethality in 
the MSH6 deficient U251.TR3 cells. Taken together, these results strongly suggest 
the Triamterene synthetic lethality in MMR deficient cells, is dependent on TS 
expression.  
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Figure 41: Triamterene synthetic lethality requires thymidylate synthase 
expression 
A-C: Cells were transfected in 6-well plates with a siCtrl, siPLK1 or two siRNA 
targeting TS. The following day, cells were counted and seeded into either 6-well 
(A) or 96-well plates (B, C). A: Protein was extracted from DLD1 and DLD1+chr2 
cells in 6-well plates after 2 days and TS expression was measured by western blot 
using TS and β-actin antibodies. β-actin is used as a loading control. B, C: Cells 
plated in 96-well plates were treated with increased concentration of Triamterene. 
After 4 days treatment, cell viability was measured using an ATP luminescence 
assay. Experiments were carried out in triplicate and error bars represent SEM. 
P-values derived from 2way ANOVA (** p < 0.01, *** p < 0.001).  
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1.5.2 Triamterene synthetic lethality can be rescued by TS inhibitors 
We have previously shown that TS expression was required for the Triamterene-
induced synthetic lethality in MMR deficient cell lines. Two widely used 
chemotherapeutic treatments in CRC, 5-FU and Raltitrexed, are TS inhibitors. They 
inhibit the active complex form of THF-TS-dUMP, either by competing with dUMP 
in the case of 5-FU or by competing with THF in the case of Raltitrexed. We 
hypothesised that, if TS expression was required for Triamterene cytotoxicity, 5-FU 
and Raltitrexed would be able to rescue the cytotoxic effect of Triamterene in MMR 
deficient cells. To investigate this, we treated cells with either 2 µM 5-FU or 1 nM 
Raltitrexed in addition to Triamterene treatment and measured cell viability after 
4 days treatment. Our results indicate that Triamterene cytotoxicity can be rescued 
by addition of TS inhibitors in the DLD1 and U251.TR3 MSH6 deficient cells 
(Figure 42). Interestingly, we observed a greater rescuing effect of the Triamterene 
cytotoxicity, with Raltitrexed treatment compared to 5-FU. This difference may be 
explained by the fact that Raltitrexed has only one mechanism of action, the 
inhibition of TS; however, 5-FU has three known mechanisms of action: the 
inhibition of TS, the misincorporation of FdUTP into DNA and the misincorporation 
of FUTP into RNA (Figure 8). Taken together, these results suggest the requirement 
for TS for the Triamterene-induced synthetic lethality in MMR deficient cell lines. 
 
Results – Chapter 2 150 
 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
5-FU
DLD1 (MSH6-ve)
DLD1+chr2 (MSH6+ve)
- -+ + Triamterene- + - -+ + - +
- +- + - - - +- + - -
- -- - + + - -- - + + Raltitrexed
***
*
***
S
u
rv
iv
in
g
 F
ra
c
ti
o
n
0.0
0.2
0.4
0.6
0.8
1.0
1.2
U251.TR3 (MSH6-ve)
U251 (MSH6+ve)
5-FU
- -+ + Triamterene- + - -+ + - +
- +- + - - - +- + - -
- -- - + + - -- - + + Raltitrexed
***
NS
***
S
u
rv
iv
in
g
 F
ra
c
ti
o
n
 
Figure 42: Triamterene synthetic lethality can be rescued by TS inhibitors 
A, B: Cells were treated with either Triamterene (10 µM in DLD1 and DLD1+chr2 
cells; 20 µM in U251 and U251.TR3 cells), 2 µM 5-FU, 1 nM Raltitrexed or a 
combination of Triamterene and 5-FU or Raltitrexed. Cell viability was measured 
4 days after treatment by ATP-luminescence assay. Experiments were carried out in 
triplicate and error bars represent SEM. P-values are derived from 1way ANOVA 
(NS p > 0.05, * p < 0.05, *** p < 0.001). 
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1.5.3 Over-expression of TS does not affect Triamterene synthetic lethality 
There is a requirement for TS activity for the Triamterene-induced synthetic lethality 
in MMR deficient cell lines. Therefore, we hypothesised that TS over-expression 
could modulate the Triamterene cytotoxicity in the MMR deficient cells. To this end, 
we over-expressed TS using a TS-expressing plasmid and transfected the cells with 
this construct or an empty plasmid as a control. We validated TS over-expression by 
western blotting (Figure 43A). 48 hrs after transfection, we measured the effect of 
TS over-expression alone or in combination with Triamterene treatment on DLD1 
and DLD1+chr2 cell viability (Figure 43B). We observed that over-expression of TS 
was not cytotoxic in DLD1 and DLD1+chr2 cells in comparison with the control 
plasmid. Moreover, TS over-expression did not modulate the Triamterene selective 
lethality. We did not include a positive control such as 5-FU in the assay and 
therefore, we cannot be assured that TS over-expression is correlated with an 
increase in TS activity. THF is the rate-limiting factor of TS activity; therefore, over-
expression of TS might not be correlated with an increase in TS activity. Taken 
together, our results suggest that up-regulation of TS does not mediate Triamterene 
synthetic lethality in MMR deficient cells.  
We previously observed an up-regulation of DHFR expression and an increase in 
DHFR activity upon Triamterene treatment. In addition, we identified a dependency 
for TS expression in the Triamterene synthetic lethality with MMR deficiency. We 
speculated that over-expression of DHFR may produce an excess of THF and 
therefore, in combination with over-expression of TS, this may correlate with an 
increase in TS activity, which may induce Triamterene synthetic lethality in MMR 
deficient cells. We over-expressed TS and DHFR proteins by plasmid transfection 
and measured whether over-expression of both TS and DHFR together, either 
untreated or upon Triamterene treatment could induce synthetic lethality in DLD1 
cells (Figure 43C). Over-expression of DHFR/TS was not cytotoxic in DLD1 and 
DLD1+chr2 cells in comparison with the control plasmid. In addition, over-
expression of DHFR/TS together did not modulate Triamterene cytotoxicity. Taken 
together, our results suggest that TS over-expression is not the mechanism of 
Triamterene synthetic lethality in MMR deficient cells and that the over-expression 
of DHFR and TS, alone or in combination, do not modulate Triamterene synthetic 
lethality in MMR deficient cells. 
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We have shown that Triamterene induces a non toxic up-regulation of DHFR. We 
have also shown that Triamterene requires TS expression and activity to be 
synthetically lethal. However, over-expression of TS alone or in combination with 
DHFR, does not induce selective lethality and does not modulate Triamterene 
synthetic lethality in MMR deficient cell lines.  
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Figure 43: Over-expression of TS does not modulate Triamterene synthetic 
lethality 
A: Cells were transfected in 6-well plates with an empty vector or a TS plasmid. 
After 2 days transfection, protein was extracted and TS over-expression was 
measured by western blot using FLAG and β-actin antibodies. β-actin is used as a 
loading control. B: Cells were transfected in 96-well plates with empty vector or TS-
expressing plasmid. The following day, cells were treated with 10 µM Triamterene. 
Cell viability was measured on day 6 by ATP-luminescence assay. C: Cells were 
transfected in 96-well plates with empty vector or a combination of both the TS and 
DHFR-expressing plasmids. The following day, cells were treated with 10 µM 
Triamterene. Cell viability was measured on day 6 by ATP-luminescence assay. 
Experiments were carried out in triplicate and error bars represent SEM.   
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2 Triamterene is cytotoxic through an increase in reactive 
oxygen species 
2.1 Triamterene induces an increase in ROS level 
Previous studies have shown that MMR deficient tumours are sensitive to oxidative 
stress [315, 317-319]. Oxidative stress is caused by an imbalance between ROS 
production and degradation via the antioxidant response [21]. We investigated 
whether Triamterene was synthetically lethal in MMR deficient cell lines due to an 
increase in ROS levels. We treated the cells for 48 hrs with either 5, 10 or 20 µM 
Triamterene in a panel of MMR deficient and proficient matched paired cell lines 
and measured ROS levels (Figure 44). ROS was measured using an DCFDA-
Cellular ROS Detection Assay. DCFDA is converted in DCF by ROS. DCF, which 
is proportional to ROS levels, can be measured by fluorescence. Our results showed 
a dose-dependent increase in ROS levels in the MMR deficient cell lines, whilst 
ROS was not significantly induced in the matched paired MMR proficient cell lines 
upon treatment with increasing concentrations of Triamterene. Therefore our results 
suggest that Triamterene treatment induces an increase in ROS levels, specifically in 
MMR deficient cells lines.  
 
To further investigate this Triamterene-induced increase in ROS levels, we measured 
ROS levels over time (after 2, 6, 24 and 48 hrs) following Triamterene treatment in 
both of our MSH6 proficient and deficient matched paired cell lines (Figure 45). Our 
results show an accumulation of ROS levels over-time in the MMR deficient DLD1 
and U251.TR3 cell lines compared to their matched-paired MMR proficient 
DLD1+chr2 and U251 cell lines, respectively. Taken together, our results show a 
differential accumulation of ROS levels upon Triamterene treatment in the MMR 
deficient cell lines.  
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Figure 44: Triamterene induces an increase in ROS levels in MMR deficient 
cells 
A-C: DLD1, DLD1+chr2; HCT116, HCT116+chr3; and U251, U251.TR3 cells were 
plated in 2 x 96-well plates (one to measure ROS levels, and one to measure cell 
viability). The following day cells, from both plates, were treated with either DMSO, 
5 μM, 10 μM or 20 μM Triamterene. After 48 hrs treatment, cell viability was 
measured by ATP-luminescence assay and ROS levels were measured by 
quantifying the conversion of DCFDA into DCF by fluorescence. Fluorescence data 
were normalized to the cell viability values. Experiments were carried out in 
triplicate and error bars represent SEM. P-values derived from 1way ANOVA (* 
p < 0.05, *** p < 0.001). 
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Figure 45: Triamterene-induced an accumulation in ROS levels over time in 
MMR deficient cells 
A-B: DLD1, DLD1+chr2 and U251, U251.TR3 cells were plated in 2 x 96-well 
plates (one to measure ROS levels, and one to measure cell viability). Cells from 
both plates were treated with Triamterene (10 μM in DLD1 and DLD1+chr2 cells or 
20 μM in U251 and U251.TR3 cells) at different time points (2, 6, 24 and 48 hrs 
from the end of the assay). At the end of the different time points, cell viability was 
measured by ATP-luminescence assay and ROS levels were measured by 
quantifying the conversion of DCFDA into DCF by fluorescence. Fluorescence 
values were normalized to the cell viability values. Experiments were carried out in 
triplicate and error bars represent SEM. P-values derived from 2way ANOVA (* 
p < 0.05, ** p < 0.01, *** p < 0.001). 
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2.2 The Triamterene-induced synthetic lethality in MMR deficient cell lines 
can be rescued by the addition of a ROS scavenger 
We previously shown a differential accumulation of ROS levels upon Triamterene 
treatment in MMR deficient cell lines. In order to investigate if the increase in ROS 
levels was the mechanism of Triamterene synthetic lethality in these cells, we treated 
the DLD1, DLD1+chr2, HCT116 and HCT116+chr3 cells with increasing 
concentrations of Triamterene (0, 2, 4, 6, 8 and 10 µM) alone or in combination with 
1 mg/mL N-acetylcysteine (NAC), a ROS scavenger (Figure 46). Our results showed 
a complete rescuing of Triamterene synthetic lethality with the addition of NAC in 
DLD1 cells compared to DLD1+chr2 cells and a partial rescuing of Triamterene 
synthetic lethality with the addition of NAC in HCT116 cells compared to 
HCT116+chr3 cells (Figure 47). Our results suggest that increased ROS levels are at 
least in part the mechanism of lethality upon Triamterene treatment in MMR 
deficient cell lines. 
 
 
Figure 46: Mechanism of action of NAC, a ROS scavenger 
NAC is converted into L-cysteine, itself converted into glutathione (GSH). GSH 
reduces H2O2 into H2O therefore reduces ROS levels.  
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Figure 47: The Triamterene-induced synthetic lethality can be rescued by the 
addition of the ROS scavenger, NAC 
A, B: Cells were treated with increasing concentrations of Triamterene (0, 2, 4, 6, 8 
and 10 µM) alone or in combination with 1 mg/mL NAC. After 4 days treatment, 
cell viability was measured by ATP-luminescence assay. Experiments were carried 
out in triplicate and error bars represent SEM. P-values derived from 2way ANOVA 
(*** p < 0.001). 
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2.3 Thymidylate synthase expression is required for the Triamterene-
induced accumulation of ROS levels in MMR deficient cells 
The Triamterene-induced synthetic lethality was by an accumulation of ROS levels 
in MMR deficient cells. We showed that this synthetic lethality required TS 
expression. Therefore, we investigated whether TS expression was required for the 
Triamterene-induced accumulation of ROS levels. DLD1 and DLD1+chr2 cells, 
transfected with siTS or siCtrl, were treated with 10 µM Triamterene and, ROS 
levels were measured 48 hrs after treatment (Figure 48A). As expected, we observed 
an increase in ROS levels upon Triamterene treatment specifically in the DLD1 cells 
transfected with the siCtrl. However, in the TS-silenced DLD1 cells treated with 
Triamterene, we observed no increase in ROS levels. These results suggest a TS 
dependent-accumulation of ROS levels upon Triamterene treatment in MMR 
deficient cells. To further validate these results, we repeated the same experiment in 
the U251 and U251.TR3 matched paired cell lines (Figure 48B). Significantly, we 
also observed no increase in ROS levels upon Triamterene treatment in the cells 
transfected with siRNA targeting TS. Taken together, these results suggest that 
Triamterene is synthetically lethal in MMR deficient cells through the accumulation 
of ROS, which requires expression of TS. 
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Figure 48: Thymidylate synthase expression is required for Triamterene-
induced accumulation of ROS levels in MMR deficient cells 
A, B: Cells were transfected in 6-well plates with siCtrl, siPLK1 or 2 x siTS. The 
following day cells were counted and plated in 2 x 96-well plates and treated with 
10 μM Triamterene (in DLD1 and DLD1+chr2 cells) or 20 μM Triamterene (in 
U251.TR3 and U251 cells). After 48 hrs treatment, cell viability was measured by 
ATP-luminescence assay and ROS levels were measured by quantifying the 
conversion of DCFDA into DCF by fluorescence. Fluorescence data were 
normalized to the cell viability values. Experiments were carried out in triplicate and 
error bars represent SEM. P-values derived from 1way ANOVA (*** p < 0.001). 
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2.4 Triamterene-induced accumulation of ROS levels induces DNA double 
strand breaks 
We have previously shown that Triamterene is synthetically lethal in MMR deficient 
cells through the accumulation of ROS. An increase in ROS level can lead to 
oxidative DNA damage [43]. It is known that an accumulation of oxidative DNA 
damage is synthetically lethal in MMR deficient cell lines ultimately leading to an 
accumulation of DSBs triggering cell death [317-319]. We hypothesised that 
Triamterene was synthetically lethal in MMR deficient cells through an 
accumulation of DSBs induced by an increase in ROS levels. To assess this 
hypothesis, we measured γH2AX foci by confocal microscopy after treatment with 
Triamterene, NAC or a combination of both in DLD1, DLD1+chr2, U251 and 
U251.TR3 cell lines (Figure 49 & Figure 50). It has been shown previously that the 
formation of γH2AX foci, which is the localized and focused phosphorylation at 
Ser 139 of H2A.X at the DSB, is a marker for measuring DSBs [400, 401]. It can be 
measured by confocal microscopy by counting the proportion of cells with more than 
5 foci in the nucleus. Cells with a pan-nuclear staining of γH2AX rather than specific 
γH2AX foci, may represent apoptotic cells due to DNA fragmentation during 
apoptosis [402]. Therefore cells with pan-nuclear γH2AX are not counted as γH2AX 
positive cells. We treated DLD1 and DLD1+chr2 cells with either DMSO, 10 µM 
Triamterene, 10 mg/mL NAC or a combination of 10 µM Triamterene and 
10 mg/mL NAC. After 48 hrs we observed a significant increase in γH2AX foci 
formation and a low pan-genomic γH2AX staining in DLD1 and DLD1+chr2 cells 
lines (Figure 49). We observed that 50 % DLD1 cells treated with Triamterene were 
positive for γH2AX foci; however, we did not observed an increase in γH2AX foci 
in DLD1+chr2 treated with Triamterene in comparison with the control. Upon 
treatment with NAC alone, we observed no difference in γH2AX foci formation, 
however upon treatment of the DLD1 and DLD1+chr2 cells with a combination 
treatment of NAC and Triamterene, we observed no increase in γH2AX foci in 
DLD1 cells. We confirmed these results in the MSH6 matched paired U251 and 
U251.TR3 cells lines by measuring γH2AX foci formation after 24 hrs treatment 
(Figure 50).We observed an accumulation of DSBs upon Triamterene treatment in 
the MSH6 deficient U251.TR3 cells and a rescuing effect of this accumulation with 
addition of NAC. Taken together, these results suggest that Triamterene treatment 
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can induce formation of DSBs, due to a TS-dependant ROS accumulation and these 
DSBs result in the reduced cell viability observed in the MMR deficient cells.  
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Figure 49: Triamterene induces a ROS-dependent increase in DSBs in the 
MSH6 deficient DLD1 cells 
A, B: Cells were plated on coverslips in 6-well plates and were treated with either 
DMSO, PBS, 10 mg/mL NAC, 10 μM Triamterene or a combination of 10 μM 
Triamterene and 10 mg/mL NAC. After 48 hrs, coverslips were stained using 
γH2AX antibody and DAPI and observed by confocal microscopy (x40 objective). 
Per condition, a minimum of 100 cells, in a minimum of 3 images, were counted and 
quantified for γH2AX positive cells (> 5 foci per nucleus) using ImageJ. A: 
Representative images of γH2AX staining. B: Graph representing the quantification 
of cells positive for γH2AX. Experiments were carried out in triplicate and error bars 
represent SEM. P-values derived from 1way ANOVA (*** p < 0.001). 
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Figure 50: Triamterene induces a ROS-dependent increase in DSBs in the 
MSH6 deficient U251.TR3 cells 
A, B: Cells were plated on coverslips in 6-well plates and were treated with either 
DMSO, PBS, 10 mg/mL NAC, 20 μM Triamterene or a combination of 20 μM 
Triamterene and 10 mg/mL NAC. After 24 hrs, coverslips were stained using 
γH2AX antibody and DAPI and observed by confocal microscopy (40x objective). 
Per condition, a minimum of 300 cells were counted and quantified for γH2AX 
positive cells (> 5 foci per nucleus). A: Representative images of γH2AX staining. 
B: Graph representing the quantification of cells positive for γH2AX. Experiments 
were carried out in triplicate and error bars represent SEM. P-values derived from 
1way ANOVA (*** p < 0.001). 
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3 Triamterene induces antioxidant response 
3.1 Antioxidant response induced by Triamterene treatment 
We have observed a Triamterene-induced synthetic lethality in MMR deficient cell 
lines through an increase in oxidative stress. Oxidative stress can be caused by a 
greater induction of ROS, a decreased cellular antioxidant response or by a 
combination of both. To investigate the role of the antioxidant response in 
Triamterene cytotoxicity, we analysed mRNA expression of the antioxidant response 
genes, NRF1, NRF2, SOD1 and SOD2 in our MMR matched paired cell lines 
(Figure 51). NRF1 and NRF2 are two transcription factors, which bind to AREs and 
regulate genes involved in protecting cells from oxidative damage, such as SOD1 
and SOD2. Interestingly, we observed a significant difference in the antioxidant 
profiles in the two matched-paired cell lines we analysed. We observed a significant 
decrease in NRF1 and SOD2 mRNA levels in the MSH6 deficient DLD1 cells in 
comparison to the MSH6 proficient DLD1+chr2 cells (this was not observed in the 
U251 and U251.TR3 cells). However, we observed a decrease in SOD1 and increase 
in SOD2 levels in the MSH6 deficient U251.TR3 cell line in comparison to the 
MSH6 proficient U251 cell line (this was not observed in the DLD1 and DLD1+chr2 
cells). These results potentially suggest cell line specific antioxidant responses. 
However, we consistently observed, in both MMR deficient and proficient matched-
paired cell lines, an up-regulation of NRF2 levels upon Triamterene treatment in the 
MSH6 deficient cell lines compared to their paired MSH6 proficient cell lines. 
Taken together, our results suggest a Triamterene mediated NRF2 up-regulation in 
the MSH6 deficient cell lines. 
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Figure 51: Antioxidant response induced by Triamterene treatment 
A, B: Cells were plated in 6-well plates and treated with either DMSO or 10 μM 
Triamterene (in DLD1 and DLD1+chr2 cells) or 20 μM Triamterene (in U251.TR3 
and U251 cells). After 48 hrs treatment, RNA was extracted and measured by 
RT-qPCR using NRF1, NRF2, SOD1 and SOD2 primers. Data were normalized in 
relative quantity to GAPDH mRNA level. Experiments were carried out in triplicates 
and error bars represent SEM. P-values derived from 1way ANOVA (* p < 0.05, ** 
p < 0.01, *** p < 0.001). 
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3.2 Thymidylate synthase regulates NRF2 expression 
We previously showed that the Triamterene mediated increase in ROS levels 
required TS expression. We next investigated whether TS expression was also 
required for the up-regulation of NRF2 mRNA levels observed in MSH6 deficient 
cells. To investigate this hypothesis, we silenced TS in our cells, followed by 48 hrs 
treatment with 10 μM Triamterene (in DLD1 and DLD1+chr2 cells) or 20 μM 
Triamterene (in U251.TR3 and U251 cells), and measured NRF2 mRNA levels 
(Figure 53). We observed similar results in the DLD1 and DLD1+chr2 and in the 
U251 and U251.TR3 matched paired cell lines. As expected, we observed an up-
regulation of NRF2 in the MSH6 deficient cell lines upon Triamterene treatment. We 
observed an increase in NRF2 mRNA level in the TS-silenced cell lines compared to 
the siCtrl transfected cells, regardless of treatment and MMR status. Interestingly, 
silencing TS further increased the Triamterene mediated up-regulation of NRF2. 
Taken together, our results suggest a TS dependent regulation of NRF2 that may be 
the mechanism for TS requirement in Triamterene MSH6 specific cytotoxicity.  
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Figure 52: Thymidylate synthase regulates NRF2 mRNA expression 
A, B: Cells were plated in 6-well plates and transfected with siCtrl, siPLK1 or siTS. 
The following day, cells were plated in 12-well plates and were treated with either 
DMSO or Triamterene (10 µM in DLD1 and DLD1+chr2 cells or 20 µM in U251 
and U251.TR3 cells). After 48 hrs of treatment, RNA was extracted and measured by 
RT-qPCR using NRF2 primers. Data were normalized in relative quantity to 
GAPDH mRNA level. Experiments were carried out in triplicates and error bars 
represent SEM. P-values derived from 1way ANOVA (** p < 0.01, *** p < 0.001). 
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3.3 Triamterene and the Antioxidant response 
We showed that treatment with Triamterene and silencing TS could induce an 
increase in NRF2 mRNA expression. NRF2, when active, binds to the AREs in the 
promoter region of many antioxidant genes and initiates their transcription [29-31]. 
To analyse the functional cellular consequences of increased NRF2 levels, we 
transfected U251.TR3 and U251 cells with luciferase reporter constructs that 
measures the transcriptional activity of NRF1 and NRF2 through binding to AREs, 
and consequently the activity of the cellular antioxidant pathway. The luciferase 
reporter constructs are a firefly luciferase construct regulated by ARE and a renilla 
luciferase construct regulated by CMV, to measure cell viability. We used a positive 
control to measure transfection efficiency. It is a firefly luciferase construct and a 
renilla luciferase both regulated by CMV (Table 10). We transfected our cells with 
either control or TS siRNA, followed by the ARE luciferase reporter transfection and 
treatment with 20 μM Triamterene (Figure 15). After 48 hrs treatment, we measured 
by luminescence, the activity of the antioxidant pathway. Firefly luciferase 
measurements were normalized to the renilla luciferase data (cell viability) and to the 
positive control (transfection efficacy) (Figure 53). We observed a significant higher 
antioxidant response in the MSH6 deficient U251.TR3 cells compared to the MSH6 
proficient U251 cells which increased upon Triamterene treatment. These results 
were not expected as we did not observe a significant difference in ROS levels and 
NRF1 and NRF2 mRNA levels in U251 compared to U251.TR3 cell lines. This 
suggested a higher basal oxidative stress in the MMR deficient cells. We showed 
previously that Triamterene treatment induced an up-regulation of NRF2 mRNA 
expression in MMR deficient cell lines. We observed here, that Triamterene 
treatment highly increased the antioxidant pathway in the MSH6 deficient U251.TR3 
cells specifically; suggesting that the Triamterene-induced up-regulation of NRF2 
can trigger an increase in the antioxidant response. However, the up-regulation of 
NRF2 observed upon TS silencing was not correlated with an increase in antioxidant 
response. Significantly, we observed a significant decrease in antioxidant response in 
TS silenced cells treated with Triamterene compared to the siCtrl transfected cells 
treated with Triamterene. Taken together, these results indicate that there was an 
increase in the antioxidant response in the MSH6 deficient cells compared to the 
MSH6 proficient cells. Upon Triamterene treatment we observed a greater increase 
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in the antioxidant response in the MSH6 deficient cells, which is significantly 
decreased upon silencing of TS. These results further suggest that Triamterene is 
cytotoxic in MSH6 deficient cells through an increased oxidative stress.  
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Figure 53: Increased antioxidant response in MMR deficient cells 
Cells were plated in 6-well plates and transfected with siCtrl, siPLK1 or siTS. The 
following day, cells were plated in 96-well plates and were transfected with the 
luciferase reporter construct and then treated with either DMSO or 20 µM 
Triamterene. After 48 hrs treatment, the luminescence was measured and normalized 
to the controls. Experiments were carried out in triplicates and error bars represent 
SEM. P-values derived from a 1way ANOVA (** p < 0.01, ** p < 0.001).  
 
 
3.4 Antioxidant response in vivo 
We have previously shown that Triamterene treatment induced an up-regulation of 
NRF2 mRNA level and an increased antioxidant response in vitro in MMR deficient 
cells. We also observed a Triamterene-induced synthetic lethality in MSH6 deficient 
xenografted tumours in vivo. In order to further investigate the role for the 
antioxidant response in Triamterene synthetic lethality in MMR deficiency in vivo, 
we measured NRF1, NRF2, SOD1 and SOD2 mRNA levels in the harvested 
xenografted MSH6 deficient and proficient tumours (Figure 54). We previously 
observed in vitro a decrease in NRF1 and SOD2 in DLD1 cells compared to 
DLD1+chr2 cells and a Triamterene-induced decrease in NRF1 and increase in 
NRF2 mRNA levels in the DLD1 cells specifically (Figure 51A). In this experiment, 
we observed a minor, although significant, decrease in NRF1 expression but no 
difference in SOD2 expression in DLD1 compared to the DLD1+chr2 xenografted 
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tumours (Figure 54A, D). We did not observe a Triamterene-induced regulation of 
NRF1, NRF2, SOD1 or SOD2 levels in the xenografted tumours (Figure 54). Taken 
together, these results validated the differential regulation of NRF1 levels observed 
in vitro in the MSH6 proficient and deficient cell lines. However, these results did 
not validate the Triamterene mediated regulation of NRF1 and NRF2 in the MSH6 
deficient cells observed in vitro. Taken together, these results do not confirm the 
regulation of the antioxidant response upon Triamterene treatment in MSH6 
deficiency in vivo. However, we could speculate the antioxidant response was an 
early mechanism of protection upon Triamterene treatment. The tumours were 
harvested when their sizes reached their maximum which therefore could explain the 
absence of NRF1/NRF2 regulation upon Triamterene in the xenografted tumours. 
 
Vehicle Triatmerene Vehicle Triamterene
0.0
0.5
1.0
1.5
2.0
2.5
DLD1
(MSH6-ve)
DLD1+chr2
(MSH6+ve)
**
***
R
e
la
ti
v
e
 q
u
a
n
ti
ty
 (
N
R
F
1
)
Vehicle Triatmerene Vehicle Triamterene
0.0
0.5
1.0
1.5
2.0
2.5
DLD1
(MSH6-ve)
DLD1+chr2
(MSH6+ve)
R
e
la
ti
v
e
 q
u
a
n
ti
ty
 (
N
R
F
2
)
Vehicle Triatmerene Vehicle Triamterene
0.0
0.5
1.0
1.5
2.0
DLD1
(MSH6-ve)
DLD1+chr2
(MSH6+ve)
R
e
la
ti
v
e
 q
u
a
n
ti
ty
 (
S
O
D
1
)
Vehicle Triatmerene Vehicle Triamterene
0.0
0.5
1.0
1.5
2.0
DLD1
(MSH6-ve)
DLD1+chr2
(MSH6+ve)
R
e
la
ti
v
e
 q
u
a
n
ti
ty
 (
S
O
D
2
)
 
Figure 54: Antioxidant response in vivo 
A-D: RNA was extracted from the harvested xenografted tumours and measured by 
RT-qPCR using NRF1, NRF2, SOD1 and SOD2 primers. Data were normalized in 
relative quantity to GAPDH mRNA level. Error bars represent SEM. P-values 
derived from a 1way ANOVA test (** p < 0.01; *** p < 0.001).  
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Our data showed that Triamterene is synthetically lethal in MMR deficient cells 
through its antifolate activity. Triamterene can induce a TS-dependent increase in 
ROS levels that triggers oxidative stress and ultimately lethal DSBs in the MMR 
deficient cell lines specifically. We also identified a Triamterene mediated up-
regulation of NRF2 expression and an increase in the antioxidant response in the 
absence of MMR. We observed that TS silencing could rescue the cells from 
Triamterene cytotoxicity by inhibiting the increase in ROS levels and in antioxidant 
response, and also by up-regulating NRF2 expression (Figure 55). Therefore our data 
suggest a potential role for the antioxidant response in Triamterene cytotoxicity.  
 
 
Figure 55: Effect of Triamterene treatment and/or TS silencing on ROS levels, 
NRF2 mRNA levels and antioxidant response in the U251.TR3 MSH6 deficient 
cells 
A: Triamterene treatment in cells expressing TS leaded to cell death. It induced an 
increase in ROS and an increase in NRF2 mRNA levels leading to an increase in 
antioxidant response. B: Silencing TS did not lead to cell death. It increased 
increases NRF2 mRNA level but did not modulate ROS levels and the antioxidant 
response. C: Triamterene treatment in TS-silenced cells was not toxic for the cells. It 
induced no increase in ROS levels and an increase in NRF2 levels as well as a small 
increase in antioxidant response. 
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Chapter 3: High-throughput siRNA screen 
to identify synthetic lethal interactions with 
MSH6 deficiency 
 
1 High-throughput siRNA screen 
In order to identify genes and pathways that are synthetically lethal with MMR 
deficiency we carried out an siRNA screen on the DLD1 and DLD1+chr2 cells. We 
have chosen to carry out an siRNA screen targeting 779 siRNAs targeting protein 
kinases and kinase-associated genes successfully used previously. This library 
contains SMARTpool siRNAs which are a pool of 4 individual siRNAs targeting 
one gene of interest [318, 403]. Targeting kinases using the siKinome library is 
relevant to drug discovery as the kinase superfamily plays a key role in many 
biological processes and has an inherent pharmacological tractability. We carried out 
a series of optimisation experiments to determine the appropriate protocol to perform 
the siRNA screen. We tested different cell density (1 000, 2 000 and 3 000 cells per 
well) and two different TR (lipofectamine 2000 and RNAiMAX) (Figure 56). We 
validated the following protocol: day 1, seed 2 000 cells per well; day 2, transfect 
cells with RNAiMAX TR; day 3, change the media; day 6, measure cell viability 
with an ATP-luminescence assay (Figure 14). Transfection controls for each 
experiment were included which included transfecting cells with a non-targeting 
siCtrl and siRNA targeting PLK1. The cell viability of cells transfected with siCtrl 
was compared to the cells grown in media alone to validate that the transfection itself 
did not affect cell viability. Transfection with siPLK1 is used as a positive 
transfection control. PLK1 is a polo-like kinase implicated in mitosis and apoptosis 
[404], its silencing causes cell death in most cell lines.  
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Figure 56: Optimization of the siRNA transfection protocol 
A: 3 000 cells were seeded in 96-well plates. The following day, cells were 
transfected with either lipofectamine 2000 or RNAiMAX and the media was 
changed after 24 hrs. After 4 days transfection, we measured ATP-luminescence 
assay. B: Different densities were plated in 96-well plates (1 000, 2 000 and 3 000 
cells/well). The following day, cells were transfected with lipofectamine RNAiMAX 
and the media was changed after 24 hrs. After 4 days transfection we measured 
ATP-luminescence assay. Experiments were carried out in triplicates and error bars 
represent SEM. 
 
 
After an additional validation experiment for the protocol to carry out a high-
throughput siRNA screen (Figure 57A), 1 800 DLD1 and DLD1+chr2 cells were 
plated in 9*96-well plates and transfected with the siRNA library. We included 6x 
siCtrl and 4x siPLK1 on each plate for transfection controls, and to allow us to 
determine the transfection efficiency across all plates and how it differed. After 
24 hrs the media was changed and after 5 days transfection, cell viability was 
B 
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measured by ATP luminescence assay. The cell viability results were normalized 
onto ΔZ-scores (Figure 57B). Luminescence readings from each well were log 
transformed and normalized according to the median signal on each plate and then 
standardized by use of a Z-score statistic, using the MAD to estimate the variation in 
each screen (Figure 13). Z-score analysis has been described as a reliable method to 
analyse high-throughput screens [356]. The Z-score represents the magnitude of 
difference between one siRNA compared to the rest of the screen. This is based on 
the assumption of a normal distribution of cell viability upon siRNA library 
transfection in a specific cell line. The standardization and normalization of the data 
in each cell line allow us to compare the 2 cell lines using ΔZ-scores. Negative 
ΔZ-scores represent genes synthetically lethal in the MSH6 deficient DLD1 cells 
compared to the MSH6 proficient DLD1+chr2 cells. We enforced a threshold of hit 
identification based ΔZ-scores lower than -1.5. Based on this threshold and on their 
known function, we selected 5 hit genes from the siRNA screen results for further 
validation. These include Janus kinase 2 (JAK2), Copine-III (CPNE3), RIOK2, 
1,3,4,5,6-pentakisphosphate 2-kinase (IPPK) and AURKA (Table 14).  
JAK2 is a non-receptor tyrosine kinase and intracellular signalling effectors of 
cytokine receptors. JAK2 is involved in a range of processes such as cell growth, 
differentiation or histone modifications. Previous preclinical and clinical reports 
have described the inhibition of JAK2 as a promising inhibitor of tumour growth 
[405-408]. Ruxolitinib is a FDA-approved JAK2 inhibitor used for psoriasis, 
myelofibrosis and rheumatoid arthritis treatment [409]. No report has associated 
JAK2 with MMR pathway. CPNE3 is a calcium-dependent phospholipid-binding 
protein which may function in membrane trafficking. It has been identified to 
promote cell migration and invasion in lung cancer and in breast cancer [410, 411]. 
RIOK2 is part of the RIO kinase family required for ribosome biogenesis and cell 
cycle progression [412]. Inhibition of RIOK2 accelerates mitotic progression [413]. 
RIOK2 silencing results in Akt pathway inhibition and cell cycle arrest and apoptosis 
in glioblastoma cells [414]. IPPK forms inositol-1,2,3,4,5,6-hexakisphosphate 
(InsP6) by phosphorylation [415]. InsP6 has various functions such as stimulation of 
DNA repair, mRNA export and endocytosis. For example, InsP6 binds to KU70 
protein implicated in NHEJ in order to increase NHEJ activity [416]. The anticancer 
activity of InsP6 has been shown to be through a G1 phase arrest of the cell cycle 
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[417]. AURKA is a member of the Aurora kinase family. AURKA has a role in 
mitosis by maintaining the microtubule assembly; in other phases of the cell cycle 
and in HR by inhibiting BRCA1/2 and RAD51 [418]. AURKA is significantly up-
regulated in solid tumours including CRC, breast, ovarian neuroblastoma and 
cervical cancer [419, 420]. AURKA inhibitors have been identified as potential 
anticancer agents [421, 422].  
Although all the selected kinases have been described to play a role in cancer, only 
AURKA has been described to play a role in CRC onset in LS [333]. However, this 
role has not been confirmed in another study [335]. Therefore, our selected hit genes 
might be promising novel synthetic lethal kinases for the treatment of MMR 
deficiency. 
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Figure 57: siRNAs screen validation and results 
A: 1 800 cells were transfected with mock, siCtrl or siPLK1 and the media was 
replaced 24 hrs after transfection. Cell viability was measured, after 5 days 
transfection, by ATP-luminescence assay. Experiments were carried out in triplicate 
and error bars represent SEM. B: Dotplot representing the ΔZ-score for each siRNA 
of the library. ΔZ = 0: no difference in cytotoxicity between DLD1 and DLD1+chr2 
cells, ΔZ > 0: DLD1+chr2 are more sensitive to the silencing than DLD1 cells and 
ΔZ < 0: DLD1 are more sensitive to the silencing than the DLD1+chr2 cells.  
 
 
Gene  ΔZ-score Role Reference 
JAK2 -9.6118 JAK/STAT pathway  [423] 
CPNE3 -6.9372 membrane trafficking  [411] 
RIOK2 -6.3989 cell cycle, mitotic progression  [413, 414] 
IPPK -3.8040 
DNA repair, endocytosis, mRNA export, 
NHEJ  [415] 
AURKA -1.9110 microtubule formation, cell cycle  [424-426] 
Table 14: siRNAs selected from the high-throughput siRNA screen 
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2 High-throughput siRNA screen validation 
The performed siRNA screen allowed us to select 5 potential synthetic lethal genes 
in the MSH6 deficient DLD1 cells. In order to validate them, we carried out 
experiments in DLD1 and DLD1+chr2 cells using 5 siRNAs per selected gene (the 
SMARTPool siRNA originally used in the screen and the 4 individual siRNAs 
deconvoluted from the SMARTpool siRNA). As shown in Figure 58A, AURKA 
silencing showed, in 3 out of the 5 siRNA, to be selectively lethal in DLD1 cells 
compared to DLD1+chr2 cells. Only one siRNA targeting CPNE3, JAK2 and IPPK 
showed higher toxicity in DLD1 compared to DLD1+chr2 cells. Surprisingly, 
RIOK2 silencing showed higher toxicity in DLD1+chr2 compared to DLD1 cells 
with all siRNAs. Our experiments and validation may be limited due the fact that we 
performed the siRNA screen only once, and there was only one well per targeted 
gene in the library, which could explain the difference observed in the siRNA screen 
compared to the validation experiments. Our results however validate the 
cytotoxicity of silencing AURKA in the MSH6 deficient DLD1 cells compared to 
the MSH6 proficient DLD1+chr2 cells. 
To determine whether this synthetic lethal effect was cell line specific to the DLD1 
cells, we transfected the matched paired U251 and U251.TR3 cell lines, proficient 
and deficient in MSH6 respectively with siRNAs targeting the 5 selected kinases 
(Figure 58B). We measured the cell viability after 5 days transfection. The results in 
U251 and U251.TR3 cells suggest no selective cytotoxicity of siCPNE3, siIPPK and 
siJAK2 in the MSH6 deficient U251.TR3 cells compared to the MSH6 proficient 
U521 cells. We previously showed a significant increased selectivity for siRIOK2 in 
the MSH6 proficient DLD1+chr2 cells, in comparison with the MSH6 deficient 
DLD1 cells. However, this observation was not validated in the MSH6 proficient 
U251 cells. Silencing of AURKA gene showed a synthetic lethality in the MSH6 
deficient DLD1 cells in comparison with the DLD1+chr2 cells and interestingly, our 
experiments in the U251 and U251.TR3 cells suggest comparable results. The 
siAURKA_pool, siAURKA_2 and siAURKA_4 showed higher cytotoxicity in the 
MSH6 deficient U251.TR3 cells, compared to the MSH6 proficient U251 cells, as 
observed in the DLD1 compared to the DLD1+chr2 cells (Figure 58A & B). These 
results suggest a synthetic lethal relationship between AURKA and MSH6.  
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To further validate whether this synthetic lethal interaction was due to MSH6 
deficiency or to MMR deficiency in general, we transfected the MLH1 deficient 
HCT116 and MLH1 proficient HCT116+chr3 cell lines with siRNA targeting 
AURKA (Figure 58C). We did not observe any cytotoxic difference upon AURKA 
silencing in the MLH1 deficient and proficient cells. These results suggest no 
synthetic lethality upon AURKA silencing in the MLH1 deficient cell lines. 
Therefore perhaps AURKA inhibition is specific to MSH6 loss rather than MMR 
deficiency in general. Further experiments are required to determine whether this is 
truly the case as, due to lack of time, these experiments were only performed in 
triplicate, once. Further experiments are also required to determine whether AURKA 
silencing can cause synthetic lethality in cells with mutations in other members of 
the MMR pathway such as MSH2 and PMS2. 
 Taken together, the validation experiments, carried out in the different MMR 
proficient and deficient matched paired cell lines, suggest AURKA as a potential 
synthetic lethal interactor with MSH6 loss, specifically. However, further 
experiments in the U251, U251.TR3, HCT116 and HCT116+chr3 cells are necessary 
to confirm these observations.  
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Figure 58: High-throughput siRNA screen validation 
A-C: Cells were transfected with siCtrl, siPLK1 and siRNAs targeting the 5 genes 
selected from the screen and the media was changed after 24 hrs. After 5 days 
transfection, cell viability was measured by ATP-luminescence assay. A: The graph 
represents the mean of 3 independent replicates and error bars represent SEM. P-
values derived from 2way ANOVA (* p < 0.05, ** p < 0.01, *** p < 0.001). B, C: 
Graph representative of one replicate. Experiments were carried out only once. 
A A 
B 
C 
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3 AURKA as a potential therapeutic target in MMR 
deficiency 
To investigate the potential synthetic lethal interaction between loss of AURKA and 
MSH6 deficiency, we treated the MSH6 deficient and proficient cells with increasing 
concentrations (0, 40, 80, 120, 160 and 200 nM) of the AURKA inhibitor, Alisertib 
(MLN8237). Alisertib is an AURKA inhibitor currently in phase III clinical trial for 
treatment of patients with relapsed or refractory peripheral T-cell lymphoma 
(NCT01482962). This compound has the main advantage to be specifically 
inhibiting AURKA and not AURKB as it was the case with previous generations of 
AURKA inhibitors [427, 428]. As shown in Figure 59, we observed a greater and 
significant cytotoxicity of the increasing concentrations of AURKA inhibitor in the 
MSH6 deficient cell lines compared to their paired MSH6 proficient cell lines. These 
results suggest the inhibition AURKA as synthetically lethal in MSH6 deficient cell 
lines. 
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Figure 59: AURKA inhibition as a potential therapeutic target in MSH6 
deficiency 
A, B: Cells were treated with an increased concentration of the AURKA inhibitor 
Alisertib. After 4 days treatment, cell viability was measured by ATP-luminescence 
assay. Experiments were carried out in triplicate and error bars represent SEM. 
P-values derived from 2way ANOVA (*** p < 0.001).  
 
 
AURKA is part of Aurora kinase family composed of AURKA, AURKB and 
AURKC. Aurora kinase family is responsible for microtubule formation. AURKA is 
required for the microtubule organisation, AURKB functions in the attachment of the 
microtubules to the centromere and AURKC function is not known [426]. AURKB 
was not present in the high-throughput screen data and AURKC was not 
synthetically lethal with MSH6 deficiency (ΔZ-score = 0.7062). We have previously 
mentioned the potential role for AURKA and Cyclin D1 in the onset for CRC in LS 
(see the introduction section 3.2.3.4) [333]. The siRNA library used for the screen is 
composed of kinases therefore there is no siRNA targeting Cyclin D1. The drug 
library used to carry out the high-throughput compound screen included two 
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compounds targeting microtubules, Colchicine and Paclitaxel, and one AURKB 
inhibitor, Hesperidin [429, 430]. Our data from the drug screen suggests that 
Colchicine and Paclitaxel were cytotoxic in both the MSH6 deficient and proficient 
cell lines and Hesperidin was not cytotoxic in any of the cells (Table 15). In the 
compound screen, compounds were used at a fixed concentration of 10 µM which 
might explain the lack of selectivity with these compounds. AURKB was not present 
in our siRNA screen, and the AURKB inhibitor Hesperidin, did not show 
cytotoxicity in the compound screen. Therefore, we cannot conclude on a possible 
synthetic lethality between the other Aurora kinases and MSH6 deficiency. In 
addition, these compounds, Colchicine and Paclitexel, are not inhibitors of AURKA 
and they have different mechanisms of action than AURKA inhibition on the 
microtubules. A synergistic relationship has been published between Alisertib and 
Paclitaxel in ovarian cancer cells in vitro and in vivo, and an over-expression of 
AURKA gene has been observed as a mechanism of resistance to Paclitaxel 
treatment [425]. These observations suggest complementary mechanism of action of 
Paclitaxel and Alisertib. Therefore, further experiments are required to deepen our 
understanding of AURKA as a novel synthetic lethal gene in MSH6 deficiency 
and/or MMR deficiency.  
 
 
 
DLD1 (MSH6-ve) DLD1+chr2 (MSH6+ve) 
 Compound Replicate 1 Replicate 2 Replicate 1 Replicate 2 Function 
Hesperidin  0.700 2.192 0.331 2.727 AURKB inhibitor 
Colchicine -11.791 -12.425 -10.544 -11.785 
Inhibits microtubule 
assembly 
Paclitaxel -9.099 -6.980 -9.324 -11.353 
Stabilises 
microtubules 
Table 15: Z-score results from the high-throughput compound screen 
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We carried out an siRNA screen in order to identify novel synthetic lethal 
relationships with MMR deficiency. We identified and validated a potential synthetic 
lethal interaction between MSH6 deficiency and AURKA inhibition. A role for 
AURKA has been previously shown in the age of CRC development associated with 
LS; with a potential difference for MLH1 and MSH2 deficient LS [333]. The 
mechanism through which AURKA delays CRC onset in LS has not been further 
investigated. Therefore these results need further validation to understand the 
relationship between AURKA and MMR deficiency. The first step would be to 
further validate the synthetic lethal relationship between AURKA and MMR 
deficiency by measuring cell viability in our panel of matched paired cell lines upon 
Alisertib treatment or upon transfection with siAURKA. To understand why we 
validated the synthetic lethal relationship between AURKA and MSH6 with three 
out of five siRNAs only, we would measure AURKA protein levels in DLD1 and 
DLD1+chr2 cell lines transfected with siAURKA to investigate the inverse 
correlation between protein expression and cytotoxicity. In addition, to understand 
the mechanism of synthetic lethality, we would start by measuring cell cycle 
progression in MSH6 deficient and proficient cell lines upon Alisertib treatment to 
investigate the role for MSH6 in AURKA regulation of the cell cycle.  
Taken together, we identified a promising synthetic lethal relationship between 
AURKA and MSH6 genes. Further investigations are necessary to better understand 
this synthetic lethal relationship. 
Discussion 184 
 
 
 
 
Discussion 
  
Discussion 185 
 
1 Using a high-throughput compound screen to identify 
novel therapeutics for the treatment of MMR deficient 
tumours 
The MMR pathway, one of the major DNA repair pathways, repairs base-base 
mismatches and insertion deletion loops that occur during DNA replication [12]. 
Deficiency in MMR, highly increases the predisposition to a wide range of cancers 
with, for example, an 80 % risk of developing CRC [131]. It has been shown that, in 
comparison to MMR proficient tumours, MMR deficient tumours are more resistant 
to a range of chemotherapies such as 5-FU, the major treatment for CRCs [134]. In 
this PhD project we aimed to identify novel therapeutic strategies for the treatment 
of MMR deficient tumours using high-throughput compound and siRNA screens. 
 
1.1 Panel of cell lines 
In order to identify new therapeutic strategies in MMR deficient tumours, we used a 
panel of MMR deficient and proficient matched paired cell lines. Our panel of cell 
lines (Table 11 & Figure 17), represent a wide range of tumour types, and are MMR 
deficient due to number of different processes. To generate isogenic matched paired 
models of MMR deficiency, the parental cell lines that harbour mutations in MMR 
genes (DLD1, HEC59 and HCT116 cell lines) were matched paired with cell lines 
generated by the stable addition of a chromosome (DLD1+chr2, HEC59+chr2 and 
HCT116+chr3 cell lines). Alternatively, parental cell lines that were MMR proficient 
(U251 and A2780cp70 E1 cell lines) were compared to matched paired MMR 
deficient cell lines generated by acquired mutation due to continuous exposure to a 
drug (TMZ in the case of U251.TR3 cells and Cisplatin in the case of A2780cp70 A2 
cells). The cell line panel is composed of matched paired cell lines that differ only 
from their MMR status (DLD1, DLD1+chr2, HCT116, HCT116+chr3, HEC59 and 
HEC59+chr2 cell lines) and matched paired cell lines that differ due to their MMR 
status and also their secondary mutations (U251, U251.TR3, A2780cp70 A2 and 
A2780cp70 E1 cell lines). The advantage for using matched paired cell lines that 
differ only due to their MMR status is a better identification of MMR dependent 
synthetic lethal relationships. However, the advantage for using matched paired cell 
lines that differ due to their MMR status, in addition to their secondary mutation is 
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that these cell lines are closer to a MMR deficient tumour phenotype in patients. 
MMR deficiency was first described in CRCs but is present in a wide range of 
cancers such as endometrial, ovarian and glioblastoma cancers, which are all 
represented in our panel of cell lines. Moreover, loss of MLH1 due to methylation 
represents a major proportion of tumours associated with MMR deficiency (see the 
introduction section 2.4) which is represented in our panel with the MLH1 
methylated A2780cp70 A2 cell line. Therefore, this panel represents a great tool for 
the study of MMR dependent mechanisms. 
 
1.2 5-FU resistance in MMR deficiency 
There is controversy with regards to 5-FU resistance in MMR deficiency [259]. In 
vitro, where the parameters can be better controlled, MMR deficient cell lines have 
shown 5-FU resistance in comparison to MMR proficient cell lines [261]. With our 
panel of cell lines, we validated that 5-FU resistance strongly associates with MMR 
deficiency. A previous study reported the MLH1 deficient HCT116 cells were 18-
fold more resistant to 5-FU than the MLH1 proficient HCT116+chr3 cells [262]. In 
our experiments, the difference observed with these matched paired cell lines was 
not as high as reported. However, they carried out a long-term clonogenic assay to 
measure 5-FU response which might explain why we observed a smaller difference 
in our short-term experiment. The MSH6 deficient cell lines showed the most 
consistent resistance to 5-FU in comparison to their matched paired MSH6 proficient 
cell line. This result was not expected as, in MSH6 mutated cells, MSH3 can 
complex with MSH2 to form the heterodimer MutSβ which can also recognize 5-FU, 
but with lower affinity than MutSα [264]. No previous study has demonstrated a 
greater 5-FU resistance in MSH6 deficiency compared to deficiency in the other 
MMR genes.  
 
1.3 High-throughput compound screen 
To identify modulators of the MSH6-mediated 5-FU resistance, we performed a 
high-throughput compound screen composed of 1120 compounds previously in 
clinical use, 90 % of which were marketed drugs, the remaining 10 % being 
bioactive alkaloids. This compound library has been successfully screened in 
previous studies [317, 319]. Each study used the compound library at different 
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concentrations: 10 µM and 100 µM. The concentration of 100 µM would potentially 
be more toxic to the cells than 10 µM in both MSH6 proficient and deficient cell 
lines, therefore limiting hit selection. We decided, in this study to carry out the 
screen with compounds at a concentration of 10 µM. The advantage of using this 
compound library is that this library is composed of drugs previously used in the 
clinic therefore enabling them to progress quickly to clinical trial. We performed the 
compound screen in duplicate with only one data point per drug, one scheduling 
regime and one drug concentration. Therefore, some potential hit compounds may be 
missed. Alternatively, we could have carried out the screen using two different drug 
concentrations as all compounds have different potencies and therefore the use of 
two different concentrations may have helped us to further select hits and identify 
new ones. Experiment scheduling is important; for example, a compound might 
modulate 5-FU resistance in a combination treatment but not if treated sequentially 
(that would be the case for example if a compound was inhibiting the cellular 
internalization of 5-FU); conversely, a compound might modulate 5-FU resistance 
when used sequentially and not in a combination treatment (that would be the case, 
for example, for compounds with a mechanism of cytotoxicity dependant on 
pathways activated or inhibited upon 5-FU treatment). We decided to carry out both 
repeats in the same conditions by treating first the cells with 5-FU followed by 
10 µM of the library of compounds as we believed, similar biological replicates 
would help selecting stronger hits. 
 
 
2 Clotrimazole as a modulator of 5-FU resistance in DLD1 
cells 
We identified Clotrimazole as a modulator of 5-FU resistance in DLD1 cells only. 
We did not measure the Clotrimazole effect upon 5-FU treatment in U251 and 
U251.TR3 cell lines. Therefore, we cannot conclude if Clotrimazole is a modulator 
of MSH6-mediated 5-FU resistance or if this modulation is specific to DLD1 cells. It 
is possible that Clotrimazole is not only MSH6 specific but also depends on other 
mutations present in DLD1 and DLD1+chr2 cell lines. In a previous study, Liu et al. 
demonstrate that Clotrimazole can induce an arrest in the late G1-phase of the cell 
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cycle and sensitize glioblastoma cells to irradiation [431]. This study suggests a 
potential role for Clotrimazole in the DDR. However, the mechanism of enhanced 
sensitivity to irradiation by Clotrimazole treatment has not been intensely 
investigated. In order to understand the mechanism of this 5-FU modulation, we 
would need to investigate the effect of Clotrimazole alone or in addition to 5-FU in 
DLD1 and DLD1+chr2 upon cell cycle progression. Further investigation is 
necessary to identify if Clotrimazole modulates 5-FU response through a G1-phase 
cell cycle arrest and if this modulation is DLD1 cell line specific or specific to 
MSH6 deficiency.  
 
 
3 Triamterene as a novel therapeutic strategy for the 
treatment of MMR deficient tumours 
3.1 Triamterene is synthetically lethal in MMR deficient cell lines in vivo 
We validated in vitro the synthetic lethal relationship between Triamterene treatment 
and MMR deficiency. We also measured this Triamterene-induced synthetic lethality 
in the DLD1 and DLD1+chr2 xenografted mice in order to validate Triamterene 
synthetic lethality in MMR deficiency in vivo, which is a necessary step, before 
initiating a clinical trial, to observe an overall effect of the treatment within the 
tumour microenvironment and eventual toxicity. We observed a significant decrease 
in tumour growth in the DLD1 xenografted mice treated with Triamterene in 
comparison with the vehicle treatment. We had issues to optimize the in vivo 
experiment in order to obtain the same rate of tumour growth in the DLD1 and 
DLD1+chr2 xenografted mice treated with vehicle treatment, which could be 
explained by the different proliferation rate of these cell lines in vitro. U251.TR3 
cells have a slower proliferation rate compared to the MSH6 proficient U251 cells; 
which is the opposite of what was observed in DLD1 and DLD1+chr2 cell lines. The 
U251.TR3 cell line has been generated by continuous exposure to TMZ in U251 
cells leading to an acquired MSH6 mutation. Therefore, the U251 and U251.TR3 
cell lines do not only differ by their MMR status but also with regards to their 
secondary mutations; therefore, suggesting that these matched paired cell lines are 
closer to a MMR deficient tumour phenotype. Consequently it would be relevant to 
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carry out in vivo experiments with this matched paired cell lines. We decided to 
carry out a pilot experiment on the U251 and U251.TR3 cell lines in order to confirm 
whether the reduction in tumour growth in the DLD1 cells upon Triamterene 
treatment is independent of the difference in the proliferation rate of the cells. In this 
pilot experiment we did not observe tumour growth 4 weeks after cell injection (1 or 
2.5 million cells in 1X PBS or 1 million cells in matrigel (1:1)) using the U251 and 
U251.TR3 cells. Tumours generally take 1-2 weeks to be visible and measurable 
after xenografting. According to previous reports, IP injection of 1 million U251 
cells in matrigel (1:1) or 1.5 million in 1X PBS should lead to tumour formation in 
nude mice [432, 433]. We observed a small tumour after one week in the mouse 
injected with 2 million U251 cells, but the tumours had reduced and disappeared a 
week later. We carried out this pilot experiment in NOD-SCID mice rather than nude 
mice (as used for the published report using U251 cells) as they have been shown to 
be a better model to study anticancer treatment response in vivo [361]. However, it is 
arguably possible that U251 and U251.TR3 cells grow in nude mice and not in 
NOD-SCID mice. Therefore it would be necessary to repeat this pilot experiment in 
nude mice. 
We did not observe toxic effect of Triamterene treatment on the mice. In total, four 
mice (for a total of 80 mice) showed signs of sickness. Two of which did not receive 
Triamterene but vehicle treatment, and one was underweight compared to the other 
ones prior to the experiment (Figure 16). Therefore we validated that Triamterene 
was synthetically lethal in MMR deficient tumours at a dose not toxic for the animal. 
This validates the potential use in the clinic for Triamterene treatment in patients 
with MMR deficient tumours. 
 
3.2 Triamterene cytotoxicity in MMR deficient cells, is not due to its role as 
a sodium channel antagonist 
The first step to understand the mechanism of Triamterene synthetic lethality in 
MMR deficient cell lines was to investigate the major known mechanism of action of 
the compound, which is the inhibition of the ENaC [383-385]. To this end, we used 
another compound, Amiloride, known to share the same mechanism of inhibition of 
the ENaC, and siRNA transfection to silence the different subunits of the ENaC 
[378]. We only validated siENaC transfection efficiency with internal siRNA 
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controls (siCtrl and siPLK1). We did not validate the silencing of ENaC subunits by 
western blot, which may suggest that the silencing of the ENaC was not synthetically 
lethal in MMR deficient cells due to low depletion efficiency of the ENaC siRNAs. 
However, the inhibition of the ENaC with Amiloride treatment did not trigger cell 
cytotoxicity; therefore suggesting that Triamterene is not synthetically lethal with 
MMR deficiency through the inhibition of the ENaC siRNAs. Another approach to 
identify the role for the ENaC in Triamterene cytotoxicity would be to investigate if 
reactivation of the ENaC would be able to rescue the cells from Triamterene 
cytotoxicity. There is no ENaC activator or ENaC inhibitor antagonist available. The 
addition of Na
+
 in the media would potentially lead to an increase in ENaC activity 
and could enable us to further understand whether the ENaC subunits have any role 
in the Triamterene-induced cytotoxicity in MMR deficient cells. 
 
3.3 Triamterene and the folate transporters 
The pteridine structure of Triamterene implies it has an antifolate activity (Figure 33) 
[390-392]. It has been shown that Triamterene is incorporated into the cells by the 
same transporters as the folates [382, 434]. The fact that Triamterene cytotoxicity 
could be rescued with a range of folates could suggest a competition between 
Triamterene and these folates at the folate transporters and therefore, the addition of 
folate may inhibit the import of Triamterene into the cells. In that case, Triamterene 
would not be synthetically lethal in MMR deficiency through its antifolate activity. 
To investigate this further it would be interesting to know if the folate transporters 
are similarly expressed in MMR deficient and MMR proficient cells as to date there 
is no report on a differential activity of the folate transporters in MMR deficient 
cells.  
If Triamterene was competing with folates at the folate transporter, we could 
speculate that Triamterene induces folate deficiency. However, it has been reported 
that Triamterene treatment does not trigger folate deficiency [435]. Moreover, MMR 
deficiency has been associated with resistance to folate deficiency through the 
decrease in TS activity [436, 437]. Taken together, these reports suggest that 
Triamterene is not cytotoxic through folate-depletion in cells. 
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3.4 Triamterene and DHFR activity 
Triamterene was primarily described as a DHFR inhibitor, sharing the same 
mechanism of action as Methotrexate. There is a discrepancy with regards to the 
Triamterene effect on DHFR activity [390-392]. For example, Schalhorn et al. 
published in 1981 the effect of 1, 10 and 80 µM Triamterene treatment on cell 
viability, DHFR activity and dUMP/dTMP ratio [397]. They concluded that 
Triamterene inhibited DHFR activity which triggered a decrease in dTMP pool and 
cell death. However, these observations were true with 80 µM Triamterene and not 
with 1 and 10 µM Triamterene where they observed an increase in DHFR activity 
with no consequences on cell viability and dTMP pool. In our study, we observed 
that 10 µM Triamterene induces an increase in DHFR activity in DLD1 and 
DLD1+chr2 cells, and synthetic lethality in MMR deficient cell lines. Therefore, 
Schalhorn et al. report supports our results showing a Triamterene dependent up-
regulation of DHFR activity at a concentration synthetically lethal for MMR 
deficient cells. Martin et al. showed that Methotrexate, a DHFR inhibitor, was 
synthetically lethal in MSH2 deficient tumours but not in MSH6 and MLH1 
deficient tumours [317]. This further suggests that Triamterene is not synthetically 
lethal in MMR deficiency through the same mechanism of action as Methotrexate, 
the inhibition of DHFR. Methotrexate inhibits DHFR which triggers nuclear 
oxidative DNA damage that are cytotoxic in MSH2 deficient cells. We showed here 
that Triamterene was not a DHFR inhibitor and therefore is synthetically lethal in 
MMR deficient tumours through a different mechanism than Methotrexate. 
In this PhD project, we showed that silencing DHFR leads to a higher Triamterene 
cytotoxicity; suggesting the observed up-regulation of DHFR upon Triamterene may 
act as a protective mechanism of action in Triamterene cytotoxicity. An up-
regulation of DHFR activity would potentially increase the cellular folate pool and 
therefore protect the cells from Triamterene cytotoxicity by increasing the 
competition between folates and Triamterene at the folate transporters and therefore 
decreasing Triamterene incorporation into the cells. Our data on the Triamterene 
dependent up-regulation of DHFR do not allow us to conclude whether Triamterene 
is synthetically lethal through the folate pathway or whether Triamterene shares the 
same transporters as folates. Moreover, exogenous over-expression of DHFR was 
not cytoprotective for the Triamterene effect. DHFR activity may depend on the 
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folate present in the cells and therefore, DHFR over-expression alone might not be 
correlated with an up-regulation of DHFR activity. Therefore, suggesting a potential 
role for the folate transporters to increase the folate pool present in the cells. Taken 
together, we could not conclude if Triamterene was cytotoxic through a modulation 
of the folate pathway or was only dependent on the folate transporter. 
We validated the requirement of TS expression and activity in Triamterene 
cytotoxicity through three different mechanisms: siRNA targeting TS and two TS 
inhibitors, 5-FU and Raltitrexed. These results convincingly validate the requirement 
for TS in Triamterene cytotoxicity. Inhibition of TS is not known to modulate folate 
transport but only the folate pathway and the production of dTMP in the cells. 
Therefore the requirement of TS expression suggests that Triamterene is 
synthetically lethal in MMR deficiency through the modulation of the folate pathway 
and does not only depend on the folate transporters.  
 
3.5 Triamterene requires thymidylate synthase expression 
Our data suggest that DHFR is not required for the synthetic lethality upon 
Triamterene treatment in MMR deficient cells. As previously mentioned, Schalhorn 
et al. report no cytotoxicity and a DHFR up-regulation upon 1 and 10 µM 
Triamterene, and also suggests that Triamterene does not modulate dTMP 
production and therefore does not modulate TS activity [397]. This has been 
confirmed by Chang et al. who reported no variation in dTMP incorporation into 
DNA upon Triamterene treatment in vitro and in vivo [438]. Taken together, these 
reports suggest that Triamterene does not modulate TS activity. As previously 
mentioned, MMR deficient cell lines are resistant to TS inhibition induced by 5-FU 
treatment or folate depletion [134, 436, 437]. However, we observed a requirement 
of TS expression for Triamterene cytotoxicity in MMR deficient cells. This suggests 
that the Triamterene synthetic lethality in MMR deficient cell lines is not due to a 
Triamterene dependent inhibition of TS activity.  
Interestingly, we did not observe modulation of Triamterene synthetic lethality in TS 
over-expressed cells. However, THF is the rate limiting factor of TS activity, 
therefore, TS over-expression might not be associated with an increase in TS activity 
and therefore, TS over-expression would not necessarily modulate cell viability. We 
did not include a control such as 5-FU to validate a potential correlation between TS 
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over-expression and TS activity. The addition of THF, the rate-limiting factor of TS, 
rescued the cells from Triamterene synthetic lethality in MMR deficient cell lines 
which could be due to a THF mediated increase in TS activity. 
 
3.6 Triamterene and MTHFR 
Our results suggest that DHFR over-expression was a mechanism of protection upon 
Triamterene treatment and we validated the requirement for TS in the Triamterene-
induced cytotoxicity. An increase in DHFR activity combined with an inhibition of 
TS activity would theoretically lead to an increase in the THF pool and potentially to 
an increase in MTHFR activity, as THF is a substrate for TS but also for MTHFR 
(Figure 11). Therefore, we could hypothesize that TS silencing can rescue the cells 
from Triamterene cytotoxicity through an increase in MTHFR activity and therefore, 
Triamterene would potentially act as an MTHFR inhibitor. MTHFR is the rate 
limiting enzyme responsible for the methyl cycle of the folate pathway and is often 
mutated in cancer [439]. Polymorphisms in MTHFR have a protective effect on the 
CRC onset in LS [343, 344]. Two studies have found a correlation between MTHFR 
677TT mutation and MSI [345, 346]. However, Eaton et al. showed an inverse 
correlation between MTHFR 677TT and MSI in patients with adequate folate intake 
and no correlation in patients with low folate intake [347]. Therefore, the correlation 
between MTHFR and MSI associated CRC is not clear. To date, there is no 
antifolate known to target MTHFR. A study suggests MTHFR inhibition as a 
potential cancer therapeutic strategy [440]. They showed a 30 % decrease in cell 
viability in gastric cancer cells transfected with a siRNA targeting MTHFR. 
Inhibition of MTHFR would inhibit homocysteine conversion into methionine and 
therefore lead to hyperhomocysteine, which has been associated with oxidative stress 
(Figure 11) [441-444]. However, the mechanism of hyperhomocysteine-induced 
oxidative stress is not clear. Homocysteine can be converted into cysteine which is 
the rate-limiting factor in glutathione biosynthesis, which is the first non-enzymatic 
cellular antioxidant [445]. Taken together, it would be interesting, in our study, to 
investigate if MMR proteins and/or Triamterene treatment could modulate MTHFR 
expression and activity. In the case of a MMR and/or Triamterene dependent 
modulation of MTHFR, it would be interesting to understand how it could correlate 
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with the reports showing a protective effect of MTHFR mutation on the onset of 
CRC in LS and how this MTHFR modulation could regulate oxidative stress. 
 
3.7 Triamterene treatment induces oxidative stress 
Triamterene is synthetically lethal in MMR deficient cell lines through its TS 
dependent antifolate activity, which leads to an increase in ROS levels specifically in 
the MMR deficient cells. Previous reports have identified a synthetic lethal 
relationship between oxidative stress and MMR deficiency [315-319]. These reports 
showed an induced increase in oxidative DNA damage in MMR proficient and 
deficient cells and an MMR dependent repair leading to cell death in MMR deficient 
cell lines. Strikingly, our results showed a Triamterene dose-dependent and time-
dependent increase in ROS levels in MMR deficient cell lines specifically. We were 
expecting an increase in ROS levels in both MMR deficient and proficient cell lines 
and an ability, specifically for the MMR proficient cell lines, to repair the ROS-
induced DNA damage as it was previously shown [317, 319]. This suggests that the 
Triamterene-induced synthetic lethality in MMR deficient cells is not specifically 
due to the ability of MMR proficient cells to repair ROS-induced DNA damage but 
rather due to the ability of Triamterene to differentially induce ROS either through 
its antifolate activity or through a differential antioxidant response in the MMR 
deficient cells compared to the MMR proficient cells. 
 
3.8 MMR deficiency and antifolates 
The differential in ROS levels in MMR deficient and proficient cells upon 
Triamterene treatment questions on whether there is a potential difference in the 
folate pathway in MMR deficient and proficient cell lines. To date, no study has 
shown a significant MMR dependent regulation in the folate pathway. Two 
antifolates targeting DHFR, Methotrexate and Pemetrexed, are cytotoxic in MSH2 
deficient cell lines [317, 355]. Methotrexate has been shown in this study to induce 
oxidative stress regardless of the MMR status through DHFR inhibition. Other 
antifolates, such as Raltitrexed, are not known for a differential outcome in MMR 
deficient compared to MMR proficient tumours. However, Raltitrexed is a TS 
inhibitor and therefore, MMR deficient tumours should be more resistant to 
Raltitrexed treatment compared to MMR proficient tumours, based on the 5-FU 
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response in MMR deficient cells. To better understand the role of MMR deficiency 
in the folate pathway, it would be interesting to screen a range of antifolates, or 
compounds with a pteridine structure in our panel of MMR deficient and MMR 
proficient cell lines. This might allow us to identify other antifolates sharing the 
same mechanism of action as Triamterene. Therefore enabling us to gain a better 
understanding of the Triamterene and MMR deficiency synthetic lethal relationship 
and maybe to identify an antifolate with a better potency than Triamterene. 
 
3.9 Antioxidant response induced by Triamterene treatment 
Oxidative stress can be triggered by a greater induction of ROS, a decreased cellular 
antioxidant response or by a combination of both. The differential induction in ROS 
levels upon Triamterene treatment in MMR deficient and proficient cells questions 
whether there is a differential antioxidant response. We measured NRF2 mRNA and 
the antioxidant response upon Triamterene treatment in MMR proficient and 
deficient cell lines upon TS silencing. As summarized in Figure 55, we observed, in 
MMR deficient cells treated with Triamterene, an increase in ROS, NRF2 expression 
and the antioxidant response. In TS silenced MMR deficient cells, we observed no 
difference in ROS and in the antioxidant response but an increase in NRF2 
expression. In addition, TS silenced MMR deficient cells treated with Triamterene 
showed a partial rescuing effect of the Triamterene-mediated increase in ROS levels 
and in the antioxidant response.  
First of all, Triamterene treatment did not induce ROS, NRF2 and antioxidant 
responses in MMR proficient cells which suggest these observations were dependent 
on MMR deficiency. The basal antioxidant response in U251.TR3 cells was 
significantly higher than in the U251 cells. There is no previous report of a 
differential antioxidant in MMR deficient and proficient cell lines. We observed a 
down-regulation of NRF1 and an up-regulation of SOD2 mRNA levels in DLD1 
compared to DLD1+chr2 cell lines which was not confirmed in the U251 and 
U251.TR3 cell lines where we observed an up-regulation of SOD1 and a down-
regulation of SOD2 mRNA levels. These results further suggest a differential 
expression in antioxidant related genes in MMR deficient and proficient cell lines. 
However, it would be necessary to measure the ARE antioxidant response in our 
panel of cell lines to be able to conclude if the differential antioxidant response is 
Discussion 196 
 
due to MMR status. Also, if MMR deficient cells lines have a higher antioxidant 
response that MMR proficient cells, it is not clear how this could be correlated with a 
Triamterene dependent increase in ROS levels in the MMR deficient cell lines 
specifically. We could speculate that the MMR deficient cells use the total capacity 
of their antioxidant response in the basal condition in order to prevent lethal 
oxidative DNA damage and therefore, MMR deficient cells would be unable to adapt 
to exogenous oxidative stress. However, we showed that Triamterene treatment leads 
to an increase in the antioxidant response in MMR deficient cells specifically. The 
differential role for the antioxidant response in MMR deficient and proficient cells 
remain however intriguing and unclear. 
 
3.10 Role of NRF2 in antioxidant response 
We have described in the section 1.1.1.2 of the introduction, the key role for NRF2 
in the antioxidant response and in the section 1.4 of the introduction, its important 
role in cancer and therefore the potential interest to develop therapeutic strategies 
targeting NRF2 activity [25, 101, 102]. In our study, we have observed a 
Triamterene dependent regulation of NRF2 in MMR deficient cell lines and we also 
observed an increase in NRF2 mRNA levels induced by TS silencing which suggest 
a role for NRF2 in Triamterene synthetic lethality in MMR deficient cell lines.  
It has been published previously a role for the antioxidant response upon 5-FU 
treatment [446-449]. Two reports compared 5-FU resistant and 5-FU sensitive 
matched paired cell lines [448, 450]. The first study reported no difference in NRF2 
expression in both cell lines but an increase in NRF2 levels after 5-FU treatment and 
higher 5-FU sensitivity in NRF2-silenced 5-FU resistant cells [448]. The other study 
observed higher NRF2 expression in the 5-FU resistant cells and confirmed the 
increase in 5-FU sensitivity in NRF2-silenced cells [450]. They did not describe the 
mechanism of acquired resistance to 5-FU, which might explain the different results 
on basal NRF2 expression. Other studies confirmed the increased sensitivity to 5-FU 
treatment in NRF2 silenced cells [446, 447]. One study identified an increase in 
NRF2 activity and ARE dependent antioxidant response upon 5-FU treatment [449]. 
This last study does not correlate with our results as we observed an increase in 
NRF2 mRNA levels in TS silenced cells but no difference in antioxidant response. In 
their study however, the 5-FU dependent increase in antioxidant response was not 
Discussion 197 
 
directly associated with TS silencing therefore, it might be due to another 
mechanism of action of 5-FU. Also, they measured 5-FU dependent regulation of 
NRF2 and antioxidants in the colorectal HT-29 and SNUC5 cell lines, therefore, the 
correlation between NRF2 and antioxidant response upon 5-FU treatment might 
depend on the cell lines. Furthermore, we measured the antioxidant response 24 hrs 
after treatment and NRF2 expression 48 hrs after treatment. Therefore, TS- 
dependent antioxidant response might be a later event and therefore we did not 
observe it after 24 hrs treatment. It is also possible to hypothesise that in U251 and 
U251.TR3 cell lines, the up-regulation of NRF2 is not correlated with an increased 
antioxidant response due to the regulation of NRF2 activity by Keap1, and the 
regulation of ARE dependent antioxidants by NRF2 and NRF1. Therefore, it would 
be interesting to measure the expression of NRF2, but also NRF1 and Keap1, and the 
antioxidant response in a time-course experiment upon Triamterene treatment in TS-
silenced cells.  
In addition, we observed that Triamterene, in TS-silenced MMR deficient cells, does 
not induce ROS levels but induces an increase in NRF2 levels and a lower 
antioxidant response (compared to the TS expressing MMR deficient cells). These 
results suggest that the silencing of TS, which can rescue the cells from Triamterene 
cytotoxicity, can partially rescue both Triamterene-induced ROS and Triamterene-
induced antioxidant response. We could speculate that TS silencing can abrogate the 
increase in ROS levels and therefore the ROS-induced protective antioxidant 
response is decreased. Further investigations are necessary to understand the 
potential direct role of TS in NRF2 and the antioxidant response by for example 
silencing NRF2 and TS in our cells lines to see if NRF2 would inhibit the TS 
dependant effect on Triamterene treatment. 
Moreover, if the Triamterene dependent induction in the antioxidant response is a 
mechanism of cytoprotection, the combination of Triamterene treatment with an 
inhibitor of NRF2 might increase the MMR deficient tumour sensitivity to 
Triamterene treatment. However, further investigations are necessary to measure if 
the inhibition of NRF2 would be cytotoxic in MMR proficient cells. 
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3.11 Triamterene-induced accumulation of ROS levels triggers DNA double 
strand breaks 
Oxidative stress induces oxidative DNA damage that, if not repaired, can lead to 
lethal DSBs. It has been shown that MMR deficient cell lines are unable to repair 
oxidative DNA damage leading ultimately to lethal DSBs. To see if the Triamterene 
dependent increase in ROS levels was cytotoxic through an accumulation of 
oxidative DNA damage and ultimately DSBs, we measured DSBs by measuring the 
formation of γH2AX foci. It has been shown previously that the formation of 
γH2AX foci, which is the phosphorylation at Ser 139 of H2A.X at the DBS, was a 
good marker for measuring DSBs [400, 401]. The comet assay, a single cell gel 
electrophoresis, is another method for identifying DSBs [451]. The pattern of DNA 
migration will resemble a comet with a ratio tail/body proportional to DNA strand 
breaks. γH2AX foci can be measured by confocal microscopy by counting the 
number of cells with more than 5 foci in the nucleus. In dying cells, DNA becomes 
degraded and therefore γH2AX is recruited. These cells will have a pan-genomic 
staining of γH2AX rather than γH2AX foci. Therefore, pan-genomic γH2AX 
staining is a marker for apoptotic cells and therefore is not counted as positive of 
γH2AX [400, 401]. Using γH2AX foci as a marker for DSBs is more accurate than 
the comet assay as the comet assay does not permit to differentiate SSBs and exclude 
apoptotic cells. We observed after 48 hrs treatment with Triamterene a significant 
increase in γH2AX foci formation and a low pan-genomic γH2AX staining. 
Therefore, we considered that the analysis of DBSs after 48 hrs treatment was 
relevant. In the U251 and U251.TR3 cells, we observed a higher number of cells 
with pan-genomic phosphorylation of H2A.X. Therefore, we decided to measure 
γH2AX foci in U251 and U251.TR3 cell lines after 24 hrs treatment with 
Triamterene. DSBs could be caused by an accumulation of DNA damage other than 
oxidative DNA damage; however, the addition of NAC, a ROS scavenger, could 
rescue the accumulation of DSBs therefore suggesting that the observed DSBs were 
caused by an increase in ROS levels. Avidin has been shown to bind 8-oxodG and an 
Avidin antibody has been successfully used in a recent study to show an increase in 
8-oxodG into DNA by confocal microscopy analysis [452]. In this study, further 
experiments would be necessary to measure the level of 8-oxodG in MMR deficient 
and proficient cell lines upon Triamterene treatment by confocal microscopy using 
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an Avidin antibody. Taken together, we did not directly validate the correlation 
between the increase in ROS levels and the accumulation of DSBs by measuring 8-
oxodG; however, we indirectly validated this correlation by observing a rescuing of 
the accumulation of DSBs upon Triamterene treatment and the addition of NAC. 
 
3.12 Triamterene as a novel synthetic lethal compound in MMR deficient 
tumours 
The high-throughput compound screen carried out in DLD1 and DLD1+chr2 cell 
lines upon 5-FU treatment allowed us to identify Triamterene, a potassium-sparing 
diuretic drug, as synthetically lethal in vitro and in vivo MMR deficiency through its 
antifolate activity. Triamterene was previously described as a weak antifolate [382]. 
Here we described Triamterene novel role for the treatment of MMR deficient 
tumours through its antifolate activity. We showed that Triamterene can induce an 
increase in ROS levels, leading to an accumulation of DSBs, in the MMR deficient 
cell lines specifically. The specific role for MMR pathway in the Triamterene-
mediated increase in ROS levels is still not clear; however, this result is highly 
relevant for the clinic as a moderate increase in ROS level has been associated with 
cancer development [22, 23] and therefore, the ROS induction in MMR deficient 
tumours specifically would prevent an adverse effect of an increase in ROS levels in 
MMR proficient cells. We also identified the role for TS in Triamterene synthetic 
lethality through the regulation of ROS levels. TS over-expression has been 
described as a mechanism of resistance of 5-FU treatment [453]. It would be 
interesting to see if tumours with an acquired resistance to 5-FU treatment associated 
with an up-regulation of TS would be more sensitive to Triamterene treatment and if 
this would be dependent on MMR status. We also investigated the role of NRF2 and 
the antioxidant response but the Triamterene and TS-dependent regulation of NRF2 
and ARE requires further investigation to further understand if it has a cytoprotective 
or cytotoxic role in response to Triamterene treatment. Taken together, we showed 
Triamterene as synthetically lethal in MMR deficiency through a TS-dependent 
increase in ROS levels, leading to an accumulation of DSBs (Figure 60). 
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Figure 60: Triamterene is synthetically lethal with MMR deficient cell lines 
Triamterene is synthetically lethal in MMR deficient cell lines through its antifolate 
activity and requires TS expression. It induces an increase in ROS levels specifically 
in the MMR deficient cell lines which ultimately leads to DSBs that are potentially 
lethal for the cells. The role for MMR pathway is not clear but is potentially 
upstream the increase in ROS levels. Further investigations to understand the role for 
the antioxidant response and more precisely NRF2 are necessary. 
 
 
3.13 Limitations in Triamterene treatment for the treatment of MMR 
deficient tumours 
The first limitation for Triamterene treatment in MMR deficiency would be long-
term acquired resistance to the treatment. One of the mechanisms of Methotrexate 
resistance is through the up-regulation of the folate transporter [348]. Therefore, we 
could speculate that a long-term Triamterene treatment might lead to the same 
mechanism of resistance as they share the same folate transporters [434].  
Another limitation for the treatment with Triamterene is a tumour dependent 
expression of different proteins in the folate pathway. For example, MTHFR is 
mutated in a number of tumours so we would need to investigate the role for these 
mutations in Triamterene treatment [454]. 
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4 High-throughput siRNA screen to identify synthetic 
lethal interactions with MSH6 deficiency 
4.1 High-throughput siRNA screen validation 
To carry out the high-throughput siRNA screen, we used a siKinome library 
composed of SMARTpool siRNAs. The main advantage of using a library composed 
of SMARTpool siRNAs is to minimize the off-target effects by decreasing the 
concentration of each individual siRNA and by maximizing the on-target effect by 
using 4 siRNAs targeting the same gene [455]. To carry out this screen, we used one 
single concentration of siRNA (50 nM) which might represent a limitation for high-
throughput screen because at a defined concentration, a number of siRNAs might be 
unable to efficiently silence their targeted genes or might efficiently silence their 
target as well as off-target genes. Two previous studies have successfully used the 
same kinome library at 50 nM. This concentration was also successfully used during 
the siRNA optimization experiments (with low toxicity of the siCtrl and high 
transfection efficiency measured with siPLK1). Therefore, we carried out the high-
throughput screen at the concentration of 50 nM [318, 403]. 
 
4.2 AURKA inhibition in MMR deficiency 
Based on our screen analysis, we selected 5 genes that are potentially synthetically 
lethal in MMR deficiency and validated AURKA as synthetically lethal in MSH6 
deficiency. Further experiments are necessary to completely validate the synthetic 
lethal relationship between AURKA and MMR genes. Firstly, we would need to 
measure cell viability in a short and long-term experiment upon AURKA inhibitor 
treatment in our panel of MMR proficient and deficient cell lines. It would be 
interesting to know if AURKA inhibitor is only synthetically lethal with MSH6 or 
with MSH6 and MSH2 or with all MMR genes. We know that loss of MSH2 leads to 
MSH6 instability and therefore loss of MSH6 expression, and we also know that 
nuclear MSH2 is decreased in MSH6 deficient cells [140, 163]; therefore we could 
expect AURKA to be synthetically lethal with MSH6 and MSH2 deficiency. Our 
preliminary results showed no synthetic lethality in MLH1 deficiency; however 
repeats are necessary to be able to conclude.  
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4.3 AURKA inhibitors in clinic 
The Aurora kinase family plays a critical role in regulating mitosis. AURKA is 
involved in regulating many of the early mitotic events. AURKA is located at the 
centrosome in interphase and at the spindle poles in mitotic cells. One target of 
AURKA is CDC25B, which plays a role in regulating entry into mitosis. AURKA 
also moderates the recruitment of proteins essential for centrosome maturation and 
separation. In addition, it regulates the microtubule network that forms mitotic 
spindles [456]. AURKA has been referred to as an oncogene and is significantly up-
regulated in solid tumours including CRC, breast, ovarian neuroblastoma and 
cervical cancer [419, 420]. Due to the role of AURKA in mitosis, tumours with up-
regulated AURKA manifest chromosome instability [457, 458]. The mechanism of 
AURKA in tumour progression is by facilitating checkpoint recovery allowing 
aberrant progression through mitosis [459].  
Alisertib (MLN8237) is an AURKA inhibitor. It induces a G2/M phase cell arrest, 
chromosome misalignment and spindle defects [422]. A number of clinical trials are 
investigating its response in tumours alone (NCT00962091, NCT01045421); in 
combination with Irinotecan and TMZ in neuroblastoma (NCT01601535); in 
combination with erlotinib for the treatment of non small cell lung cancer 
(NCT01471964); or in combination with paclitaxel in ovarian and breast cancer 
(NCT01091428). So far, the clinical results have shown modest effect probably due 
to patient heterogeneity [456]. Alisertib has not yet been investigated in MSI 
cancers, therefore, we could speculate that the modest response observed in clinic 
might be representative of MSI tumours. 
 
4.4 AURKA as a potential DNA repair modulator 
AURKA has been described as a potential DNA repair modulator [418]. AURKA 
has a role in cell cycle progression by repressing G1 and G2 checkpoint arrests [460, 
461]. AURKA has been shown to interact with p53 and over-expression of AURKA 
increases p53 expression [462]. However, in cancer tissues AURKA and p53 
expression are inversely correlated [463]. Reports suggest that AURKA may play a 
role in DNA damage response through p53 inhibition [418]. Silencing AURKA 
facilitates p53 phosphorylation at ser15, which enhances the NHEJ pathway [464]. 
AURKA has also been shown to inhibit HR by inhibiting BRCA1/2 and RAD51 
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[456]. A combination treatment with IR and AURKA inhibitor increases IR-induced 
HR repair in p53 deficient cells [465]. Taken together, these data on AURKA role in 
DNA repair could help us to understand its synthetic lethal relationship with MMR 
deficiency. Primarily, as AURKA plays an important role in cell cycle progression, it 
could be hypothesized that AURKA inhibition mediated cytotoxicity was correlated 
with a higher proliferation rate. The MSH6 deficient DLD1 cells have a higher 
proliferation rate compared to their paired DLD1+chr2 cells and the MSH6 deficient 
U251.TR3 cells have a lower proliferation rate compared to their paired U251 cells; 
suggesting that AURKA synthetic lethality in MSH6 deficiency is independent of 
the cell proliferation. Therefore, it would be interesting to measure cell cycle 
progression in MSH6 deficient and proficient cell lines upon Alisertib treatment to 
investigate the role for MSH6 in AURKA regulation of the cell cycle. 
As AURKA has been associated with HR and NHEJ, it would be relevant to measure 
γH2AX foci upon Alisertib treatment in our cell lines to measure if AURKA 
inhibition triggers unrepaired DSBs leading to apoptosis. As described in section 
2.3.3 of the introduction MSH6 interacts with Ku70 and that MSH6 deficiency 
results in an impaired NHEJ repair [177]. Therefore, it would be interesting to 
investigate the NHEJ pathway upon treatment with Alisertib in our MSH6 proficient 
and deficient cell lines. 
There is discrepancy with regards to the role of AURKA in the onset of CRC in LS 
[333, 335] and the mechanism behind this potential association has not been 
investigated (see the introduction section 3.2.3.4). Therefore, this synthetic lethal 
relationship is novel and promising and it would be relevant to test in vivo the role 
for AURKA inhibition in MMR deficient tumour development and growth.  
 
Taken together, we identified a novel synthetic lethal relationship between AURKA 
and MSH6 using a high-throughput siRNA screen. Our results are very promising as 
AURKA is up-regulated in a number of solid tumours and associated with an early 
development of CRC in LS. AURKA inhibitors are already used in clinic and 
therefore, this synthetic lethal relationship could rapidly be translated into clinic. 
Therefore, there is a clinical need to investigate and understand the synthetic lethal 
relationship between MSH6 and AURKA gene. Further investigations are necessary 
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to better understand this synthetically lethal relationship but our preliminary results 
are promising. 
 
My PhD project was to identify, via high-throughput compound and siRNA screens, 
modulators of 5-FU resistance and/or novel synthetic lethal relationships as new 
potential therapeutic targets in MMR deficient tumours. We identified a synthetic 
lethal relationship between Triamterene and MMR deficiency using a high-
throughput compound screen and between AURKA and MSH6 using a high-
throughput siRNA screen. We also identified the folate pathway as a novel 
therapeutic target for the treatment of different forms of MMR deficient tumours.  
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Appendix 1: Z-scores of the compound 
screen 
 
 
 
 GeneSymbol DLD1 DLD1 + 5-FU DLD1+chr2  DLD1+chr2 + 5-FU 
  REP1 REP2 REP1 REP2 REP1 REP2 REP1 REP2 
(-) -Levobunolol hydrochloride 0.6585 0.2511 0.2557 -0.2044 1.2558 -0.2042 -0.3925 -0.3183 
(-)-Adenosine 3',5'-cyclic monophosphate 0.2556 0.4657 1.0684 -1.3065 2.1727 0.5965 -0.2942 -1.0620 
(-)-Cinchonidine 0.9572 1.0686 0.3041 0.8750 0.3145 0.2363 1.0602 0.5761 
(-)-Eseroline fumarate salt -0.4556 -0.0497 -0.0139 -1.6025 -0.1399 -0.1815 -0.3769 -0.5017 
(-)-Isoproterenol hydrochloride 0.5960 0.6064 -0.7886 -0.9084 0.5521 -0.2874 0.6921 -0.9197 
(-)-MK 801 hydrogen maleate 0.2867 0.9344 0.1971 0.2076 0.3022 0.4308 0.1874 -1.5465 
(-)-Quinpirole hydrochloride 0.2290 1.3965 0.4091 2.2819 0.8297 -0.0410 0.3186 0.5188 
(+) -Levobunolol hydrochloride 0.8687 0.1141 0.7762 0.3437 0.5833 0.2986 -7.1229 0.2839 
(+)-Isoproterenol (+)-bitartrate salt -0.9624 -1.0817 0.1532 -1.5110 -2.3120 -1.0112 -0.2656 -0.7479 
(+,-)-Octopamine hydrochloride 0.0407 0.2852 -0.1988 0.3054 0.8151 0.7650 -0.9122 0.2768 
(+,-)-Synephrine -0.6728 -0.6037 -0.6184 -0.6344 -0.5292 -0.0257 -0.6847 0.5469 
(±)-Nipecotic acid  0.5977 0.7378 -1.1126 -0.1288 0.7101 0.9528 -0.0805 -0.3130 
(1-[(4-Chlorophenyl-4-methylpiperazine) 0.3225 0.7428 -1.4405 0.1459 0.4068 -0.0708 0.3954 -0.4140 
(cis-) Nanophine 0.3242 0.0340 0.6384 -0.3568 0.2615 -0.0012 0.0244 1.0106 
(d,l)-Tetrahydroberberine 0.4344 -0.7638 0.0127 0.8104 -0.3987 -1.4582 -1.0087 -1.1189 
(R) -Naproxen sodium salt -1.5235 0.0657 1.1919 0.0279 -0.2231 -0.0619 0.7017 0.3620 
(R)-(+)-Atenolol -0.0166 -0.0916 1.0209 -0.1796 -0.5257 0.2342 0.4426 0.4643 
(R)-Propranolol hydrochloride 1.8874 1.2946 0.7580 1.5084 0.6192 1.3880 1.6777 1.3942 
(S)-(-)-Atenolol 0.8461 0.6789 1.0493 -0.2597 0.3073 0.2241 -0.4054 -0.5638 
(S)-(-)-Cycloserine -0.4949 -0.4962 -0.8114 -0.1882 -0.5752 -0.6235 -0.4909 0.0698 
(S)-propranolol hydrochloride -0.1216 -1.2513 -1.1748 -0.7439 -1.2147 -1.1033 -0.7398 -0.8023 
2-Aminobenzenesulfonamide -0.5443 -0.2388 0.2679 0.5207 0.5274 -0.7343 0.4201 0.4550 
2-Chloropyrazine 0.5539 0.3078 -0.1180 -0.1771 -0.2099 0.4061 -0.5182 0.6865 
3-Acetamidocoumarin 0.0209 0.8479 -0.2762 1.5284 -0.3478 1.5594 0.9973 0.3681 
3-Acetylcoumarin 0.7753 -0.8362 -0.4865 -1.7978 -3.1114 -0.6387 -0.0981 0.0093 
 3-alpha-Hydroxy-5-beta-androstan-17-one 0.6632 -0.0863 -0.4269 -0.1708 0.0947 -0.4451 -0.3285 -0.6944 
6-Furfurylaminopurine 0.4580 -0.5691 -1.3625 -0.1002 -0.7614 -0.0132 -0.1855 -0.5523 
6-Hydroxytropinone 1.5949 0.8376 -1.3220 1.3425 -0.0481 1.8382 0.9729 -0.7939 
Acacetin 0.4591 0.1533 0.5190 1.0067 0.4848 0.1316 0.5144 -0.3666 
Acebutolol hydrochloride -1.2854 0.1637 0.8843 0.4490 0.4156 0.4622 -0.4893 -0.8880 
Aceclofenac -0.2443 0.4431 0.2926 0.6910 0.5921 0.4009 0.3227 0.1711 
Acemetacin 1.2675 -0.1768 0.4565 1.0670 0.5016 0.1412 0.2055 0.0923 
Acenocoumarol -0.2642 0.4830 -0.3706 0.6555 0.6228 0.4223 -0.5106 1.0092 
Acetaminophen 0.1728 0.6088 0.4368 -0.0357 0.2844 -0.2517 0.0687 -0.3526 
Acetazolamide 0.3019 0.8450 0.9391 1.0348 0.3416 0.4603 2.4577 0.7798 
Acetohexamide -0.4612 -0.0268 -0.4251 -0.7620 -0.0567 -0.1786 -0.6987 0.4670 
Acetopromazine maleate salt -1.0161 0.0527 0.9004 -0.0163 0.0251 -0.1502 -1.1509 -0.7471 
Acetylsalicylsalicylic acid -0.4698 0.0082 1.3164 -0.4906 1.1123 -0.0328 0.0922 1.4974 
Aconitine -0.0358 0.2848 0.0437 0.3837 -0.2956 0.5969 -0.3674 0.9946 
Acyclovir 0.2206 -0.3110 0.5895 1.8363 2.2438 1.9617 -0.0473 2.3817 
Adamantamine fumarate 0.5222 0.0102 0.9179 0.2275 1.2619 -0.3900 0.9144 0.5706 
Adenosine 5'-monophosphate monohydrate 0.5443 1.5780 1.7975 0.0554 1.2130 0.9455 1.1784 0.5104 
Adiphenine hydrochloride 1.6022 2.0033 0.9123 0.8941 1.0627 1.5979 0.8320 1.2000 
Adrenosterone 0.0025 0.2394 -0.1668 0.0903 -0.9235 -0.0249 -1.0593 0.7492 
Ajmalicine hydrochloride 0.1056 -0.2034 -0.0091 0.4725 -0.3697 -0.5286 1.2020 0.8790 
Ajmaline -0.1355 -0.9907 -0.3808 -0.2029 -0.4161 -0.3057 0.8713 -0.4580 
Albendazole -10.0363 -7.3534 -7.2350 -10.4863 -7.5805 -6.3195 1.2691 -4.7381 
Alclometasone dipropionate -1.2327 -0.3755 -0.6796 -1.0509 -1.0933 -1.1626 -0.2238 -0.9272 
Alcuronium chloride 1.1098 0.7442 1.2529 1.0260 1.5052 0.6912 0.4303 -0.1813 
Alexidine dihydrochloride -8.3798 -4.5348 -6.3699 -7.4139 -7.6046 -8.6891 -0.7880 -8.7479 
Alfadolone acetate -0.0691 -0.9352 0.6592 -0.8729 -0.1693 -0.7951 -0.9518 -0.4352 
Alfaxalone 0.9237 -0.8220 -0.2021 0.1871 -0.6940 -0.2904 -0.1013 0.9953 
 Alfuzosin hydrochloride 2.2875 -1.1738 -0.2710 2.0067 -0.7685 0.2056 -0.6065 1.4880 
Allantoin -0.0900 1.4190 0.1699 -0.2927 -0.0158 1.1858 2.6976 0.1102 
alpha-Santonin -0.3197 -0.1693 -0.3970 -0.0290 0.1352 -0.3453 -0.0564 -1.0674 
Alprenolol hydrochloride 0.6890 0.2657 0.2841 0.6499 1.7270 1.5041 0.8843 1.3361 
Alprostadil -0.0209 -0.4047 -0.2015 -0.0250 0.1892 -0.3999 -0.8973 -2.1216 
Althiazide 0.4988 -0.1957 -0.4348 0.2209 -0.6972 1.7593 2.7292 0.1163 
Altretamine -0.2158 0.5590 -0.1062 -0.1096 0.5712 0.1604 -0.9343 -0.6882 
Alverine citrate salt -0.7330 0.3883 -1.1141 0.4050 0.9957 0.1903 -1.1180 0.6156 
Ambroxol hydrochloride 0.6853 1.6711 0.3476 0.7728 1.2478 1.4406 0.1732 -0.2487 
Amethopterin (R,S) -9.1469 -14.9028 -7.0399 -11.0071 -12.2200 -16.0272 -1.1625 -11.8547 
Amidopyrine 0.2602 -0.4218 -0.0843 2.2386 1.6074 1.5438 -0.8717 2.3498 
Amikacin hydrate 0.3347 0.9990 0.3684 0.6920 0.3434 1.7027 1.1512 0.7590 
Amiloride hydrochloride dihydrate 0.7486 0.8734 1.1736 0.9634 -0.2074 -0.5354 -0.0391 0.7642 
Aminocaproic acid 0.9329 1.6788 -1.1112 0.5115 0.5878 1.9729 0.1226 1.2017 
Aminohippuric acid 0.2773 0.6796 0.0241 0.6262 -0.4235 1.0543 0.8822 0.2869 
Aminophylline -0.1799 -0.3413 0.5841 0.9053 -0.1910 0.0278 0.3362 0.2286 
Aminopurine, 6-benzyl 0.6688 -0.7836 1.0137 -0.4988 0.4374 -0.8699 -0.4038 -0.3865 
Amiodarone hydrochloride 0.2437 -1.0049 -1.2824 -0.5336 0.3718 -1.5219 1.2869 1.2312 
Amiprilose hydrochloride 0.7890 1.9554 1.2144 0.9484 0.9038 1.0972 -0.0259 1.1673 
Amitryptiline hydrochloride 0.0227 1.5599 0.6792 1.7455 0.9088 0.8103 0.1461 0.5430 
Amodiaquin dihydrochloride dihydrate -0.0095 0.2646 0.4142 -0.2511 -0.2237 0.3819 -0.5624 -0.4343 
Amoxapine 1.3022 -0.9007 1.3333 0.2583 -0.1654 -2.3732 -1.4283 0.7485 
Amoxicillin -0.3996 0.8905 -0.3621 0.7025 0.9647 -0.1606 -0.7027 0.1739 
Amphotericin B 0.7741 -1.0839 -0.2452 0.9360 1.8532 -1.5629 1.4207 0.9273 
Ampicillin trihydrate 0.5422 -0.0810 1.8551 -0.3065 0.6386 -0.3082 0.6527 -0.0094 
Amprolium hydrochloride 0.2487 0.9352 -0.2612 0.4226 0.3388 0.2475 1.3398 0.7318 
Ampyrone -0.5397 -0.6360 -0.5750 -0.1211 -1.7552 -0.3061 -1.4380 0.1419 
 Amrinone 0.7731 1.4025 0.6652 0.2963 0.9956 1.3528 -0.1080 0.4734 
Amyleine hydrochloride -0.4843 -0.7250 0.2796 0.1500 0.1196 -0.1664 0.1136 -0.2703 
Anabasine 0.3092 0.1956 -0.6916 0.4793 0.2087 0.2420 -0.1528 -0.4527 
Androsterone 1.7373 -1.4072 0.0575 0.7519 -2.6252 0.3698 -1.2932 1.1223 
Anisomycin -13.2894 -17.1099 -11.5947 -13.4594 -10.8019 -14.3161 -0.3474 -9.6832 
Antazoline hydrochloride -0.1985 -0.2927 -1.1813 0.5834 0.5960 0.4261 0.3519 -0.9370 
Antimycin A -1.2505 -22.6619 -0.9318 -4.3591 -2.9644 -14.9649 0.0223 -4.7220 
Antipyrine 0.6914 0.2100 -0.1839 -0.3519 -0.0699 -0.7039 0.1298 -0.1593 
Antipyrine, 4-hydroxy 0.5819 -0.2946 0.2704 -0.3721 0.2774 -0.8168 -0.1591 0.5193 
Apigenin -0.8991 -0.0856 -1.1600 -0.6162 -0.8458 -0.3258 -1.2697 -0.3136 
Apramycin 1.3722 1.6147 1.1233 1.8006 1.4792 1.6203 2.0599 1.9626 
Arbutin 0.4508 0.0581 0.2227 -0.5358 0.6018 0.2753 -2.4337 0.3041 
Arcaine sulfate -0.0087 0.4889 0.9354 1.5328 0.9560 0.9158 1.0194 1.5824 
Arecoline hydrobromide 0.9479 -0.5128 -0.3866 0.5023 0.0086 2.1618 0.7450 0.9867 
Artemisinin -1.3869 -0.5771 -0.5233 -1.0659 -0.7551 -0.9598 -0.1210 -0.3276 
Articaine hydrochloride 0.9480 -1.0590 0.2077 -0.0053 1.1204 0.3577 0.8798 0.3440 
Ascorbic acid 1.5737 0.8650 0.4087 1.0602 1.4897 0.2639 -2.9136 2.0150 
Asiaticoside -1.6695 0.1545 -0.4914 0.0053 -0.2663 -0.9303 0.3649 1.0438 
Aspartic acid, N-acetyl (R,S) 1.3957 -0.0102 -0.1015 0.8490 -0.2900 -0.0911 -0.2371 0.4784 
Astemizole -3.2985 -0.8630 -2.5111 -2.5395 -0.5907 -0.4544 0.6101 -2.1926 
Atovaquone 0.9362 0.4510 0.1640 -0.2217 -0.0003 0.1210 -0.1231 -0.5013 
Atractyloside potassium salt 1.4464 0.1795 0.0299 0.3842 0.0144 0.1255 -1.4580 1.1610 
Atracurium besylate -0.8065 1.3394 0.9374 0.7173 0.0882 0.0010 0.5983 0.4087 
Atropine sulfate monohydrate 0.7653 -0.7247 1.3122 2.0760 -0.5601 -0.0896 0.7298 0.2079 
Austricine -0.9110 -1.0291 -0.2308 -1.5792 -1.9258 -0.2963 0.0579 -0.8505 
Avermectin B1 -0.8027 -0.2262 -1.3961 -0.6461 -1.0272 -0.0072 -1.6203 0.3257 
Azacyclonol 0.4629 -0.3790 0.5745 -0.8868 -0.4574 0.5187 -0.4344 1.9682 
 Azacytidine-5 -0.6458 0.3501 -0.7286 -0.1803 0.8533 0.0537 -0.2662 0.4908 
Azaguanine-8 -1.1486 -0.3515 -2.1494 -1.6599 -2.2279 -1.6899 -0.9409 -1.4958 
Azaperone 0.4195 1.1268 -1.6793 1.8678 0.6456 1.0902 0.4001 0.3503 
Azapropazone 0.2845 -0.1846 0.5185 0.9083 0.6931 0.0069 -6.4949 0.1706 
Azathioprine -5.6200 -7.1008 -4.1993 -7.6597 -8.8199 -12.9128 -0.2385 -7.8120 
Azathymine, 6 1.5752 -0.2705 0.9091 1.5375 0.3079 0.9845 -5.4889 1.9130 
Azlocillin sodium salt -0.6217 -2.3452 -0.5699 -1.6357 -2.8611 -2.1236 -1.6403 -1.1499 
Aztreonam 0.9369 -0.2133 0.5585 0.2369 0.6573 -0.0029 0.4242 0.6510 
Bacampicillin hydrochloride 0.8335 -1.2355 0.3978 0.9897 -1.1314 -1.2440 0.2934 -0.4197 
Bacitracin 0.1757 -0.0002 -0.1465 -0.1369 0.7888 -0.4714 -0.6374 0.3252 
Baclofen (R,S) 0.2243 0.5666 0.4407 2.5817 1.9189 2.0306 0.3805 1.8718 
Bambuterol hydrochloride 0.0861 -0.2473 0.5244 -1.8689 -0.6035 -0.0289 -2.8669 0.9225 
Beclomethasone dipropionate 0.2955 0.0613 -0.2648 -0.6800 0.6469 0.0313 -0.0395 -0.1739 
Bemegride 0.0907 0.1543 1.1279 0.9289 -0.6076 0.1195 0.6198 1.1781 
Bendroflumethiazide -0.3143 0.4131 0.9413 0.1527 0.3874 0.0963 -0.9949 0.1749 
Benfluorex hydrochloride 0.3485 0.3088 0.2341 1.1337 0.4736 0.4749 0.3163 -0.8406 
Benfotiamine -0.2945 -0.6296 0.8246 1.1744 0.5475 -0.6819 -0.3454 0.2606 
Benoxinate hydrochloride -0.0952 0.0583 0.2319 -0.0502 0.0694 0.2144 -0.1688 -0.0811 
Benperidol -0.0398 0.2135 -1.6791 1.8726 -0.3006 1.6033 0.0037 2.3105 
Benserazide hydrochloride -0.6249 -0.0343 0.0552 0.1567 0.2162 -0.0106 0.1897 -0.2740 
Benzamil hydrochloride -0.0102 -0.7286 -1.0334 -1.5847 -1.6663 -0.8873 -0.1768 -1.2435 
Benzathine benzylpenicillin 0.8735 0.2796 -0.0819 -0.2482 0.3636 0.1854 -6.2133 -1.5218 
Benzbromarone 0.0423 -0.0401 0.1029 -0.0056 0.7844 -0.7514 -0.4229 -0.4899 
Benzethonium chloride -1.1237 -0.5285 -0.6652 -0.3374 0.0389 -0.2711 0.5012 -0.3900 
Benzocaine -0.2264 1.4611 -0.5447 1.5328 0.2560 1.3047 0.3104 0.5293 
Benzonatate 0.1709 0.9067 1.2863 0.8158 -0.2749 1.2651 -0.2105 1.2779 
Benzthiazide 0.7324 -0.8176 0.1177 -0.3138 -0.8563 -0.4447 0.9207 -0.3202 
 Benzydamine hydrochloride 0.6524 0.6100 -0.1805 0.9339 -0.3873 0.7212 -0.1633 0.5871 
Benzylpenicillin sodium -0.1662 0.0926 -0.6031 -1.2501 -0.2034 -0.2130 -8.4500 -1.0999 
Bephenium hydroxynaphthoate -0.3223 0.1385 -1.2637 0.8694 -0.0663 0.1722 1.2748 0.0552 
Bepridil hydrochloride  -5.9149 -3.7333 -6.2894 -6.4649 -2.5645 -3.8066 0.0115 -6.0762 
Berberine chloride -0.4378 -2.3711 -0.8624 -1.2676 -0.8941 -3.4468 -9.9241 -1.7170 
Bergenin monohydrate -1.3083 -3.3166 -1.2463 -2.1632 -2.0138 0.7378 -0.6366 -0.6164 
beta- Belladonnine dichloroethylate -1.0326 -0.7462 -0.1896 -0.8238 -1.9731 -0.9493 -0.3918 -0.6244 
Beta-Escin -0.0538 0.7761 0.5910 0.9930 0.8844 0.5865 0.9158 0.2467 
Betahistine mesylate 0.8921 0.2727 0.3307 0.4992 0.2988 0.9475 0.6584 0.0367 
Betamethasone -0.8920 -0.6394 0.0416 0.8916 -0.9399 -0.1311 -1.4252 -0.2053 
Beta-sistosterol 0.9423 -0.0704 0.3277 0.6467 0.6492 -0.0982 0.2751 0.0569 
Betaxolol hydrochloride 0.5894 0.0615 0.8485 0.2294 -0.3954 0.0794 -7.0292 0.0013 
Betazole hydrochloride 0.1065 -0.0463 0.7717 -0.1706 0.3146 -0.4358 -0.5889 -0.0213 
Bethanechol chloride 0.0295 0.8079 0.3185 -0.0377 -0.1638 0.2455 0.5746 0.9210 
Betonicine 1.1583 1.0957 0.5623 -0.0271 0.2836 0.9464 -0.5192 1.5200 
Betulin -1.1587 -0.1585 -0.0833 0.2740 -0.4290 -0.7525 -0.3632 0.2631 
Betulinic acid 0.8687 0.1021 0.2712 -0.1659 0.5643 -0.8087 -0.4744 -0.6755 
Bezafibrate 0.3064 -0.0162 -0.1119 0.0825 0.3544 0.0647 -1.1644 0.1732 
Bicuculline (+) -0.7310 -1.3397 0.7893 0.6730 -0.0366 -0.7425 0.0101 -0.3736 
Biotin -0.9038 -0.1810 -1.8438 0.5566 0.7590 -0.3142 0.1712 -1.1719 
Biperiden hydrochloride -0.4236 -0.1345 -0.3126 0.2872 -0.4437 0.3562 -1.0225 1.0546 
Bisacodyl -3.8232 -4.6765 -4.2456 -4.4547 -5.9507 -6.8975 -1.1107 -5.6136 
Bisoprolol fumarate 1.4259 0.8061 0.9108 0.2198 1.6761 0.4949 0.7227 1.0377 
Boldine -0.4540 -1.0416 0.0371 -0.0278 0.1050 -0.1877 -0.3310 -0.0135 
Bretylium tosylate 0.2199 -0.5404 0.0144 -0.2440 -1.0464 -0.3878 0.0087 -0.7484 
Brinzolamide 0.3493 1.2556 -0.3233 0.4494 1.5196 1.5697 0.4123 1.0166 
Bromocryptine mesylate -0.0195 -0.3293 -0.1238 -2.4985 -0.8281 -1.0825 -0.3553 -1.6855 
 Bromopride -0.9820 0.4338 -0.9086 -1.5065 -0.0813 -0.1789 -0.2385 -0.3788 
Bromperidol 0.0454 -0.5208 0.7280 -0.4680 -0.2690 0.0681 -0.5912 -0.7737 
Brompheniramine maleate 1.1527 1.8858 1.1538 1.1380 1.4235 1.1478 0.8296 0.9197 
Bucladesine sodium salt 0.5005 -1.2511 -0.0266 0.0784 -0.7879 0.0703 -0.0341 0.1502 
Budesonide -0.4223 -0.3806 -1.3666 0.3436 -0.0334 -1.1683 -0.2088 -0.9641 
Bufexamac -0.8871 0.4876 1.9872 1.5787 1.5429 2.5917 -1.8089 1.5199 
Buflomedil hydrochloride 1.1285 0.3769 0.2491 0.1888 0.6916 0.5823 0.7992 -0.0257 
Bumetanide 1.4459 0.3321 0.8103 -0.1677 1.3952 1.1576 0.6672 0.8965 
Bupivacaine hydrochloride  0.5900 0.2563 -1.3502 -0.3304 -0.4747 -0.0087 -2.2121 -0.2935 
Bupropion hydrochloride 0.2843 0.7544 -0.0832 0.3885 1.6601 1.1381 0.6233 0.8895 
Buspirone hydrochloride 0.6271 -0.1213 -0.4583 0.3937 0.9401 0.5751 0.1611 -0.1992 
Butacaine -2.4313 -0.9015 -0.0781 -1.1036 -2.1698 -1.4684 -1.1275 -0.5213 
Butamben -1.8033 -1.7877 -1.4975 -1.7396 -1.6178 -0.7321 -0.0060 -1.1855 
Butirosin disulfate salt 0.7249 0.9490 0.6800 0.7546 0.0069 1.8952 0.3145 1.4317 
Butoconazole nitrate -1.0291 -0.6107 -1.6086 -0.0659 -1.4747 -0.2080 -0.3286 0.3092 
Butylparaben -0.0025 -0.1422 -1.0220 -0.5761 -0.9153 0.7330 1.6326 0.8388 
Caffeic acid -0.6708 -0.0282 0.4482 0.4742 0.1475 -0.5446 -0.8896 -0.0027 
Calciferol -0.3827 -1.2390 0.0709 0.8067 0.4125 -0.8638 -0.0709 0.1763 
Calycanthine 0.6798 0.1691 1.3044 1.4556 0.7365 0.8356 0.1512 1.3857 
Camptothecine (S,+) -15.2384 -19.3831 -12.0842 -17.0756 -18.1104 -27.5889 0.0394 -19.0685 
Canavanine sulfate monohydrate (L,+) 0.0507 -0.3234 -0.2253 -0.8793 0.3704 -0.7406 -0.5854 -0.2318 
Canrenoic acid potassium salt 0.1288 0.3520 0.2342 0.5350 -0.4708 0.2412 0.1889 0.1463 
Cantharidin -9.3595 -6.2389 -9.4561 -10.8550 -8.6002 -10.6448 1.9976 -8.1100 
Capsaicin -0.9497 0.8043 0.4325 0.5777 1.0960 1.5204 0.0256 0.2358 
Captopril -0.5946 -0.3172 -0.3013 -0.7627 -0.7416 -0.8519 -1.2419 0.0813 
Carbachol -0.8647 1.3491 1.2794 2.2509 0.6873 1.4020 -0.2075 1.8374 
Carbamazepine -0.3432 0.8251 0.1209 0.3110 0.6975 0.2496 0.9734 -0.3494 
 Carbarsone 1.0842 -0.5923 -0.6675 1.2601 -1.1554 0.1033 -1.0702 0.6002 
Carbenoxolone disodium salt -0.2681 0.7449 -0.4641 -0.3004 1.0011 0.0142 0.5864 -0.4920 
Carbetapentane citrate 0.2578 0.3215 0.3022 0.3741 -0.1346 0.6399 0.2596 -0.4569 
Carbimazole 0.4110 -1.2299 -0.5443 -0.0452 0.0869 -0.0746 -0.0013 0.3902 
Carbinoxamine maleate salt 0.0087 -1.1836 -0.4093 0.0312 -0.9494 1.0194 0.3831 0.4050 
Carcinine 1.0635 0.4273 0.1357 1.0690 -1.2801 0.7433 -1.4672 1.0591 
Carisoprodol 0.7117 0.0164 0.1389 1.3355 -0.5058 0.5604 0.0013 1.1913 
Carteolol hydrochloride 0.3883 0.8166 0.0963 0.5418 0.6301 0.8675 1.3822 1.3904 
Catechin-(+,-) hydrate 0.7981 -0.1984 0.8370 -0.0825 -0.6712 -0.5531 0.5706 0.5175 
Cefaclor -0.4381 -0.0687 1.1280 0.4556 0.0003 1.5440 -9.3367 2.2977 
Cefadroxil -0.4682 0.3115 0.1661 0.9859 -0.0920 0.1072 1.4786 -0.6516 
Cefalonium 0.6145 0.6784 -0.7735 0.6739 0.8467 0.7615 1.3879 0.6427 
Cefamandole sodium salt 1.2502 0.7815 0.1014 0.9028 0.3724 -0.1927 0.5637 0.7092 
Cefazolin sodium salt -0.0835 -0.5414 -0.0583 0.5010 0.6933 0.2777 0.4998 -0.0202 
Cefepime hydrochloride -0.3278 0.4328 -0.0483 0.5691 0.9875 -0.0033 0.7737 0.5522 
Cefixime 0.7563 1.1247 0.4680 0.7672 0.6568 -0.1119 -0.5213 -0.0954 
Cefmetazole sodium salt 0.0102 -0.4892 -0.4613 0.3289 0.3416 0.4523 -0.0446 0.1869 
Cefoperazone dihydrate -0.1613 1.6672 1.0112 0.9340 1.9014 -0.9946 0.7171 1.2101 
Ceforanide -0.1946 -0.5147 0.0475 -1.0687 0.2080 -0.2126 -0.1700 0.3328 
Cefotaxime sodium salt -0.0824 0.7323 -0.1372 -0.3033 0.3456 0.5490 0.1626 0.1319 
Cefotetan -1.2111 1.6217 0.6959 0.6566 0.4581 0.7156 -0.9915 -0.0638 
Cefotiam hydrochloride 0.5500 0.6330 0.3742 1.9136 0.0658 1.5959 -0.9987 2.2930 
Cefoxitin sodium salt -0.3362 0.1171 0.4128 -0.8471 -0.5047 0.0058 1.1252 -1.3771 
Cefsulodin sodium salt 0.4215 -1.1642 1.5890 0.9220 -0.0365 -0.2090 0.0392 -0.0206 
Ceftazidime pentahydrate -0.8554 -0.5202 0.1141 0.6584 0.6188 0.8562 0.0956 0.4087 
Cefuroxime sodium salt 0.8638 1.6043 1.2871 0.8648 0.9089 2.5400 0.4372 1.0969 
Cephaeline dihydrochloride heptahydrate -13.0400 -13.8626 -11.4975 -13.7170 -12.9033 -16.3530 -5.5625 -12.5135 
 Cephalexin monohydrate -0.0639 1.1120 0.1216 -0.0063 0.7402 0.4786 0.4784 -0.3371 
Cephalosporanic acid, 7-amino 0.6014 0.9433 1.0720 1.0604 -0.5811 0.4633 0.9748 0.4568 
Cephalothin sodium salt 0.7575 1.5601 1.3265 -0.6743 0.9083 1.7766 0.6216 1.1010 
Cetirizine dihydrochloride 0.7247 -0.0921 0.7309 -0.3048 -0.4897 -0.4120 0.8494 1.0575 
Chelidonine (+) -11.8685 -8.1023 -8.4351 -8.3030 -8.9972 -10.0665 -19.4341 -6.9415 
Chenodiol 2.2178 1.7541 1.2515 0.3191 1.6435 1.5095 0.6346 0.7382 
Chicago sky blue 6B 0.7438 0.1935 0.7996 0.7989 1.0383 0.6069 -0.3217 0.0897 
Chlorambucil -0.5114 0.1603 -0.5913 -0.2381 -0.0898 0.0668 -0.9043 -0.2018 
Chloramphenicol 0.7205 -0.9509 -0.2508 -0.8268 -0.9339 -1.3733 -0.4802 1.4032 
Chlorhexidine -0.0312 -0.1795 -0.3755 -0.5173 -0.3548 -1.0535 0.1050 -0.9780 
Chlormezanone 0.0963 0.8863 1.7203 0.0555 0.6856 0.6141 0.1552 0.0094 
Chlorogenic acid -0.1276 -0.3687 -2.0388 -0.9482 0.0133 0.1947 0.3668 -0.6564 
Chloropyramine hydrochloride 1.2471 1.1351 0.8392 1.0915 -0.4076 1.1848 0.3063 0.2570 
Chloroquine diphosphate -0.3948 0.3830 0.5804 -0.9431 0.3895 0.3636 -0.5390 -0.2983 
Chlorothiazide -0.3264 -0.4163 2.1104 1.0893 -1.3926 0.7106 -0.3373 -0.4088 
Chlorotrianisene -0.3884 -0.1800 0.4143 -0.3604 0.1148 -0.4922 1.0403 -0.6759 
Chlorpheniramine maleate 0.5106 0.5547 1.0154 0.9572 0.7824 0.2904 0.4635 -0.1283 
Chlorphensin carbamate 0.5109 2.6025 0.6161 0.3536 -0.3862 1.2174 -8.4812 1.0293 
Chlorpromazine hydrochloride -1.0367 -2.3760 -2.4674 -0.5641 -1.0664 -2.0580 -1.3946 -1.7968 
Chlorpropamide 1.3090 -0.1821 -0.5031 1.6630 0.1102 0.3817 0.7369 1.2380 
Chlorprothixene hydrochloride -1.5951 -0.8664 -0.3184 -0.8851 0.0512 -1.4092 -6.1589 -0.6482 
Chlortetracycline hydrochloride -0.2118 0.3545 1.2185 -0.2422 -0.1028 0.0509 0.2788 -1.0010 
Chlorthalidone -1.0722 -0.4373 -0.2294 -0.5421 -1.0787 -0.7309 -2.1392 -0.2441 
Chlorzoxazone 0.4736 0.9508 0.6168 0.9927 -0.1586 0.5148 1.1474 1.0367 
Cholecalciferol -0.1395 -0.7936 0.2173 0.6529 0.4560 -0.4356 0.7868 0.5580 
Chrysene-1,4-quinone -8.3785 0.2632 -2.1983 -0.2956 -0.5803 0.5051 0.3119 -0.3214 
Chrysin 1.1483 0.9068 0.9393 -0.8981 0.8238 0.4424 0.7693 -0.7622 
 Ciclopirox ethanolamine -5.4754 -8.5130 -5.7074 -12.0652 -5.9572 -7.6349 -1.3811 -11.6191 
Cimetidine 0.7782 0.5527 -0.9897 -0.3007 0.4546 -0.3625 0.3762 0.5446 
Cinchonine -0.2440 0.1363 -0.3062 -0.3729 0.2987 -0.5587 0.1581 -0.6397 
Cinnarizine 0.9763 0.0944 0.2811 -0.4874 1.2587 -0.3236 0.9496 -0.1300 
Cinoxacin -0.4291 0.3928 0.0642 -0.0069 -0.5306 -0.6187 -1.3673 -0.8075 
Ciprofibrate 0.6871 0.9591 1.6949 0.2693 0.7998 0.9700 -5.4904 0.5084 
Ciprofloxacin hydrochloride 0.7785 0.0409 2.1281 -0.7830 0.7149 -1.0182 0.0742 0.7464 
Cisapride -0.2291 -1.6675 0.2897 -0.0079 0.9481 -0.2974 -2.6738 -0.2503 
Citalopram Hydrobromide -0.1882 -0.2082 -0.0127 -0.1942 -1.1596 0.0683 0.0503 0.1889 
Clebopride maleate 0.1742 0.2966 -1.0666 0.6544 0.9008 -0.1721 -0.6157 -0.1673 
Clemastine fumarate -1.1639 -0.6419 -0.7370 -0.7424 -0.3251 -0.6461 -0.4777 -0.7625 
Clemizole hydrochloride -0.4458 0.0777 -0.8957 -1.4816 -0.8223 -0.7494 0.5588 -0.3183 
Clenbuterol hydrochloride -0.2867 1.1335 0.8584 0.7184 1.1778 -0.0050 0.0381 0.1767 
Clidinium bromide -0.1525 -0.8326 0.8560 -0.2403 -1.2387 -0.1708 0.8313 0.0064 
Clindamycin hydrochloride 0.9205 0.3051 -0.1903 -0.2219 0.3694 0.2017 0.5926 -0.2031 
Clioquinol -0.8413 0.7867 -1.0196 0.1468 -0.1581 -0.5254 0.3625 -0.0963 
Clobetasol propionate -1.4611 -1.0480 -1.6673 -1.4085 -1.3223 -1.1778 0.0030 -1.0594 
Clocortolone pivalate 0.3158 0.1518 1.4747 1.0663 0.6743 1.0854 0.1459 0.1211 
Clofazimine -6.2548 -5.6064 -5.7027 -7.1204 -4.3411 -5.3049 -0.1609 -6.4398 
Clofibric acid -0.4820 0.6299 -1.5123 -0.2343 -0.5720 -0.0350 -0.8787 0.2037 
Clofilium tosylate 0.4629 1.5540 -0.6700 0.3945 -0.3901 0.6389 0.0883 0.9309 
Clomiphene citrate (Z,E) -5.0003 -2.2767 -3.4909 -3.1480 -3.9490 -1.0626 1.5009 -1.0315 
Clomipramine hydrochloride -0.7395 -2.5012 -0.5532 -1.8752 -0.0589 -1.8900 0.0733 -1.7089 
Clonidine hydrochloride -0.9588 1.2428 0.2044 0.0984 1.3862 1.7109 0.7927 1.3596 
Clopamide -0.2718 0.8021 1.3317 0.2668 0.5507 0.4137 0.6367 0.2850 
Cloperastine hydrochloride -1.6345 -0.4724 -0.6874 0.2790 -0.9762 -0.3698 1.0973 0.4554 
Clorgyline hydrochloride 0.3420 0.5629 0.0573 0.1373 1.1954 0.0855 0.3494 0.1161 
 Clorsulon -0.4189 -0.5951 -0.8129 -1.7331 -0.0371 0.5513 0.5725 -0.8003 
Clotrimazole -1.8675 -1.9626 -3.0619 -3.2614 -0.3097 -1.5379 1.3807 -1.2697 
Cloxacillin sodium salt 0.6521 0.3400 1.5880 -0.0538 0.4440 -0.8950 -1.0114 0.5746 
Clozapine -0.0472 -0.9668 -0.0017 -0.3813 0.9248 -0.5038 0.0942 -0.1976 
Colchicine -11.7908 -12.4254 -8.5046 -9.8702 -10.5441 -11.7848 -0.8539 -8.3685 
Colistin sulfate -0.2872 0.0772 -0.1029 0.9670 0.4842 0.5281 -1.1479 0.1886 
Condelphine -0.1259 0.0021 0.3676 0.4403 -0.4203 0.1189 -0.2602 -0.1987 
Conessine 0.8559 1.3325 1.3945 2.0405 1.3557 1.7953 -0.3917 0.5487 
Convolamine hydrochloride -0.2068 0.3197 0.9500 0.1632 0.3273 0.1349 -0.5119 1.1202 
Coralyne chloride hydrate -0.7465 -1.0881 0.0641 -0.2087 -2.0933 -1.6730 -0.4779 0.0708 
Corticosterone -0.1027 0.1496 0.2107 0.4459 0.2533 0.4252 -0.9442 -0.0665 
Cortisone 1.8144 0.0395 0.8398 0.0589 0.8509 0.1747 0.1854 0.6242 
Corynanthine hydrochloride 0.6352 -0.3596 -1.5165 0.0915 -0.0004 -1.1446 -1.4288 -0.3392 
Cotinine (-) -0.3361 -1.1750 -0.4232 1.9637 -0.2118 1.8924 -1.2016 2.6624 
Cromolyn disodium salt -0.5604 -1.7810 0.3932 -0.1327 -0.9328 0.5456 0.7310 1.3258 
Crotamiton -2.2086 -1.2517 1.0822 0.0599 -1.2425 0.1105 0.0217 -0.7769 
Cyanocobalamin 0.4334 0.0370 -0.0719 0.8092 1.2191 0.4651 0.5375 1.7761 
Cyclacillin 1.2592 0.5110 1.0696 1.2126 1.3531 1.2017 -12.3375 -0.3275 
Cyclizine hydrochloride 0.5498 -0.2037 -0.2984 -0.9730 0.2776 -0.3326 -0.2451 -0.7235 
Cyclobenzaprine hydrochloride 1.8001 1.3480 0.6179 1.6937 1.3440 1.4247 1.5057 1.8099 
Cycloheximide -8.2885 -5.7627 -5.6171 -6.9842 -8.1054 -8.3972 -1.0541 -7.7022 
Cyclopenthiazide 0.9055 0.4450 0.2744 0.9730 0.2862 0.4723 0.3815 0.9919 
Cyclopentolate hydrochloride 0.2673 0.9980 1.4263 0.8190 0.8782 0.7722 0.1184 -0.5039 
Cyclosporin A 0.9157 0.0946 0.2578 1.5842 1.8273 0.4779 0.5934 1.3543 
Cyproheptadine hydrochloride 0.0803 -1.3557 -0.2413 0.2313 -0.2270 -0.7727 -0.5863 0.2767 
Cyproterone acetate 1.1645 0.7978 1.2786 0.4219 0.3023 0.5555 0.5745 1.4712 
Cytisine (-) 0.0386 -0.4045 1.1955 -0.0634 0.3811 0.2905 -0.3969 0.1934 
 Dacarbazine -1.2696 -0.4423 -0.6010 -0.2297 -1.2120 -1.0067 1.0150 -2.7275 
Danazol 0.6426 0.3417 0.4199 -0.7059 0.4002 -0.0856 0.5235 -0.5058 
Dantrolene sodium salt  -0.4773 -1.8635 -0.1185 0.0636 -0.7665 -1.4133 -0.3421 -0.3226 
Dapsone 1.9495 0.9242 0.2664 1.1747 0.0088 0.7802 1.0663 1.3246 
Daunorubicin hydrochloride -11.1394 -2.8526 -8.4682 -5.7646 -13.8311 -13.4280 -0.0045 -11.5996 
D-cycloserine 0.7720 0.8812 0.9460 1.6595 0.3181 1.0379 0.5884 0.5333 
Debrisoquin sulfate -0.4760 0.4687 0.0789 -0.0611 -0.6803 -0.4776 -1.4307 0.4350 
Decamethonium bromide 1.4597 0.7657 0.0220 0.4485 -0.4796 1.1251 0.8361 -0.0160 
Deferoxamine mesylate -3.5992 -0.9348 -2.0747 -1.6172 -3.2429 0.4040 1.7155 -1.1773 
Dehydrocholic acid 1.1823 -0.0690 0.5045 -0.6777 0.2315 -0.9951 -0.5787 0.9185 
Dehydroisoandosterone 3-acetate -0.6430 0.4017 -0.5058 0.4734 0.9584 -0.4734 -0.2675 -0.1305 
Delcorine -0.4284 -0.3568 0.9296 -0.0158 -0.2212 0.2690 -0.0355 -0.0021 
Delsoline -0.3891 0.1541 0.0203 -0.2732 -0.0240 0.0335 -0.0553 -0.9266 
Deltaline 0.7766 -0.0340 1.0066 0.5364 -0.1890 -0.4561 0.8247 -0.1655 
Demecarium bromide 0.1405 0.3232 0.6060 -1.3303 0.0537 0.0380 0.9105 0.5560 
Demeclocycline hydrochloride 0.4084 0.5873 -1.0071 -0.5968 -0.4672 0.3583 1.0387 -0.9235 
Denatonium benzoate -0.0780 -0.9870 0.3593 0.8547 -2.2032 0.7154 1.3746 0.1867 
Deoxycorticosterone -0.0478 1.1746 0.4507 1.3169 0.4314 1.4247 0.4173 -0.4761 
Deptropine citrate -0.0551 -0.4249 -0.8070 -0.7568 -0.2026 -0.2574 -11.1526 -1.2840 
Dequalinium dichloride -3.8695 -3.2822 -3.1960 -2.3696 -5.1401 -2.8623 0.8778 -2.9317 
Desipramine hydrochloride -0.8290 -0.4791 -0.5996 -0.1312 -0.6799 -1.3525 -1.0598 -0.0452 
Dexamethasone acetate -0.3425 -0.0104 0.2161 0.6431 0.4961 0.0754 0.3142 0.5901 
Dextromethorphan monohydrate -0.0494 0.7319 -0.3632 -0.2750 0.3134 -0.0477 -1.6206 0.2954 
Diazoxide 1.3142 0.8941 0.6204 2.7133 1.7815 2.2921 -11.8092 1.8101 
Dibucaine 0.5140 1.7917 -0.0056 2.0449 0.7256 1.6073 1.1685 1.1502 
Dichlorphenamide 1.3526 0.3449 0.2292 0.1411 0.4391 0.4558 1.3380 1.0450 
Diclofenac sodium 0.4795 0.0321 1.0870 1.2166 0.1357 -0.1454 1.5746 0.5113 
 Dicloxacillin sodium salt -0.2615 -0.9785 -0.6323 -0.1048 0.4062 -0.4759 -0.0743 0.2245 
Dicumarol 0.5254 -0.4562 -0.2856 0.5189 -0.0228 -0.9908 0.1202 -0.9918 
Dicyclomine hydrochloride 0.2088 -0.1043 0.1935 0.2775 0.0670 -0.3536 -0.4488 -0.9550 
Dienestrol -0.2474 1.4736 0.9026 0.6851 1.1741 1.0764 0.5839 1.6350 
Diethylcarbamazine citrate 2.1345 0.4576 0.9043 1.4358 0.8784 0.1470 0.9798 0.1001 
Diethylstilbestrol 1.3112 1.0595 1.8206 -0.7553 1.3616 0.8427 0.2932 0.4343 
Diflorasone Diacetate 0.0991 0.1917 -1.2396 -1.4320 0.8933 0.0349 -0.6285 -0.7805 
Diflunisal 0.9596 0.1145 0.1572 -1.3110 -1.6782 -0.3841 0.5520 -0.2803 
Digitoxigenin -8.9621 -7.9132 -9.4008 -9.7768 -7.4044 -6.0036 1.1945 -4.7274 
Digoxigenin -10.6264 -11.0669 -9.5291 -11.6926 -7.1985 -9.4316 1.7106 -7.3923 
Digoxin -13.2141 -12.6405 -14.4103 -14.8958 -12.0641 -9.5917 -0.2993 -7.1805 
Dihydroergocristine mesylate -0.8168 -1.0837 0.6805 1.0336 -0.8820 0.2451 0.3505 0.2060 
Dihydroergotamine tartrate 0.1570 1.1284 -0.9085 -0.0834 0.3424 0.8898 -1.4209 -0.0200 
Dihydroergotoxine mesylate 0.2012 -2.3719 -0.3030 -0.4631 -0.0070 -0.5925 0.0510 0.0004 
Dihydrostreptomycin sulfate 1.3314 1.8846 -1.0142 0.3624 0.5331 2.1367 -0.1877 2.4497 
Dilazep dihydrochloride 1.0432 2.8829 0.8590 0.7500 -0.6289 1.5869 -0.0737 0.6588 
Diloxanide furoate 0.5822 -0.9137 -0.1448 0.7488 0.2870 -0.3566 0.9309 -0.0473 
Diltiazem hydrochloride 0.4589 -0.7614 0.5557 -0.5615 -0.2038 -0.8808 0.3027 -0.6495 
Dimaprit dihydrochloride 0.9991 -0.2491 0.7164 0.4902 -0.0423 0.6904 -0.2361 1.0276 
Dimenhydrinate 0.2581 0.0837 0.9368 0.7342 1.5408 0.9361 1.1779 -0.1636 
Dimethadione -0.1508 -0.5531 -0.8589 -0.1266 0.0814 0.1595 -0.2236 0.4097 
Dimethisoquin hydrochloride 0.7223 -0.1146 0.3943 0.0191 0.0778 -0.4133 -0.3093 -0.1120 
Dinoprost trometamol 0.2749 -0.0766 0.2506 -0.4088 -0.2602 -0.3202 0.2059 -0.4629 
Dioxybenzone 1.1398 -0.4340 -0.1194 -0.4331 -0.9310 -0.3441 0.8862 -0.5598 
Diperodon hydrochloride -0.1230 -0.2987 -0.1697 -0.0589 -0.3804 -0.3648 -0.3258 0.0864 
Diphemanil methylsulfate 0.5027 2.0561 -1.2927 2.2443 0.8508 1.7255 0.6637 -0.0748 
Diphenhydramine hydrochloride 0.4539 0.1373 0.5872 0.9732 0.3604 0.0371 -0.3994 -0.7460 
 Diphenidol hydrochloride -0.0970 0.5124 0.7800 -0.7285 -0.7754 1.5219 0.3939 0.4384 
Diphenylpyraline hydrochloride -0.3106 0.4842 -0.3310 -0.0058 0.5057 0.2883 0.4732 -0.8150 
Dipivefrin hydrochloride -0.1023 0.8810 0.1344 1.3945 1.3175 1.4054 0.2258 0.7784 
Diprophylline 0.5225 0.5049 0.7827 -0.1059 0.3544 0.4870 1.1578 0.6310 
Dipyridamole 0.2993 0.4189 -1.8603 0.1777 -0.7196 -0.8870 0.6447 -0.0598 
Dipyrone -1.7843 1.5165 -0.6365 1.1079 -0.0743 1.0126 0.2079 0.2941 
Dirithromycin 0.3687 0.9724 0.6167 1.2572 1.0178 1.3921 0.6461 2.2213 
Disopyramide 0.2825 0.5558 0.0064 0.2406 0.3810 0.9849 1.8441 0.7245 
Disulfiram -4.9934 0.8349 -4.1883 0.3402 0.9648 0.9967 0.4315 0.0941 
Dizocilpine maleate 0.7511 0.4797 0.1992 0.1930 1.3711 0.2279 -0.2293 0.6493 
DO 897/99 0.2402 2.4662 0.1234 1.1659 0.7969 1.7763 1.0740 0.8249 
Dobutamine hydrochloride -0.2737 0.9776 -0.1421 0.1667 -0.6119 0.1694 -1.7438 -0.0181 
Domperidone maleate -0.3280 0.8229 0.9425 0.1190 -0.8057 -0.4725 -0.4567 -0.0864 
Dorzolamide hydrochloride 0.1667 -0.0441 1.1555 0.5084 0.8882 0.4770 0.5745 0.1291 
Dosulepin hydrochloride -0.4400 0.7771 -0.9361 0.2142 -0.1668 0.9720 -0.4306 -0.0919 
Doxazosin mesylate 0.3446 0.0817 -0.6039 -0.4992 0.4723 -0.3515 -0.5133 -0.9225 
Doxepin hydrochloride 2.0027 0.0152 0.5735 0.4292 0.0037 0.6584 0.4603 0.6831 
Doxorubicin hydrochloride -9.3018 -4.9217 -7.3497 -7.7180 -9.3085 -11.9234 -0.0696 -7.7097 
Doxycycline hydrochloride -2.5487 -1.0619 -1.4182 -0.0446 -1.1341 -1.3180 -0.1579 -1.8178 
Doxylamine succinate 0.4200 -0.3238 -0.9971 0.8089 -0.2899 -0.8430 -0.0293 0.0479 
Drofenine hydrochloride -0.7636 0.2213 -1.2908 0.1900 -0.1823 -0.1494 -0.1795 -0.2263 
Droperidol -0.1050 0.6276 -0.2669 -0.1793 0.0913 0.1232 0.4806 0.2774 
Dropropizine (R,S) -1.6571 1.0873 0.3560 1.1189 2.4708 2.1590 0.5069 1.3730 
Dubinidine 1.2927 1.6942 1.6546 1.5532 0.7648 1.8610 0.0963 1.0240 
Dyclonine hydrochloride 0.4425 -0.1999 1.0285 1.7102 0.5352 0.7776 1.4527 0.6981 
Dydrogesterone -0.4767 -0.9061 -0.9389 -1.1240 -1.6494 -0.8638 -0.5005 -0.6581 
Ebselen -0.7264 -0.3198 0.1182 0.2499 -0.5046 -0.2032 -8.7838 0.9851 
 Eburnamonine (-) 0.4744 -0.2613 0.2246 -0.2074 0.5209 -0.1314 -0.8941 -0.0790 
Econazole nitrate -0.2524 -0.0309 -1.1188 -2.0878 -0.6829 -1.0413 -0.2039 -0.3825 
Edrophonium chloride 0.8628 0.1138 0.1278 3.1846 1.0894 2.1914 0.1177 2.5258 
Ellipticine -17.9786 -24.4589 -17.8691 -17.3602 -17.6602 -25.0310 -0.5154 -19.4442 
Emetine dihydrochloride  -11.4306 -12.4664 -10.6107 -11.9873 -10.2428 -14.5263 -0.0101 -11.4579 
Enalapril maleate 0.5671 1.5632 0.8833 1.3173 0.2114 0.9428 0.2496 0.8436 
Enilconazole 0.2751 -0.6794 0.1051 0.3983 -1.1096 0.9334 2.1307 0.6324 
Enoxacin 0.8951 0.6312 0.0208 0.4506 0.4109 0.7358 -1.8275 0.8981 
Epiandrosterone 0.9724 -1.3015 -0.2303 -0.3730 0.5496 -0.1137 -0.4509 0.7744 
Epicatechin-(-) 0.5828 2.0171 0.5038 1.8925 0.7951 1.1131 1.0900 1.7075 
Epirizole -0.2260 0.7947 -0.0818 -0.3758 0.2331 0.2453 0.5391 1.1688 
Epitiostanol 0.7500 0.2680 -0.0608 0.1868 1.1026 0.3434 0.5680 0.4847 
Epivincamine -0.6539 0.9256 1.1787 0.8712 0.8400 1.2561 -0.4511 0.8227 
Equilin -0.0322 -0.2088 -0.7359 0.2636 0.0948 -0.0058 -8.6450 -0.3855 
Ergocryptine-alpha -0.2276 -0.8312 -1.0124 -0.5436 0.9406 1.4804 0.6723 0.6380 
Erythromycin -0.2182 -0.1690 0.1430 -0.8905 0.9697 0.1407 0.0185 -0.7014 
Esculetin -0.3554 -0.1712 -0.0001 -0.0861 0.2929 -0.1141 0.0166 -0.6951 
Esculin Hydrate 0.3191 0.4540 -0.1132 -0.7190 -1.9943 0.6035 -0.0640 0.1652 
Eserine sulfate, physostigmine sulfate 0.1766 0.2073 0.5209 0.7847 -0.0042 0.5224 0.5860 0.8941 
Estradiol-17 beta 0.7789 0.9505 0.5818 0.4705 -0.9999 -0.3941 -3.2942 0.6877 
Estriol 0.0158 0.3415 0.2994 0.1608 2.2483 0.3935 -1.0818 -0.5313 
Estrone -0.1932 0.3431 0.6167 0.8636 0.8229 -0.5149 0.5272 -0.5401 
Estropipate 0.5103 -0.3142 0.3357 0.4096 0.1281 -0.0974 0.1261 -0.7321 
Etanidazole 0.6946 1.4893 -0.4604 1.1677 -0.0069 1.5389 0.0802 1.5136 
Ethacrynic acid 0.1738 0.2552 1.4150 -0.2953 1.0520 0.3230 0.3483 -1.0389 
Ethambutol dihydrochloride 0.7462 0.0190 0.2894 -0.1171 -0.1160 -0.8759 1.1323 -1.0729 
Ethamivan 0.4683 -0.7205 -0.7804 0.8931 -0.3821 -0.6399 0.4352 0.3032 
 Ethamsylate 0.3291 0.5749 0.9663 0.7891 0.8959 0.1621 -0.6117 0.6400 
Ethaverine hydrochloride -1.7157 -3.0895 -2.5103 -2.8057 -2.6585 -4.1079 -0.5242 -4.3786 
Ethionamide 0.9518 1.4157 0.9777 0.3240 0.6697 0.8545 0.5877 -0.2198 
Ethisterone -2.3816 -0.0938 -2.9129 -3.0377 -2.1311 -3.3645 1.6844 -3.2328 
Ethopropazine hydrochloride -0.5116 -0.7915 -1.3983 -1.0319 -0.2502 -0.5959 -14.3331 -1.2214 
Ethosuximide -0.4409 0.8394 1.7121 1.7104 1.6153 0.7633 0.5180 1.1119 
Ethotoin 0.3837 0.2110 -0.4667 -0.6592 0.5050 -0.4580 -0.1259 0.4653 
Ethoxyquin 0.2860 0.5618 0.8674 0.6292 1.5664 1.3824 0.6636 -0.0171 
Ethynodiol diacetate 1.1070 0.0276 0.7431 -0.4788 -0.1311 0.0454 -0.4569 -0.2425 
Ethynylestradiol 3-methyl ether 1.2265 0.9847 0.7214 0.4855 1.1943 -0.1241 1.1444 1.1371 
Etidronic acid, disodium salt -1.3903 -0.3521 -2.1738 0.2407 -0.0652 -0.6569 0.2711 -0.7138 
Etifenin 0.4673 -0.1407 0.8761 1.0117 -0.0238 0.4477 -0.8697 1.3196 
Etilefrine hydrochloride 0.6344 0.6499 1.5944 0.1774 1.0800 -0.1946 -0.1591 0.4013 
Etodolac -0.1852 1.8492 0.0673 -0.1090 -0.0977 1.0801 -0.0798 1.0106 
Etofylline 0.3406 0.2258 0.0230 1.0793 0.5794 -0.1062 -2.3517 0.5300 
Etomidate -0.4304 0.2079 -0.7687 -0.3421 0.1059 -0.1559 1.9992 0.5943 
Etoposide -0.9310 1.2682 0.2089 0.4817 -1.8928 2.3549 1.6505 0.3489 
Eucatropine hydrochloride -0.7087 0.5188 0.9215 -0.3015 0.3043 1.0803 1.3289 1.1591 
Evoxine -0.7510 -0.8353 0.5668 0.5446 -0.8400 -0.1855 -0.0887 0.1674 
Famotidine 0.9739 0.3714 0.1844 -1.5123 1.2369 0.1393 -0.7036 1.2865 
Famprofazone -1.3841 0.1012 -0.8418 -0.5758 -0.0820 -0.3848 -0.0244 0.2939 
Felbinac 0.5705 -0.6709 -0.2958 -0.6538 -0.9273 0.4990 0.3932 -0.6053 
Felodipine -0.3289 1.2882 0.1439 1.4470 0.8833 2.0250 1.1462 0.4139 
Fenbendazole -10.1649 -9.2580 -8.3047 -9.8932 -8.5624 -10.5877 -0.0126 -9.8748 
Fenbufen -0.3520 0.1589 -0.4641 0.0983 -0.1556 -0.0835 0.2980 -0.3707 
Fendiline hydrochloride -1.2695 -1.2919 -0.9098 -2.3054 -0.0218 -0.9628 -0.3276 -1.7712 
Fenofibrate 0.7903 1.1996 0.5469 1.1557 1.3486 1.5833 1.1070 1.0201 
 Fenoprofen calcium salt dihydrate -0.0426 -0.0603 0.4814 -0.5906 0.3962 0.9828 0.6748 0.0292 
Fenoterol hydrobromide 0.6759 -0.2554 0.5868 0.6875 -0.3234 -0.8462 -0.1602 -0.7029 
Fenspiride hydrochloride 0.6528 0.3328 0.2322 -0.1516 0.6020 0.4669 -1.5765 -0.3849 
Fillalbin -0.6783 -0.7310 -0.3414 -1.1260 -1.1310 -0.1911 0.7234 -0.5733 
Finasteride 0.0102 1.8220 -0.8529 1.1977 0.7688 1.9996 0.9345 0.1946 
Fipexide hydrochloride 0.2545 0.0198 -0.8189 0.0888 0.4948 -0.0416 -0.4048 0.1752 
Flavoxate hydrochloride -2.6655 0.7982 0.4054 1.0037 0.7455 1.8574 -1.2485 1.8008 
Flecainide acetate 0.4532 0.1911 -0.3547 0.6217 -0.1008 0.5677 1.6829 -0.2722 
Florfenicol -0.5855 -0.9302 0.4360 0.5849 -0.8409 -1.1621 -1.4812 -0.3283 
Flucloxacillin sodium -0.7708 -1.1550 -0.5433 0.2222 -0.0036 -0.7691 -1.1397 -0.8502 
Flucytosine -0.1170 0.0430 -0.2854 0.5224 0.3484 0.2910 0.0894 0.3036 
Fludrocortisone acetate 0.7571 -1.0485 -0.0064 -0.2752 -0.5868 -0.9741 -1.1220 -0.2085 
Flufenamic acid 1.0153 -0.1533 0.0904 -0.0021 0.6393 -0.5296 0.2948 -0.1307 
Flumequine 1.3440 0.0150 -0.2190 1.1908 1.3060 0.5244 -0.2662 0.7617 
Flumethasone 0.5558 -0.5531 -0.3153 -0.5203 -0.5297 -0.2384 -4.7241 -0.5335 
Flunarizine dihydrochloride -0.0013 0.2519 -1.1950 1.4477 0.2660 -1.4344 0.4376 0.1114 
Flunisolide 1.0508 1.0660 0.1163 1.8363 0.2823 0.7572 -0.4844 2.3383 
Flunixin meglumine 1.0174 -0.2970 0.6615 1.0929 0.2353 0.1417 0.4352 0.2569 
Fluocinonide 0.8447 0.2805 0.6406 0.5575 0.7481 0.0028 0.5993 -0.2278 
Fluorocurarine chloride -0.6796 0.0900 0.8645 0.3028 -0.2004 0.4130 -7.1043 0.1106 
Fluorometholone -0.2077 1.5507 0.4506 0.4460 0.9199 1.7805 0.7575 0.3299 
Fluoxetine hydrochloride -0.9686 0.0020 -0.1801 0.3784 -0.5836 -0.3384 -1.7794 -0.0973 
Flupentixol dihydrochloride cis-(Z) 0.1661 0.2227 -0.2510 0.2632 0.0221 0.4407 0.2007 0.2682 
Fluphenazine dihydrochloride -0.0017 1.0980 -1.6529 0.4260 -0.5472 1.1297 0.7836 1.9990 
Flurandrenolide 0.9680 0.7814 -0.8566 -0.7106 0.5355 1.2214 -0.9216 1.3419 
Flurbiprofen -0.0141 0.3282 0.5464 -0.0735 0.3675 -0.0939 0.7287 0.3682 
Fluspirilen 1.0073 0.3442 0.2276 -0.0668 0.8079 -0.7571 1.3875 0.0837 
 Flutamide -0.3364 -1.5206 0.1571 0.3494 0.8828 -1.3960 -0.3319 -0.7486 
Fluticasone propionate 0.6640 0.3300 -0.6114 -0.3714 0.6557 0.3603 0.0586 -1.0170 
Fluvastatin sodium salt -1.0961 -1.0680 -2.2768 -2.7809 -2.3104 -3.2042 -0.7648 -3.4384 
Fluvoxamine maleate 1.0514 1.2990 0.1504 1.4353 0.9140 0.3409 -3.4899 1.7040 
Folic acid 0.4328 -0.1957 0.2933 1.0861 0.6655 0.2693 -0.9488 0.9985 
Folinic acid calcium salt 0.4960 -0.6966 -0.0769 -0.1280 -0.7008 0.1239 -0.1353 0.1101 
Foliosidine 0.4683 -0.4065 -0.6812 -0.1588 0.3763 -0.2393 0.1282 -0.7543 
Fosfosal 0.4136 -0.4177 1.0763 0.0366 -0.0284 -0.1692 1.6968 0.2559 
Furaltadone hydrochloride -1.1030 0.2472 0.8431 0.5508 0.6512 -0.0847 1.0854 -1.0586 
Furazolidone 0.1866 0.6079 -0.3634 -0.2659 -0.6545 0.3184 0.5602 -0.7695 
Furosemide -0.2411 -1.2177 -1.2701 0.3745 -1.0706 0.3988 -2.4503 0.3301 
Fursultiamine Hydrochloride 0.8756 0.2305 0.3515 0.1130 1.0429 0.0174 0.5405 -0.4087 
Fusaric acid 0.0453 0.6029 -1.0446 -0.9029 -0.8761 0.2790 -0.6488 0.8557 
Fusidic acid sodium salt 0.2250 0.5784 1.1105 -0.6206 -0.2027 0.0050 -7.3399 -0.4215 
Gabapentin -0.9162 -1.3002 -0.6946 -0.6170 -1.8656 -1.3846 -1.2658 -0.7999 
Gabazine 0.6201 -0.0442 -0.3406 -0.0625 -0.0565 0.8833 1.1032 0.9334 
Gabexate mesilate 0.3575 0.2429 -0.1940 -0.3224 1.1417 -0.0968 -4.6025 -0.3658 
Galanthamine hydrobromide -0.7251 -0.0254 0.4280 -0.3924 0.3096 -1.0498 -0.6082 -1.4557 
Gallamine triethiodide 1.2904 1.2857 0.2580 0.3340 0.4549 2.0895 0.7713 1.2048 
Ganciclovir -0.2151 0.1434 0.0228 0.0700 0.2993 -0.4511 -0.3183 -0.9990 
GBR 12909 dihydrochloride -4.3819 -3.2422 -2.6530 -3.3739 -1.7892 -1.8078 -0.0781 -1.9064 
Gelsemine -0.2672 -1.0746 -0.5068 0.2464 -1.4092 -0.2536 -0.1859 -1.1326 
Gemfibrozil 1.0424 -0.0344 0.6021 0.2522 0.5420 0.3184 -18.9290 0.0043 
Gentamicine sulfate 1.1089 2.3823 0.3401 1.9553 0.8868 2.3095 -1.0010 1.6412 
Gibberellic acid 0.8853 0.4087 -0.3611 0.7016 -0.3991 1.5312 1.9096 1.0206 
Ginkgolide A 0.3157 1.4473 1.3980 1.7129 0.2543 0.9032 0.8249 -0.1770 
Glafenine hydrochloride 0.6263 -0.4961 0.5750 0.8195 -0.1284 -0.2740 -0.6636 0.3367 
 Glibenclamide 1.1391 1.4242 1.2887 1.6487 -0.0791 1.0275 0.6741 0.8313 
Gliclazide 0.2619 1.1225 0.8478 1.5785 0.7093 1.6136 0.6097 0.9798 
Glimepiride -0.9182 -0.9425 -0.9146 1.2630 -1.4182 -0.8239 -0.6557 -0.9590 
Glipizide 0.4674 -0.2136 -0.1256 -1.4608 -1.5498 -0.5968 0.2191 -0.6986 
Gliquidone -0.5743 -0.9045 0.5259 -1.7486 -0.4425 -1.1368 -1.2241 -0.4355 
Glutethimide, para-amino 0.3829 0.7217 1.7914 1.3240 1.8240 2.3009 -0.3670 2.0498 
Glycocholic acid 0.5494 0.3997 0.7276 -0.7572 0.3388 0.0373 -0.9625 0.4735 
Glycopyrrolate 0.1223 0.2053 0.4383 0.0016 0.5399 -0.3539 1.2084 0.0610 
Gossypol 1.0328 -0.3267 0.5877 0.1564 0.4050 -0.0421 0.1329 0.1830 
Gramine 0.3799 0.5472 -0.0760 -0.3053 0.9576 0.8915 -0.2717 0.1557 
Graveoline -0.5707 0.5007 0.8901 0.2588 -0.2502 -0.8041 0.4561 -0.4805 
Griseofulvin 0.6063 0.6458 -0.2346 0.0216 0.0948 0.0177 -0.0095 0.3574 
Guaifenesin 0.0665 0.3574 -0.1900 -0.0016 0.2232 -0.5326 -2.3899 -0.6337 
Guanabenz acetate -0.1170 -0.5962 1.4982 0.1934 0.2200 -0.8445 -0.0044 -0.2246 
Guanadrel sulfate 0.7698 0.3384 0.5062 -0.8615 0.5131 -0.5564 -1.5875 -0.4613 
Guanethidine sulfate  0.5823 1.9882 0.3346 1.4064 1.0905 0.8084 0.0844 1.6950 
Guanfacine hydrochloride 0.1724 -2.3377 0.0881 -0.0171 0.1601 0.3094 0.4485 1.3343 
Halcinonide -0.3834 -1.1312 -0.6261 -0.4796 -0.6081 -0.3765 -0.0818 -1.3371 
Halofantrine hydrochloride -1.5569 -1.3849 -1.3106 -0.6347 0.0754 -2.0822 0.1072 -0.5874 
Haloperidol 1.0998 1.6048 1.3560 0.2666 1.4684 1.2162 0.5417 1.1240 
Harmaline hydrochloride dihydrate -0.4384 -0.0264 -0.6618 -0.3931 -0.0004 0.1206 -0.7906 0.3256 
Harmalol hydrochloride dihydrate -0.2402 0.1211 -1.0290 -0.7892 -0.4316 0.7826 0.5592 0.0411 
Harmane hydrochloride -0.1110 0.5300 -0.8935 -0.4381 0.1949 0.1921 -0.5885 -0.0507 
Harmine hydrochloride -1.6100 0.3189 -0.9301 -0.6650 -1.3977 -0.2994 0.5847 -1.2008 
Harmol hydrochloride monohydrate -1.4997 -0.2304 0.0091 -0.8270 -0.5169 1.1973 0.5995 -1.2028 
Harpagoside 0.1111 -0.6246 -0.1651 0.0273 0.0019 -0.4376 -1.4346 0.7690 
Hecogenin 0.2543 -0.3482 -0.3960 0.8608 -1.0452 0.8827 0.9774 1.9626 
 Heliotrine 0.2644 -0.1720 2.2864 -0.1801 -0.4102 -0.1077 0.4499 0.6020 
Helveticoside -9.1939 -10.2313 -10.1399 -11.5354 -8.5015 -7.2062 0.9337 -5.1342 
Hemicholinium bromide 1.7053 1.0658 0.3863 0.8923 0.6771 1.4309 -2.1530 0.8271 
Heptaminol hydrochloride 0.5278 0.2250 -0.2374 1.6158 -0.2969 -0.1241 0.3354 0.5756 
Hesperetin 0.5160 0.4879 1.6358 -0.2757 0.6585 0.4352 1.0735 0.1795 
Hesperidin  0.6996 2.1924 -0.4622 0.9765 0.3305 2.7275 -0.3170 0.3222 
Hexamethonium dibromide dihydrate 0.1060 -0.5122 0.6419 -0.1594 -0.5303 -0.3078 0.1406 0.0172 
Hexestrol 0.0277 0.5149 0.6390 -0.5730 0.4236 -0.2071 0.0354 0.0324 
Hexetidine -1.3232 1.1743 0.2941 0.0141 0.3202 1.9383 0.3536 0.5112 
Hexylcaine hydrochloride 0.3176 0.2500 -0.6307 1.0919 0.5032 -0.1945 0.8517 -0.6682 
Hippeastrine hydrobromide -0.2971 0.7769 0.4021 1.5410 0.4092 1.4191 1.2190 0.5334 
Homatropine hydrobromide (R,S) -1.4716 0.7465 0.0487 1.1251 0.5149 0.3444 -0.4227 -0.1206 
Homochlorcyclizine dihydrochloride 2.0082 -0.2258 0.2039 -1.2749 0.7547 -0.2018 -0.2600 -0.1978 
Homosalate -0.1487 -1.1004 1.4087 0.0272 0.0970 -0.6308 -0.0493 0.2186 
Hycanthone -3.5097 -0.1741 -2.9759 -2.8543 -3.1799 -0.4336 0.8424 -3.1016 
Hydralazine hydrochloride -0.1231 0.1399 0.9174 0.1559 1.3617 0.7222 0.1302 0.4313 
Hydrastine hydrochloride -1.8897 -0.7034 -1.3045 0.3280 -1.6051 -0.5714 0.2882 -0.6076 
Hydrastinine hydrochloride 2.1302 0.8957 1.2383 1.5771 1.3843 1.3771 1.7811 1.2245 
Hydrochlorothiazide 0.2253 0.7820 0.0903 -1.5509 -0.0088 -0.6221 1.5573 0.7024 
Hydrocortisone base 0.3979 0.4588 -0.3477 -0.1914 0.6294 0.6962 0.9181 0.2233 
Hydrocotarnine hydrobromide 0.6336 0.8661 0.9237 1.7148 1.1427 0.8459 0.8294 1.1281 
Hydroflumethiazide 0.2707 -0.7281 -0.4914 -0.3302 -0.2337 0.4604 0.9691 1.0792 
Hydroquinine hydrobromide hydrate 0.0499 1.1909 0.8723 2.1811 1.0373 1.6905 0.2872 0.5431 
Hydroxytacrine maleate (R,S) 0.0200 0.7204 -1.5671 0.2061 0.0443 0.0953 0.7303 -0.5100 
Hydroxyzine dihydrochloride 1.2903 0.1149 -0.0931 0.5860 -0.0186 0.0538 0.5558 -0.9662 
Hymecromone -0.0880 -1.4623 -0.8330 -0.1352 -1.1510 -0.8494 0.0498 0.0777 
Hyoscyamine (L)  0.7397 2.0966 0.2173 0.4967 -0.3470 1.6051 -0.3680 0.5766 
 Idazoxan hydrochloride 0.8259 0.7410 1.3759 1.2759 1.2782 0.6540 -1.9589 1.0781 
Idoxuridine -0.6158 -0.4369 -0.0513 -1.6893 -0.8512 -0.9879 -0.0787 0.4539 
Ifenprodil tartrate -0.2897 0.6344 -0.4183 1.4454 0.7875 0.7738 0.6801 1.1380 
Ifosfamide -0.0652 -0.2103 2.2404 -0.9119 -0.1080 -0.2798 1.0522 -1.0351 
Imidurea -0.6323 -2.1535 -0.3733 -0.1329 -0.6274 -2.0757 -0.9724 0.0428 
Imipenem -0.0791 0.7073 -0.9740 -0.5096 -0.0164 -0.4928 -0.3552 -1.1660 
Imipramine hydrochloride -0.6303 1.0996 0.0608 1.3435 0.4105 0.7053 0.6236 0.2016 
Indapamide -0.2234 0.8876 -0.5583 0.4141 -0.3032 0.1382 -0.1032 -0.1471 
Indomethacin 0.6150 -0.9843 -1.2106 -1.0012 0.2561 -0.5441 -0.2432 -0.2565 
Indoprofen 0.0446 1.7540 1.1642 0.4945 1.4069 0.2588 1.4784 0.0818 
Iobenguane sulfate 0.0032 -0.4048 -0.9811 0.3862 -0.3543 -2.0105 0.6184 -0.0279 
Iocetamic acid -0.5570 0.4139 0.0602 -0.4891 -0.0017 -1.0480 0.9625 -0.4510 
Iodipamide -0.3269 0.0769 -0.6552 0.4157 0.4763 0.2244 -0.8763 0.2785 
Iodixanol 0.6784 0.1914 0.2890 0.6069 0.4258 -0.8931 0.2394 -0.6056 
Iohexol 0.5290 0.4881 0.5883 1.2709 -0.0019 0.7357 -0.3436 0.4317 
Iopamidol -0.5058 -0.1899 -0.0228 -0.3576 0.2165 0.4441 -0.1761 0.2059 
Iopanoic acid 1.0047 0.0626 0.0194 0.4147 -0.7900 0.4836 -9.1306 0.0395 
Iopromide -0.7692 -0.1595 0.7409 1.2065 0.0017 1.1762 -0.0178 0.5899 
Ioversol 0.2478 1.1798 0.2355 1.1709 0.8764 1.5911 0.0051 0.3345 
Ioxaglic acid  0.2551 -0.5799 0.1246 -1.1399 -0.8946 -0.0080 0.3181 0.4370 
Ipratropium bromide 0.0052 -0.3633 -0.2645 0.7243 -0.3039 -0.2192 -0.4016 -0.0773 
Iproniazide phosphate -0.1665 -0.2994 0.4287 0.8002 1.2329 0.2740 -0.5708 0.6832 
Isocarboxazid -0.0894 0.6595 0.0286 0.8657 0.8284 1.0857 -6.9879 0.5539 
Isoconazole -0.3274 0.2110 -0.8544 0.7572 -0.0836 -0.3053 0.0462 -0.7071 
Isocorydine (+) 0.0944 0.3091 0.1957 -0.7380 0.4934 -0.8987 -1.5379 0.5974 
Isoetharine mesylate salt 0.1301 0.2504 -0.4961 -0.0359 -0.0733 -0.2710 0.2363 -0.4655 
Isoflupredone acetate 1.0612 0.6838 0.0327 1.3662 -0.0332 0.0069 -0.0455 1.3681 
 Isometheptene mucate 0.8441 0.0049 0.1869 -0.5162 0.6313 0.3581 0.0523 -0.3859 
Isoniazid -0.9696 0.9031 -1.0586 1.4911 -1.2235 0.5096 -0.2119 1.8393 
Isopropamide iodide 0.2077 -0.6301 0.8114 -0.3366 -0.0048 -0.4620 -1.1891 1.1868 
Isopyrin hydrochloride 0.0426 0.6309 0.1761 -0.0541 0.7228 2.6540 1.7962 1.2399 
Isoquinoline 0.5380 0.8520 0.5316 -0.0814 0.0406 0.2425 -0.5090 0.6185 
Isosorbide dinitrate -0.6429 1.3005 0.3648 0.5270 0.3731 1.4895 0.3763 0.5741 
Isotretinoin -0.3280 0.3578 1.1562 -0.1927 1.0332 1.0470 -6.9612 0.1778 
Isoxicam 0.4213 -0.4910 0.0157 1.1469 1.0010 0.1348 0.6803 -0.6529 
Isoxsuprine hydrochloride -0.3264 -0.0444 1.1476 1.0557 0.1940 0.3106 -0.0742 -0.8665 
Isradipine -0.6976 -0.6493 0.1918 -0.0088 -0.0241 -0.3019 -0.5251 -0.3474 
Ivermectin -0.1029 0.0847 1.2202 -0.5926 -0.1052 0.3865 -5.3198 0.6179 
Josamycin 0.6851 0.7136 -0.2299 0.1573 -0.0455 1.4631 0.7206 -0.2300 
Kaempferol 0.1980 -0.0021 1.2424 -0.2160 0.1403 0.2451 0.4627 -0.5460 
Kanamycin A sulfate -0.0423 1.2875 0.9112 0.1591 0.1620 1.6379 0.5683 0.1258 
Karakoline 1.0638 0.3997 0.0293 0.2599 0.3305 0.1920 0.9684 0.2883 
Kawain 0.5432 0.1509 0.4174 -0.6911 0.5253 0.4206 0.4700 -0.1635 
Ketanserin tartrate hydrate 0.9791 1.3019 0.7876 0.3809 0.4312 2.2450 -0.3650 1.5809 
Ketoconazole 0.4879 1.0101 0.1572 0.3577 0.3822 0.7815 -0.6191 -0.9477 
Ketoprofen -0.0432 0.3443 0.3512 -0.1482 0.0745 0.1078 -0.3097 -0.1618 
Ketorolac tromethamine 0.2336 -0.1348 -0.1020 -0.0274 0.4079 -0.4470 0.1220 0.3502 
Ketotifen fumarate -0.4406 -0.3654 -0.8863 -0.3854 -0.1834 0.1664 -1.4372 0.1135 
Khellin -0.4915 -1.0304 0.2573 0.1307 -1.9193 -0.4693 -1.0623 0.8150 
Kynurenine, 3-hydroxy (R,S) -0.5215 0.8849 -0.7413 -0.3653 -0.8870 0.3792 -1.0910 -0.1637 
L(-)-vesamicol hydrochloride -0.6595 0.0002 -0.6835 0.7154 -0.2982 0.2899 -0.1039 0.6978 
Labetalol hydrochloride 0.6565 0.0386 0.4417 -0.3098 1.0402 0.0172 -0.0147 0.2406 
Lactobionic acid -0.5736 1.4910 0.0269 0.5723 -0.9901 0.3072 -1.2392 0.3683 
Lanatoside C -15.0569 -15.0227 -14.1654 -14.6998 -13.0280 -11.2218 -0.4002 -6.7280 
 Lansoprazole -0.8724 -0.2697 -0.2763 -0.0132 -0.8603 -0.8361 0.6056 -0.4177 
Lasalocid sodium salt -3.2676 -3.4683 -3.6186 -3.9492 -4.5715 -6.8756 -0.0051 -6.2887 
Laudanosine (R,S) -0.5331 -0.9398 -0.7049 0.4938 -1.4144 -1.1739 0.0756 -0.3660 
Leflunomide -0.4416 0.1595 -0.3972 -0.3908 -0.4680 0.9318 -0.2701 -0.1700 
Letrozole -0.6227 0.4348 0.6747 -0.2682 0.7222 0.3026 -11.6073 -1.7143 
Leucomisine 0.5847 0.3256 1.1301 0.8886 0.2795 0.4914 0.4842 1.0532 
Levamisole hydrochloride 0.3209 -0.1939 -0.8416 -0.4706 -0.8835 -1.1438 -0.9599 0.0708 
Levocabastine hydrochloride -0.1436 1.1606 -0.0515 -0.3425 1.2274 1.0462 0.2620 -0.4413 
Levodopa -0.1872 -0.1543 0.2556 -0.5663 -1.0207 -0.8248 -1.5449 -0.1038 
Levonordefrin -0.2072 0.0002 -0.2016 0.2913 -0.5881 -0.2083 -0.0030 0.3621 
Levopropoxyphene napsylate -0.0099 0.0761 0.7454 -1.3549 -0.3243 0.1126 -0.6127 -0.2744 
Lidocaïne hydrochloride 0.5586 -0.2420 1.2152 -1.1874 0.4687 -0.3696 -0.6899 -0.6330 
Lidoflazine 0.7763 -1.0728 0.5017 -0.6284 -0.0182 -0.5416 -1.3689 -0.6874 
Lincomycin hydrochloride 0.4912 0.5647 0.2440 -1.1635 -0.3903 -1.1112 -0.4913 -0.5135 
Liothyronine -1.3308 0.3667 -0.4669 -0.2101 0.0834 -0.2735 0.0710 0.2591 
Lisinopril 0.1763 -0.5925 -0.6761 0.2386 -0.7307 -0.3356 -1.4275 0.9945 
Lisuride (S)(-) 1.5138 0.1079 0.8278 0.4671 1.4433 -0.2292 0.3236 1.0140 
Lithocholic acid -0.5597 1.1158 0.4992 0.7508 1.0520 1.1381 0.2833 0.5822 
Lobelanidine hydrochloride 0.6848 -0.1150 -0.8743 0.6595 -0.7618 0.3640 -0.1274 1.0113 
Lobeline alpha (-) hydrochoride 0.1306 -0.4713 0.2463 -0.5652 -0.1282 0.0213 0.5498 -1.0143 
Lomefloxacin hydrochloride 0.6570 2.8066 0.9548 0.7658 0.0389 1.3162 0.9501 0.7699 
Loperamide hydrochloride -1.1117 -1.0535 0.2982 -0.8222 -0.8438 -1.3318 1.2328 -0.5602 
Loracarbef -0.5855 -0.5261 0.1527 0.1870 -0.5769 -1.1422 -0.1291 -0.6860 
Lorglumide sodium salt 1.5929 1.9210 2.1375 1.4392 1.5572 1.2400 1.6227 1.6433 
Lovastatin -0.4378 0.8740 -0.0118 -0.9276 -1.0320 -0.3414 0.2659 -1.3863 
Loxapine succinate -0.3688 -0.9461 -0.9065 -0.0743 -0.9114 -3.4089 -0.0097 -0.6242 
Lumicolchicine gamma 0.9134 1.2175 -0.5174 0.0451 0.0056 0.7931 0.1947 0.0906 
 Luteolin -0.3330 0.3510 -0.8801 0.7746 -0.6797 0.4980 -0.4520 0.2381 
Lycorine hydrochloride -7.4552 -5.5147 -6.8653 -6.9344 -7.5920 -9.7467 0.1524 -6.8765 
Lymecycline -1.3922 -0.1027 -0.2936 0.1395 0.2125 -0.2941 -0.1035 -0.3284 
Lynestrenol -6.9863 0.8549 0.7649 -1.0524 1.1653 0.4630 0.6707 0.6188 
Lysergol 0.8354 1.2746 0.4982 0.0079 0.2280 1.4187 -0.4371 -0.0812 
Mafenide hydrochloride 0.2501 1.2220 2.8080 0.4579 1.0064 1.1365 0.8843 0.8201 
Maprotiline hydrochloride 0.2672 -0.0765 0.0704 -0.6478 0.0569 -1.1131 0.0962 -1.2250 
Mebendazole -9.7106 -8.3089 -7.3245 -9.8774 -9.0624 -6.6234 0.3406 -8.0074 
Mebeverine hydrochloride -0.7971 0.0635 -0.5913 -0.3960 -0.4333 0.6252 -4.2543 0.5909 
Mebhydroline 1,5-naphtalenedisulfonate -0.8449 0.6739 0.0043 0.7726 -0.4605 0.3858 0.6467 0.5988 
Mecamylamine hydrochloride -0.5390 -0.3632 0.8565 0.7483 1.1068 0.0033 -5.7943 -0.6838 
Meclocycline sulfosalicylate -0.8385 0.8941 -0.2519 -1.1020 -1.3420 -0.4487 0.6521 -1.6452 
Meclofenamic acid sodium salt monohydrate 1.1795 0.8651 0.7154 0.9604 1.3387 0.6555 0.2100 -0.1444 
Meclofenoxate hydrochloride -0.5068 -0.6858 -1.3070 -0.3708 0.4585 -0.0475 0.0374 -0.9872 
Meclozine dihydrochloride 0.6069 1.3682 -1.0000 0.0848 1.2247 1.0546 0.3487 0.8307 
Medrysone -0.9830 -0.7411 0.1779 0.5478 -0.4472 -0.0028 -0.4482 -0.9675 
Mefenamic acid 0.5114 0.1957 0.2824 -0.0279 0.6196 -0.6765 -0.4121 -1.0654 
Mefexamide hydrochloride 0.4844 0.7999 -0.3445 -0.0765 0.2137 0.5641 -8.1821 -0.1735 
Mefloquine hydrochloride -2.0969 -0.5229 0.4608 0.1389 0.3338 -0.3519 1.1848 0.2738 
Megestrol acetate 0.2859 -0.1684 -2.0818 0.9871 0.4819 1.7374 0.8690 0.2708 
Meglumine 1.0818 0.9015 0.2583 -0.7157 0.1988 0.6308 2.4209 0.8605 
Melatonin 0.2257 -0.3605 0.4454 0.1087 0.3048 0.2638 -0.9571 0.3002 
Memantine Hydrochloride 0.5936 -0.4092 0.8043 -1.1590 -0.3784 -1.4786 0.7780 -0.5822 
Menadione -0.0200 0.1118 -0.1839 -1.2069 -0.0056 -0.2203 -2.5882 -1.2145 
Mepenzolate bromide 0.0617 0.0682 -0.1516 0.1703 -1.1224 0.1877 -0.2181 0.0952 
Mephenesin -0.5713 -0.0030 -0.6595 0.2590 0.2742 -0.0834 -0.0161 -0.1868 
Mephentermine hemisulfate 0.7430 -0.4681 -0.6826 -0.3104 0.6539 1.3971 1.7625 0.4087 
 Mephenytoin -0.0072 -0.5736 0.4159 0.0132 -0.0494 -0.7351 0.3929 -0.3531 
Meprylcaine hydrochloride  0.8602 0.0793 1.1409 0.0203 0.0965 0.4602 -0.0348 0.1076 
Meptazinol hydrochloride -0.2504 0.7343 -0.6707 0.7046 1.0138 1.1432 -0.4310 0.7421 
Merbromin -0.5582 0.5871 0.1530 0.1767 0.5487 0.3322 -0.1225 0.0171 
Meropenem -0.0047 -0.0977 1.0882 1.1753 0.1124 -0.3831 0.4798 0.1192 
Mesalamine -0.2709 0.1000 -0.3434 -0.3748 -0.1836 0.3327 -0.0491 0.1761 
Mesoridazine besylate -0.3654 0.1393 -0.5138 -1.5518 0.1713 0.3375 -0.1748 -0.5047 
Metampicillin sodium salt 0.4840 2.5042 0.8258 0.4784 0.4936 1.6242 -0.1173 0.6902 
Metanephrine hydrochloride DL 0.0248 -0.1391 0.0164 -0.1629 -0.2096 -0.4668 -0.0683 -0.3609 
Metaproterenol sulfate, orciprenaline sulfate 0.3401 -0.1151 0.3734 -0.0357 0.1853 0.1227 0.5871 0.8175 
Metaraminol bitartrate 0.0550 -0.4405 0.3368 0.4550 0.4054 0.1482 0.3028 -0.6231 
Metergoline -3.0480 0.2989 -1.0826 -1.7366 -1.1583 0.1020 0.0419 -0.0283 
Metformin hydrochloride 0.0293 1.5409 -0.9669 0.5244 0.2027 1.0662 1.6611 0.5067 
Methacholine chloride 0.0557 0.5818 0.6091 -0.5241 -0.0743 -0.6345 -0.7834 0.1422 
Methacycline hydrochloride 1.0439 0.9298 0.1513 0.7710 -0.9628 0.7987 0.8679 0.2829 
Methantheline bromide 0.6115 -0.1173 0.9667 0.5258 0.1328 -0.0766 0.0026 0.4729 
Methapyrilene hydrochloride 0.0463 0.7098 0.6659 1.0536 0.1399 0.2121 -1.0362 0.2978 
Methazolamide 1.1146 0.3507 0.6786 1.7545 0.0139 0.1839 1.4522 0.6291 
Methiazole -9.8207 -8.9253 -7.5109 -9.5101 -8.6962 -8.3529 0.4860 -8.8924 
Methimazole 0.4417 0.2190 -0.2670 0.5680 1.0059 -0.5186 -0.3526 0.2720 
Methionine sulfoximine (L) 0.5106 0.9025 1.0915 0.4937 0.1761 -0.0153 1.1668 0.9049 
Methiothepin maleate -0.6257 -1.4113 -0.1350 0.3524 -0.1819 -0.5710 -0.1082 -0.7043 
Methocarbamol 1.1040 -0.1937 1.1222 -0.0671 0.9911 -0.0466 0.4717 0.6433 
Methotrexate -8.3646 -15.0067 -7.3348 -13.6595 -11.1177 -16.6247 1.3970 -13.8662 
Methotrimeprazine maleat salt 0.1789 -0.4471 0.8668 -1.1834 0.3956 0.5323 0.4898 0.4057 
Methoxamine hydrochloride 1.3244 -0.1281 0.3691 -0.2085 0.4394 -0.1119 -0.9489 0.2896 
Methoxy-6-harmalan -1.5039 0.0254 0.7895 -1.6706 0.0004 -0.0967 -0.3998 -0.0571 
 Methoxy-8-psoralen 0.3880 0.7274 -0.2790 0.3786 1.0857 1.8489 0.4349 -0.0103 
Methyl benzethonium chloride -1.7309 0.3236 -2.4002 -1.2067 -1.1349 -0.4572 -0.9029 -1.3748 
Methylatropine nitrate 0.2359 -0.2714 0.6258 -0.6079 -0.6809 0.0549 -0.7719 -0.1058 
Methyldopa (L,-) 1.6038 1.4946 0.0878 1.4359 0.7240 -0.2345 1.4046 0.9890 
Methyldopate hydrochloride 1.0621 0.7559 0.2779 -1.2811 0.9809 0.8008 0.8811 0.5064 
Methylergometrine maleate 0.7372 -1.4519 0.5025 0.0559 0.0182 0.1843 0.5260 -0.0964 
Methylhydantoin-5-(D) -1.7475 0.5279 -0.5082 -0.5124 -0.1254 -0.1580 0.2184 -0.8880 
Methylhydantoin-5-(L) -0.1583 -0.1637 -0.1173 -0.5342 0.2253 0.3613 -0.8036 -0.0024 
Methylprednisolone, 6-alpha 0.1245 -0.5803 -0.4193 0.2780 0.7180 -0.5714 -0.5582 0.0011 
Meticrane 0.9862 -0.4851 -0.1795 -0.2124 -0.7763 0.7931 -0.7661 1.3258 
Metixene hydrochloride -1.3171 0.3935 0.1092 0.1034 -1.0573 -0.9880 -1.4595 0.8962 
Metoclopramide monohydrochloride -0.4823 -0.2965 -0.9204 -0.9065 0.3474 -0.1467 0.0726 -0.4124 
Metolazone 0.8989 -0.2767 0.2105 -0.0606 -0.0422 -2.8736 0.0044 -0.0574 
Metoprolol-(+,-) (+)-tartrate salt 0.2673 -1.1689 -1.1991 -0.2371 -0.3189 -0.1730 1.8795 0.0330 
Metrizamide -1.0979 0.4256 -0.0806 -0.6524 -0.4007 0.3923 -0.2177 0.2217 
Metronidazole 0.2103 0.1488 0.1061 2.3377 -0.2377 1.9399 -0.0528 1.4975 
Metyrapone 0.1864 0.2029 0.3640 0.3295 0.1695 -0.1910 1.2600 0.7460 
Mevalonic-D, L acid lactone 0.8594 -0.1346 -0.2697 0.5091 -0.0690 -0.2954 -0.5845 -0.4862 
Mexiletine hydrochloride -0.1322 0.3536 0.7470 1.4544 -0.1390 1.6185 -2.3010 1.8325 
Mianserine hydrochloride -0.2087 -0.7707 -1.2617 0.3280 0.0186 0.0057 0.1443 -0.2739 
Miconazole -1.4426 -0.2312 -0.8195 0.0342 -0.3373 -0.5990 -0.7149 -2.1975 
Midecamycin -0.3626 0.6918 0.2265 0.0038 0.8854 1.1832 0.0786 0.3148 
Midodrine hydrochloride 0.4524 -0.6477 -0.4762 -0.4845 -2.2661 -0.7871 -1.1532 -0.2736 
Mifepristone 0.6366 0.1297 -0.0381 -0.5406 0.4204 -0.1462 0.0147 -0.0042 
Milrinone 2.1896 -0.1033 0.2228 0.2188 0.2737 0.6731 -0.4396 0.0897 
Mimosine -0.2764 -1.1471 -0.8552 0.8801 0.6283 0.1248 -0.1626 0.4034 
Minaprine dihydrochloride -0.7793 0.4086 0.1757 0.9859 0.2447 0.3857 0.6306 -0.4071 
 Minocycline hydrochloride -0.3197 1.0833 0.0647 -0.3761 -1.7310 -1.0311 0.8494 -2.6759 
Minoxidil 0.8786 -0.4393 0.5891 -1.9502 -0.6245 -1.1598 0.7129 0.1431 
Mitoxantrone dihydrochloride -11.1268 -11.6850 -9.8560 -11.1455 -14.6502 -17.4142 0.5832 -11.3322 
Molindone hydrochloride 1.5672 0.7234 1.1183 -0.8198 1.3894 1.1337 1.1817 0.2861 
Molsidomine 0.2539 0.4295 -0.4036 0.1322 0.5154 0.1674 0.2068 -0.4340 
Mometasone furoate -2.9484 -0.6504 -3.0873 -0.4813 -2.2514 -0.3761 0.9050 -1.3229 
Monensin sodium salt -7.9082 -3.8261 -7.4964 -6.9538 -6.1435 -4.7245 0.8166 -7.1686 
Monobenzone -0.9716 -0.4100 -0.3879 0.0020 0.2652 -1.1891 0.1943 -0.8904 
Monocrotaline 0.3253 -1.2377 0.7273 0.7988 -0.0582 -0.9308 1.3136 0.2067 
Morantel tartrate -0.5597 -0.0517 0.8526 0.5492 -0.0779 0.2600 0.4085 -0.7796 
Moricizine hydrochloride 0.0891 -1.4393 -0.4654 -2.0013 -0.4568 -0.9304 -1.6520 -0.6832 
Moroxidine hydrochloride 0.3936 1.1571 -0.4292 2.4051 2.0721 2.0705 0.8293 1.6588 
Moxalactam disodium salt 0.6048 -0.5124 -0.1989 -0.2096 -0.4490 0.0346 -0.6480 0.2976 
Moxisylyte hydrochoride -0.5739 -0.7392 -0.0893 0.0128 0.3883 -0.1833 0.7447 -0.2773 
Moxonidine -0.7610 -0.0778 0.3628 1.2676 0.3740 0.0501 -4.8925 0.0160 
Muramic acid, N-acetyl 0.5810 1.6523 -1.4007 0.3464 0.1768 0.8352 -0.2383 -0.6288 
Mycophenolic acid -6.7716 -6.0946 -5.7244 -6.6943 -5.1556 -6.7793 1.3848 -6.7712 
Myosmine 0.6772 0.7193 -0.0799 -0.1110 0.5253 1.1537 -1.4123 1.0922 
Myricetin 1.1692 0.4507 0.1988 0.4967 0.5689 0.2297 -0.3330 0.2712 
N6-methyladenosine 0.2540 0.7049 0.0269 -0.4993 0.8792 -0.0206 0.7821 0.7385 
Nabumetone 0.3917 -0.4122 0.4866 -0.6198 -0.1287 -0.2497 -0.5528 -0.5101 
N-Acetyl-DL-homocysteine Thiolactone 1.7063 1.1295 0.1555 1.5773 0.4081 1.2347 0.5853 1.2087 
N-Acetyl-L-leucine 0.8206 -0.3491 -0.3890 -0.4736 0.0064 -0.2469 1.4855 0.1793 
Nadide -1.7140 -0.4941 -0.0130 -0.1591 -2.2371 -1.8582 -0.1531 -0.8948 
Nadolol 1.0487 -0.5489 0.4337 0.3577 -0.4833 -0.4947 0.3272 -0.3328 
Nafcillin sodium salt monohydrate -0.3347 0.5564 1.3394 -1.1072 0.6907 -0.7042 0.4281 -0.5455 
Nafronyl oxalate -0.6653 -0.9843 -1.2082 0.6712 -0.6747 -0.0582 -7.3228 -0.5183 
 Naftifine hydrochloride 0.3292 -0.1649 0.9368 0.1174 -0.1131 -0.0045 0.1270 0.0453 
Naftopidil dihydrochloride 0.4565 -0.2538 -0.9628 -1.5046 -0.8078 -0.2756 -0.0190 0.2690 
Nalbuphine hydrochloride -0.0077 0.3381 0.4480 0.0574 0.6097 -0.2746 0.1304 -0.4064 
Nalidixic acid sodium salt hydrate -0.0443 -0.4144 1.1540 0.6736 0.6088 -0.3431 -6.5058 0.4342 
Naloxone hydrochloride 0.0594 -1.5155 -0.4726 -0.9147 -0.3093 -2.1908 -0.8405 0.0945 
Naltrexone hydrochloride dihydrate 1.1854 0.4298 1.6403 0.3735 1.3274 -0.0244 -1.2511 0.7411 
Napelline 0.5016 -0.5113 0.2928 -0.6518 0.3297 0.5286 -0.8337 0.1602 
Naphazoline hydrochloride -0.6526 0.1280 0.2239 0.5074 0.5681 0.2010 0.0293 0.6575 
Naproxen 1.5910 0.9120 -0.3920 1.5775 0.8518 0.7072 0.4672 -0.1982 
Naringenine 0.9317 0.6814 0.5056 -0.4059 1.1110 0.1841 -0.7295 -0.0069 
Naringin hydrate 0.8510 0.9025 -0.9826 -0.3785 1.5409 0.5516 0.3943 0.2032 
Natamycin 0.5950 0.2429 0.4266 0.2498 0.1118 -0.1992 0.6114 -0.1076 
Nefopam hydrochloride 0.0405 0.5828 -0.6538 0.0173 -0.7784 0.1925 0.3271 0.0768 
Neomycin sulfate 1.3819 1.0819 0.9457 -0.0038 0.4756 1.3770 0.3301 1.1824 
Neostigmine bromide -0.6087 0.0119 0.0319 0.1958 0.6943 -0.0122 0.2811 -1.0993 
Netilmicin sulfate -0.7563 -0.8458 -1.0165 -0.0253 -1.4825 -1.6477 -0.3742 -1.8692 
Niacin -0.0712 -0.1375 1.2198 -1.9189 -0.9579 -0.7274 -0.4916 0.1967 
Nialamide 0.0264 0.1062 0.3454 -0.6565 -0.3770 -0.4181 -1.2390 -1.3419 
Nicardipine hydrochloride -0.2949 0.0162 0.3294 -2.8609 -0.2968 -0.0897 -0.2818 -1.2575 
Nicergoline 0.2176 0.2695 0.7583 0.6076 -0.1490 0.4763 0.8353 0.6943 
Niclosamide -0.7753 -0.6633 -1.2227 -2.6331 -0.1784 -1.9065 -0.7658 -0.3595 
Nifedipine 0.2365 -0.4830 -0.0688 0.6409 -0.0243 0.1249 -0.6900 -0.9389 
Nifenazone 0.9233 1.1288 -0.2978 -0.2046 0.3751 0.1621 0.0724 1.1717 
Niflumic acid 0.4026 0.2703 1.5577 1.5435 0.4392 1.1100 1.4606 0.8419 
Nifuroxazide 0.3980 1.0142 -0.1202 0.6627 0.1484 1.6818 0.7691 0.5383 
Nifurtimox -0.6884 0.2455 -0.8869 -0.8625 0.3244 -0.1610 0.9915 -1.0793 
Nilutamide 0.9141 -0.0811 -0.7567 0.4910 0.8708 0.0106 0.1011 0.4632 
 Nimesulide 1.1117 -0.7773 2.4016 0.2729 0.1921 -0.4506 0.7355 -0.6250 
Nimodipine -0.2208 -0.3916 -1.0209 -0.5924 -0.6066 -0.5938 0.3834 0.1025 
Niridazole 0.4467 1.0812 -0.0043 -0.6955 0.9698 -0.4463 -0.2304 -0.0200 
Nisoxetine hydrochloride 0.2021 -1.0021 0.0627 0.9989 -0.4032 -0.5408 -0.5507 -0.0614 
Nitrarine dihydrochloride 0.8660 0.2362 0.7719 1.5136 0.8298 1.0052 0.9053 1.5844 
Nitrendipine 0.7758 0.1751 0.6513 0.3959 1.1642 0.1429 0.1980 1.1618 
Nitrocaramiphen hydrochloride -0.3285 -2.1483 0.5311 -0.2771 -1.2473 -1.1937 -1.4028 -0.6150 
Nitrofural -0.6787 0.4519 0.4574 1.0967 -1.5489 0.8758 0.6695 1.4416 
Nitrofurantoin -0.9931 1.2621 1.3157 0.2416 1.7642 1.2955 0.8273 0.7999 
Nizatidine 0.2714 -0.9354 0.0649 -0.2080 -0.4229 -0.4129 0.2150 0.0827 
Nocodazole -11.6404 -8.5557 -9.2541 -8.5399 -8.8561 -10.8045 -0.1020 -6.1323 
Nomegestrol acetate 0.4113 0.4191 0.8673 -0.2961 1.2235 0.9441 1.7658 -0.3415 
Nomifensine maleate 0.6769 0.2742 1.2121 0.1970 0.4491 -0.3297 -0.5024 0.0542 
Norcyclobenzaprine 0.2981 -0.4372 0.4691 1.2720 -0.1702 -0.2144 1.4046 -0.2540 
Norethindrone 1.5406 -0.0152 1.1804 0.2503 0.6113 1.1481 0.4516 -0.7115 
Norethynodrel 0.1644 0.4937 0.2830 0.4988 0.6595 0.0565 0.9657 1.1791 
Norfloxacin -0.0338 0.3918 0.0082 -0.5415 -0.5104 -0.4491 -0.2588 0.2397 
Norgestrel-(-)-D 0.5757 -0.7009 -0.0609 0.1619 -0.1874 0.0128 0.4915 -0.6947 
Nortriptyline hydrochloride 0.6617 -1.4624 -0.1308 -0.3596 -0.5579 -0.1661 1.0274 -0.6252 
Noscapine -1.7930 0.5270 -0.3393 1.6454 0.2418 -0.0113 0.8525 -1.3531 
Novobiocin sodium salt -0.2748 -0.1315 1.6063 -0.9925 -0.0888 -0.5823 2.2142 -0.4377 
Nystatine 0.5457 -0.0448 -0.1414 0.7926 0.2857 -0.4809 0.5361 -0.6735 
Ofloxacin 0.0759 2.5260 -0.6067 1.0770 -0.0401 2.1307 0.7464 1.9768 
Oleandomycin phosphate -0.0046 0.1036 -0.2286 0.1100 0.4074 -1.1724 0.5381 -0.6384 
Omeprazole 0.2941 -0.1280 0.8849 2.0561 -1.3191 0.2105 2.2044 1.4960 
Ondansetron Hydrochloride -1.1035 -0.2060 -1.7195 -1.3471 -0.7605 -0.6484 0.1851 -0.9138 
Ornidazole 1.1974 1.0778 2.0852 1.4626 0.4661 0.9442 1.2401 1.4804 
 Orphenadrine hydrochloride 1.1867 2.0841 -1.4360 0.3636 -0.6151 1.4700 1.1773 1.7149 
Oxalamine citrate salt 1.0182 -0.0588 0.9287 -0.9547 -0.3900 -0.6407 1.0053 -0.1451 
Oxantel pamoate 0.9534 2.4860 0.4543 0.2134 0.0227 2.7025 0.7656 -0.0038 
Oxaprozin -0.8144 -0.7955 -0.7186 -1.6169 -0.2071 -0.9226 0.3255 -0.1196 
Oxethazaine -0.9945 -0.7226 0.8391 -0.6845 -0.0614 -0.7286 -0.3576 -0.3126 
Oxolinic acid 1.0151 0.0030 0.8059 1.0448 0.5903 0.4599 0.4614 0.7177 
Oxprenolol hydrochloride -1.4387 -0.2518 -1.4231 -2.2548 -0.8714 -0.2203 1.0873 -0.0060 
Oxybenzone 1.7338 2.4910 -0.7119 0.2211 0.9122 -0.9994 -6.8724 0.6553 
Oxybutynin chloride 0.7117 0.4549 0.6944 0.5682 0.6806 0.0931 1.0612 0.3930 
Oxymetazoline hydrochloride 0.9886 1.2408 1.0027 0.2240 0.0417 0.0561 -0.3611 -0.0981 
Oxyphenbutazone -0.6124 0.3620 -0.5799 0.0851 -0.0852 1.0115 0.1848 0.4921 
Oxytetracycline dihydrate 1.3839 0.7736 0.0183 0.9655 0.0442 -0.0387 -0.3202 -0.1060 
Ozagrel hydrochloride -0.8501 -0.2034 -0.3706 0.7953 -0.9352 -0.8673 0.5063 0.3568 
Paclitaxel -9.0994 -6.9804 -6.9408 -8.3411 -9.3243 -11.3532 0.1258 -7.1257 
Palmatine chloride 0.8223 -1.8346 -1.4605 -0.2267 -0.4714 -0.9354 0.1053 -0.3519 
Pancuronium bromide 0.6941 0.4919 0.2476 -0.1791 1.0293 0.5386 2.3770 -0.2058 
Panthenol (D) 0.0253 1.0560 0.6408 0.0757 1.0415 0.5458 1.0373 1.1194 
Pantothenic acid calcium salt monohydrate 0.8527 2.1697 0.4455 0.4864 0.1824 1.6838 0.6343 0.0069 
Papaverine hydrochloride -0.3970 -3.5132 -0.1929 -0.1855 -1.6182 -3.3095 0.9607 -1.2744 
Parbendazole -9.9899 -9.2412 -3.8848 -6.4864 -9.3868 -8.5899 -0.0026 -7.5440 
Pargyline hydrochloride 0.7235 -0.0105 0.0933 -0.6140 0.1428 -0.3653 -1.0539 0.6109 
Paromomycin sulfate 0.2611 -0.0249 -0.7081 0.5174 0.1504 0.2295 -2.1813 -0.1235 
Paroxetine Hydrochloride -1.7756 -2.0617 -1.8087 -1.7746 -1.6971 -1.1334 -0.9170 -1.4458 
Parthenolide -2.2838 -0.6259 -4.1964 -2.7264 -0.0516 -0.3649 0.5386 -1.3405 
Pempidine tartrate -0.7493 0.1769 0.2532 -0.2644 -0.2168 -0.7267 0.1435 -0.0622 
Penbutolol sulfate 0.5351 1.1647 0.2431 0.0434 -0.6961 0.4774 1.8679 -0.1006 
Pentamidine isethionate -0.7434 -1.5498 -0.1190 0.1400 -0.1130 -0.8358 0.8977 -2.0184 
 Pentetic acid -0.6847 -1.0536 0.0154 -0.3429 -2.0333 -0.7220 0.0197 -0.3448 
Pentolinium bitartrate -0.4609 -0.6727 1.1838 0.2053 0.1859 -0.3166 0.2951 0.4368 
Pentoxifylline 3.4068 -0.1277 0.6644 0.5615 1.1190 0.1964 1.3371 -0.5758 
Pentylenetetrazole -2.6569 0.5671 -0.3139 0.6487 -0.0389 1.0766 0.4846 0.3051 
Pepstatin A 2.0572 -0.2902 0.7092 1.0670 0.7029 -0.0020 0.3940 1.8880 
Pergolide mesylate 1.7026 0.6512 -0.2600 0.2366 0.2092 0.3804 -0.1725 0.5372 
Perhexiline maleate -3.5171 -0.9921 -4.5170 -3.0514 -1.2025 -1.4678 -6.3774 -1.2786 
Perphenazine 0.3631 0.3631 -0.5430 0.2188 0.8518 0.2855 1.7631 0.2785 
Phenacetin 1.2376 0.1141 2.2653 0.4124 0.3830 -0.2339 -0.5758 0.3160 
Phenazopyridine hydrochloride -1.4882 0.7434 0.1891 -1.3349 -0.8193 0.6383 0.1999 -1.3270 
Phenelzine sulfate 0.7233 0.8441 1.9800 -0.1096 1.4228 0.7453 -9.4634 0.2784 
Phenethicillin potassium salt 0.6675 -0.0540 -0.0747 1.3756 1.3451 1.9997 2.4752 0.9317 
Phenformin hydrochloride -0.0248 -1.4010 -0.1780 -0.4061 -0.2763 -4.0785 -0.0133 -1.3193 
Phenindione -0.4906 -0.0034 -0.9210 -0.6447 0.3185 -0.4752 0.4145 -1.0640 
Pheniramine maleate -0.8607 -0.0014 0.0721 -1.3464 0.4503 0.0976 0.3029 -1.1384 
Phenoxybenzamine hydrochloride -0.3334 -0.3564 -1.0849 -0.0020 -0.3932 0.0883 -0.8514 -0.7256 
Phensuximide -0.5657 -1.2436 -0.9023 -2.2599 -0.5758 -1.3677 -1.5148 0.5997 
Phentolamine hydrochloride 0.0767 1.6058 -0.7639 -0.0439 -0.4157 0.4065 -0.1811 -0.0043 
Phenylpropanolamine hydrochloride 0.9778 0.8473 0.4853 0.9837 1.3165 0.5051 0.9893 1.0979 
Phthalylsulfathiazole -1.2618 -0.1662 -1.0272 0.0435 0.4428 0.4313 -0.7142 0.0176 
Picotamide monohydrate -0.2237 0.3867 0.1103 1.0467 1.1352 0.1719 0.1184 -0.6236 
Picrotoxinin -0.6805 -0.0997 0.4790 1.4657 -0.3825 0.2937 -0.0782 1.3015 
Pilocarpine nitrate -0.6162 -1.4217 0.0974 -0.6178 0.3529 0.8666 -0.1583 -0.6192 
Pimethixene maleate 0.4113 -0.8470 0.9358 0.2451 0.0265 -0.6377 -0.0614 -0.0654 
Pimozide -0.0986 -1.3301 -1.7821 -0.1545 0.1315 -1.8801 -0.9237 -0.2377 
Pinacidil -1.2312 0.3644 -0.1654 0.2214 1.4501 1.1067 -5.7705 0.7079 
Pindolol 0.4953 -0.4685 -0.9488 1.3864 1.6026 1.4897 -1.5755 2.2406 
 Pipemidic acid 1.0557 0.4454 -0.0989 -0.1461 -0.8000 0.2804 0.3450 0.2442 
Pipenzolate bromide -0.2082 -0.1402 1.0493 0.5826 0.0048 -0.4885 -0.6648 -0.2345 
Piperacetazine -0.4228 1.0833 -1.2844 0.2898 0.1379 0.8396 0.3683 0.5534 
Piperacillin sodium salt 1.1864 1.6839 0.6477 1.4472 0.0790 1.6741 1.3805 0.8740 
Piperidolate hydrochloride 1.3584 0.5859 -0.7239 -0.8935 -0.1121 0.6876 1.8407 0.8368 
Piperine 0.5079 1.8473 0.0204 0.4590 0.3298 1.5620 0.7643 -0.5027 
Piperlongumine -0.2110 0.0749 -1.8741 -0.9144 0.0059 0.4092 1.1882 0.0866 
Piracetam -0.1728 -0.0020 0.0703 0.0920 0.3355 -0.0103 0.8121 -0.6332 
Pirenperone 0.7776 0.6802 0.8114 -0.6298 0.0605 0.6594 -0.9309 0.7992 
Pirenzepine dihydrochloride 0.9337 0.1654 0.8790 0.0707 0.0696 0.3976 -0.6641 1.1839 
Piretanide 0.3213 0.5932 -1.9393 0.7156 0.2169 1.4454 1.5643 -0.0563 
Piribedil hydrochloride -1.1713 -0.4025 -0.0416 -0.5569 -0.6617 -0.0069 0.4207 1.0493 
Pirlindole mesylate 0.3201 -0.5343 1.2173 -0.0666 -0.7399 -0.1275 0.2638 0.3534 
Piromidic acid 1.2145 1.3024 -0.4681 0.3933 -0.0822 1.6247 1.6048 1.1891 
Piroxicam -0.4684 -0.4374 -1.2917 -0.1713 -1.3911 -0.1114 -2.4790 -0.1796 
Pivampicillin -1.4542 0.1589 -0.2640 -0.3371 0.7446 -0.2531 0.1570 -0.5073 
Pivmecillinam hydrochloride -0.0985 0.0698 -1.2297 0.2177 0.2018 0.2758 0.6865 -0.2292 
Pizotifen malate -0.7785 -1.3813 -0.8345 0.3873 -0.2471 -0.9377 -0.4500 0.7711 
Podophyllotoxin -12.2032 -13.1279 -11.5430 -10.5838 -8.9742 -11.4319 0.1939 -7.0560 
Practolol 1.4082 -0.4395 1.0098 -0.2298 0.2587 0.7211 -1.1104 0.9962 
Pralidoxime chloride -0.6247 0.1732 0.8494 -0.2157 -0.7059 0.1432 -0.2131 -0.8867 
Pramoxine hydrochloride 0.0764 1.8686 1.2157 0.7514 0.9648 1.8724 1.3019 0.2424 
Praziquantel 0.0023 -0.4600 -1.3064 -0.2794 1.3707 -0.0099 0.4974 -1.0466 
Prazosin hydrochloride -0.6366 0.5646 -0.4573 -0.4523 0.1498 0.3776 -0.0820 -0.0032 
Prednicarbate 1.3798 0.9380 0.1043 2.1845 0.5090 0.9424 2.3940 0.9928 
Prednisolone 1.7739 0.1636 0.0730 -1.1320 1.4866 0.3377 1.1986 0.0941 
Prednisone 0.7596 1.6511 0.0227 1.0134 1.0320 1.7055 -0.0746 0.6129 
 Pregnenolone 1.0789 0.5622 1.0379 -0.1526 0.4763 0.5192 0.3279 0.3237 
Prenylamine lactate -0.0032 -0.3625 -0.3994 0.2709 0.0070 0.7304 0.6681 -0.3046 
Pridinol methanesulfonate salt -0.5659 0.5272 0.3240 -0.1977 0.8205 1.2939 1.0808 0.3700 
Prilocaine hydrochloride 0.3752 -0.5799 -0.8526 -0.5926 0.0871 -1.1069 0.1926 -1.9598 
Primaquine diphosphate -0.7610 2.3343 -0.2358 0.6553 1.2056 1.7434 0.8736 0.4176 
Primidone -0.4000 -0.1343 -0.5215 0.2323 -0.6866 0.0146 -0.3710 -0.2731 
Proadifen hydrochloride -0.0614 0.0254 -2.2474 -0.3254 -0.5551 -0.6731 -19.1546 -2.1051 
Probenecid 0.3061 1.1012 0.2356 -0.7117 0.7096 1.7098 -0.3332 0.6565 
Probucol 0.8887 -0.1459 0.6541 -0.7625 -0.1874 -0.4220 0.7028 -0.6452 
Procainamide hydrochloride 0.1034 1.0108 0.0017 -0.9261 1.1658 0.6752 -0.2069 0.3236 
Procaine hydrochloride -0.0459 -0.8255 -0.4939 -0.6154 0.0330 -0.3953 0.3102 0.5290 
Procarbazine hydrochloride 0.2501 0.8560 1.4517 1.3460 0.4696 0.6925 0.4991 -0.7021 
Prochlorperazine dimaleate 1.0063 1.6718 -0.2389 -0.0197 -0.1854 2.2455 -0.1852 -0.8300 
Procyclidine hydrochloride 0.3410 0.9567 1.6745 0.3434 0.1200 -0.6416 0.2816 0.1754 
Progesterone 0.7858 1.3890 -1.2194 0.8725 0.9980 0.9369 0.8654 0.7996 
Proglumide 0.5339 2.8239 -1.0052 0.3411 -0.0794 1.7938 0.0295 0.9134 
Proguanil hydrochloride -1.4418 -0.0049 -1.1743 -1.2708 -0.0286 -0.6443 -0.6038 -0.1954 
Promazine hydrochloride -0.5926 -0.7689 -0.6484 -0.2523 -1.1119 -1.2375 -0.0259 0.0347 
Promethazine hydrochloride 1.6061 0.2101 -0.0528 -0.7585 1.0362 -0.7886 -0.3482 1.1433 
Pronethalol hydrochloride 0.6730 0.2121 0.0639 0.5306 0.1641 0.1194 0.5819 -0.2054 
Propafenone hydrochloride -0.8838 -0.7534 -0.3792 -0.1452 -0.2198 -1.0768 -0.0863 -1.1993 
Propantheline bromide 0.1693 -0.2866 0.8194 -0.4908 0.0981 -0.7122 0.4064 -0.7084 
Proparacaine hydrochloride -0.1950 1.3482 -0.1130 0.9881 0.5862 1.5661 -0.3336 0.1476 
Propidium iodide -0.5333 0.0952 0.0130 0.5808 -0.4193 0.3904 1.4290 0.0470 
Propofol -1.3228 -0.9651 0.4750 -1.6360 -1.8734 -0.9954 0.1093 -1.3136 
Propoxycaine hydrochloride -0.1195 -0.0454 -2.6525 -1.3409 -0.6447 -0.9895 -5.9277 -0.2263 
Propranolol hydrochloride -1.1533 -1.0358 -0.1876 0.3502 -0.8517 0.2093 -1.0757 -0.7774 
 Propylthiouracil 0.0892 0.8039 -0.4685 1.3163 -0.2137 -0.3302 0.8282 0.4351 
Proscillaridin A -13.4107 -13.9577 -12.6317 -15.6228 -12.2211 -12.7556 -0.7601 -11.0272 
Protoveratrine A 0.3827 1.6653 2.3266 1.5506 1.2427 1.9769 0.4501 1.1892 
Protriptyline hydrochloride 0.3350 -0.9864 0.8237 -0.4343 -0.0562 -0.5835 0.3961 -0.6947 
Proxyphylline 1.2705 0.9676 1.5807 -0.4892 -0.0305 0.7370 0.5029 1.1481 
Pseudopelletierine hydrochloride 0.8633 0.2586 0.6743 0.0648 0.5018 0.1636 -0.3789 0.3512 
Puromycin dihydrochloride -6.4675 -1.8855 -6.7723 -6.9249 -11.5332 -17.3642 1.3559 -13.4882 
Pyrantel tartrate -0.5618 -0.7580 -0.0082 -0.9528 0.1272 -0.2234 -1.9572 0.0296 
Pyrazinamide 1.1516 0.9170 -0.2787 0.7303 0.5093 0.2290 1.0529 0.3302 
Pyridoxine hydrochloride -0.0052 -0.0837 -0.1317 -0.3236 0.7242 0.0109 1.0796 0.2900 
Pyrilamine maleate 1.8302 -0.3615 0.4144 -0.0709 1.0129 0.2310 -0.5580 0.3498 
Pyrimethamine -7.6459 -10.4182 -7.0888 -12.4550 -6.0241 -5.9983 -5.4734 -5.1452 
Pyrithyldione 0.3322 0.7212 -0.0804 2.1651 0.0833 1.4492 2.1385 0.3382 
Pyrvinium pamoate -3.6629 -0.4540 -4.0134 -1.8962 -6.1464 -2.6682 0.7849 -2.2738 
Quercetine dihydrate -0.5880 -0.1773 0.4865 -0.1774 0.4960 -0.9541 -0.1601 -1.0580 
Quinacrine dihydrochloride dihydrate -2.4038 1.2208 -5.2810 -0.2155 -1.2288 0.0814 0.5427 -0.5143 
Quinethazone 0.4586 0.4628 -0.4455 -1.7220 0.7496 0.4916 1.2333 0.4820 
Quinic acid 0.0047 -0.0181 1.0488 0.3573 -0.7071 -0.3106 -0.1095 -0.6930 
Quinidine hydrochloride monohydrate -1.4082 -1.3894 0.5417 -0.3337 0.3705 -0.5221 0.1337 -0.0011 
Quipazine dimaleate salt 0.1592 0.6752 0.1428 -0.2348 0.5211 -0.1826 -1.3699 0.1328 
R(-) Apomorphine hydrochloride hemihydrate 0.3147 -0.5267 0.0216 -1.4659 -2.1106 -0.0057 -1.0750 -0.3021 
Racecadotril 0.7074 0.1394 0.5597 0.3922 0.3296 0.6339 0.5221 -0.0004 
Raloxifene hydrochloride -2.0792 -0.2817 -1.5947 -0.1467 -1.4558 -1.4111 -1.8864 0.1669 
Ramipril 0.3809 -0.0915 -1.4644 -0.0618 -0.0270 -0.5756 0.4864 -0.0898 
Ranitidine hydrochloride -0.7147 -0.5804 0.1710 -0.0016 -0.8789 -0.2784 -7.5050 -0.1081 
Rauwolscine hydrochloride -1.1109 0.2342 0.3581 -0.5144 -0.4905 -1.1071 -0.9739 0.0651 
Remoxipride Hydrochloride -0.7013 -1.6379 0.6533 0.0586 -2.0419 -0.8946 0.1696 -1.8242 
 Repaglinide 0.7834 1.4085 0.7899 0.8134 0.0270 0.8897 0.9546 0.9391 
Rescinnamin 0.3231 -0.2087 -0.2498 0.6018 -0.9354 -0.3560 -0.1585 0.1479 
Reserpine 0.3956 0.8043 0.3122 0.7932 0.6477 1.0799 1.3737 1.3705 
Reserpinic acid hydrochloride  0.6841 -0.0124 0.7709 -0.0600 0.2700 0.0931 0.0190 0.7682 
Resveratrol -0.2168 -0.4214 -0.6234 -0.0449 0.5356 -0.5071 -0.0037 -0.7549 
Retinoic acid  -1.2533 0.5042 -0.2758 0.0604 1.4481 1.2958 0.1546 -1.7609 
Retrorsine 0.8961 1.7623 1.8023 1.2173 1.3563 1.7804 -0.1281 1.3570 
Ribavirin 0.6760 1.4137 0.7149 0.5283 -0.4097 0.5037 -0.4638 0.6938 
Riboflavine -11.3832 0.1874 -9.7572 -1.3652 -6.9816 -2.5846 0.4692 -4.0668 
Ribostamycin sulfate salt 0.7531 0.1995 0.7646 -0.0728 0.0647 -0.6275 -0.3262 -0.1757 
Ricinine 0.4914 -0.5570 -0.2883 0.2017 0.5429 0.1329 0.3075 -0.1680 
Rifabutin -0.9159 -0.5305 0.3862 1.5600 -0.5142 -0.7476 0.0328 -0.7806 
Rifampicin 1.9502 1.4105 0.5882 1.4167 0.8774 1.3292 -1.0306 2.0455 
Rilmenidine hemifumarate 0.3229 -0.4903 0.4342 0.8605 -0.7487 -0.7762 -1.1896 1.1210 
Riluzole hydrochloride -0.6056 0.3153 1.5433 -0.8045 1.6751 1.0208 0.4878 0.7626 
Rimexolone -0.8418 0.0178 -0.6863 -0.5806 0.2678 -0.3674 -0.0423 -0.0324 
Risperidone -1.5067 0.0413 -0.4133 0.1237 0.5355 -0.1428 0.1913 -0.4401 
Ritodrine hydrochloride 0.2221 -0.8785 -0.5271 0.2928 0.4153 -0.0462 -0.0115 -0.1562 
Rolipram 0.2582 0.1131 1.8827 0.3576 0.8894 0.6070 1.4760 0.9266 
Rolitetracycline 0.3898 0.0382 0.5982 0.7902 0.2738 -0.0266 -0.0150 -0.2621 
Ronidazole 0.3571 0.4931 -2.8545 1.4685 0.1403 1.3940 0.8720 0.3377 
Roxarsone -0.1623 1.1799 -0.0976 1.0720 -0.9164 2.2581 1.1011 0.9532 
Roxithromycin 0.7288 0.2925 -0.6199 0.3971 0.8086 0.0293 0.5468 -0.0437 
S(-)Eticlopride hydrochloride -1.1591 -0.0667 0.5148 -0.2508 -1.3583 -0.4254 -0.3798 -0.1175 
S(-)-terguride hydrogen maleate -0.0437 -0.4375 0.5487 1.0300 0.9448 -0.2041 0.4305 0.8182 
S-(+)-ibuprofen 0.7642 0.5860 0.9542 0.7998 -0.0090 -0.4222 0.2941 0.4745 
Salbutamol 1.6360 -0.6042 -1.2785 -0.6621 0.0518 -0.2902 0.0856 -1.6649 
 Salmeterol 0.0467 0.4145 -0.4584 -0.2832 0.4600 -0.3816 -0.5825 -0.5982 
Salsolinol hydrobromide 0.8702 0.2221 -0.7573 0.0163 0.9982 0.2710 -0.2625 -0.0146 
Sanguinarine -17.1693 -20.7820 -18.1952 -26.4478 -18.7017 -29.1133 -12.2206 -22.1436 
Saquinavir mesylate 0.4650 0.3894 0.1134 0.8846 0.4010 1.1947 0.0488 0.4954 
Scopolamine hydrochloride 0.3345 0.3766 0.1188 1.3481 0.9876 0.6925 0.2966 0.3263 
Scopolamin-N-oxide hydrobromide 0.6503 1.2768 -0.4736 0.7187 0.4636 1.2022 -0.1907 0.3646 
Scopoletin -0.3971 0.5815 -0.2336 1.1973 -1.2248 1.6481 0.8509 0.5574 
Scoulerine -8.5310 -4.3963 -7.7195 -6.7401 -7.2100 -4.9172 -0.0295 -4.5043 
Securinine -2.9039 -1.2267 -1.6029 -2.8870 -3.7101 -2.8614 -1.2285 -2.7645 
Selegiline hydrochloride -0.0574 1.6080 0.5810 0.7030 0.6905 3.0719 0.0305 1.9881 
Seneciphylline 0.5244 -0.6988 -0.6066 -0.2473 0.2775 -0.2774 -1.0673 0.1017 
Serotonin hydrochloride 0.5772 -0.0700 1.6034 1.9992 -0.4058 1.1642 -1.8198 1.8228 
Sertaconazole nitrate -0.9100 0.8908 -1.7507 -0.7790 -0.5397 1.8431 1.8348 0.1706 
Sertraline -0.3546 -0.9099 -0.0128 0.1307 0.3980 -0.1615 0.0300 -2.0425 
Simvastatin -1.3291 -0.0219 -0.2206 -0.5368 -0.0025 -0.3352 -0.1795 -0.3243 
Sisomicin sulfate 1.1805 0.6008 1.7651 -0.3058 0.0293 0.7093 0.4940 0.0279 
Skimmianine 1.0317 -0.5505 0.3190 -0.0839 -0.2990 0.1816 -0.3921 0.0468 
Solanine alpha 0.0234 1.4391 -2.8816 0.7027 1.6222 2.1981 -11.1202 1.1253 
Solasodine 0.0855 -0.3421 -0.5999 0.0625 -1.4520 -0.0964 0.0799 0.5135 
Sotalol hydrochloride -0.2114 -0.3086 -1.1568 0.7626 -0.7742 0.2619 0.6087 0.3336 
Spaglumic acid -0.3944 -0.0806 0.7557 -0.1063 1.1089 -1.7832 -0.3895 -0.3791 
Sparteine (-) 0.1861 0.7997 0.5187 -0.1732 1.1361 0.5306 -0.9928 -0.5364 
Spectinomycin dihydrochloride 1.5616 0.6416 1.7723 1.5944 0.2256 2.2786 1.8322 0.2570 
Spiperone 1.0805 -0.7390 -0.3931 -0.4240 0.5281 -0.7543 -0.1366 -0.4735 
Spiramycin 1.2717 -0.0837 -0.2769 0.2136 0.1454 0.5448 -0.3472 1.2422 
Spironolactone 0.0346 -0.0082 -0.3609 0.1547 0.5109 0.3414 -0.6688 0.0334 
SR-95639A 1.7607 -1.0916 1.1829 -0.0109 1.6511 -0.3226 1.2259 1.6603 
 Stachydrine hydrochloride -0.5613 0.3821 0.1215 -0.3553 0.6686 0.9181 0.4046 0.3607 
Streptomycin sulfate 0.9467 -1.3141 0.3920 1.4578 -0.5628 0.8941 -1.2598 1.7239 
Streptozotocin 0.0773 0.2337 -1.7499 1.1736 -0.0603 1.1201 0.9435 0.4278 
Strophanthidin -12.4280 -11.3972 -9.0961 -11.1715 -7.7558 -6.8591 -7.0114 -3.8935 
Strophantine octahydrate -11.7411 -14.8386 -10.1322 -18.6534 -8.5376 -18.5993 -0.2959 -12.2891 
Succinylsulfathiazole -0.5929 0.6557 0.0240 0.6505 -0.6130 -0.3607 -0.2046 -0.4260 
Sulconazole nitrate 0.5724 0.7626 -0.2774 0.2217 -0.2920 0.3858 0.6215 0.0823 
Sulfabenzamide -0.1440 0.7851 0.2422 0.4890 0.0750 0.3960 1.0832 -0.0769 
Sulfacetamide sodic hydrate 0.1090 0.6936 0.6335 0.0897 0.1841 0.4967 1.4458 0.3244 
Sulfachloropyridazine 0.7574 1.0271 0.8666 1.4779 0.9255 1.4456 0.7856 1.3331 
Sulfadiazine 0.6118 0.6606 -0.4312 -0.9387 0.2066 0.1997 0.5514 0.4986 
Sulfadimethoxine 0.7189 -0.6489 0.3014 -0.1626 0.5067 1.3131 1.8582 0.2983 
Sulfadoxine 0.5937 0.7413 1.6325 0.1932 0.3148 0.7047 0.1890 -0.9607 
Sulfaguanidine 0.5471 -0.4855 0.9719 0.0481 -0.0318 -0.8363 0.4236 0.7509 
Sulfamerazine 0.3453 -0.2796 1.0638 0.0058 0.4415 0.1875 0.8885 0.0021 
Sulfameter 0.3410 -0.4661 0.4742 -0.2255 0.1695 -0.5898 2.4651 -0.7456 
Sulfamethazine sodium salt 0.3120 0.3326 0.0906 0.2282 0.6858 0.0730 -11.3929 0.3926 
Sulfamethizole -0.6824 0.0811 0.6730 0.7159 -0.4190 0.8899 -0.6993 0.2920 
Sulfamethoxazole -0.3403 -0.0919 -0.2512 1.0223 0.1808 -0.1234 0.3398 0.4206 
Sulfamethoxypyridazine 1.1340 -0.1074 1.1637 -0.1036 0.3174 1.7993 2.1620 -0.1554 
Sulfamonomethoxine -0.9477 -0.6386 -0.3109 -0.0312 -0.2400 -0.3242 1.8174 0.4270 
Sulfanilamide 0.0544 -1.0929 0.6246 0.3026 0.3894 1.1451 1.3351 1.3516 
Sulfaphenazole 0.9341 0.1397 -0.0241 0.0105 -0.4270 0.0257 0.0722 0.7998 
Sulfapyridine -0.6270 -0.0002 -0.2957 -0.4271 -0.4211 0.3052 -1.1137 -0.9463 
Sulfaquinoxaline sodium salt -1.0309 -1.7155 -1.2995 -0.8011 -1.4615 -1.4427 -0.6905 -0.3784 
Sulfasalazine 0.0179 -0.3602 0.0910 -0.0141 0.0332 -0.6177 -0.2391 -0.6780 
Sulfathiazole -0.4708 -0.7840 0.7580 0.5429 0.0954 -0.2353 0.9926 0.8388 
 Sulfinpyrazone 0.7136 -0.4013 0.4629 0.1889 0.3436 -0.3111 -0.0528 -0.0531 
Sulfisoxazole 0.9461 0.3814 2.0034 -0.0429 0.5328 0.2394 0.7847 1.1534 
Sulindac 0.3714 1.3246 0.7412 0.2161 1.1179 1.5571 0.5954 0.4287 
Sulmazole 0.6146 0.6464 -0.3551 2.1286 -0.1228 1.2009 -0.2133 -0.7920 
Suloctidil -1.2654 -0.3474 -2.0348 -0.6603 -3.2326 -0.0521 -1.2518 -0.6631 
Sulpiride -0.0738 0.0014 0.2283 0.6850 0.5788 -0.2457 0.3560 -0.2936 
Suprofen 0.7415 0.0219 0.3304 -0.1445 -0.4123 -0.7327 0.8835 0.0525 
Suxibuzone 0.1184 -0.8298 0.1569 -0.2022 -0.0825 -0.0983 -0.5856 -0.1713 
Syrosingopine 0.7580 -0.5299 0.0352 1.7255 -0.2009 0.4867 -0.8841 1.1228 
Tacrine hydrochloride hydrate 0.4999 1.6498 0.4566 0.9445 1.3010 0.2518 1.1156 0.4036 
Talampicillin hydrochloride -0.8588 -0.3620 0.2511 -0.3331 -0.2191 -0.4841 0.5596 0.1465 
Tamoxifen citrate -0.8818 0.3063 0.8483 0.3799 0.4792 0.2433 0.6430 0.4434 
Telenzepine dihydrochloride 0.4719 0.1763 -0.8476 0.3222 0.2833 0.1012 -1.7220 0.2809 
Tenoxicam 0.5526 0.3084 -0.7618 0.2042 0.7666 0.0103 0.1869 -0.3383 
Terazosin hydrochloride -1.7417 -0.9638 -0.3046 -1.7022 -1.8045 -1.0278 0.5553 -0.4151 
Terbutaline hemisulfate 0.3718 0.8838 0.0491 0.0056 0.3487 1.2909 0.4441 1.3077 
Terconazole -16.9738 0.3985 -0.5956 -0.2297 -0.9568 -0.2733 -0.4366 0.9215 
Terfenadine -17.6016 -26.3361 -0.2788 -0.2652 -18.0506 -0.4052 0.0044 -1.7246 
Testosterone propionate 1.8308 -0.7893 0.9243 0.5775 -0.1696 1.5478 0.2195 1.2094 
Tetracaïne hydrochloride -1.2090 -0.4422 -0.4950 0.6383 -0.6140 0.3621 0.5186 -0.7952 
Tetracycline hydrochloride -1.7017 0.7252 -0.7032 -1.1481 0.0985 0.2857 -0.7816 -0.8560 
Tetrahydroxy-1,4-quinone monohydrate 1.5076 1.3456 1.8907 1.6310 1.6409 1.0950 2.4892 0.0024 
Tetrahydrozoline hydrochloride 0.1053 -0.2976 0.2938 -0.2263 0.1364 -0.2074 -0.2789 -0.1547 
Tetramisole hydrochloride 0.5997 0.1326 0.0551 -0.2305 0.2331 0.7684 0.0928 -0.7613 
Tetrandrine -0.9115 -0.3953 -1.0439 -0.3751 -0.9255 0.3014 -0.3793 -0.8942 
Thalidomide 0.5749 -0.1783 1.7681 -0.8489 -0.7103 -0.5879 -1.0533 -1.0167 
Theobromine 0.2320 0.0448 0.6554 0.8635 0.7866 1.2075 0.5095 0.1298 
 Theophylline monohydrate -0.3861 -0.6889 -0.4686 0.1623 0.3753 0.9861 0.7413 1.0131 
Thiamine hydrochloride -0.3363 1.0274 -0.2634 1.6305 0.8485 1.2004 -0.5082 0.1610 
Thiamphenicol -0.0591 -1.3133 -0.9107 -0.4195 -0.7970 -2.8457 -0.8483 0.6082 
Thiethylperazine malate -0.4097 -0.2803 -1.8488 -0.4290 -0.1725 -0.4795 -12.0424 0.0317 
Thiocolchicoside 0.1921 0.7346 0.0118 -1.0695 0.3012 -1.1963 -0.0252 -0.8968 
Thioguanosine -10.8458 -12.8421 -9.9201 -11.4013 -12.0507 -16.7969 0.6170 -12.1044 
Thioperamide maleate -0.3443 -1.4120 1.2012 -0.3111 -0.7395 -0.8679 -0.2716 -0.8689 
Thioproperazine dimesylate -0.2811 0.7283 -1.1875 0.0830 -0.6140 1.0206 0.2822 -0.5942 
Thioridazine hydrochloride -2.1241 0.7988 -2.4411 -0.2420 -0.0878 0.2757 -2.0486 -2.0946 
Thiorphan -0.1190 1.2623 0.2442 1.3612 1.0121 1.2709 0.7253 1.0880 
Thiostrepton 0.2664 -1.6651 -0.4710 -1.6505 -0.6861 -2.1367 -0.3998 -0.3996 
THIP Hydrochloride 0.1410 -0.3082 0.8151 0.2587 -0.0330 -0.5105 1.1087 0.4610 
Thonzonium bromide -1.0254 1.0874 0.4859 0.2293 -0.3038 0.4937 0.9960 -2.2013 
Thyroxine (L) 0.6768 -0.2071 1.3389 -0.5154 1.0426 0.4428 -0.0930 -0.3668 
Tiabendazole 1.2236 0.7722 0.1994 0.0561 0.3734 1.4119 0.3623 0.8746 
Tiapride hydrochloride 1.4400 0.5803 0.0953 0.3267 0.6951 -0.1367 -0.0514 -0.2782 
Tiaprofenic acid 0.1458 0.1532 0.1945 1.2398 -0.8093 -0.5512 0.2755 -0.1471 
Ticarcillin sodium -0.9112 -0.1304 -0.7800 -0.8865 -0.2164 -0.0901 -0.8982 0.0060 
Ticlopidine hydrochloride -0.2680 0.1814 -0.9157 0.2614 0.2550 -0.2774 0.6419 -0.2575 
Tiletamine hydrochloride -0.1993 0.5486 0.0128 -0.7926 -0.1689 0.2777 0.5837 -0.9751 
Timolol maleate salt -0.6169 0.0841 -0.5514 -0.2854 0.5931 0.2462 0.1661 -0.2625 
Tinidazole 0.0961 0.2796 0.8478 0.4802 1.0173 0.4864 0.0524 -0.0852 
Tiratricol, 3,3',5-triiodothyroacetic acid 0.9548 -0.0324 -0.1429 -0.1999 -0.2051 -0.7094 -0.5827 -0.1428 
Tobramycin 0.8506 1.0158 1.6022 1.2300 0.1274 -0.1470 -0.3121 -0.7191 
Tocainide hydrochloride -0.2712 0.3780 0.2696 -0.4939 0.4388 0.4501 0.3000 -1.3189 
Tocopherol (R,S) 1.7959 -0.2437 0.6653 0.5785 0.9385 -0.3661 1.6223 1.1452 
Todralazine hydrochloride -0.1832 1.2779 -0.6295 1.1183 0.8370 1.4166 1.0071 0.4719 
 Tolazamide 0.2641 1.6176 0.4797 1.3883 0.3530 2.0740 0.0936 0.9488 
Tolazoline hydrochloride -0.4917 -0.4462 0.0056 0.0277 0.3786 -0.3742 -0.1254 -0.2922 
Tolbutamide -0.1046 -0.7396 0.4916 -0.4671 0.2748 0.0173 0.0095 -0.7913 
Tolfenamic acid 1.1151 1.0980 0.2670 1.1942 1.6020 1.8213 0.6938 0.2925 
Tolmetin sodium salt dihydrate 0.9965 0.2629 -0.2481 0.2702 0.8924 -0.3222 0.1959 0.7466 
Tolnaftate 0.4794 0.1044 0.2421 0.5826 0.0620 0.1075 -0.1568 -0.1534 
Tomatidine 0.2225 0.5688 -1.2502 1.5420 -0.4386 0.6001 0.0773 -0.0277 
Tomatine 0.7795 0.7121 -0.0865 0.1146 0.6931 0.6464 0.6266 0.8819 
Torsemide -0.2864 0.6361 -0.0915 -0.5709 0.6312 -0.0492 -0.1800 -0.1012 
Tracazolate hydrochloride -0.1171 -0.5932 -0.5675 -0.3427 -0.6108 -1.3836 0.4698 -1.4073 
Tranexamic acid -0.5535 -0.6361 -0.8578 0.5563 -1.5764 -0.1117 -0.9875 0.0419 
Tranylcypromine hydrochloride -0.4099 -0.1746 0.2894 1.2676 -0.3193 0.1097 -0.7928 0.1709 
Trapidil 0.0727 -0.1945 -0.4311 -1.9922 -0.0019 -0.0138 0.2593 -1.9730 
Trazodone hydrochloride -1.0717 -0.8576 -0.8748 0.3979 -0.2385 -0.6738 -0.0918 -0.3504 
Tremorine dihydrochloride 1.2251 -0.8161 -0.4263 0.3422 -0.1259 -0.5218 -3.5654 0.6355 
Triamcinolone -0.3170 0.3627 0.5143 0.9153 0.7909 0.6613 -0.2627 0.6477 
Triamterene -2.0784 -0.6789 -3.2047 -2.4284 -0.4760 -0.6824 -0.1118 -0.0526 
Tribenoside -0.9470 -0.3645 -1.4918 -0.5356 -0.1223 -0.6020 -0.1462 -1.3879 
Trichlorfon -0.0381 -0.6973 -0.7970 -1.4862 0.1858 -0.0010 -0.7231 -0.1934 
Trichlormethiazide 0.1391 0.1904 -0.3778 0.1843 0.1445 0.1429 0.5497 -0.0028 
Tridihexethyl chloride -0.3740 0.2748 -0.5586 1.5540 -0.1764 0.7537 1.7438 0.1719 
Trifluoperazine dihydrochloride -0.2019 1.0055 -1.0826 0.1327 -0.0037 0.3348 0.3975 0.7402 
Triflupromazine hydrochloride 0.7531 -0.7800 -0.3002 -1.2806 -0.2345 -0.5846 -0.0741 0.0855 
Trifluridine -1.6467 -0.2333 -0.2534 -2.1292 -3.5519 -2.0545 1.1864 -1.0407 
Triflusal 0.7201 0.3979 -1.5000 -0.0349 0.1666 -0.0860 -0.6983 -0.4414 
Trigonelline 0.5282 0.3086 -0.4606 1.0698 -0.1491 -0.0109 2.0302 0.7373 
Trihexyphenidyl-D,L Hydrochloride -0.9801 -0.5830 -0.9163 -0.1386 -1.6186 -1.1582 -0.4538 -0.5392 
 Trimeprazine tartrate -0.8056 -2.3082 0.0527 -0.1336 -1.2755 -1.4983 0.5772 -0.6493 
Trimetazidine dihydrochloride -0.2318 0.8455 0.1059 0.9340 0.1868 0.5259 -0.0496 -0.2055 
Trimethadione 1.8530 0.8555 0.8133 1.8262 1.0412 0.9699 1.3517 0.5951 
Trimethobenzamide hydrochloride 1.3375 1.7267 -0.4307 1.0718 0.8466 1.2632 0.7727 0.6922 
Trimethoprim  0.2561 -0.1240 0.5776 -0.1457 0.3513 0.0029 0.1831 -1.4115 
Trimethylcolchicinic acid 0.1868 -1.2007 -0.6990 -0.7804 -0.2514 -0.2567 -0.3187 -0.8012 
Trimipramine maleate salt 1.3089 -0.7133 -1.4150 1.5501 -0.8336 0.6094 1.8672 -0.3191 
Trioxsalen -0.6406 0.1728 -1.0530 -0.8988 0.2407 0.0012 -0.5156 -0.8761 
Triprolidine hydrochloride 0.0016 -0.8230 1.2143 -0.6683 -1.2186 -0.0323 -0.1105 0.7125 
Troleandomycin 0.5945 0.6503 -1.3647 -0.0105 0.3201 0.4012 0.1197 0.8324 
Trolox 0.0905 -0.5023 -0.6982 -0.7172 0.1622 -0.5111 0.5343 -0.7367 
Tropicamide 0.3059 1.0242 0.5595 -0.7391 -0.2077 0.3591 0.3080 0.4041 
Tropine 0.6660 0.2336 -0.4934 -1.4211 0.0615 -0.1151 -10.8733 0.0764 
Tubocurarine chloride pentahydrate (+) -0.1007 -0.2725 0.3902 0.8107 -0.4010 0.7802 1.1776 -0.4636 
Tyloxapol -0.1621 -0.0523 -0.1461 1.1474 0.0719 0.6552 0.4144 -0.6365 
Ungerine nitrate 0.2308 -0.2381 0.4855 0.6949 0.3485 -0.0217 -0.6263 -0.1258 
Urapidil hydrochloride 0.2705 -0.1849 0.1196 1.3325 0.5281 1.0370 0.9590 0.5367 
Urosiol -0.1217 1.3729 -0.2443 1.9158 0.5165 1.2303 -1.6394 0.7123 
Ursolic acid 0.9147 -0.0524 0.6764 1.8959 1.6633 1.9550 0.7902 1.2654 
Vancomycin hydrochloride -0.7583 0.4725 0.1148 1.1794 -0.0613 -0.5859 0.4065 0.3677 
Verapamyl hydrochloride 0.4758 -1.2027 -0.6917 -0.9622 -0.8602 -0.9969 -7.8718 -0.5775 
Verteporfin -3.1278 -1.0866 -3.3684 0.5164 -1.1916 -1.5628 0.0048 -2.0995 
Vidarabine 0.3909 -0.7818 0.1114 0.4845 0.7599 -0.4845 -0.8779 -0.9955 
Vigabatrin 0.4491 0.1017 -0.7194 -0.1086 -0.9292 -0.2886 -2.1008 0.9970 
Vincamine 0.7873 -1.1802 -0.0583 -0.6890 -1.0957 -0.6978 -0.8374 -0.0625 
Vinpocetine 0.0013 -0.8495 1.0972 -0.8161 0.0085 0.0087 -0.8876 0.3627 
Viomycin sulfate -0.0682 -0.1981 0.1706 0.6455 0.0891 0.4595 1.0119 -0.6924 
 vitamin D -0.5412 -0.6735 -1.7898 -2.0806 -1.3024 -0.8576 -1.9099 0.2078 
Vitamin K2 -0.6488 -0.9946 1.3710 -0.8133 1.4984 -1.2260 -0.3633 -1.3754 
Vitexin -1.1864 -2.2242 0.8919 -0.9144 -1.7712 -0.7146 0.1947 -0.8364 
Xamoterol hemifumarate 0.1555 0.1018 1.1999 0.4369 -0.0064 -0.3637 -0.3382 -0.0701 
Xylazine -0.1855 -0.4368 -1.6201 -0.4689 0.2918 -0.9790 -0.4151 -0.5337 
Xylometazoline hydrochloride 0.3263 0.4859 0.4883 1.0226 -0.0621 -0.0194 0.5862 0.7575 
Yohimbine hydrochloride -0.0567 0.2189 0.4184 0.2540 -0.3706 0.2483 1.0266 -0.2295 
Yohimbinic acid monohydrate 0.6181 -0.0901 0.2256 0.3188 -0.1683 -0.4569 -0.5165 0.3426 
Zalcitabine -0.0911 0.8276 0.3016 -0.8427 1.4459 2.1229 -1.2991 1.3575 
Zaprinast 1.1568 0.7800 -0.7232 0.6206 0.7514 0.2095 0.6448 0.4376 
Zardaverine -0.2700 -0.4554 0.0263 0.2573 -0.7549 -0.8062 0.6177 0.0872 
Zidovudine, AZT 1.3724 0.0220 1.0604 -1.4963 0.5082 0.7904 -1.6130 0.7684 
Zimelidine dihydrochloride monohydrate 0.0116 -0.7579 1.3186 0.6104 -0.3353 -0.9218 -0.4200 1.8692 
Zomepirac sodium salt 0.3268 0.4525 -0.8400 0.2929 0.2890 -0.3991 -0.2973 0.9307 
Zoxazolamine 1.2335 1.3646 0.8576 1.0316 1.4255 -0.5102 1.0251 -0.0576 
Zuclopenthixol hydrochloride 0.0774 0.5377 -0.3373 -0.7556 0.1579 0.0229 0.3474 -0.8398 
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Appendix 2: ΔZ-scores of the siRNA 
screen 
 
 
Gene 
Symbol 
ΔZ-
scores 
AATK -1.1362 
ABL1 -0.5420 
ACVR2B -1.6242 
ADRBK1 3.2001 
AIP1 -0.7245 
AK1 -0.0850 
AK2 -0.0801 
AK3L1 -0.1428 
AK7 -0.7821 
AKT1 -1.1905 
ALS2CR7 6.5185 
AMHR2 -0.7525 
ANKK1 -0.2568 
ANKRD3 3.4949 
ARAF1 -0.4774 
ARK5 -0.4630 
ATR -0.0824 
AURKA -1.9110 
AURKC 0.7062 
BAIAP1 0.4156 
BCKDK 5.0849 
BCR 0.0729 
BLK 7.2034 
BMP2K 0.8351 
BMPR1A -0.3566 
BMPR1B 0.7043 
BMPR2 0.3154 
BMX -0.4127 
BRAF 0.0608 
BRD2 -8.9891 
BRD3 -0.6315 
BRD4 -0.0577 
BRDT 0.1785 
BUB1 -0.3878 
C10ORF89 0.0132 
C14ORF20 -0.4357 
C7ORF2 -0.8909 
C9ORF12 -3.8041 
C9ORF96 0.4248 
CALM1 -0.0913 
CALM2 -0.5202 
CALM3 -1.2498 
CAMK1 -0.7367 
CAMK1D -0.4001 
CAMK2A -0.0241 
CAMK2B -0.2675 
CAMK2D -0.6576 
CAMK2G 1.7399 
CAMK4 0.2418 
CAMKK1 -0.0717 
CAMKK1 0.1469 
CAMKK2 -0.2467 
CCRK 0.2017 
CDADC1 -0.4568 
CDC2L1 -0.0780 
CDC2L2 0.1595 
CDC42BPB 4.4886 
CDK10 -5.5877 
CDK2 0.4080 
CDK3 -0.1334 
CDK4 -1.1851 
CDK5R1 0.5354 
CDK8 -0.2060 
CDK9 0.2497 
CDKL1 -0.6807 
CDKL2 -0.8871 
CDKL3 -6.3042 
CDKL5 3.3947 
CDKN1C 1.6061 
CDKN2B 0.3049 
CDKN2C -0.8528 
CDKN2D -0.0176 
CHEK2 0.8371 
CHKA 0.4742 
CHKB 0.1611 
CHUK -0.2237 
CKB 0.3892 
CKM -1.2317 
CKS1B -0.1804 
CLK1 0.1934 
CLK3 1.0648 
CLK4 0.1026 
COASY -0.5724 
COL4A3BP 0.1736 
COMMD3 -0.4168 
CPNE3 -6.9373 
CRIM1 0.0422 
CRK7 0.2804 
CRKL 0.4620 
CSK 0.3189 
CSNK1A1 -0.0667 
CSNK1A1L 0.1089 
CSNK1G1 0.3685 
CSNK2A1 -0.5132 
CSNK2A2 -0.8995 
DCAMKL1 -0.1707 
DDR1 -0.3492 
DDR2 -0.3236 
DGKA 6.6224 
DGKB -0.4458 
DGKD -0.0344 
DGKH -0.2795 
DGKK -0.6130 
DGKQ -1.2252 
DGUOK 3.4762 
DKFZP434 0.1960 
DLG1 0.6026 
DLG2 -0.0987 
DLG3 -0.4635 
DLG4 -0.9935 
DMPK -0.4989 
DUSP21 -0.4758 
DYRK1A -0.1204 
DYRK1B -0.5344 
DYRK2 -1.2254 
DYRK4 0.1431 
EFNA3 0.5744 
EFNA5 -0.3309 
EFNB3 -0.1268 
EIF2AK3 0.7770 
EIF2AK4 -0.4881 
EPHA1 0.1913 
EPHA10 -1.1217 
EPHA4 0.1804 
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EPHA5 0.0074 
EPHA6 0.3782 
EPHB1 -0.6153 
EPHB2 -0.6546 
EPHB3 0.0391 
EPHB4 0.2671 
EPHB6 -0.2316 
ERBB3 0.6306 
ERN1 -0.5697 
ERN2 -0.4812 
EXOSC10 -0.1026 
FASTK -1.2096 
FER 0.3877 
FES -1.0333 
FGFR1 -0.7329 
FGFR2 -0.0178 
FGFR3 -0.1518 
FGFR4 -0.5210 
FGFRL1 0.1892 
FGR -0.3792 
FLJ10761 0.1916 
FLJ13052 -0.6153 
FLJ25006 -0.7474 
FLJ34389 -0.2650 
FLT1 0.4160 
FN3K -0.5458 
FUK -1.5844 
FYN -0.5284 
GAK -0.0314 
GALK1 -0.0672 
GALK2 0.8709 
GCK -1.1166 
GK 0.3638 
GK2 -0.2717 
GNE -0.3527 
GOLGA5 -0.2858 
GRK1 -0.5816 
GRK6 -0.4676 
GRK7 0.1070 
GSG2 0.4070 
GSK3A 0.3769 
GSK3B -0.6754 
GTF2H1 0.6703 
GUCY2C 0.2750 
GUCY2D -3.8166 
GUCY2F -0.3308 
GUK1 0.8274 
HAK 0.0681 
HCK 0.2932 
HIPK4 0.1566 
HK1 -0.9225 
HK2 -3.4199 
HSPB8 3.4576 
HUNK 0.5050 
HUS1 0.4061 
ICK 0.3455 
IGF1R -0.2413 
IGF2R 0.8380 
IHPK1 -0.3091 
IHPK2 0.2694 
IHPK3 0.2145 
IKBKAP -0.2090 
IKBKB 0.1155 
IKBKE -0.5186 
IKBKG -0.1102 
ILK -0.9624 
ILK-2 -0.1504 
INSR 0.1090 
INSRR 0.4356 
IPMK 0.0956 
IRAK3 -0.6053 
IRAK4 0.7903 
ITPK1 0.5232 
ITPKA 0.2105 
ITPKB 0.0513 
JAK1 0.1616 
JAK2 -9.6118 
JIK -0.0921 
KALRN 6.1814 
KCNH8 5.5232 
KDR 0.6364 
KHK -0.0347 
KIAA1639 -0.2607 
KIAA1765 0.1261 
KIAA2002 -0.6992 
KIT 0.2394 
KUB3 0.7405 
LAK 4.6959 
LATS1 0.8305 
LCK 0.2238 
LIMK2 -0.6073 
LMTK2 4.9509 
LMTK3 0.5394 
LOC340156 0.2656 
LOC390226 -0.2639 
LYK5 0.0636 
MAGI-3 0.3502 
MAK 0.3483 
MAP2K1 0.3729 
MAP2K2 -0.7447 
MAP2K5 -0.7782 
MAP2K6 -0.1853 
MAP2K7 5.7255 
MAP3K1 -0.2376 
MAP3K10 -0.7835 
MAP3K11 -0.7090 
MAP3K13 -0.0715 
MAP3K14 -1.2408 
MAP3K15 -1.0959 
MAP3K4 -0.0748 
MAP3K5 0.1827 
MAP3K6 0.0784 
MAP3K7 -1.0219 
MAP3K8 -0.3918 
MAP3K9 0.5961 
MAP4K2 -0.6885 
MAP4K3 -0.3878 
MAP4K4 -0.7280 
MAP4K5 0.2205 
MAPK10 -0.4821 
MAPK12 0.1224 
MAPK14 -0.4760 
MAPK4 -0.4755 
MAPK6 -0.9201 
MAPK7 -0.5321 
MAPK9 -0.3647 
MAPKAPK
5 0.0960 
MARK4 0.9129 
MAST3 0.1286 
MAST4 0.0184 
MATK 0.3930 
MELK 0.1017 
MERTK -0.8349 
MET -0.1559 
MGC16169 0.0465 
MGC42105 0.2917 
MGC45428 1.2126 
MGC4796 -0.8883 
MGC4796 -0.6204 
MGC8407 0.0166 
MIDORI 0.2422 
MINK -0.7897 
MKNK1 -0.7710 
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MKNK2 0.4724 
MLCK -6.8983 
MOS -0.2126 
MPP1 0.1755 
MPP3 1.3329 
MST1R -0.2362 
MYLK -0.1835 
MYLK2 -1.0275 
MYO3B 0.7135 
N4BP2 -0.1624 
NEK1 0.0946 
NEK11 -1.0479 
NEK2 0.4267 
NEK3 1.2799 
NEK4 3.3101 
NEK6 0.6969 
NEK7 -1.0707 
NEK9 0.3649 
NME1 -0.2431 
NME2 0.2806 
NME3 -0.5411 
NME4 -0.0991 
NME6 -0.2484 
NME7 -0.5958 
NPR2 -0.0385 
NRBP2 -2.2019 
NRK -0.0155 
NTRK1 0.0645 
NYD-SP25 -0.3774 
OSR1 0.3282 
P101-PI3K -0.3580 
PAK2 -0.6841 
PAK3 0.3910 
PAK6 -1.1951 
PANK2 -0.5729 
PANK3 -0.1607 
PANK4 -0.0998 
PASK -1.4546 
PCK2 0.7097 
PCTK1 -0.1120 
PCTK2 0.8055 
PCTK3 -0.0565 
PDGFRA 0.3637 
PDIK1L 0.3283 
PDK1 -0.0817 
PDK4 0.3925 
PFKFB1 0.9943 
PFKFB2 -0.4939 
PFKFB4 0.0975 
PFKL 0.4071 
PFKM 0.1509 
PFKP 0.2878 
PFTK1 -0.2891 
PGK1 -0.0012 
PGK2 -1.0533 
PHKB -0.3384 
PI4K2B -0.5890 
PIK3C2A 0.0688 
PIK3C2B 0.3994 
PIK3C3 0.6241 
PIK3CA -3.2893 
PIK3CB 0.1341 
PIK3CD 0.6283 
PIK3CG -0.5412 
PIK3R4 0.5625 
PIK4CA -1.6802 
PIM1 -0.3634 
PIM3 -0.0019 
PIP5K1A 0.2617 
PIP5K1C 2.7507 
PIP5K2B 0.4752 
PIP5K2C -0.0989 
PIP5K3 -0.1976 
PKIA 0.3301 
PKIB 0.9084 
PKLR -0.5593 
PKM2 0.9850 
PKN3 -0.6977 
PLK3 0.2125 
PMVK -1.4498 
PNCK 0.2634 
PRKAA1 -0.0162 
PRKAA2 -0.4687 
PRKAB1 -0.6487 
PRKAB2 -0.4403 
PRKACG 0.4874 
PRKAG1 -0.3479 
PRKAG2 -1.3497 
PRKAG3 3.7424 
PRKAR2B 0.8502 
PRKCA -0.6439 
PRKCB1 0.4312 
PRKCD 0.0540 
PRKCE 0.1515 
PRKCH 0.5920 
PRKCI -0.6407 
PRKCL1 0.1616 
PRKCL2 3.2261 
PRKCN -0.2768 
PRKCQ -0.3348 
PRKCSH -0.1614 
PRKCZ 2.8588 
PRKDC 0.3030 
PRKG1 0.4342 
PRKG2 -0.1300 
PRKR -0.0472 
PRKWNK1 0.4638 
PRKWNK2 -0.6047 
PRKWNK3 0.3138 
PRKY -0.9873 
PRPF4B -1.0101 
PRPS1L1 -0.7832 
PRPS2 -2.4037 
PSKH1 0.3973 
PSKH2 0.6727 
PTK2 -0.4360 
PTK2B 0.5726 
PTK6 0.0416 
PTK9 -0.2958 
PTK9L -0.2344 
PXK -0.2000 
RAF1 -0.0353 
RAGE 0.1641 
RET -0.0654 
RFK 0.6618 
RIOK2 -6.3990 
RIOK3 0.1780 
RIPK1 -1.4787 
RIPK3 -0.4787 
RNASEL -0.6602 
ROCK1 0.5041 
ROCK2 1.4203 
ROR1 -0.0897 
ROR2 -0.0227 
ROS1 -0.0291 
RP6-
213H19.1 -0.3798 
RPS6KA1 -0.0223 
RPS6KA2 0.8358 
RPS6KA4 -0.1918 
RPS6KA5 0.0542 
RPS6KA6 -0.4310 
RPS6KC1 -0.9462 
RYK 0.1601 
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SAST -0.0525 
SCAP1 -0.0447 
SCYL1 0.2226 
SGK 0.3527 
SGK2 0.4021 
SGKL -0.6869 
SIK2 0.3606 
SLK 2.5186 
SMG1 0.6726 
SNARK 0.2385 
SNF1LK 0.3735 
SNRK -0.6685 
SPHK1 -0.8344 
SPHK2 -0.0833 
SRMS -0.7131 
SRP72 -1.4150 
SRPK2 0.0089 
SSTK -0.1434 
SSTK 3.9546 
STK10 -0.7597 
STK11 0.0805 
STK16 0.4717 
STK17A -0.0556 
STK17B -0.5788 
STK19 -0.1012 
STK24 -0.7200 
STK25 -7.3425 
STK29 4.2860 
STK32A 0.0727 
STK32C 0.8206 
STK33 0.3361 
STK36 0.1526 
STK38 -0.0609 
STK38L -1.6414 
STK39 0.4515 
STK4 0.4084 
SYK -0.5127 
TAF1 0.3739 
TAO1 -1.2308 
TBK1 -0.9884 
TEC -0.1571 
TESK1 -0.0661 
TEX14 -0.2656 
TGFBR3 -0.0417 
THNSL1 -0.1508 
TJP2 0.1743 
TK2 -0.1022 
TLK1 0.7019 
TLK2 -0.4134 
TNIK 8.9723 
TNK2 0.2602 
TOPK -0.3789 
TPK1 -0.6430 
TRIB1 -0.3995 
TRIB3 0.0972 
TRPM6 0.1106 
TRPM7 0.0273 
TSKS 0.0012 
TYK2 0.1000 
TYRO3 3.9665 
UCK1 0.0026 
ULK1 0.1436 
ULK2 0.6388 
ULK4 1.5188 
VRK1 0.4347 
VRK2 0.3988 
VRK3 0.0246 
WEE1 0.2839 
WNK4 0.7495 
XYLB 0.3765 
YES1 4.0901 
ZAK 0.0519 
ZAP70 0.1186 
 
